Meeting Abstracts

AMCP Managed Care & Specialty Pharmacy
Annual Meeting 2017
Denver, Colorado
March 27-30, 2017
The AMCP Abstracts program provides a forum through which authors can share their insights and outcomes of advanced managed care practice through publication in AMCP’s *Journal of Managed Care & Specialty Pharmacy* (*JMCP*). Poster presentations are Tuesday, March 28, from 5:45 pm to 7:30 pm. The posters will also be displayed on Wednesday, March 29, from 11:45 am to 2:45 pm. Podium presentations for the Platinum award-winning abstracts are Wednesday, March 29, from 4:30 pm to 5:45 pm. The reviewed abstracts are published in the *JMCP Meeting Abstracts supplement*.

The AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 in Denver, Colorado, is expected to attract more than 3,800 managed care pharmacists and other health care professionals who manage and evaluate drug therapies, develop and manage networks, and work with medical managers and information specialists to improve the care of all individuals enrolled in managed care programs.

Abstracts were submitted in the following categories:

**Research Report:** Describe completed original research on managed care pharmacy services or health care interventions. Examples include (but are not limited to) observational studies using administrative claims, reports of the impact of unique benefit design strategies, and analyses of the effects of innovative administrative or clinical programs.

**Economic Model:** Describe models that predict the effect of various benefit design or clinical decisions on a population. For example, an economic model could be used to predict the budget impact of a new pharmaceutical product on a health care system.

**Solving Problems in Managed Care:** Describe a problem or issue that exists in managed care; the goal for the intervention or practice; and the intervention or best practice implemented to address a specific issue (e.g., introduce a needed change, develop and implement a new system or program, plan and organize an administrative function, or solve other types of problems in managed care settings). Describe what was observed after or when the intervention or best practice was implemented. Provide a general overview of subjective and objective findings and recommendations for future research. Procedures for abstracts in this category are not as rigorous as those for a research report when describing the outcomes of an intervention and do not contain hypothesis testing, thus, they do not have firm conclusions.

**Abstract Review Process**

Twenty-eight reviewers and 3 *JMCP* editorial reviewers were involved in the abstract review process for the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting. Each abstract (with author name and affiliation blinded) was reviewed by reviewers and scored using a 1-5 scale on the following 5 criteria (15 rating scores per abstract) used by *JMCP* to evaluate manuscripts for publication:

- Relevance
- Originality
- Quality
- Bias
- Clarity

Each of the reviewers also made an independent accept/reject recommendation. The 15 rating scores and 3 accept/reject recommendations for each abstract were reviewed by a *JMCP* editorial reviewer, who made an accept/reject decision. These decisions were further reviewed by the *JMCP* editor-in-chief to ensure consistency in decision making. The mean rating scores were used to award Platinum, Gold, Silver, and Bronze medals for the best abstracts submitted. The abstract reviewers for the 2017 Annual Meeting were as follows:

**Reviewers**

- Jennifer W. Baker, PharmD, BCACP, BCPS, VA Tennessee Valley Healthcare System
- Brandon K. Bellows, PharmD, MS, University of Utah Dept. of Pharmacotherapy
- Joseph Couto, PharmD, Cigna Healthcare
- Pooya Desai, PhD, Amgen
- Beckie A. Fenrick, PharmD, Cambridge Advisory Group
- Patrick Gleason, PharmD, Prime Therapeutics
- Boris Gorsht, PharmD, GlaxoSmithKline
- Bonnie C. Greenwood, PharmD, BCPS, UMass Medical School, Clinical Pharmacy Services
- James Grzegorczyk, RPh, MS, Blue Cross Blue Shield of Michigan
- Tianze Jiao, PhD, L S. Skaggs Pharmacy Institute, University of Utah
- Shelli Keast, PharmD, PhD, University of Oklahoma College of Pharmacy
- Donald Kleesper, PhD, MBA, University of Nebraska Medical Center College of Pharmacy
- Jeff Lee, PharmD, FCCP, Lipscomb University College of Pharmacy
- Greg Low, RPh, PhD, Massachusetts General Hospital
- Rohan Mahabaleshwarkar, PhD, Carolinas HealthCare System
- Josephine Mauskopf, PhD, Health Economics
- Hemalkumar Mehta, MS, PhD, Department of Surgery, University of Texas Medical Branch
- Arinze Nkemdirim Okeke, PharmD, MS, MBA, BCPS, Florida A&M University College of Pharmacy and Pharmaceutical Sciences
- Elan Rubinstein, PharmD, MPH, EB Rubinstein Associates
- Natalia Ruiz-Negrón, PharmD, University of Utah Department of Pharmacotherapy
- Craig S. Stern, PharmD, MBA, Pro Pharma Pharmaceutical Consultants
- Kent Summers, PhD, Astellas Pharmaceuticals
- Andy Sezoetka, PharmD, Emdeon
- Patty Taddei-AIlen, PharmD, WellDyne
- Alexandra Tungol Lin, PharmD, Blue Cross Blue Shield of Michigan
- Karen Worley, PhD, Humana
- Joanne Wu, MD, MS, University of Southern California

**JMCP Editorial Reviewers**

- Robert P. Navarro, PharmD, University of Florida College of Pharmacy
- Karen L. Rascati, PhD, The University of Texas College of Pharmacy
- Kaen M. Stockl, PharmD, OptumRx
# Table of Contents

**Annual Meeting Abstracts**

*AMCP Managed Care & Specialty Pharmacy*

*Annual Meeting 2017*

*Denver, Colorado*

*March 27-30, 2017*

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>S3</td>
<td>2017 Annual Meeting Poster Presenters and Exhibit Hall Map</td>
</tr>
<tr>
<td>S14</td>
<td>Medal-Winning Abstracts</td>
</tr>
<tr>
<td>S18</td>
<td>Podium Abstracts</td>
</tr>
<tr>
<td>S21</td>
<td>Professional (Reviewed) Abstracts (Arranged by ICD-10 Code)</td>
</tr>
<tr>
<td>S27</td>
<td>A00-B99 Certain Infectious and Parasitic Diseases <em>(e.g., HIV, Hepatitis C)</em></td>
</tr>
<tr>
<td>S39</td>
<td>C00-D49 Neoplasms <em>(e.g., Breast Cancer, Lung Cancer, GIST, Melanoma, CML, CLL, Multiple Myeloma)</em></td>
</tr>
<tr>
<td>S39</td>
<td>E00-E90 Endocrine, Nutritional, and Metabolic Diseases <em>(e.g., Growth Hormone, Diabetes, Lipids)</em></td>
</tr>
<tr>
<td>S50</td>
<td>F00-F99 Mental and Behavioral Disorders <em>(e.g., Depression, Antipsychotics, Schizophrenia, Bipolar Disorder)</em></td>
</tr>
<tr>
<td>S58</td>
<td>G00-G99 Diseases of the Nervous System <em>(e.g., Multiple Sclerosis, Migraine, Seizures, Restless Leg, Sleep Apnea)</em></td>
</tr>
<tr>
<td>S67</td>
<td>H00-H95 Diseases of the Eye and Adnexa <em>(e.g., Macular Degeneration)</em></td>
</tr>
<tr>
<td>S67</td>
<td>I00-I99 Diseases of the Circulatory System <em>(e.g., Atrial Fibrillation, ACS, Pulmonary Hypertension)</em></td>
</tr>
<tr>
<td>S75</td>
<td>J00-J99 Diseases of the Respiratory System <em>(e.g., Asthma, COPD, Rhinitis, RSV)</em></td>
</tr>
<tr>
<td>S80</td>
<td>K00-K93 Diseases of the Digestive System <em>(e.g., Crohn’s Disease, IBD, IBS)</em></td>
</tr>
<tr>
<td>S83</td>
<td>L00-L99 Diseases of the Skin and Subcutaneous Tissue <em>(e.g., Psoriasis, Pressure Ulcers)</em></td>
</tr>
<tr>
<td>S85</td>
<td>M00-M99 Diseases of the Musculoskeletal System and Connective Tissue <em>(e.g., RA, OA, Osteoporosis, Gout, Dupuytren’s Contracture)</em></td>
</tr>
<tr>
<td>S89</td>
<td>N00-N99 Diseases of the Genitourinary System <em>(e.g., ESRD)</em></td>
</tr>
<tr>
<td>S91</td>
<td>R00-R99 Symptoms, Signs, and Abnormal Clinical and Laboratory Findings Not Elsewhere Classified <em>(e.g., Pain, Opioids, Vasomotor, Urticaria, Nausea &amp; Vomiting)</em></td>
</tr>
<tr>
<td>S92</td>
<td>T00-T98 Injury Poisoning and Certain Other Consequences of External Causes <em>(e.g., Adverse Events, Side Effects)</em></td>
</tr>
<tr>
<td>S93</td>
<td>U00-U99 Codes for Special Purposes and AMCP Unclassified Abstracts <em>(e.g., Care Management, Specialty Pharmacy, Rare Diseases, Star Ratings, Pharmacist Services, MTM, Outcome Analyzers, Part D, Multidisease Studies, ACO, ACA)</em></td>
</tr>
<tr>
<td>S111</td>
<td>Z00-Z99 Factors Influencing Health Status and Contact with Health Services <em>(e.g., Adherence, Oral Contraceptives)</em></td>
</tr>
</tbody>
</table>
At AbbVie, we build bonds with oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

LEARN MORE ABOUT THE BONDS WE’RE BUILDING AT AMCP.
A1 Cost Comparison Analysis of Recurrent Clostridium Difficile Treated with Fecal Microbiota Transplants Versus Antimicrobial Therapy

B1 Assessing the Impact of Vaccine Coverage Under Medical and Pharmacy Insurance Benefit Versus Medical Only on the Herpes Zoster Vaccine and Pneumococcal Vaccination in a Commercially Insured Population

B2 Comparing the Estimated Potential Health Impact of 2 Herpes Zoster Vaccines in the United States

B3 Role of the Pharmacist in Promotion of Appropriate Hepatitis C Regimen Selection and Treatment Completion

B4 Prevalence of Baseline Hepatitis C Virus NS5A Polymorphisms Observed in Molina Healthcare Medicaid and Health Insurance Exchange Populations

B5 Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment

B6 Incidence of Significant Drug Interactions with Direct-Acting Antiviral Hepatitis C Drugs in the Medicaid Population

B7 Real-World Clinical Outcomes with Newer Hepatitis C Drugs for Patients Receiving Care from a Specialty Pharmacy

B8 Real-World Analysis of Harvoni Therapy Completion Rates and Members Achieving Sustained Virologic Response

B9 Real-World Experience in Treating Non-Cirrhotic Patients with Genotype 1 Chronic Hepatitis C Using Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir with or Without Ribavirin: A Prospective Study in a Large Community-Based U.S. Health Care System

B10 Outcomes Evaluation of Medicaid-Insured Hepatitis C Patients Co-infected with HIV After 8 Weeks of Treatment with Ledipasvir/Sofosbuvir

B11 An Updated Estimate of Chronic Hepatitis C Prevalence in the Managed and FFS Medicaid Population During the Era of Oral Direct-Acting Antivirals

B12 Evaluating Hepatitis C Screening and Treatment for Medicaid, Medicare, and Commercially Insured Patients

B13 Budget Impact Analysis of Tenofovir Alafenamide Fumarate, a Novel Nucleotide Reverse Transcriptase Inhibitor, for the Management of Chronic Hepatitis B in the United States

B14 Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Virus Genotype 1: A Retrospective Cohort Study in a Medicaid Population

B15 An Impact Analysis on Expanding Hepatitis C Virus Liver Fibrosis Staging Criteria for Medicaid Plans

B16 Evaluation of Adherence and Efficacy of Hepatitis C Virus Drug Treatment in Patients Who Use Intravenous Drugs

B17 The Impact of a Prior Authorization Policy Change for Hepatitis C Agents on Medication Access

B18 Hepatitis C Retreatment Rates Between Commercial and Medicaid Patients

B19 Adherence to Antiretrovirals in Medicaid-Insured Patients Living with Human Immunodeficiency Virus

B20 An Evaluation of Persistence and Adherence in Treatment-Naive Human Immunodeficiency Virus-Infected Patients on Efavirenz/Etricitabine/Tenofovir Disoproxil Fumarate Versus Other Recommended Single-Tablet Regimens

B21 Estimated Cost of HIV Treatment Failure Based on Pill Burden Among HIV-Infected Individuals in the United States
2017 Annual Meeting Poster Presenters and Exhibit Hall Map (continued)

B22 Pharmacy Cost Savings Analysis of Implementing a Human Immunodeficiency Virus Pilot Program for Truvada When Used for Preexposure Prophylaxis and Postexposure Prophylaxis

C1 Cost-Effectiveness of Pembrolizumab Versus Standard-of-Care Chemotherapy in First-Line Treatment of PD-L1 Positive Metastatic NSCLC Patients in the United States

C2 Clinical and Economic Impact of Hypersensitivity Reactions in Patients Receiving First-Line Chemotherapy for Metastatic NSCLC

C3 Economic Analysis of Molecular Mutation Testing in Real-World Practice Using Claims Data: Costs of Single Gene Versus Panel Tests in Patients with Lung Cancer

C4 Treatment Patterns and Costs Associated with Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Receiving Ceritinib: Analysis of Administrative Claims Data

C5 Comorbidity in Patients with Extensive Disease Small Cell Lung Cancer

C6 Economic Impact of Immunotherapy Choice in the Treatment of All-Comer Metastatic Non-Small Cell Lung Cancer

C7 Indirect Naive Comparison of Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement After Crizotinib Failure

C8 Evaluation of Medications for Malignant Melanoma in Medicare Beneficiaries: A Utilization Review and Cost Analysis

C9 Economic Burden of Patients with Advanced Melanoma in the United States: Comparisons by Insurance Types and Geographic Regions

C11 Progression-Free Survival with First-Line Endocrine-Based Therapies Among Postmenopausal Women with HR+/HER2-Metastatic Breast Cancer: A Network Meta-Analysis

C12 Budget Impact Analysis of the PARP Inhibitor Rucaparib in the Third-Line Treatment of Patients with Deleterious BRCA Mutation Associated Advanced Ovarian Cancer in the United States

C13 The Number Needed to Treat to Achieve 1 Additional Patient Free of Clinical Event: Comparison of Enzalutamide and Bicalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

C14 The Number Needed to Treat to Achieve 1 Additional Patient with Metastatic Castration-Resistant Prostate Cancer Free of Clinical Event: Comparison of Enzalutamide and Bicalutamide in the TERRAIN Trial

C15 Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Pazopanib or Sunitinib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Data

C16 ENESTFreedom Trial of Treatment-Free Remission: Patient-Reported Quality of Life Before and After Stopping Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase

C17 ENESTop Trial of Treatment-Free Remission: Patient-Reported Quality of Life Before and After Stopping Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase

C18 Evaluating Value-Based Frameworks Used for Relapsed or Refractory Multiple Myeloma Regimens: ICER Report, ASCO Value Framework, and NCCN Evidence Blocks

C19 Hospitalization for Patients Treated with Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in a Global Phase 3 Randomized Controlled Trial

C20 Budget Impact Analysis of Treating Chemotherapy Patients with Home-Administered TBO-Filgrastim, Filgrastim-sndz, and Filgrastim in the United States

C21 Health and Economic Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with RVd Versus CyBord: A U.S. Claims-Based Analysis

C22 Characteristics and Treatment Patterns of Patients Receiving Oral Ibrutinib Therapy for Treatment of Chronic Lymphocytic Leukemia

C23 Real-World Treatment Patterns and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia

C24 Daratumumab Compared to Pomalidomide for Refractory Multiple Myeloma: A Cost-Effectiveness Analysis

C25 Medication Adherence and Persistence of Dasatinib and Nilotinib in a National Cohort of Veterans

C26 Budget Impact Analysis of Treating Patients with Chronic Lymphocytic Leukemia and Rituximab-Refractory Indolent B-Cell Non-Hodgkin Lymphoma with Bendamustine Hydrochloride in the United States

C27 Cost Impact of Elotuzumab in Second-Line+ Versus Third-Line+ Relapsed Refractory Multiple Myeloma in a Commercial Health Plan

C28 Concordance of Health Technology Assessment Recommendations for Multiple Myeloma and Lung Cancer Drugs

D1 Health Care Resource Utilization and Costs in Women with Symptomatic Uterine Fibroids: A Cohort Analysis

D2 Economic Evaluation of Patient-Centered Medical Homes Among Long-Term Cancer Survivors in the United States

D3 U.S. Medical and Pharmacy Director Cancer Concerns

D4 A Systematic Review on Progression-Free Survival Using Precision Oncology

D5 Immune-Related Adverse Effects Associated with Checkpoint Inhibitor Therapy: Incidence, Management, and Effect on Outcomes

D6 A Quality Analysis of Pharmacy Oral Oncology Monitoring Services

D7 Adherence, Persistence, and Dosing Patterns of Eltrombopag for Treatment of Immune Thrombocytopenia

D8 Trend Analysis of Medicare Hemophilia Drug Utilization, 2011-2015
D9 Real-World Data Analysis of U.S. Claims Database on Coagulation Factor VIII Costs in Specific Patients with Hemophilia A Switching from Standard Half-Life to Extended Half-Life Products

D10 Improving Payer-Provider Collaboration and Data Reporting for Hemophilia Management: Metric Development for Quality Improvement

D11 Current Formulary-Based Cholesterol Management in the United States

D12 A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis or Treatment of Chemotherapy-Induced Febrile Neutropenia

D13 A Real-World Cost Comparison of IVIG- and SCIG-Treated PIDD Patients

D14 Immunoglobulin Product Utilization and Drug Spend by Diagnosis Among 1.5 Million Commercially Insured

D15 Real-World Treatment Patterns and Health Outcomes of Treatment Regimens for Patients with Hereditary Angioedema

D16 Considerations for Formulary Addition of Biosimilar Infliximab-dyyb, Inflectra, Within a Health System

E1 The Impact of Various Clinical Strategies on Achieving 5 Stars for the MTM Program Completion Rate for CMR Star Rating Measure

E2 Evaluating Frequency and Cost Impact of Pharmacist Interventions in Phase 3 Clinical Trials for Patients with Suboptimally Controlled Diabetes

E3 Implementation of a Scalable Chronic Disease Management and Preventative Care Tele-Health Service

E4 Medicare Part D Plan Formulary Coverage, Utilization Management Tools, and Cost Sharing for Insulins and Other Newer Antidiabetic Drugs

E5 Clinical Outcomes of Patients with Type 2 Diabetes Who Switched to Insulin Glargine 300 U/mL from Insulin Glargine 100 U/mL in Real-World U.S. Treatment Settings

E6 Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Initiating or Switching to Insulin Glargine 300 Units/mL in a Real-World Setting

E7 Pharmacist-Led Diabetes Wellness Clinical Outreach Program Significantly Decreases Hemoglobin A1c

E8 Real-World Analysis of Patient Characteristics in Patients who Received an Eye Exam Within the First Year of Type 2 Diabetes Mellitus Diagnosis Compared with Patients Who Did Not Receive an Exam

E9 Any Statin Use Among Commercially Insured Members with Diabetes Age 40-64 Without History of Atherosclerotic Cardiovascular Disease and Association Between Adherence to Statin Therapy in 2014 and Adverse Cardiovascular Events in 2015

E10 Total 2014 and 2015 Claims Expense by Drug, Diagnosis, and Procedure Codes: 250,000 Commercially Insured Members with Diabetes Compared with 1,000,000 Matched Members Without Diabetes

E11 Real-World Basal Insulin Intensification Patterns in the United States

E12 Zero Dollar Diabetes Drug Coverage: Impact on Utilization, Costs, and Adherence

E13 Primary Care Physician Perception of the Diabetes Empowerment Education Program Within a Medicare Advantage Plan

E14 Evaluating the Impact of Pharmacist Support for Medication Adherence and Patient Compliance in Clinical Trials for 2 NIGLMs in Suboptimally Controlled Patients with Diabetes

E15 Formulary Change Impact on Health Care Resource Use and Cost Among Patients with Type 2 Diabetes Treated with Insulin

E16 Assessment of New Onset Diabetes and Statin Medication Utilization

E17 Cost Offsets Predicted with Empagliflozin in Patients with Type 2 Diabetes and Established Cardiovascular Disease

E18 The Burden of Severe Hypoglycemia in Type 1 Diabetes

E19 Health Care Resource Costs and Utilization for Type 2 Diabetes Patients on New Antidiabetic Classes Compared to Traditional Classes in Central Texas

E20 The Burden of Severe Hypoglycemia in Type 2 Diabetes

E21 Pharmacist-Directed Population Health Management Program Improves Clinical Outcomes for Patients with Diabetes

E22 Evaluation of Outcomes After Initiation of Triple Antidiabetic Therapy for Patients with Type 2 Diabetes Mellitus on Metformin and a Sulfonlurea

E23 Effect of Prescriber and Member Education on Statin Use in Diabetic Patients: A Part D Star Measure Pilot Program

E24 Modeling the Budget Impact of Antidiabetic Formulary Changes for a National Payer

E25 Examine the Sociological Influences on Physician Prescribing Behavior of Type 2 Diabetic Medications in U.S. Outpatient Setting

E26 A Cost Analysis of the Use of Insulin Degludec Injection (100 units/mL and 200 units/mL) and Insulin Glargine (300 units/mL) as Compared to Insulin Glargine Injection (100 units/mL) in a Managed Medicaid Health Plan

E27 Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis

E28 Assessing the Impact of a Pharmacy-Based Therapy Management Program on Adherence and Health Care Utilization in Cystic Fibrosis

E29 Evaluating Physician-Perceived Benefit of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis


E31 Cost-Effectiveness of Adding Lesinurad to Allopurinol for Second-Line Urate-Lowering Therapy in Gout Patients: A U.S. Payer Perspective
2017 Annual Meeting Poster Presenters and Exhibit Hall Map
(continued)

E32 Osteoarthritis and Gout: Real-World Evidence Evaluating
Patient Characteristics, Treatment Patterns, and Health Care
Utilization

E33 Utilization and Cost of Diabetic Medications Among U.S.
Medicare Part D Beneficiaries

E34 Health Care Resource Utilization Among School-Aged Children
with Cystic Fibrosis

E35 Productivity Loss Associated with Pulmonary Exacerbations
Among Patients with Cystic Fibrosis and Caregivers

E36 Assessing Impact in a Competitive Branded Marketplace:
A Review of Statin Average Wholesale Price

E37 Evaluation of a Value-Based Insurance Design Program on
Medication Adherence, Utilization, and Cost in Diabetes

F1 A Multichannel Prescriber-Directed Program Including Case
Management to Reconcile Potential Opioid Overutilization

F2 Impact of a Managed Care Pharmacist Consultation Program on
Controlled Substance Drug Cost, Emergency Room Visits, and
Hospitalizations

F3 Employing Bayesian-Calibrated Microsimulation to Assess the
Cost-Effectiveness of Long-Acting Injectable Buprenorphine
Versus Sublingual Buprenorphine to Treat Opioid Use Disorder

F4 Economic Analysis of Buprenorphine Subdermal Implant Versus
Standards of Care for Primarily Treatment-Naive Primarily
Heroin-Addicted Patients with Opioid Use Disorder

F5 Retrospective Evaluation of the Impact of an Appropriate Pain
Management Drug Utilization Review Program

F6 Predictors of Opioid Use in the United States Using the National
Ambulatory Medical Care Survey Data

F7 Prevalence of Concurrent Opioid and Benzodiazepine Use
Among 19 Million Commercial Members

F8 Duplicate Opioid and/or Benzodiazepine Therapy from Multiple
Prescribers Following Pharmacy Lock-In in a Medicaid
Managed Care Population: A Drug Utilization Review

F9 Analysis of Tighter Control of Buprenorphine-Containing
Products and Its Effect on Utilization for a Medicaid Plan

F10 Opioid Overuse Pilot Program: Impact of Provider Education on
Chronic Opioid Prescribing Practices in the Aetna Better Health
of West Virginia Medicaid Population

F11 An Analysis of Commercial Members Filling Opioid
Prescriptions Eligible for Pharmacy Lock-In

F12 Budget Impact Analysis Comparing Aripiprazole and
Aripiprazole Lauroxil Based on Real-World Dosage Patterns

F13 Measuring the Relationship Between Patient Adherence to
Atypical Antipsychotics and Their Other Medications

F14 Two-Year Acute Care Utilization and Cost Outcomes for
Schizophrenia Patients in Medicaid Treated with Paliperidone
Palmitate or Oral Atypical Antipsychotic

F15 Relationship Between EMR Utilization, Health Care Quality, and
Patient Outcomes: Analysis from a Nationally Representative
Sample of Schizophrenia Physicians

F16 Projection-Based Methods to Assess the Population Effectiveness
of Once-Monthly and Once-Every-3-Months Formulations of
Paliperidone Palmitate Versus Oral Antipsychotics in a Medicaid
Population

F17 Health Care Costs and Resource Utilization in Patients with
Schizophrenia and Cardiometabolic Comorbidities Treated with
Once-Monthly Paliperidone Palmitate Versus Oral Atypical
Antipsychotics

F18 Economic Utility: Combinatorial Pharmacogenomics and
Medication Cost Savings for Mental Health Care in a Primary
Care Setting

F19 Direct and Indirect Cost Burden and Change of Employment
Status Among Employees with Treatment-Resistant Depression
in the United States

F20 Cost-Effectiveness Evaluation of Vortioxetine in Patients with
Major Depressive Disorder Switching from First Antidepressant
Therapy in the United States

F21 Potential Drug-Drug Interactions on Atypical Antidepressants in
U.S. Ambulatory Settings

F22 Patient Adherence to Antidepressant Therapy and Impact on
Resource Utilization in a Managed Care Population with a
Diagnosis of Depression

F23 Efficacy and Safety of HLD200 in Children with Attention-Deficit/
Hyperactivity Disorder: Results from a Pivotal Phase 3 Trial

F24 Early Morning Functional Impairments in Stimulant-Treated
Children and Adolescents with Attention-Deficit/Hyperactivity
Disorder: Impact on the Family

F25 Comparing the Medication-Specific Child Core Set Among
Commercial Health Plans, Managed Medicaid, and Marketplace
Children in 2015

F26 Evaluating the Impact of Interventions by a Multidisciplinary
Pediatric Behavioral Health Medication Initiative Workgroup on
Medication-Prescribing Trends in a Medicaid Population

F27 Utilization Trends of Medications for Attention-Deficit
Hyperactivity Disorder Among Members of a Commercial
Population

F28 Association Between Physician Care Coordination and the Use
of Psychotropic Polypharmacy in the Management of Pediatric
Mental Disorders

F29 Analysis of the Clinical and Economic Impact of a Pharmacist-Led,
Behavioral Health Provider Education Program in a Managed
Care Setting

F30 Retrospective Analysis of Adherence Rates and Persistence in
Children and Adolescents Initiating Antidepressant Medications

G1 Efficacy and Safety of Edaravone (MCI-186) for the Treatment of
Amyotrophic Lateral Sclerosis

G2 A Safety Analysis of Edaravone (MCI-186) During the First
6 Cycles (24 Weeks) of Amyotrophic Lateral Sclerosis Therapy
from the Double-Blind Period in 3 Randomized Placebo-
Controlled Studies

G3 Determining the Cost of Care for Spinal Muscular Atrophy
Using Retrospective Claims Analysis
2017 Annual Meeting Poster Presenters and Exhibit Hall Map (continued)

G4 Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis

G5 A Descriptive Analysis of a Real-World Population with Huntington-Associated Chorea Treated with Tetrabenazine: Findings from an Electronic Medical Records Database

G6 Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)

G7 Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from 3 Studies

G8 Parkinson's Disease and Comorbidity: A U.S. National Perspective

G9 Health Care Utilization and Costs for Patients with Tardive Dyskinesia

G10 ADS-5102 (Amantadine Hydrochloride) Extended-Release Capsules Improve Clinician's Global Impression of Change and Activities of Daily Living by Reducing Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID Study)

G11 Systematic Review of Valbenazine and Tetrabenazine for Treatment of Tardive Dyskinesia

G12 Hospitalizations and Emergency Department Visits in Patients with Parkinson's Disease in the United States: A National Perspective

G13 Comparing Quality of Life Between People Who Use Injectable Disease-Modifying Therapies and Those Who Switch to Oral Therapies: A Study from the Pacific Northwest Multiple Sclerosis Registry

G14 Disease-Modifying Drug Treatment Before, During, and After Pregnancy in Women with Multiple Sclerosis and a Live Birth

G15 Patient-Reported Outcomes Based on Disease-Modifying Drug Treatment Status in Patients with Multiple Sclerosis

G16 Alemtuzumab Durably Slows Brain Volume Loss over 6 Years in the Absence of Continuous Treatment in Patients with Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II)

G18 Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

G19 Prior Disease-Modifying Drug Use and the Relationship with Patient-Reported Outcomes

G20 Impact of Multiple Sclerosis Relapse Severity on Health Care Costs

G21 The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Intramuscularly Administered Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

G22 The Burden of Relapsing-Remitting Multiple Sclerosis on Workers in the United States: A Cross-Sectional Analysis of Survey Data

G23 The Burden of Relapsing-Remitting Multiple Sclerosis on Individuals in the Labor Force

G24 Multiple Sclerosis Medication Adherence Within Walgreens Local Specialty Pharmacies Is Significantly Higher Compared to Other Class of Trade Pharmacies

G25 Subcutaneous Immunoglobulin to Treat Chronic Inflammatory Demyelinating Polyneuropathy: The Costs to Payers

G26 Implementing a Pharmacist-Led Multiple Sclerosis Specialty Pharmacy Clinical Outreach Program

G27 Comparative Effectiveness of Delayed-Release Dimethyl Fumarate Versus Fingolimod and Teriflunomide on Risk of Relapse

G28 Hospital Readmissions in Epilepsy Patients: A U.S. National Perspective

G29 Burden of Epilepsy in the Medicare Population

G30 Dosage Titration of AED Treatments and Related Health Care Resource Use and Costs: A Retrospective Chart Review in the United States

G31 Cost Sharing for Antiepileptic Drugs: Implications for Medication Utilization and Health Plan Costs

G32 Utilization Patterns of Topiramate Formulations in Epilepsy and Migraine: Analysis of Administrative Claims Comparing Trokendi XR (Extended-Release Topiramate) and Immediate-Release Topiramate

G33 Evidence Regarding the Use of Duloxetine in the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Targeted Review and Real-World Insight on Practical Approaches

G34 Escalating Doses of IncobotulinumtoxinA (400U-800U) Lead to Increasing Improvements in Disability Due to Multilocular Upper- and Lower-Limb Spasticity

G35 Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity over 48 Weeks: A Phase 3, Placebo-Controlled Study with an Open-Label Extension

G36 Utilizing Electronic Health Records to Assess the Severity and Impact of Chronic Pain

G37 Evaluating the Opioid Safety Initiative Implementation to Determine if Opioid Therapy Changes in Veterans Met the Intended Goal of Sale and Effective Management of Pain

H1 Burden of Noninfectious Inflammatory Eye Diseases: A Systematic Literature Review

H2 Statins Are Differentially Sensitive to the Medication Possession Ratio

H3 The First Real-World Clinical and Health Economic Outcomes of a Digital Health Offering in a Patient Population with Cardiovascular and Metabolic Chronic Diseases

H4 A Systematic Review of Cost-Effectiveness Analyses of Antihypertensive Medications

H5 A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence

H6 Application of Medication Adherence Tools in an Accountable Care Setting

H7 Evaluation of Home Blood Pressure Monitors as a Pharmacy Benefit in a Medicaid Population
2017 Annual Meeting Poster Presenters and Exhibit Hall Map (continued)

17 Primary Medication Nonadherence in Patients Prescribed Statins, Ezetimibe, or Statin + Ezetimibe Combination Therapy

18 Time to Approval in Patients Requesting Access to PCSK9i Therapy by Payer Type

19 Treatment Patterns Among Early Initiators of Evolocumab and Alirocumab

10 Cost-Effectiveness of Influenza Vaccination Against Major Adverse Cardiac Events

11 Utilization and Adherence Rates to Pulmonary Arterial Hypertension Medications

12 Characteristics of Patients Treated for Pulmonary Arterial Hypertension in Real-World Database Representing a Large U.S. Health Plan

13 Impact of Entresto on Overall Medical Cost in Heart Failure Patients

14 Retrospective Cohort Study to Assess the Differences in Persistence Between Dabigatran and Warfarin in Patients with Nonvalvular Atrial Fibrillation

15 Estimation of Decrements of Utility Associated with Hospitalizations in a Population with Heart Failure from the Systolic Heart Failure treatment with the IF inhibitor ivabradine Trial (SHIFT)

16 Hyperkalemia in Heart Failure Was Associated with Excess Emergency Department Visits and Hospital Admissions

17 Identifying Cost Opportunities Associated with Reducing Inpatient Admissions for Acute Decompensated Heart Failure in the Medicare Heart Failure Population

18 A Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

19 Novel Oral Anticoagulants and Risk of Major and Gastrointestinal Bleeding: A Systematic Review

20 Pre- and Post-Cost Analysis of Sacubitril/Valsartan-Treated Heart Failure Patients in a Commercial and Medicare Population

21 Comparing the Cost-Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Patients in Atrial Fibrillation and High Risk of Bleeding

22 Real-World Effectiveness and Safety of Dabigatran, Apixaban, Rivaroxaban, and Warfarin in Patients with Nonvalvular Atrial Fibrillation

23 Impact of Having a Single Preferred Agent with Exclusive Contracts Versus Parity Access for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Cost and Product Uptake in Medicare Plans

24 Sustained Attainment of Low-Density Lipoprotein Cholesterol Thresholds with Alirocumab Beyond 24 Weeks: Pooled Analysis of ODYSSEY Phase 3 Trials

25 Impact of CYP3A4/P-gp Interacting Medications on Clinical Outcomes in Rivaroxaban Patients at a Health Plan Located in Central Texas

126 Awareness of the Atherosclerotic Cardiovascular Disease Risk Estimator Among Primary Care Physicians in a Medicare Advantage Plan

127 Assessing the Adoption and Application of the 2013 ACC/AHA Guidelines for Statin Prescribing

1 J Relationship Between Antibiotic Treatment Failure and 30-Day Mortality in Adult Outpatients with Community-Acquired Pneumonia

2 Medical and Pharmacy Costs Associated with the Treatment of Adult Patients with Community-Acquired Pneumonia in the Outpatient Setting

3 Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus in High-Risk Infants in a Managed Care Organization

4 EXHANCE-12: EDS-FLU Reduces Symptoms, Need for Surgery in Chronic Rhinosinusitis

5 Per-Member-Per-Month Cost of Subcutaneous Immunotherapy in a Large Insured Population in the United States

6 Effectiveness of a Multidisciplinary Intervention to Encourage Appropriate Albuterol Inhaler Utilization Among Patients with Asthma

7 Changes in Symptom Control, Work Productivity and Activity Impairment, and Anxiety Symptoms in Chronic Idiopathic Urticaria Patients After 24-Week Treatment with Omalizumab

8 Reduction in Asthma Exacerbations, Hospitalizations, and Work Productivity and Activity Impairment After Omalizumab Initiation: Results from a 48-Week Single-Arm, Open-Label Treatment Registry

9 Health Care Costs in Asthma and/or Chronic Obstructive Pulmonary Disease Patients Using Albuterol Inhalation Aerosol with and Without an Integrated Dose Counter

10 Development and Validation of a Predictive Model to Identify Patients at Risk of Severe Chronic Obstructive Pulmonary Disease Exacerbations Using Administrative Claims Data

11 Prescription Fill Patterns After Reaching the Medicare Part D Coverage Gap Among Chronic Obstructive Pulmonary Disease Patients on Maintenance Bronchodilators

12 The Burden of Childhood Asthma in the United States: Impact on Productivity Loss in a Nationally Representative Study

13 Clinical Outcomes and Costs Associated with Removing a Combination Long-Acting Beta-Agonist and Inhaled Corticosteroid Product from the Formulary in Managed Care Medicaid Plans

14 Asthma Severity and Medication Patterns for Patients Self-Elected into a Value-Based Insurance Design Versus Conventional Coverage

15 Evaluation of Admission and Discharge Asthma Controller Medication Prescribing in Patients Discharged After Asthma Exacerbation: Characterizing Opportunities for Improvement

16 Identification and Assessment of the Functionality of Mobile Health Applications for COPD Management

17 Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib or Pirfenidone
2017 Annual Meeting Poster Presenters and Exhibit Hall Map (continued)

**M16** Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed by Matching-Adjusted Indirect Comparison: An Analysis Based on all Pivotal Phase 3 Clinical Trial Data

**M17** Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the U.S. Perspective

**M18** A Budget Impact Analysis of Total Disc Replacement for Single-Level Lumbar Degenerative Disc Disease: A U.S. Private Health Insurer Perspective

**M19** Implementation of a Health Plan-Driven Opioid Tapering Program to Decrease Chronic Opioid Utilization for Conditions of the Back and Spine in a Medicaid Population

**M20** Impact of Co-occurring Overactive Bladder in Medicare Patients with Osteoporosis

**N1** Economic Burden of Anemia in Patients with Nondialysis-Dependent Chronic Kidney Disease

**N2** Health Care Cost Rises Exponentially by Stage of Chronic Kidney Disease

**N3** The Economic Burden of Overactive Bladder Among Medicare Beneficiaries with Employer-Sponsored Supplemental Coverage

**N4** Refill Gaps and Dose Reductions in Patients with Prostate Cancer and Visceral Metastases Treated with Abiraterone Acetate Plus Prednisone or Enzalutamide

**N5** Potential Drug-Drug Interaction Events in Patients Treated with Abiraterone Acetate Plus, Prednisone, or Enzalutamide

**O1** A Retrospective Claims Database Analysis of Postpartum Diabetes Screening Following Gestational Diabetes

**R1** Prophylactic Antiemetic Use Reduces Opioid-Induced Nausea and Vomiting and Improves Patient Recovery in the Outpatient Setting

**R2** How Pricing Changes and Dose Optimization Affected Compound Pharmaceutical Use in the Missouri Medicaid Population

**T1** Characteristics Associated with Opioid Overdose in a Medicaid Population

**T2** Costs of Serious Adverse Events Associated with Targeted Specialty Therapies in the Treatment of Inflammatory Diseases at a Managed Care Plan: A Historical Claims Analysis

**T3** Adverse Outcomes of Double and Triple Threat Therapy

**T4** Abuse-Deterrent Opioids and Prescription Drug-Monitoring Programs: A Systematic Review of Their Impact on Misuse, Abuse, and Opioid-Related Harms

**U1** Systematic Literature Review of Performance-Based Risk-Sharing Arrangements in the United States

**U2** A Global Context for Drug Value

**U3** Relative Versus Absolute Risk Framing in Health Care Decision Making: A Survey of U.S. Payers

**U4** FDAMA 114 for the Exchange of Health Care Economic Information: Manufacturer Experiences, Attitudes, and Perceptions of Current Legislation and Future Directions

**U6** How Do Payers Utilize the AMCP eDossier System for Preapproval Information and Could It Qualify as a Safe Harbor?

**U7** Targeted Prescriber Office Outreach to Grow Adoption of Electronic Prior Authorizations

**U8** Assessment of Health Care Providers’ Training, Awareness, and Management Practices for Chronic Opioid Therapy

**U9** Creating a Quality Audit Process to Identify Fraud, Waste, and Abuse

**U10** Impact of Motivational Interviewing on Medication Adherence

**U11** Early Integrated Scientific Advice as a Tactic to Support Successful Regulatory Approval, Reimbursement, and Patient Access

**U12** Validation of a Budget Impact Model for a Clinical Management Program for Zarxio

**U13** Improving Patient Care One Consult at a Time Through Clinical Quality Oversight of Medication Therapy Management

**U14** Wearable Health Technologies to Treat Chronic Pain: Establishing Baseline Treatment Effects in a Multidisciplinary Pain Program

**U15** Treatment Interruption Patterns Among Adalimumab Users in a Commercially Insured Managed Care Population

**U16** Clinical Quality Oversight of Fast-Tracking Utilization Management Strategies

**U17** Utilization of Geriatric Care Among Medicare Beneficiaries

**U18** Epidemiology of Opioid Use in a State Medicaid Program

**U19** Impact of Oxycodone HCl Extended-Release Formulary Restrictions on Extended-Release Opioid Market Share, Health Care Resource Utilization, and Costs in Commercial and Medicare Plans

**U20** Assessing the Impact of a Community-Based Overdose Prevention in Rural North Carolina

**U21** Adverse Drug Event Reporting Rates: Comparing FAERS to Clinical Trials

**U22** Helping Seniors in the Denver Community: Medicare Part D Outreach and Plan Optimization

**U23** Analyzing the Success Rates of Pharmacist Interventions in Resolving Medication Therapy Problems at University of Florida's Medication Management Center

**U24** A Cost-Effective Medication Therapy Management Program for the Medicaid Population

**U25** Opioid and Benzodiazepine Utilization Patterns Across Multiple Employer Group Plans in Eastern Tennessee

**U26** Prescription Opioid Deaths in a State Medicaid Population, 2012-2014

**U27** Medicaid Brand and Generic Drug Utilization Trends: A Quantitative Analysis of Uptake Dynamics Within the First Year of Introducing Generic Competition

**U28** Payer Viewpoints on, and Use of, Real-World Evidence

**U29** ICER Reports: The Role of Cost/QALY Evaluations in the Evolving U.S. Reimbursement Landscape
2017 Annual Meeting Poster Presenters and Exhibit Hall Map (continued)

U30 The Future of U.S. Pharmaceutical Pricing and Reimbursement: What Can We Learn from Europe?
U31 A Retrospective Identification of Venous Thromboembolism Events Peri-Operatively Using Claims-Based Data
U32 Risk of Emergency Department Use and Hospitalization in Patients Without Access to Medications in the United States
U33 The U.S. Payor Landscape: Results from a Survey of Medical and Pharmacy Directors on Formulary Management
U34 Covered California's Specialty Drug Cap Regulation: Impact on Cost and Utilization
U35 Impact of a Site of Service Redirection Program on Specialty Drug Spend
U36 Understanding Factors that Contribute to Opioid Misuse and Diversion
U37 A Four-State Assessment of Patient-Centered Medical Home Elements at Physician Practices
U38 FDAMA 114 for the Exchange of Health Care Economic Information: Payer Experiences, Attitudes, and Perceptions of Current Legislation and Future Directions
U39 Real-World Evidence on Everolimus Compliance and Persistence Among Tuberous Sclerosis Complex Patients with Renal Angiomyolipoma or Subependymal Giant Cell Astrocytoma
U40 Implementation of Electronic Prior Authorization Process in an Integrated Health System
U41 Retrospective Analysis of Pregabalin and Gabapentin Concomitant Utilization in a Medicaid Population
U42 Recent Trends in Payer Perception and Use of Value Frameworks in the United States
U43 Formulary Change Notification: A Two-Tiered Approach
U44 Patient Perceptions of a Posthospitalization, Transitions-of-Care Program
U45 Impact of Cash Prescriptions and Use of Affiliate Provider Identifiers on Measures of Opioid Use from Multiple Providers
U46 Preparing Pharmacy Students to Meet Challenges in Managed Care: Evidence of Student Learning About Managed Care Pharmacy from a U.S. Pharmacy School
U47 Generic Drug Appearance Variation: Can Looks Be Deceiving?
U48 A Deep Dive into Minnesota's Pharmaceutical Expenditures and Use from 2009 to 2013
U49 Pairing Medication Therapy Management and Pharmacogenomic Testing in the Clinic Setting
U50 An Evaluation of Process Change Implementation with Nebulized Medication Payment Under Part B Benefits in a Medicare Population
U51 Budget Impact of Biosimilar Approvals for Reference Products Remicade, Humira, and Enbrel in 7 Medicaid Plans
U52 Predictive Modeling: An Analysis of Select Oncolytic Drug Cost Through the Commercial Medical and Pharmacy Benefits
U53 Triplet Threat: Analysis of Opioid, Benzodiazepine, and Muscle Relaxant Discontinuation Rates After Pharmacy Benefit Manager Intervention to Prescribers
U54 Impact of Integrated Pharmacy and Medical Benefits in a Chronic Disease Management Program
U55 Development, Implementation, and Assessment of a Site-of-Care Program for Specialty Infusion Products
U56 Impact of a Medication Therapy Management Program and Intervention on Reducing Hospital Readmissions
U57 Cost Analysis and Expansion of a Split Fill Program
U58 Retrospective Analysis of a Utilization Management Strategy Targeting Duplicate Opioid Therapy in a Medicare Population
U59 A Survey of Patient, Provider, and Payor Perspectives on Biosimilars
U60 Strategies for Increasing Clinician Awareness of Pharmacogenomic Testing
U61 Medicare Part D Fraud, Waste, and Abuse Prevention Programs: A Literature Review
U62 Impact of Comprehensive Medication Reviews on Adherence to Centers for Medicare and Medicaid Services' Measured Medication Classes and Effect of Clinical Mailings on Subsequent Utilization of High-Risk Medications
U63 A Multichannel Marketing Approach on a Medication Synchronization Program in a Pharmacy Benefit Manager Setting
U64 Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Simple Prescription and Administered Drugs in California Workers’ Compensation System
U65 Inefficiencies and Challenges in the Mail-Order Prescription Fulfillment Process: A Systematic Review
U66 A Pass-Through Prescription Benefit Manager Drug Trend Report
U67 Effect of Formulary Restriction of Transdermal Fentanyl, Levorphanol, and Extended-Release Morphine Products on Texas Workers' Compensation Claims
U68 Impact of Medication Synchronization on Outcomes: A Systematic Review
U69 Identifying Common Adverse Drug Reactions and Over-the-Counter Options to Manage Patient Health
U70 A Retrospective Evaluation of Pricing and Medication Development of Oral Contraceptives Pre- and Post-Affordable Care Act Cost-Sharing Mandate
U71 Impact of a Pharmacist-Led Opioid Intervention Program on High-Risk Utilization Patterns in a Commercial Population
U72 Evaluation of Mobile Health Applications for Chronic Diseases Using Mobile Application Rating Scale
U73 Evaluation of Barriers Implementing Medication Therapy Management in Outpatient Pharmacies
U74 New Opportunities for Reaching Patients in Provision of Medication Therapy Management Services: An Update on the Provider Outreach Program
U75 Collaborative Academic-Community Partnership in the Provision of a Medication Therapy Management Service for Medicaid Beneficiaries in Rural Arizona
2017 Annual Meeting Poster Presenters and Exhibit Hall Map

(continued)

U77 Accuracy and Improvement of Clinical Algorithms Used to Conduct Medication Therapy Management Services at SinfoniaRx
U78 Measuring the "Sentinel Effect" of Prior Authorization on Medication Requests and Administrative Costs
U79 An Evaluation of Compliance with the VISN 17 Prior Authorization Committee Process for Request of Drug Therapy and Required Reporting of Safety and Efficacy Outcomes
U80 Retrospective Pharmacist Medication Review for Home- and Community-Based Members of Medicaid Long-Term Services and Supports
U81 Drug Savings Review: Impact on Various Lines of Business Through the Analysis of Clinical Edit Categories
U82 Impact of Telephonic Medication Therapy Management Services on Patient Satisfaction
U83 Impact of Compound Utilization Management Strategy on Costs for Pain-Related Compounds and Utilization Trend of Prescription Pain Medications
U84 The Impact of Physician Referral on Comprehensive Medication Review Participation in a Medicare Part D Medication Therapy Management Program
U85 Disease State Prevalence and Medication Utilization in On-Exchange and Off-Exchange Individual and Family Plan Members
U86 Creation of Exclusion List for Nonrebateable NDCs and Process Improvement to Promote Pharmacy Encounter Acceptance
U87 The Association Between Medication Therapy Management Program Completion Rate for Comprehensive Medication Review and Medication Adherence in Part C and D Plans: An Exploratory Study
U88 A Multidisciplinary Team Model Approach to Medicaid Lock-in Programs
U89 Survey to Examine the Perceptions of Manufacturer Copay Subsidy Coupons for Specialty Drug Products from Commercial Payers and Members
U90 Identification of Fraud, Waste, and Abuse Pharmacies Using Pharmacy Claims Data
U91 Evaluation of Intervention Alert Frequency and Acceptance Rates by Medicare Insurance Type in a Medicare Part D Population
Z1 Impact of Removing Member Cost-Share for Contraceptive Products per the Affordable Care Act in a Commercial Population
Z2 Effect of AbbVie’s Patient Support Program on Patient Adherence and Work Productivity in Patients Initiating Adalimumab Therapy
Z5 Demographic and Socioeconomic Factors Associated with Nonadherence to Chronic Medications in a Marketplace Population
Z6 Undertreatment of Chronic Interstitial Cystitis in the United States: A Population-Based Study
Z7 Examining Pharmacy Quality Among Medicare Patients with Hypertension: Implications of Pharmacy Impact on Star Ratings
Z8 Thinking Outside the Bottle: How a Clinical Pharmacist Team Adds Value and Saves Money in a Managed Care Plan
Z9 Preemptive Pharmacogenetic Testing: Exploring the Knowledge and Perspectives of U.S. Payers
Z10 The Impact of Medication Therapy Management and Text Message Reminders on Medication Adherence and Health Care Utilization in a Disabled Medicaid Population
Z11 Initiation of a University-Based Medication Therapy Management Call Center Working Together with Accountable Care Organizations to Improve Quality Measures: A Report from the ACO Research Network, Services, and Education
Z12 The Impact of Community Pharmacy-Delivered Medication Synchronization on Health Care Costs and Utilization
Z13 Comparing Adherence to Treatment Guidelines After an Opioid-Dependence Hospitalization in Medicaid and Commercially Insured Populations
Z14 Analysis of Telephonic Outreach Strategies on Adherence Rates in a Medicare Population
OUR HEART IS ALWAYS IN OUR WORK BECAUSE OUR PATIENTS ARE ALWAYS ON OUR MIND.

AbbVie applauds and supports the efforts of AMCP in creating remarkable impacts.

abbvie.com
Medal-Winning Abstracts

Each abstract was assessed by reviewers using a 1-5 scale on the following 5 criteria: relevance, originality, quality, bias, and clarity. These are the same criteria used by JMCP to evaluate manuscripts. The abstract’s mean score on the 5 criteria was used to award Platinum, Gold, Silver, and Bronze medals.

Cynthia L. Gong, PharmD, [C10] Applying Pharmacoeconomic Modeling to Formulary Decision Making: The Case of Trabectedin

Manish Mittal, PhD, [Z3] Effect of Adalimumab Initiation at a Specialty Pharmacy on Adherence, Persistence, and Cost Outcomes Across Autoimmune Diseases

Yang Qiu, MS, [U49] Does Consumer Purchasing Data Improve Medication Adherence Predictions for the CMS Star Categories?

JaeJin An, PhD, [D2] Economic Evaluation of Patient-Centered Medical Homes Among Long-Term Cancer Survivors in the United States

Richard A. Brook, MS, MBA, [D3] U.S. Medical and Pharmacy Director Cancer Concerns

Laurence M. Djatche, PharmD, [C18] Evaluating Value-Based Frameworks Used for Relapsed or Refractory Multiple Myeloma Regimens: ICER Report, ASCO Value Framework, and NCCN Evidence Blocks

Jackie Gladman, BPE, [U6] How Do Payers Utilize the AMCP eDossier System for Preapproval Information and Could It Qualify as a Safe Harbor?

Marc A. Hixson, MBA, [K7] The Impact of Plecanatide on Quality of Life for Patients with Chronic Idiopathic Constipation: Results from Two Phase 3 Clinical Studies

Nicholas J. Keeling, MS, [Z9] Preemptive Pharmacogenetic Testing: Exploring the Knowledge and Perspectives of U.S. Payers

Maryam Khazraee, PharmD, [Z8] Thinking Outside the Bottle: How a Clinical Pharmacist Team Adds Value and Saves Money in a Managed Care Plan

Thomas Lodise, PharmD, PhD, [J2] Medical and Pharmacy Costs associated with the Treatment of Adult Patients with Community-Acquired Pneumonia in the Outpatient Setting

Donna Mildvan, MD, [J1] Relationship Between Antibiotic Treatment Failure and 30-Day Mortality in Adult Outpatients with Community-Acquired Pneumonia

Kathy L. Nguyen, PharmD Candidate, [U32] Risk of Emergency Department Use and Hospitalization in Patients Without Access to Medications in the United States


Catherine I. Starner, PharmD, [F2] Impact of a Managed Care Pharmacist Consultation Program on Controlled Substance Drug Cost, Emergency Room Visits, and Hospitalizations

Melissa E. Stauffer, PhD, [I1] Statins Are Differentially Sensitive to the Medication Possession Ratio


Christie Teigland, PhD, MA, [Z13] Comparing Adherence to Treatment Guidelines after an Opioid Dependence Hospitalization in Medicaid and Commercially Insured Populations

David L. Veenstra, PharmD, PhD, [I18] A Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Katie Wilbers, PharmD, [R2] How Pricing Changes and Dose Optimization Affected Compound Pharmaceutical Use in the Missouri Medicaid Population

Douglas C. Wolf, MD, [K6] Health Care costs of Patients with Crohn’s Disease Receiving Certolizumab Pegol with and Without Home Health Nurse Assistance: Results from a Retrospective Analysis of Patient Claims Data
Medal-Winning Abstracts (continued)

Kevin Bowen, MD, MBA, [E10] Total 2014 and 2015 Claims Expense by Drug, Diagnosis, and Procedure Codes: 250,000 Commercially Insured Members with Diabetes Compared with 1,000,000 Matched Members Without Diabetes

Steven M. Brunelli, MD, MSCE, [N1] Economic Burden of Anemia in Patients with Nondialysis-Dependent Chronic Kidney Disease

Chelsey M. Campbell, PharmD, MBA, MS, [U42] Recent Trends in Payer Perception and Use of Value Frameworks in the United States

Huang-Chia Chang, PharmD, [U41] Retrospective Analysis of Pregabalin and Gabapentin Concomitant Utilization in a Medicaid Population

Ilia Ferrusi, PhD, [D1] Health Care Resource Utilization and Costs in Women with Symptomatic Uterine Fibroids: A Cohort Analysis

Vaidyanathan Ganapathy, PhD, [J11] Prescription Fill Patterns After Reaching the Medicare Part D Coverage Gap Among Chronic Obstructive Pulmonary Disease Patients on Maintenance Bronchodilators

Cynthia L. Gong, PharmD, [C24] Daratumumab Compared to Pomalidomide for Refractory Multiple Myeloma: A Cost-Effectiveness Analysis

Svetlana Krasnokutsky Samuels, MD, [E32] Osteoarthritis and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization

Eugene Daniel Kreys, PharmD, PhD, [C25] Medication Adherence and Persistence of Dasatinib and Nilotinib in a National Cohort of Veterans


Sagar Makanji, PharmD, [E1] The Impact of Various Clinical Strategies on Achieving 5 Stars for the MTM Program Completion Rate for CMR Star Rating Measure

Joseph Martinez, RPh, PDE, PPD, [E2] Evaluating Frequency and Cost Impact of Pharmacist Interventions in Phase 3 Clinical Trials for Patients with Suboptimally Controlled Diabetes

Rohan Medhekar, MPharm, [F28] Association between Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders

Cathrine Misquitta, PharmD, MBA, BCPS, CGP, FCSHP, [U10] Impact of Motivational Interviewing on Medication Adherence

Breanna Popelar, PharmD, MS, [U38] FDAMA 114 for the Exchange of Health Care Economic Information: Payer Experiences, Attitudes, and Perceptions of Current Legislation and Future Directions

Sujith Ramachandran, PhD, [U45] Impact of Cash Prescriptions and Use of Affiliate Provider Identifiers on Measures of Opioid Use from Multiple Providers

Catherine I. Starner, PharmD, [F7] Prevalence of Concurrent Opioid and Benzodiazepine Use Among 19 Million Commercial Members

Jan Tack, MD, PhD, [K5] Patient-Reported Outcomes with Naldemedine Long-Term Treatment of Opioid-Induced Constipation in Subjects with Chronic Noncancer Pain
Medal-Winning Abstracts (continued)

Blessing O. Adodo, PharmD, [E13] Primary Care Physician Perception of the Diabetes Empowerment Education Program Within a Medicare Advantage Plan

Tim Batholow, MD, [M3] Adverse Event Data as Proxy to Determine Total Medical Costs for TNF-Alpha Inhibitors

Seth J. Baum, MD, FASCP, [I8] Time to Approval in Patients Requesting Access to PCSK9i Therapy by Payer Type

Lauren Belemjian, PharmD, [C8] Evaluation of Medications for Malignant Melanoma in Medicare Beneficiaries: A Utilization Review and Cost Analysis

Kevin Bowen, MD, MBA, [E9] Any Statin Use Among Commercially Insured Members with Diabetes Age 40-64 Without History of Atherosclerotic Cardiovascular Disease and Association Between Adherence to Statin Therapy in 2014 and Adverse Cardiovascular Events in 2015

Anand A. Dalal, PhD, MBA, BSPharm, [C4] Treatment Patterns and Costs Associated with Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Receiving Ceritinib: Analysis of Administrative Claims Data

Steven R. Feldman, MD, PhD, [L4] Treatment Patterns with Systemic Therapy or Phototherapy in Patients with Moderate-to-Severe Psoriasis

Sameer R. Ghate, PhD, [C15] Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Pazopanib or Sunitinib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Data

Jerrold Hill, PhD, [I7] Primary Medication Nonadherence in Patients Prescribed Statins, Ezetimibe, or Statin + Ezetimibe Combination Therapy

Leanne L. Lai, PhD, [Z6] Undertreatment of Chronic Interstitial Cystitis in the United States: A Population-Based Study

Jeetvan Patel, PhD, [I23] Impact of Having a Single Preferred Agent with Exclusive Contracts Versus Parity Access for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Cost and Product Uptake in Medicare Plans

Trevor J. Pike, PharmD, [E29] Evaluating Physician Perceived Benefit of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis

Dominic Pilon, MA, [N4] Refill Gaps and Dose Reductions in Patients with Prostate Cancer and Visceral Metastases Treated with Abiraterone Acetate Plus Prednisone or Enzalutamide

Dominic Pilon, MA, [N5] Potential Drug-Drug Interaction Events in Patients Treated with Abiraterone Acetate Plus Prednisone or Enzalutamide


Francine Snyder, PharmD, [U8] Assessment of Health Care Providers’ Training, Awareness, and Management Practices for Chronic Opioid Therapy


Patty Taddei-Allen, PharmD, [G26] Implementing a Pharmacist-Led Multiple Sclerosis Specialty Pharmacy Clinical Outreach Program

SOLVING THE WORLD’S TOUGHEST HEALTH CHALLENGES TAKES ALL OF US.

AbbVie starts with research and innovation to develop and deliver new treatments to manage some of the world’s most difficult diseases.

Our global biopharmaceutical company builds our pipeline to provide solutions in therapeutic areas served by our proven expertise.

To make new solutions available to patients, we team with our scientific peers, physicians, governments, and advocacy groups.

When we work together, the result is a remarkable impact on patients’ lives and the healthcare systems which serve them.

Learn more at abbvie.com
C10 Applying Pharmacoeconomic Modeling to Formulary Decision Making: The Case of Trabectedin

Gong C1, Studdert A1, Ganjoo K2. 130 Monterey Rd, #103, South Pasadena, CA 91030; gc1@stanfordhealthcare.org; (650) 736-1749
1Stanford Health Care; 2Stanford University Medical Center

BACKGROUND: Trabectedin was recently approved for metastatic soft-tissue sarcoma, which is a hard-to-treat disease with few therapeutic options. Cost-effectiveness models are often not developed for formulary decision support.

OBJECTIVE: To determine the cost-effectiveness of trabectedin vs. dacarbazine for metastatic soft tissue sarcoma from an institutional perspective using internal cost and outcomes data, and to apply the results to guide formulary decision-making.

METHODS: Trabectedin was approved for formulary addition in April 2016. Six months later, we developed a Markov model with lifetime horizon to simulate a patient with metastatic soft tissue sarcoma moving between the health states of stable disease, progressed disease, and death. Transition probabilities and quality-of-life utilities were derived from the literature. Costs were based on our institution's finances and included drug acquisition and administration, lab, nursing, and ancillary support costs. Because of trabectedin's marginal effectiveness compared to dacarbazine, the model was also run over a shorter time horizon until all patients had either progressed or expired. Discounted costs, quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) of trabectedin relative to dacarbazine were calculated, and robustness of these estimates assessed through one-way sensitivity analyses. Internal patient outcomes were collected and presented to the oncology specialist prescribing the drug, along with the economic model. Data were then presented to the P&T specialty subcommittee for review.

RESULTS: Dacarbazine dominates trabectedin due to trabectedin's higher costs and poorer outcomes over a lifetime perspective. Trabectedin remained beyond the threshold of cost-effectiveness based on a US willingness-to-pay of $150,000/QALY even at a shorter time horizon (ICER of $516,656/QALY). At our institution, fewer patients than expected were treated, and their outcomes were significantly worse than those in the clinical trial. Based on the economic model, low utilization, and real-world outcomes, trabectedin was removed from formulary, and a treatment pathway with a set of clinical restrictions for non-formulary use was developed by the primary prescriber.

CONCLUSIONS: Internal cost-effectiveness models in combination with real-world patient outcomes data can be effective formulary management tools.

SPONSORSHIP: None.

U49 Does Consumer Purchasing Data Improve Medication Adherence Predictions for the CMS Star Categories?

Qiu Y, Gleason P. 1305 Corporate Center Dr, Eagan, MN 55121; qyiu@primetherapeutics.com; (612) 777-5581
Prime Therapeutics

BACKGROUND: The three drug categories that CMS assesses adherence in comprise approximately 28% of the Part D plan (PDP) sponsor and 11% of the Medicare Advantage (MA PDP) total score. When performing adherence predictive modeling, little is known about the additional predictive value of consumer purchasing data to already available pharmacy benefit manager (PBM) member information.

OBJECTIVE: Identify adherence predictors in the three Medicare Star ratings drug categories with and without consumer purchasing data and assess the added value of consumer purchasing data.

METHODS: Adherence was calculated using the CMS proportion of days covered (PDC) method in 2013 and 2014 among 1 million Medicare members for drug categories: diabetes, cholesterol (statins), and hypertension (RAS antagonists). The 2013 dataset was partitioned into training and validation datasets to fit the best model. The models incorporated 80 potential predictors from each individual's pharmacy claims, demographic derived from zip code, pharmacy risk grouper (PRG) severity of illness score, insurance type (MAPDP or PDP), cost share (copay), and enrollment data. The consumer purchasing data consisted of an additional 300 potential predictors. Logistic regression models were developed with and without the consumer purchasing data, to identify significant adherence predictors and to make model accuracy comparisons using the receiver operator curve (ROC) with a range of 0 to 1 where 1 is a perfect prediction.

RESULTS: The predictive models consisted of 166,593 diabetes, 607,374 statin, and 585,656 hypertension members. The predictive models without consumer purchase information found the following independent predictors of future adherence (PDC ≥ 80%): prior year adherence, a 90 day supply claim, generic drug category cost share of $4 or less, PRG score, zip code derived: percent of white, percent of high school graduate and median income; enrollment in a Medicare Advantage plan, not receiving a low income subsidy, younger age, and new enrollment to the plan in the previous year. Consumer purchasing data was matched to 48% of members and resulted in two new predictors: self reported household income and interest in changing auto insurance policy. The ROC scores with and without consumer purchasing data were: diabetes 0.720 vs. 0.711, cholesterol 0.727 vs. 0.704, and hypertension 0.708 vs. 0.703.

CONCLUSIONS: In this Medicare Star medication adherence categories predictive modeling study, the addition of consumer purchasing data did not substantially change the list of independent predictors or improve the predictive model accuracy.

SPONSORSHIP: Prime Therapeutics.

Z3 Effect of Adalimumab Initiation at a Specialty Pharmacy on Adherence, Persistence, and Cost Outcomes Across Autoimmune Diseases

Liu Y1, Liu H2, Chen N3, Beppu M4, Ganguli A3, Mittal M4. 1 N Waukegan Rd, North Chicago, IL 60064; abstracts02@jkmed.com; (847) 935-9190
1University of Missouri, Kansas City; 2RAND Corporation; 3AbbVie

BACKGROUND: Patients using specialty pharmacies (SPs) to fill adalimumab (ADA) prescriptions have greater refill adherence than those using retail pharmacies (RPs) [1] suggesting that SPs may offer better medication management. The effect of early fill at SPs compared with RTs on ADA adherence and medical costs has not been studied.

OBJECTIVE: To examine the relationship between initiation of ADA at SPs vs. RPs and outcomes (adherence, persistence, and medical costs) in patients with an indicated autoimmune disease: rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.

S18 Journal of Managed Care & Specialty Pharmacy JMCP March 2017 Vol. 23, No. 3-a www.jmcp.org
METHODS: A longitudinal retrospective cohort study was conducted using OptumInsight database from 1/2008 to 12/2015. Date of first ADA claim was the index date. Patients were included if they were ≥ 18 years with ≥2 claims for an indicated disease and biologic-naïve in the 12 months before the index date. Medical and pharmacy coverage ≥12 months before and after index date was required. Patients were placed into 2 cohorts: SP patients (patients who initiated ADA within 3 months at SP and refilled ADA at SP for 12 months) and RP patients (patients who initiated and refilled ADA at RP for 12 months). SP and RP patients were propensity score matched based on age, sex, Charlson Comorbidity Index, diagnosis, year of ADA initiation, and baseline medical costs and copayment. Outcomes were assessed for 12 months after index date (follow-up). Adherence was analyzed by calculating medication possession ratio (MPR). Persistence was assessed using Kaplan-Meyer analysis of discontinuation rates. Medical, drug, and total costs were calculated.

RESULTS: Data from 2,364 patients (1,182 per cohort) were analyzed. Baseline characteristics were similar between cohorts after matching; mean age was 46 years, 60% were female, 40% had rheumatoid arthritis. Compared with RP patients, SP patients had a significantly greater MPR (71% vs. 60%, P<0.0001) and a lower discontinuation rate (40% vs. 52%) with mean time to discontinuation being 291 vs. 255 days (P<0.0001). Yearly total costs did not differ significantly between cohorts ($43,908 vs. $43,228, P=0.15), whereas medical costs in SP patients were 17% lower ($12,986 vs. $15,641, P<0.0001).

CONCLUSIONS: Patients who initiate ADA at an SP have better treatment adherence and lower medical costs than do those who initiate therapy at an RP. Further research is required to understand this relationship better.

SPONSORSHIP: Support for this study were provided by AbbVie.
SOLVING THE WORLD’S TOUGHEST HEALTH CHALLENGES TAKES ALL OF US.

It takes the will to find a new way forward. And no one gets there alone.

That’s why AbbVie teams with peers, academics, clinical experts and others to take on the most complex health challenges.

Uniting the best of pharma with the boldness of biotech, together we’re going beyond conventional thinking to innovate end-to-end approaches that make a real difference.

Starting with science, we arrive at solutions that help millions of patients around the world live better.

abbvie.com
A health impact model was developed to compare the two-dose HZ/su vaccine in the United States.

**OBJECTIVE:** Estimate the overall health impact of the FDA approved herpes zoster vaccine when both vaccines were assumed to have equal time to loss of efficacy, a two-dose adherence rate of 45% and a first-dose efficacy of 65% for the investigational HZ/su vaccine. Keeping these assumptions constant except changing duration of efficacy for the investigational vaccine to 20 years resulted in the two-dose vaccine preventing two more cases of HZ than the one-dose vaccine (34 vs. 35).

**RESULTS:** Out of 1,000 vaccinated individuals, the one-dose HZ vaccine prevented five more cases of HZ (34 vs. 29) than the two-dose investigational HZ/su vaccine when both vaccines were assumed to have equal time to loss of efficacy, a two-dose adherence rate of 45% and a first-dose efficacy of 65% for the investigational HZ/su vaccine. Keeping these assumptions constant except changing duration of efficacy for the investigational vaccine to 20 years resulted in the two-dose vaccine preventing two more cases of HZ than the one-dose vaccine (34 vs. 35).

**CONCLUSIONS:** When series completion rates are 45% for the two-dose investigational HZ/su vaccine, the approved one-dose live attenuated HZ vaccine could prevent more HZ cases over a 15 year period. Given the unknown one-dose efficacy and uncertainty around adherence rates for multi-dose vaccines in real world settings, further analyses are needed to determine overall impact of the two-dose investigational HZ/su vaccine.

**SPONSORSHIP:** Merck & Co.
**B4** Prevalence of Baseline Hepatitis C Virus NS5A Polymorphisms Observed in Molina Health Care Medicaid and Health Insurance Exchange Populations

DiTucci-Reiter J, Raji J, Jakeman B. 8613 Cherry Hills Rd NE, Albuquerque, NM 87111; julie.ditucci-reiter@molinahealthcare.com; (505) 238-3470

**Molina Health Care; 2University of New Mexico College of Pharmacy**

**BACKGROUND:** Elbasvir-grazoprevir is a combination product used for the treatment of hepatitis C virus (HCV) infection. Reduced treatment efficacy has been demonstrated in phase 2 and 3 clinical trials when certain NS5A polymorphisms have been detected with an 11% prevalence nationwide. To date, no studies have been published evaluating post-marketing prevalence associated with NS5A polymorphisms. Molina Health Care ("Molina") is a multi-state managed care organization that focuses on government-funded programs including Medicaid, Health Insurance Exchanges, and Medicare.

**OBJECTIVE:** To determine the prevalence of NS5A polymorphisms, specifically M28, Q30, L31, and Y93, in Molina Medicaid and Health Insurance Exchange populations that have been diagnosed with hepatitis C infection and to assess if this prevalence is consistent with reported clinical trial data in the literature.

**METHODS:** This was a retrospective cohort study of Molina Medicaid and Health Insurance Exchange members from ten states diagnosed with HCV genotype 1a infection whose administrative claims data were evaluated during March through November 2016. Members included in the analysis were >18 years of age with documented baseline NS5A testing. Demographic data included the member's age, gender, and previous treatment exposure. Subsequent analysis included a percent of prevalence of the polymorphisms which was substratified by state, gender, and age.

**RESULTS:** Of the 363 members screened, 361 had baseline NS5A resistance testing data available. Two members were excluded because definitive results were not available. A total of 42 (11.6%) members had one or more NS5A polymorphisms specific to genotype 1a. Of the 42 members identified with polymorphisms and included for data analysis, the average age was 55 of which 31 were male and 12 were female. There was a prevalence of four (1.1%) members having more than one polymorphism present, one (0.3%) having three polymorphisms present and zero members with four polymorphisms present. The most common polymorphism identified was M28 with 55% prevalence. No state related prevalence was observed.

**CONCLUSIONS:** The trends and prevalence of polymorphisms seen in the Molina populations studied were similar to the rates observed in the clinical trial data reported in the literature. Based on the recommendation in the prescribing information for elbasvir-grazoprevir, prescribers should consider polymorphism diagnostic testing to maximize clinical effectiveness.

**SPONSORSHIP:** The study was sponsored by Proteus Digital Health.

**B5** Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment

Bonacini M1, Kim Y2, Pitney C3, McKown L1, Landis C1. Mission Gastroenterology and Hepatology, 1580 Valencia St, Ste. 208, San Francisco, CA 94110; bonacimi08@gmail.com; (415) 641-5430

1Mission Gastroenterology and Hepatology; 2Proteus Digital Health; 3University of Washington

**BACKGROUND:** Real-world data on adherence with the new direct-acting agents (DAAs) to treat chronic hepatitis C virus (HCV) are limited, and suboptimal adherence can lead to unnecessary treatment failures. Refill methods to measure adherence are inaccurate and do not allow patients or providers the opportunity to respond quickly. A novel digital medicine offering (DMO, Proteus Discover) consists of digital medicines (medicines co-encapsulated with an ingestible sensor pill which activates when swallowed), wearable sensor patch (measures ingestion adherence, physical activity and heart rate), patient mobile app and provider web portal to allow for timely assessment and optimization of adherence.

**OBJECTIVE:** To evaluate real-world effectiveness of the DMO in patients with chronic HCV infection prescribed sofosbuvir and ledipasvir (SOF/LDV).

**METHODS:** The primary objective was to evaluate the percent of subjects with ≥95% adherence of SOF/LDV. Each SOF/LDV tablet was co-encapsulated with an ingestible sensor. Adherence was calculated as the number of medication ingestions recorded by DMO and/or the patient (in cases where DMO missed the ingestion) divided by the number of prescribed doses. Other outcomes included adherence recorded by the DMO, medical decisions, virologic outcomes, and patient satisfaction.

**RESULTS:** Of the 28 patients enrolled (all GT1 infection, 93% treatment naïve, 61% male, mean age 59 years, 36% African American), 27 completed 8 or 12 weeks of DMO use. Most (82%) had < $25,000 annual income; 39% had a current or prior drug abuse history; and 46% had psychiatric comorbidities. Patients were connected to the DMO for 92% of expected days (1,838 cumulative days). Adherence results were as follows: 89% of patients were ≥95% adherent to therapy (1 patient was <90% adherent); mean ingestion adherence (DMO measured) was 94%. Providers used the DMO data for timely adherence counseling in 39% of patients. In this interim analysis, SVR data were available for 10 patients; 9 patients achieved SVR and 1 patient relapsed (documented suboptimal adherence of <90%). In a satisfaction survey, 92% of patients agreed the DMO was easy to use in their daily routine, and 88% agreed that the DMO helped them understand the importance of taking their medications regularly.

**CONCLUSIONS:** The DMO provided data to target opportune adherence interventions in patients; high rates of adherence were noted even in patients with risk factors for poor compliance. These early data suggest that the DMO may be a tool to optimize the real-world clinical value of specialty medications.

**SPONSORSHIP:** The study was sponsored by Proteus Digital Health.

**B6** Incidence of Significant Drug Interactions with Direct-Acting Antiviral Hepatitis C Drugs in the Medicaid Population

VH H, Obra D. 3231 W Frankfurt Dr, Chandler, AZ 85226; vub@actna.com; (602) 659-1276

1Aetna Medicaid; 2Actna

**BACKGROUND:** With the introduction of direct-acting antivirals (DAAs), treatment for Hepatitis C Virus (HCV) infection has changed significantly in the past few years, with patients' Sustained Virologic Response around 95%. The DAAs are known to have many potential drug interactions (DIs) when co-administered with other drugs. It is important to identify members taking DAAs concurrently with other drugs that can affect the efficacy of HCV therapy.

**OBJECTIVE:** The primary objective is to determine the incidence of significant DIs with DAAs in patients with HCV in a Medicaid population. The secondary objective is to implement an intervention and evaluate its impact on the incidence of significant DIs with DAAs in a Medicaid population.

**METHODS:** First, an HCV drug report will be generated targeting Medicaid Population. Evaluation of DAAs in Medicaid; 2Aetna Medicaid; 1First, an HCV drug report will be generated targeting Medicaid Population.

**RESULTS:** Of the 28 patients enrolled (all GT1 infection, 93% treatment naïve, 61% male, mean age 59 years, 36% African American), 27 completed 8 or 12 weeks of DMO use. Most (82%) had < $25,000 annual income; 39% had a current or prior drug abuse history; and 46% had psychiatric comorbidities. Patients were connected to the DMO for 92% of expected days (1,838 cumulative days). Adherence results were as follows: 89% of patients were ≥95% adherent to therapy (1 patient was <90% adherent); mean ingestion adherence (DMO measured) was 94%. Providers used the DMO data for timely adherence counseling in 39% of patients. In this interim analysis, SVR data were available for 10 patients; 9 patients achieved SVR and 1 patient relapsed (documented suboptimal adherence of <90%). In a satisfaction survey, 92% of patients agreed the DMO was easy to use in their daily routine, and 88% agreed that the DMO helped them understand the importance of taking their medications regularly.

**CONCLUSIONS:** The DMO provided data to target opportune adherence interventions in patients; high rates of adherence were noted even in patients with risk factors for poor compliance. These early data suggest that the DMO may be a tool to optimize the real-world clinical value of specialty medications.

**SPONSORSHIP:** The study was sponsored by Proteus Digital Health.
through August 31, 2016 to determine the number of DAA utilizers. Subsequently, detailed claims data will be populated with a focus on two interacting agents selected from four drug classes (anticonvulsants, anti-retrovirals, proton pump inhibitors, and HMG-CoA Reductase inhibitors). After populating eight drug-interaction reports, overlapping pharmacy claims will be assessed to further identify affected members, respective health plans, and the year in which claims were paid. An affected member is defined as a patient taking a DAA and an interacting drug at the same time. Next, incidence of affected members within each health plan will be calculated. An intervention will be implemented and evaluated based on its effect on the incidence of affected members in the selected health plans.

RESULTS: From November 22, 2013 through August 31, 2016 there were 2,084 DAA utilizers who were identified. Within the 2,084 utilizers, 342 members (16.6%) had pharmacy claims for DAs and interacting drug agents filled within the specified time period. Furthermore, 135 members (7.4%) were identified to have overlapping DIs with the DAs. The medications that had the highest percentage of affected members were high-dose omeprazole and pantoprazole, followed by efavirenz and atazanavir. Six health plans were identified as having a higher incidence of affected members compared to others. The calculated incidence based on overall membership ranged from 0.0002% to 0.58%.

CONCLUSIONS: An initial analysis in determining incidence of DDIs in a Medicaid population shows that although the incidence per health plan is low, there are drug interacting agents that are being continuously filled with DAs.

SPONSORSHIP: Aetna Medicaid Administrators.

Real-World Clinical Outcomes with Newer Hepatitis C Drugs for Patients Receiving Care from a Specialty Pharmacy

B7 Bridges G1, Iyengar R2, Dorholt M1, Henderson R2. 1640 Century Ctr Pkwy, Memphis, TN 38134; gall.bridges@accredohealth.com; (901) 233-6100

BACKGROUND: Hepatitis C costs have risen dramatically in recent years. New treatments for this non-orphan condition were introduced in the U.S. market at exorbitant, orphan-drug prices in the past two years. It is important to examine whether desired clinical outcomes follow this significant price increase. Outside of clinical trials, there has been a gap in real world evidence demonstrating cure rates of new treatments among patients.

OBJECTIVE: To ascertain cure rates of two new treatments—Harvoni and Viekira Pak—among hepatitis C patients.

METHODS: A cohort study was conducted of hepatitis C patients who filled their first prescription on or after Jan 1, 2015 and last prescription on or before Aug 31, 2015 and completed therapy on either of the two drugs. Data included claims based patient-level information from a large, nationally representative pharmacy benefit manager, specialty pharmacy clinical data for 2015, and prescriber survey information collected in 2016. Patients were grouped based on the treatment drug. Patients covered by workers’ compensation insurance or having claims for both drugs were excluded. Sustained virologic response (SVR)—cure rate—as reported by prescriber, was the primary outcome. Overall SVR and matched sample [genotype and severity of illness (cirrhosis/advanced fibrosis/excluding Child-Pugh B or C status)] SVR were computed. Descriptive analyses (t-test for continuous and chi-square test for categorical variables) were used to examine differences between SVR, demographic characteristics and patient out-of-pocket costs in the two groups.

RESULTS: The final study sample consisted of 1,305 patients (Harvoni: 551 and Viekira Pak: 754). Unadjusted SVR was 95.6% (Harvoni: 93.8%, Viekira Pak: 96.8%, P<0.05). Harvoni group had significantly (P<0.05) older patients and greater proportion of men (58.0 years, 70.6% men) compared to Viekira Pak (56.7 years, 63.1% men) and insignificant difference in patient out-of-pocket costs. About 99.0% of both groups of patients were Genotype 1 and had SVR of 95.6%. Matching for severity of illness, Harvoni and Viekira Pak patients had comparable SVR (94.4% for n=90 and 94.1% for n=152, respectively, P=0.9).

CONCLUSIONS: Real world SVR for hepatitis C patients receiving care from specialty pharmacy, on either drug, were very high and consistent with those reported in clinical trials. However, considerable costs of these drugs necessitate continued collaboration between payers, specialty pharmacies, benefit managers and pharmaceutical manufacturers to ensure appropriate use and support patient adherence to care.

SPONSORSHIP: Internally funded by Express Scripts.

Real-World Analysis of Harvoni Therapy Completion Rates and Members Achieving Sustained Virologic Response

B8 Starner C, Gleason P. 1301 Corporate Center Dr, Eagan, MN 55121; cstarn@primetherapeutics.com; (612) 777-5073

BACKGROUND: Hepatitis C therapy completion is crucial for cure. There is a paucity of data examining how often Hepatitis C laboratory testing data are collected and additionally, the rates of Hepatitis C cure.

OBJECTIVE: To examine the real world Hepatitis C sustained virologic response (SVR) among commercially insured members completing at least 8 weeks of Harvoni therapy.

METHODS: Hepatitis C members receiving specialty pharmacy drug management from November 2014 through February 2016 were eligible for the analysis. Harvoni length of therapy was based on the number of days of Harvoni supply in the member’s claims history. If a member had at least 56 days (8 or more weeks) of therapy, without a 90 or more day gap, they were considered a completor. Hepatitis C SVR laboratory data results obtained voluntarily from the prescriber via a specialty pharmacy request (when available) were merged with member-level Harvoni pharmacy claims data to evaluate SVR “cure rates”. To determine Hepatitis C cure, members were required to have an SVR laboratory test completed between 12 and 24 weeks following Harvoni therapy completion which was calculated by subtracting the Hepatitis C SVR laboratory test date from the last Harvoni claim date plus days supply. A Hepatitis C SVR result of 15 IU per mL or less was considered a Hepatitis C cure.

RESULTS: 969 members received Hepatitis C specialty pharmacy drug management from November 2014 through February 2016. 641 (66.2%) members had SVR laboratory data (test result and date) and 520 (81.1%) of the 641 members used only Harvoni therapy for their Hepatitis C therapy. 514 (98.8%) members completed at least 8 weeks of therapy, of which 311 (60.5%) met the eligibility criteria for Hepatitis C cure assessment defined as the specialty pharmacy having a Hepatitis C SVR laboratory result from the prescriber. 301 (96.8%) of the 311 members had a Hepatitis C SVR value of 15 or less indicating Hepatitis C cure and 10 members had a Hepatitis C SVR greater than 15, indicating active Hepatitis C virus infection.

CONCLUSIONS: The Hepatitis C SVR cure rates found in this real world analysis are similar to those reported in clinical trials of 94% to 99%. With one-third of individuals’ Hepatitis C SVR laboratory results not being voluntarily reported to the specialty pharmacy providing care, further assessment is required to identify alternative processes to ensure individuals completing their Hepatitis C virus treatment are cured.

SPONSORSHIP: Prime Therapeutics.
**B9** Real-World Experience in Treating Non-Cirrhotic Patients with Genotype 1 Chronic Hepatitis C Using Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir with or Without Ribavirin: A Prospective Study in a Large Community-Based U.S. Health Care System

Rathbun R1, Nyberg A1, Niho H2, Nguyen L2, Donoghue D2, Sahota A1, Towner W1, Patton H1, Nyberg L1, 12123 Corte Napoli, San Diego, CA 92128; rathbun.and@gmail.com; (805) 252-6018

1Hepatology Research, Kaiser Permanente, San Diego, CA; 2Gastroenterology/Hepatology, Kaiser Permanente, Irvine, CA; 3Hepatology, Kaiser Permanente, Los Angeles, CA; 4Infectious Diseases, Kaiser Permanente, Los Angeles, CA

**BACKGROUND:** Phase 3 registration trials evaluating the safety and efficacy of Paritaprevir/ritonavir, Ombitasvir, and Dasabuvir (PrOD ± ribavirin (RBV)) have shown high efficacy and excellent tolerability. However, when new treatment regimens are widely used in “The Real World”, the safety and efficacy may not be as good as that seen in clinical trials.

**OBJECTIVE:** The aim of this study was to evaluate the efficacy and tolerability of PrOD prospectively in a real world setting, within Kaiser Permanente Southern California (KPSC), a large U.S. based Health Care Delivery System. Efficacy was determined by a measure of sustained virologic response at post-treatment week 12 (SVR12).

**METHODS:** N = 200 patients were enrolled at four sites within KPSC. Inclusion criteria: Chronic hepatitis C, genotype 1 (GT1), age ≥18, treatment-naive (TN) or treatment-experienced (TE) with interferon-based therapy. Exclusion criteria were non-GT1 chronic hepatitis C, co-infection with HIV or HBV, prior treatment with direct-acting antiviral agent(s), glomerular filtration rate < 30 mL/minute, hemoglobin < 12 for males and < 11 for females, and/or evidence of cirrhosis and/or hepatocellular carcinoma. Cirrhosis was defined as Metavir score ≥ 2Gastroenterology/Hepatology, Kaiser Permanente, Irvine, CA; 3Hepatology, Kaiser Permanente, Los Angeles, CA; 4Infectious Diseases, Kaiser Permanente, Los Angeles, CA

**RESULTS:** Of the 200 patients enrolled, 191 have completed enrollment and 9 remain in active follow up. 170 patients have achieved SVR12, with an intention-to treat (ITT) SVR12 rate of 89% (170/191). Of the 21 failures to achieve SVR12, 10 patients completed treatment with an End of Treatment (EOT) response and had a relapse of hepatic decompensation. Genotype 1a (GT1a) patients were treated with PrOD + weight-based RBV x 12 weeks and Genotype 1b (GT1b) patients were treated with PrOD x 12 weeks.

**CONCLUSIONS:** In this study of co-infected patients who received treatment with ledipasvir/sofosbuvir for 8 weeks, the overall success rate was 70%. The results suggest that 8 weeks of treatment for the co-infected population may provide a benefit in those who cannot complete the full 12 weeks. In addition, it highlights the role of polymorphisms in predicting outcomes in the treatment of Hepatitis C. These results warrant further studies of a larger population which includes stratifying for subtype and IL28B to evaluate the use of Ledipasvir/Sofosbuvir for 8 weeks in select treatment naive, co-infected HCV/HIV patients. If proven effective for the HCV/HIV co-infected population, the shorter treatment course would result in a significant decrease in costs of care for the health care system.

**SPONSORSHIP:** Amida Care Health Plan.

**B10** Outcomes Evaluation of Medicaid Insured Hepatitis C Patients Coinfected with HIV After 8 Weeks of Treatment with Ledipasvir/Sofosbuvir

Fuadhi E, Leach T, Rambaran S. 225 W 34th St, 2nd Fl, New York, NY 10122; efaadhi@amidacareny.org; (845) 757-7672

Amida Care Health Plan

**BACKGROUND:** New hepatitis C virus (HCV) drugs have demonstrated excellent therapeutic results in clinical studies; however, the high costs of the medications have led to significant challenges for Medicaid Managed Care plans. In additional, real world studies to determine the effectiveness of the novel products in HIV/HCV co-infected populations have been limited. The German hepatitis C prospective cohort study (GECCO) demonstrated a high HCV cure rate of 96.4% in the cohort of 28 HIV/HCV co-infected patients who were prescribed 8 weeks of Ledipasvir/Sofosbuvir. The results of this study are promising and indicate that shorter duration treatment is possible for the co-infected population.

**OBJECTIVE:** To evaluate the outcomes for those co-infected members who received HCV treatment with Ledipasvir/Sofosbuvir for 8 weeks.

**METHODS:** An observational retrospective evaluation, this study describes the outcomes for those members who received 8 weeks of treatment for HCV using Ledipasvir/Sofosbuvir. The primary endpoint is SVR-12, defined as undetectable HCV viral load 12 weeks post-treatment. Inclusion criteria include all co-infected members who have received HCV treatment with Ledipasvir/Sofosbuvir for 8 weeks.

**RESULTS:** Of the 29 patients included in the analysis, only 20 were able to be evaluated for treatment success. The majority (70%) were successfully treated and cured while 30% failed treatment. The characteristics of those who were successfully treated were compared to those who did not achieve treatment cure.

**CONCLUSIONS:** In this study of co-infected patients who received treatment with ledipasvir/sofosbuvir for 8 weeks, the overall success rate was 70%. The results suggest that 8 weeks of treatment for the co-infected population may provide a benefit in those who cannot complete the full 12 weeks. In addition, it highlights the role of polymorphisms in predicting outcomes in the treatment of Hepatitis C. These results warrant further studies of a larger population which includes stratifying for subtype and IL28B to evaluate the use of Ledipasvir/Sofosbuvir for 8 weeks in select treatment naive, co-infected HCV/HIV patients. If proven effective for the HCV/HIV co-infected population, the shorter treatment course would result in a significant decrease in costs of care for the health care system.

**SPONSORSHIP:** Amida Care Health Plan.
longitudinal data from 13 fee-for-service and managed Medicaid states and 14 million patients. Patients had continuous enrollment (CE) of ≥12 months before and ≥6 after the CHC diagnosis or treatment date (index date). Total health care utilization and costs (medical and pharmacy) during the 12-month pre-period were reported as 2015 US$. CHC prevalence and incidence proportion were assessed in each year 2009-2015. Prevalence was the proportion of patients in the year with ≥1 CHC diagnosis or treatment. Incidence was the proportion of at-risk patients (no previous evidence of CHC) with ≥1 diagnosis or treatment for CHC in the year. Both measures required CE for the full year of interest.

RESULTS: CHC prevalence ranged from 1.42% in 2009 to 1.69% in 2015 and incidence proportion ranged between 0.56%-0.64%. CHC patients had a mean age of 46.9 years, were primarily female (53%), white (60%), and eligible for Medicaid due to blindness/disability (62%). Common comorbidities were mental health/abuse/substance (67%), hypertension (46%), and cardiovascular disease (34%). During the pre-period, 83% of CHC patients used psychotropic medications, 12% statins, and 9% proton pump inhibitors. During pre-period, 30% of patients had an IP admission, 67% had an emergency room visit, and 94% had ≥1 pharmacy claim. Monthly health care costs in the pre-period were $2,200, with medical costs being the largest contributor (62%).

CONCLUSIONS: Prevalence of CHC in the Medicaid population during 2009-2015 was higher than previously reported, suggesting an unmet need for CHC treatment in this population. High prevalence of comorbid conditions, such as substance abuse, highlights the challenges of treating this patient population and the need to evaluate sobriety requirements as potential treatment barriers.

SPONSORSHIP: Research funded by Gilead Sciences.

**B13 Budget Impact Analysis of Tenofovir Alafenamide, a Novel Nucleotide Reverse Transcriptase Inhibitor, for the Management of Chronic Hepatitis B in the United States**

Nguyen M1, Lim J2, Liou I3, Saint-Laurent Thibault C4, Taalazzoli A5, Gordon S5, Dusheiko G6. Division of GI and Hepatology, Stanford University Medical Center, Alway Bldg, Rm M211, 300 Pasteur Dr, Stanford, CA 94305; minidemn@stanford.edu; (650) 725-6511
1Stanford University Medical Center, 2Yale University School of Medicine; 3University of Washington, Dept of Medicine, Division of Gastroenterology; 4Evedra, 5Henry Ford Hospital, 6UCL Institute for Liver and Digestive Health, Division of Medicine

BACKGROUND: The lack of curative chronic hepatitis B (CHB) therapy, with consequent chronic antiviral use, poses a substantial unmet medical need in the aging CHB U.S. population and their evolving comorbidities. Therefore, antiviral therapy with excellent potency, high resistance barrier and improved safety profile has been of interest. Tenofovir alafenamide (TAF), recently approved by the FDA, is an efficacious CHB treatment with similar viral suppression and resistance rates, improved ALT level normalization, and improved renal and bone safety profile compared with tenofovir disoproxil fumarate (TDF), as well as better resistance profile compared to entecavir (ETV).

OBJECTIVE: To estimate the projected budget impact of addition of TAF in Commercial, Medicare and Medicaid formularies over three years.

METHODS: A budget impact model generated from cost-effectiveness analyses was developed using DICE simulation. Inputs were drawn from published randomized trials, other peer-reviewed literature, real-world database analyses and expert opinion. Model structure/assumptions/inputs were validated by 5 hepatologists and via a survey of 30 hepatologists. Market scenarios included TAF, branded/generic ETV and TDF. The cost of TAF was set at price parity with TDF. Assumed annual market uptake of TAF was 7.9%, 8.9%, and 5.9% for Commercial, Medicare and Medicaid, respectively, and the plan size was assumed to be 1 million members, with 0.3% HBV prevalence and 2.5% of CHB patients getting treated with antiviral therapy.

RESULTS: Across all payers, the addition of TAF was estimated to be cost-neutral or generate cost savings on the overall budget, beginning in year 1. When compared to current scenario, the change in per member per month (PMPM) cost was negligible with less than 0.01% in the first year across all analyses. Cost savings observed starting in year 2 were driven by lower number of renal, bone and liver complications observed with TAF when compared to alternatives. Differences in rates of liver complications were due to differences in viral suppression and/or ALT normalization rates for TAF versus TDF and/ or ETV as derived from the published literature from the REVEAL
study data. Over 3 years, TAF produced incremental budget savings PMPM ranging between $0.0006 to $0.0010. Results were consistent across payers and were robust against sensitivity analyses.

CONCLUSIONS: The formulary addition of TAF may lead to negligible budget impact of up to 0.01% change in spending in year 1, and lead to cost savings of up to -0.12% over 3 years.

SPONSORSHIP: Gilead Sciences.

B20 An Evaluation of Persistence and Adherence in Treatment-Naïve Human Immunodeficiency Virus-Infected Patients on Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Other Recommended Single-Tablet Regimens

Paul D, Kim J, Rosenblatt L, Esher S. 3401 Princeton Pike, Lawrenceville, NJ 08648; damencarie.paul@bms.com; (609) 897-2630
Bristol-Myers Squibb.

BACKGROUND: The advent of single-tablet regimen (STR) antiretroviral therapy has been associated with increased adherence and persistence in treatment naïve human immunodeficiency virus (HIV) infected patients. Efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) has demonstrated high levels of efficacy and adherence, but has been associated with central nervous system (CNS) symptoms which generally resolve after the first 2-4 weeks of therapy. Assessment of adherence and persistence after an initial period is needed to evaluate the long-term effectiveness of EFV/FTC/TDF in the majority of patients who do not experience CNS symptoms or in whom it resolves. We hypothesize that long-term persistence and adherence with EFV/FTC/TDF would not differ from other recommended STRs.

OBJECTIVE: The goal of this study is to compare long-term persistence and adherence for treatment naïve patients initiating EFV/FTC/TDF versus other STRs.

METHODS: This retrospective cohort study used data from the MarketScan EarlyView Commercial Database. Patients were ≥ 18 years old, HIV treatment-naïve, initiated an index STR between 1 January 2011 and 30 October 2015, and had at least 6 months of continuous enrollment data before and after STR initiation. Adherence and persistence to STR were measured using outpatient pharmacy claims. Patients were considered adherent if the proportion of days covered (PDC) was ≥ 0.80. Non-persistence was defined as a ≥ 30 day gap without index STR or a prescription claim for a non-index HIV therapy. Adjusted logistic regression and Cox proportional hazard regression were fit to compare adherence and non-persistence, respectively, between EFV/FTC/TDF and the other STRs.

RESULTS: The index STRs included EFV/FTC/TDF (n=4,733), rilpivirine (RPV)/FTC/TDF (n=1,367), elvitegravir/cobicistat (EVG/c)/FTC/TDF (n=1,980) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) (n=422). The mean age was 40 years and 86% were male. At 1-year follow-up the crude persistence rate was 57% for EFV/FTC/TDF compared to 64% for DTG/ABC/3TC. At 3-year follow-up, the crude persistence rate was 30% for EFV/FTC/TDF compared to 31% for EVG/c/FTC/TDF and 33% for RPV/FTC/TDF. No statistically significant differences in overall adherence were observed between EFV/FTC/TDF and the other STRs.

CONCLUSIONS: In a commercially insured population, patients on EFV/FTC/TDF had no significant differences in adherence and similar persistence at 3 years compared to other STRs, demonstrating the long-term utility of EFV/FTC/TDF in the treatment of HIV in a real world setting.

SPONSORSHIP: Bristol-Myers Squibb.

B21 Estimated Cost of HIV Treatment Failure Based on Pill Burden Among HIV-Infected Individuals in the United States

Mulligan K1, Diaz Espinosa O1, Oglesby A2, D’Antico R2, Cooper C1, Jena A1. 9433 Bee Cave Rd, Ste 255B, Austin, TX 78733; karen.mulligan@precisionhealthEconomics.com; (512) 984-7788
1 Precision Health Economics; 2 ViV Health Care; 3 University of Ottawa School of Medicine; 4 Harvard Medical School.
BACKGROUND: Combination antiretroviral therapy has dramatically improved morbidity and mortality for persons living with HIV. However, sustained virologic control depends on a number of factors including patient adherence. Although data suggest that patients receiving low-pill-burden regimens will have improved short-term adherence levels and reduced downstream costs associated with both loss of virologic control and therapy switching, the long-term effects are unknown.

OBJECTIVE: To estimate the long-term medical expenditures associated with loss of HIV viral control by varying degrees of pill burden and treatment adherence.

METHODS: A closed cohort Markov model was developed with parameters derived from the existing literature for treatment-naive HIV+ patients who were followed for fifty years. In the model, patients were considered to have switched therapy following two consecutive months of virologic failure. The model assessed the impact of single tablet regimens (STRs), two-pill, and three-pill regimens on non-treatment medical expenditures and treatment switching. The effect of pill burden and adherence on the outcomes of interest was explored while holding individual components of the regimen constant.

RESULTS: At 5 years, STRs generate an estimated $21.7 million in medical cost savings compared to 3-pill regimens, with savings increasing to $54.7 million and $95.5 million after 10 and 25 years, respectively. Additionally, patients receiving an STR were more likely to maintain virologic suppression compared to patients who received either a 2- or 3-pill regimen. Consequently, patients on STRs progress to higher lines of therapy more slowly (56% of patients have switched therapy at least once after 5 years, compared with 66% of patients on 3-pill regimens). Patients on STRs are also less likely to have switched therapy compared to patients on 3-pill regimens after 10 years (82% versus 89%), but by 25 years, the proportion who have switched is similar (99% versus 100%). Two-pill regimens also generate some medical expenditure savings relative to three-pill regimens ($2.1 million after 10 years and $3.4 million after 25 years). However, STRs generate substantial savings compared to two-pill regimens ($52.6 million after 10 years).

CONCLUSIONS: These findings demonstrate the value of lower pill burden in maintaining viral suppression and reducing medical expenditures. Streamlining regimens, even from 3 to 2 pills, is beneficial, but the most substantial clinical and economic benefits are estimated to occur when patients are prescribed STRs.

SPONSORSHIP: This analysis was sponsored by ViV Health Care.

C00-D49 Neoplasms (e.g., Breast Cancer, Lung Cancer, GIST, Melanoma, CML, CLL, Multiple Myeloma)

C2 Clinical and Economic Impact of Hypersensitivity Reactions in Patients Receiving First-Line Chemotherapy for Metastatic NSCLC

Parisi M1, Ni Q1, Pelletier C2, Patel M2. 86 Morris Ave, Summit, NJ 07901; moparisi@celgene.com; (917) 526-0156
1Celgene; 2Stanford Cancer Center

BACKGROUND: Drug hypersensitivity is defined as an immune-mediated response to a drug agent in a sensitized patient (pt) that is inappropriate or excessive. Hypersensitivity reactions (HSRs) account for 5-10% of all adverse events. Although HSRs to chemotherapy drugs are rare, they could impose a substantial clinical and economic burden if they do occur.

OBJECTIVE: The objectives of this study are to examine frequency, clinical burden and economic burden of HSRs in pts with stage IV NSCLC on first-line (1L) chemotherapy.

METHODS: This retrospective cohort study used Truven Health MarketScan databases to identify adult pts on 1L chemotherapy (index date) during January 1, 2012-June 30, 2015. Patients were required to have >1 claim with a secondary malignant neoplasm (ICD-9-CM 196.XX-198.XX), ≥2 claims with a lung cancer diagnosis (ICD-9-CM 163.XX), and be continuously enrolled in their health plans for ≥6 months prior and 3 months following the index date. To be identified as an HSR, >1 code specific to HSR (963.1X, 995.X, 999.81, 999.82) or ≥2 ICD-9-CM codes describing clinical manifestations of an HSR (dermatologic, respiratory, or cardiovascular) were required, or if ≥2 doses of Benadryl or ≥1 dose of epinephrine were given on the day of chemotherapy. Outcomes examined were median time to first HSR, percent of patients who modified treatment immediately following an HSR, severity of HSR (mild/moderate=requiring outpatient care, severe=requiring ER visit or inpatient admission), health care utilization and costs associated with a HSR.

RESULTS: 12,772 pts met the inclusion criteria as metastatic NSCLC pts initiating 1L chemotherapy. Of these, 666 (5.2%) were identified as having an HSR. In total, 1,269 HSR events were identified, as some pts experienced multiple HSRs. Median time to first HSR was 22 days and 58% of pts modified their treatment regimen following an HSR. Severe HSRs occurred in 11% of pts and for pts who were admitted into the hospital, average length of stay was 6.6 days. Of the 1,269 HSR events, 94% were treated in the outpatient setting. Mean costs associated with an HSR were $6,118, $4,874, and $28,993 in the outpatient, ER and inpatient settings, respectively. Mean costs associated with medications to treat an HSR were $1,037, $989 and $3,847 in the outpatient, ER and inpatient settings, respectively.

CONCLUSIONS: HSRs impose significant clinical burden to the patient, potentially leading to changes to pts’ chemotherapy regimens and hospitalizations for severe HSRs. Moreover, HSRs are associated with substantial economic burden which varies by setting of care.

SPONSORSHIP: Celgene.

C3 Economic Analysis of Molecular Mutation Testing in Real-World Practice Using Claims Data: Costs of Single Gene Versus Panel Tests in Patients with Lung Cancer

Dalal A1, Dea K2, Guérin A2, Culver K1. One Health Plaza, Bldg 345/5115D, East Hanover, NJ 07936-1080; anand.dalal@novartis.com; (862) 778-3999
1Novartis Pharmaceuticals; 2Analysis Group

BACKGROUND: In lung cancer, BRAF mutation, as well as other driver mutations, can be detected by single gene tests (e.g., reverse transcription polymerase chain reaction [RT-PCR]) and panel tests (e.g., next-generation sequencing [NGS]). No information exists in the literature on the costs of genetic testing from a payer perspective for patients with BRAF mutated lung cancer.

OBJECTIVE: To assess time to BRAF testing, compare characteristics between patients tested versus not tested for BRAF mutation, and describe amount reimbursed for BRAF tests, as well as the total cost for BRAF testing following a sequential versus an NGS approach.

METHODS: Patients with lung cancer diagnosed after January 1, 2013, were identified from two U.S. administrative claims databases. Patient characteristics were assessed during the 12 months preceding the first lung cancer diagnosis (index date). Molecular tests were analyzed from index date to end of continuous health plan enrollment or end of data availability (12/2015), whichever occurred first, based on combinations of CPT procedure codes recorded within 7 days. Time to BRAF mutation test was assessed using Kaplan-Meier analysis. Costs were analyzed from a payer’s perspective; thus, claims with no amount reimbursed ($0) were excluded.
RESULTS: A total of 28,011 patients newly diagnosed with lung cancer were identified. Among them, 1,260 (4.5%) were tested for BRAF, at 6 and 12 months following index date, 3.2%, and 4.2% were tested. Compared to non-tested patients, tested patients were younger (58.3 vs. 65.3 years old; P<0.001), had a lower Charlson Comorbidity Index (2.8 vs. 2.9; P=0.005), and a higher proportion had metastases (70.9% vs. 43.4%; P<0.001). In 76.0% of the cases, BRAF was tested along with KRAS mutation. Other procedure codes commonly billed with BRAF mutation included microdissection and molecular pathology procedure (level 5). BRAF was tested using NGS test in 6.6% of cases. Depending on the combination of procedure codes, average reimbursed amounts for the 10 most common combinations ranged from $207 to $2,074. When considering costs for each test individually, sequential testing that comprised KRAS, EGFR, ALK, ROS1, and BRAF mutation tests was estimated at $3,763 ($464, $696, $1,070, $1,127, and $406, respectively) while NGS testing was estimated at $2,860.

CONCLUSIONS: Amounts reimbursed for BRAF mutation tests highly vary based on the combination of procedures. Findings suggest that NGS testing is associated with cost savings compared to sequential testing of individual mutations.

SPONSORSHIP: This study was sponsored by Novartis Pharmaceuticals.

Background: Ceritinib is the first FDA-approved 2nd-generation anaplastic lymphoma kinase (ALK) inhibitor to treat patients with ALK+ non-small cell lung cancer (NSCLC) who progressed on or were intolerant to crizotinib. Given its recent approval, there is a lack of evidence on real world ceritinib use and health care costs.

Objective: To describe characteristics, treatment patterns, sequencing, and health care costs of patients receiving ceritinib.

Methods: Lung cancer adult patients receiving ceritinib were identified from 2 large U.S. administrative claims databases (2006-2015). Patients with continuous health plan coverage ≥ 6 months before (baseline period) and ≥ 1 month after ceritinib initiation (index date) were included. Patient characteristics were assessed during the baseline period. Time from first lung cancer diagnosis and from crizotinib initiation and discontinuation to index date, proportion of patients receiving therapies between crizotinib and ceritinib, and ceritinib dose were summarized. Six-month ceritinib dose decrease rate and median time to discontinuation were analyzed using Kaplan-Meier analyses. Health Care costs were measured from index date to ceritinib discontinuation, or end of data and were reported per-patient-per-month (pppm).

Results: A total of 164 patients receiving ceritinib were identified (mean age 54.2 years, 57.3% female) and were observed for an average of 7.4 months (IQR 3.2-11.3) post index date. Patients had a high comorbid burden (mean CCI 7.6) and 94.5% had metastases (respiratory system 62.8%, brain 59.1%, lymph nodes 50.0%, bone 47.0%, and liver 28.7%). Ceritinib was initiated on average 19 months after lung cancer diagnosis. Among the 91.5% of ceritinib pre-treated patients, patients initiated ceritinib on average 12 months after crizotinib initiation and 2.1 months after discontinuation (median 0 month). 23.8% of patients received a treatment between crizotinib and ceritinib (chemotherapy 17.7%; radiotherapy 9.8%). Average dose on ceritinib was 695 mg; the 6-month dose reduction rate was 12.7%. Among the 61 (37.2%) patients who discontinued ceritinib, 24 received chemo- or targeted therapy; the others did not receive antineoplastic therapy. Median time to discontinuation was 8.6 months. While on ceritinib, average total cost pppm was $20,414; $12,834 in pharmacy, $3,233 in inpatient, and $3,893 in outpatient costs.

Conclusions: Patients with ALK+ NSCLC receiving ceritinib had a high comorbid burden and started ceritinib quickly after crizotinib on the recommended dose. Medical service costs accounted for more than one third of the total health care costs.

Sponsorship: Novartis.
BACKGROUND: Immune checkpoint inhibitors represent important options for metastatic non-small cell lung cancer (mNSCLC) patients. Atezolizumab (ATEZO) and nivolumab (NIVO) have demonstrated significant improvements in survival and tolerability compared to docetaxel in mNSCLC patients who progress after platinum-containing chemotherapy and regardless of their PD-L1 status. Given increasing pressure for cost containment, initiatives to change payment and delivery models for oncology care have been explored recently.

OBJECTIVE: This study examines differential costs when ATEZO and NIVO are the treatments (Tx) of choice, to understand their fiscal impact at a societal level.

METHODS: A comparative cost framework was developed in MS Excel from the societal perspective. This model calculated costs per course of ATEZO or NIVO, assuming Tx until progression or loss of clinical benefit. Pembrolizumab was excluded due to FDA approved indication in mNSCLC patients whose tumors express PD-L1 (TPS ≥ 1%) only. Base case Tx duration reflects the mean 10.34 cycles of ATEZO from OAK, the pivotal, randomized phase III trial. NIVO Tx reflects the same time period to allow conservative cost comparison. Calculations also include administration, infusion time (ATEZO: Q3W, 60 min initial, 30 min subsequent; NIVO: Q2W, 60 min), and management of select all-cause Grade 3/4 adverse events (AEs). All-cause AE rates were derived from clinical trials. Costs reflect 2016 Medicare reimbursement, wholesale acquisition costs (WACs) for base case analysis, and average sales price (ASP) for secondary analysis.

RESULTS: In the base case, ATEZO costs are $90,720 vs. $96,028 for NIVO over equivalent time. Per patient, average costs to manage AEs are $179 for ATEZO vs. $572 for NIVO. Tx administration costs are $1,410 and $2,114 for ATEZO and NIVO, respectively. Patients have 5.2 fewer visits and 9.84 fewer infusion hours for ATEZO. The total difference in costs over a course of care is $5,308 per Pt. ATEZO remains cost saving when ASP is assumed ($3,501 less). Assuming 50% of second-line (2L) mNSCLC patient (approx. 21,450) are treated with immunotherapies per year, this difference of approximately 7% translates to over $114 million in potential savings to the U.S. health care system.

CONCLUSIONS: Immunotherapies are valuable Tx options in mNSCLC. This analysis suggests ATEZO may be less costly among cancer immunotherapies in 2L mNSCLC, with time savings for patients (fewer office visits, less infusion time). Additional research is required to characterize real world utilization and outcomes of immunotherapies.

SPONSORSHIP: ARIAD Pharmaceuticals.
RESULTS: Total Medicare spend on oral and injectable medications for malignant melanoma in the study population was $224 M in 2013 and increased to $301 M in 2014. While the largest portion of drug spend was under Medicare Part B, Part D spend accounted for $51 M (22.9%) and $124 M (29.9%) of the treatment options in 2013 and 2014, respectively. In the study population, Medicare Part B spend was comprised exclusively of Yervoy, totaling $69 M in 2013 and $86 M in 2014 in the provider office setting and $103 M and $124 M in the hospital outpatient setting. Markedly, Yervoy accounted for $2.9 M (1.66%) of the total Medicare Part D spend in 2013 and $3.8 M (1.73%) in 2014.

CONCLUSIONS: The study findings suggest a notable difference in utilization of Yervoy and resource distribution between Medicare Part B and Part D benefit programs. Total Medicare spend on Yervoy was primarily in the hospital outpatient setting in both 2013 (58.8%) and 2014 (58.1%). Yervoy accounted for 1.29% of all Medicare spend on malignant melanoma medications in 2013 and 1.25% in 2014.

SPONSORSHIP: This study was conducted without funding.

C2 Economic Burden of Patients with Advanced Melanoma in the United States: Comparisons by Insurance Types and Geographic Regions

Gupte-Singh K1, Lin J1, Lingohr-Smith M1, Menges B2, Rao S1. 777 Scudders Mill Rd, Plainsboro, NJ 08536; komal.singh@bms.com; (609) 897-2941

1Bristol-Myers Squibb; 2Novoys Health

BACKGROUND: There is little information on the variation in health care costs among patients with advanced melanoma on commercial and Medicare-supplemental insurance and in different geographic regions in the United States of America (USA).

OBJECTIVE: To evaluate the economic burden of patients with advanced melanoma in the USA by comparisons between commercial and Medicare-supplemental insurance types, and geographic regions.

METHODS: Patients ≥18 years old with a diagnosis of stage III/IV melanoma who initiated a cancer therapy (index date) were identified from the MarketScan Commercial and Medicare databases (1/1/2011-8/31/2015). Patients were grouped into cohorts stratified by insurance type and by geographic region. Patient demographic and clinical characteristics were evaluated at baseline (12 months). All-cause and melanoma-related health care costs were measured as per patient per month (PPPM, 2015 dollars) at baseline and follow-up (up to two years) and compared across the cohorts.

RESULTS: Of the study population (N=2,671) with advanced melanoma, 85.5% had stage IV melanoma, 67.5% (mean [±SD] age: 53.8 [±9.1] years) had Medicare insurance. Among the overall population, 34.6% resided in South, 25.5% in North Central, 19.3% in West, and 17.8% in Northeast regions. The mean [±SD] all-cause total health care cost (PPPM) at follow-up was greater among commercially-insured patients than among those with Medicare insurance ($54,778 [±$48,358] vs. $39,306 [±$42,853], P<0.001), with cost for outpatient medical services ($45,271 [±$48,649] vs. $33,413 [±$45,589], P<0.001) being the greatest contributor. Also, the mean [±SD] melanoma-related total health care cost (PPPM) at follow-up was greater among commercially-insured patients than among those with Medicare insurance ($44,758 [±$46,941] vs. $31,788 [±$41,128], P<0.001). The mean [±SD] all-cause total health care cost difference (PPPM) between baseline and follow-up was the most among patients in the Northeast ($33,093 [±$59,191]), followed by those in the North Central ($41,450 [±$44,235]), West ($41,174 [±$43,589]), and South ($37,849 [±$42,178], P<0.001) regions.

CONCLUSIONS: The health care economic burden of patients with advanced melanoma is substantial and differs by insurance types and geographic regions, with commercial payers and the Northeast region of the USA having the highest burden.

SPONSORSHIP: This abstract was sponsored by Bristol-Myers Squibb.

C11 Progression-Free Survival with First-Line Endocrine-Based Therapies Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer: A Network Meta-Analysis

Patterson-Lomba O1, Ayyagari R2, Tang D3, Zhou Z1, Xie J1, Ninawath P3. Prudential Center Plaza III, 111 Huntington Ave, Boston, MA 02199; rajcerv.ayyagari@analysissgroup.com; (617) 425-8422

1Analysis Group; 2Novartis Pharmaceuticals; 3Methodist Hospital, Houston

BACKGROUND: Although numerous emerging and currently available endocrine-based therapies (ETs) for postmenopausal women with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) exist, their comparative efficacy has not been well-studied.

OBJECTIVE: To synthesize the available evidence on progression-free survival (PFS) with ETs as first-line treatments for postmenopausal HR+/HER2- ABC using a mixed treatment comparison (MTC).

METHODS: A systematic literature review was conducted to identify randomized clinical trials of ETs for HR+/HER2- ABC. Pairwise hazard ratios (HRs) and 95% credible intervals (CrIs) comparing regimens were obtained via a Bayesian MTC model. The probability that each treatment was the most efficacious was estimated. Subgroup MTCs were conducted among late progressors (patients with disease free interval ≥12 months from the completion of [neo]adjuvant therapy) and among de novo patients to explore comparative efficacy in more homogeneous settings.

RESULTS: A total of 5 trials and 5 regimens (palbociclib+ an aromatase inhibitor [PAL+AI], ribociclib+AI [RIB+AI], fulvestrant 250 mg+AI [FUL+AI], fulvestrant 500 mg [FUL], and AI) were eligible. PAL+AI, RIB+AI, FUL+AI, and FUL had significantly longer PFS vs. AI (95% CrI upper bound ≤1). PAL+AI and RIB+AI both had 31% and 30% reduced hazard of progression or death vs. FUL+AI and FUL (95% CrI upper bound ≤1), respectively. No other significant differences in PFS between treatments were found. The probability of being the most efficacious of these treatments was 51% for RIB+AI and 49% for PAL+AI. Subgroup analysis among late progressors included 2 trials and 3 regimens (PAL+AI, RIB+AI, AI); RIB+AI had a 4% reduced hazard of progression or death vs. PAL+AI, although this reduction was not statistically significant. Three trials and 4 regimens (PAL+AI, RIB+AI, FUL, AI) were included in the de novo analysis; PAL+AI and RIB+AI had a 29% and 40% reduced hazard of progression or death vs. FUL, respectively, although these reductions were not statistically significant. In both subgroup analyses, all eligible therapies had significantly longer PFS as compared to AI.

CONCLUSIONS: These analyses consistently found that postmenopausal women with HR+/HER2- ABC receiving PAL+AI, RIB+AI, FUL+AI, or FUL as first line treatment had longer PFS than those who received AI alone.

SPONSORSHIP: Novartis Pharmaceuticals.
C12 Budget Impact Analysis of the PARP Inhibitor Rucaparib in the Third-Line Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer in the United States

Ladwig J1, Eisenlohr L1, Carls G2, Chawla A2. Clovis Oncology, 499 Illinois St, Ste 230, San Francisco, CA 94138; leisenlohr@clovisoncology.com; (415) 409-7217
1Clovis Oncology; 2Analysis Group

BACKGROUND: Rucaparib is a PARP inhibitor recently approved in the U.S. for monotherapy treatment of patients with deleterious BRCA-mutated advanced ovarian cancer (AOC) who have been treated with two or more chemotherapies. Patients are selected for therapy using an FDA-approved tumor tissue based companion diagnostic assay that detects both somatic and germline BRCA mutations, allowing identification of a larger number of patients who could benefit from treatment with a PARP inhibitor as compared to a test that detects germline BRCA mutations only.

OBJECTIVE: To estimate the budget impact of adding rucaparib to a U.S. health plan formulary for the third-line (3L) treatment of patients with AOC inclusive of both germline and somatic BRCA mutations.

METHODS: An Excel-based analytical model was developed to estimate the incremental budget impact on a hypothetical health plan with one million covered lives over a 3-year horizon. The model compared the difference in annual total cost of treatment with and without the availability of rucaparib. Other treatment options were olaparib, bevaciuzumab plus chemotherapy, composite of other chemotherapy regimens, and best supportive care (BSC). The size of the eligible patient population was estimated using an incidence-based approach. Modeled costs included those associated with drug acquisition, IV drug administration, BRCA mutation and laboratory testing, and medical management of adverse reactions (ARs). Patients were assumed to receive BSC after 3L therapy to focus the model on the impact of 3L treatment. Dosing schedules, duration of treatment, and AR rates are obtained from publications referenced in NCCN Guidelines.

RESULTS: The model estimated that a plan of one million members (combined 75% commercial and 25% Medicare) would include 26 patients in the target population (AOC and 3L therapy). Average total health expenditures were estimated to be $3,789,425 with rucaparib available, as a treatment option versus $3,739,381 without rucaparib, implying an incremental budget impact of $50,044 or $0.0042 PMPM averaged over years 1-3. The incremental budget impact is smaller in commercial plans and larger in Medicare plans due to higher incidence of ovarian cancer in the over 65 year old population. Sensitivity analyses showed that results were most sensitive to the number of patients treated with rucaparib.

CONCLUSIONS: Under current model assumptions, adding rucaparib for the 3L treatment of patients with BRCA-mutated AOC would result in minimal budget impact to a U.S. health plan regardless of insurance type.

SPONSORSHIP: Clovis Oncology.

C14 The Number Needed to Treat to Achieve 1 Additional Patient with Metastatic Castration-Resistant Prostate Cancer Free of Clinical Event: Comparison of Enzalutamide and Bicalutamide in the TERRAIN Trial

Shore N1, Chowdhury S2, Klats L2, Yang H1, Schultz N3, Brown B1, Barbie A4, Flanders S5. 823 82nd Pkwy, Ste B, Myrtle Beach, SC 29579; nshore@sgyoro.com; (843) 449-1010
1Carolina Urologic Research Center; 2Guy’s, King’s, and St Thomas’ Hospitals; 3Sunnybrook Health Sciences Centre, University of Toronto; 4Analysis Group; 5Astellas Pharma Global Development; 6Medivation

BACKGROUND: Enzalutamide (ENZ), a second-generation androgen receptor inhibitor, is approved for use in metastatic castration-resistant prostate cancer (mCRPC) and has shown significant survival benefits over placebo in two Phase 3 trials. Bicalutamide (BIC), a first-generation androgen receptor inhibitor, is used in clinical practice for the treatment of mCRPC. In the Phase 2 TERRAIN trial (NCT01288911), a head-to-head comparison of ENZ with BIC, ENZ demonstrated superiority over BIC in progression-free survival (PFS) (i.e., free of progression or all-cause death), radiographic PFS (rPFS), and freedom from prostate-specific antigen (PSA) progression.

OBJECTIVE: The objective of this analysis was to estimate the number needed to treat (NNT), comparing ENZ with BIC, to achieve one additional mCRPC patient with PFS or rPFS, or freedom from PSA progression at 1 year and 2 years.

METHODS: The 1-year and 2-year rates of PFS, rPFS, and freedom from PSA progression in ENZ-treated and BIC-treated mCRPC patients were obtained from the TERRAIN trial results. The NNT was calculated as the reciprocal of the event-rate difference between ENZ and BIC at 1 year or 2 years. The NNT value indicates the number of patients that need to be treated to achieve one additional patient in PFS, rPFS, or freedom from PSA progression comparing ENZ with BIC, with a lower value indicating a greater clinical benefit. The 95% confidence interval (CI) of the NNT was derived based on 95% CI of the event-rate difference.

RESULTS: The NNTs to achieve one additional patient with a PFS outcome, comparing ENZ with BIC at 1 year and 2 years, were 4.3 (95% CI: 2.9, 8.0) and 3.7 (95% CI: 2.6, 6.7), respectively. This indicates that, on average, treating 4.3 patients with ENZ, compared with BIC, would result in one additional patient free of progression or death at the end of 1 year; on average, treating 3.7 patients with ENZ, compared with BIC, would result in one additional patient free of progression or death at the end of 2 years. With respect to rPFS, the 1-year and 2-year NNTs comparing ENZ with BIC were 10.0 (95% CI: 4.4, not reported) and 2.8 (95% CI: 1.9, 3.5), respectively. The 1-year and 2-year NNTs comparing ENZ with BIC to achieve one additional patient with freedom from PSA progression were 2.1 (95% CI: 1.7, 2.9) and 3.2 (95% CI: 2.2, 5.9), respectively.

CONCLUSIONS: The use of ENZ compared with BIC in men with mCRPC leads to more patients with improved clinical outcomes (PFS, rPFS, and freedom from PSA progression). These NNT results should be considered during the management of mCRPC.

SPONSORSHIP: Astellas Pharma; Medivation (Pfizer).

C15 Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Pazopanib or Sunitinib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Data

Vogelzang N1, Ghate S2, Li N3, Swallow E1, Peoples M1, Zichlin M1, Meiselbach M1, Perez J2, Agarwal N3, One Health Plaza, 345/513B, East Hanover, NJ 07936; sameer.ghate@novartis.com; (862) 778-0550
1U.S. Oncology Research Comprehensive Cancer Centers of Nevada; 2Novartis Pharmaceuticals; 3Analysis Group; 4University of Utah Huntsman Cancer Institute

BACKGROUND: Pazopanib and sunitinib are commonly used first targeted therapies (TTs) for aRCC. There is limited real-world evidence on the comparative economic benefits of TTs.

OBJECTIVE: Assess all-cause health care resource use (HRU) and costs during time on first TT among aRCC patients who initiated pazopanib or sunitinib.
Djatche L1, Goble J2, Chun G3, Varga S4. 901 Walnut St, 10th Fl, Philadelphia, PA 19107; laurence.djatche@jefferson.edu; (215) 955-0107

OBJECTIVE: To compare ICER, ASCO, and NCCN VBFs across three therapeutic options for relapsed or refractory multiple myeloma (RRMM).

METHODS: The values of carfilzomib (CFZ), elotuzumab (ELO), and ixazomib (IX) were generated using ICER, ASCO, and NCCN VBFs. Those regimens, used for second or third line treatment of RRMM, were chosen because they share a common comparator in clinical trials, lenalidomide + dexamethasone (LEN + DEX). The ICER 2016 report of treatment options for RRMM was used to obtain results of the comparative clinical effectiveness and the cost effectiveness analysis for those regimens compared to LEN + DEX. ASCO's 2016 VBF, which incorporates clinical benefit, toxicity and bonus points was used to generate a net health benefit (NHB) score without a scale along with the drug wholesale acquisition cost (WAC) for each regimen compared to LEN + DEX. The NCCN VBF uses a score ranging from 1 to 5, with 1 as the least favorable and 5 as the most favorable, for each of five evidence blocks: efficacy, safety, quality, consistency, and affordability. The 2016 Multiple Myeloma NCCN evidence blocks was used to obtain the value of CFZ, ELO, and IX.

RESULTS: The ICER VBF suggested with moderate certainty that CFZ, ELO, and IX provide a better NHB in patients with RRMM compared to LEN + DEX. Second-line and third-line treatment costs per QALY for CFZ, ELO, and IX were $199,982, $427,607 and $433,794, respectively. The ASCO VBF generated a total NHB of 28.8, 23.7 and 23.0 with a monthly WAC of $17,364, $16,032 and $20,607 for CFZ, ELO, and IX, respectively. The NCCN VBF had an efficacy score of 5, 3, and 4 for CFZ, ELO, IX, respectively. Safety, quality, consistency, and affordability scores of 3, 4, 4, and 1, respectively, were the same across regimens.

CONCLUSIONS: ICER, ASCO and NCCN VBFs suggest CFZ may be the most valued treatment out of the three regimens. However, their applicability in stakeholder’s decision-making remains unclear due to uncertainty and challenges associated with them.

SPONSORSHIP: None.
number of hospitalization days was shorter for patients in the InO arm compared to the SOC arm (12 days vs. 26 days for cycle 1 and 17 days vs. 28 days for all cycles). Similar results were seen with mean number of hospitalization days (15 days vs. 25 days for cycle 1 and 26 days vs. 29 days for all cycles).

**CONCLUSIONS:** Treatment with InO for R/R ALL appears to be associated with lower hospital utilization despite longer duration of treatment compared to SOC. Contributing factors likely include high remission rates with limited toxicity, which reduced the need for inpatient management of disease and adverse events, and convenient one-hour weekly dosing schedule that does not require hospitalization. These may also contribute to the better patient reported outcomes, with patients being more ambulatory and reporting significantly less negative impact on their daily lives. Lower hospital utilization is expected to result in favorable budget impact on a health care system.

**SPONSORSHIP:** Pfizer.

---

**C21** Health and Economic Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Rvd Versus CyBord: A U.S. Claims-Based Analysis

Paribh K, Ni Q, Zafar F, Abouzaid S. 86 Morris Ave, Summit, NJ 07901; kparrikh@celgene.com; (201) 713-6084

**Celgene**

**BACKGROUND:** Rvd (lenalidomide, bortezomib, and dexamethasone) and CyBord (cyclophosphamide, bortezomib, and dexamethasone) are 2 common treatment (Tx) options for patients (pts) with newly diagnosed multiple myeloma (NDMM) ineligible for stem cell transplantation (SCT). However, limited data are available on real-world evidence comparing health outcomes and costs in pts who received Rvd vs. CyBord for NDMM.

**OBJECTIVE:** In this analysis, duration of Tx (DOT), time to next Tx (TTNT), and health care costs (HC) were evaluated in pts who received first-line (1L) Rvd vs. CyBord for NDMM.

**METHODS:** Data from the Truven MarketScan Commercial and Encounters Database (Medicare Supplemental) from January 2008 to May 2015 were evaluated. Pts with NDMM who had ≥ 2 claims of MM diagnosis (ICD-9-CM: 203.0x) ≥ 30-days apart, 12-months (mos) pre- and 3-mos post-index data, and had ≥ 1 full cycle of Rvd or CyBord as their 1L Tx (defined as index date) were included. Pts had to be continuously enrolled in the health plan for ≥ 12 mos pre- and post-index, with no evidence of MM diagnosis and MM Tx during pre-index, or SCT during entire study period. DOT was measured as the number of mos between the index date and Tx discontinuation or end of the study period. TTNT was defined as the time from index date to the start of the second-line therapy (addition of a new Tx > 60 days from index, or Tx restart following a > 180 day Tx gap unless the restart was maintenance therapy) and was determined using Kaplan-Meier and Cox proportional hazard models. Adjusted differences (Δ) in HC, measured over 12-mos follow up, were calculated from generalized linear regression models.

**RESULTS:** A total of 464 pts received Tx (Rvd: 318; CyBord: 146). Overall baseline characteristics were similar with the exception that comorbidity burden was higher in the CyBord vs. Rvd group (mean CCI, 5.2 vs. 4.3; P=0.0215). Rvd-treated pts had significantly longer median time on 1L therapy during the study period vs. CyBord-treated pts (14.8 vs. 9.0 mos; P<0.0001). Median TTNT was significantly longer for Rvd- vs. CyBord-treated pts (35.7 vs. 22.3 mos, hazard ratio = 0.61; P=0.0007). Rvd-treated pts had significantly higher adjusted pharmacy costs (Δ = $56,494; P<0.0001) but significantly lower adjusted costs for outpatient and MM & IV chemotherapy-related visits (Δ = -$11,378, P=0.0283, -$14,161, P=0.002, respectively) vs. CyBord-treated pts. No statistically significant difference was observed in total HC over 12 months between the two groups (Δ = $18,422; P=0.109).

**CONCLUSIONS:** Rvd was associated with significantly longer DOT and TTNT than CyBord. Total health care costs between Rvd and CyBord were comparable over a 12-month period.

**SPONSORSHIP:** Celgene.
Characteristics and Treatment Patterns of Patients Receiving Oral Ibrutinib Therapy for Treatment of Chronic Lymphocytic Leukemia

Irwin D, Wilson K. 105 Emerywood Pl, Chapel Hill, NC 27516; debra.irwin@truenhealth.com; (919) 360-2838
Truen Health Analytics

BACKGROUND: Ibrutinib is an oral therapy for patients with chronic lymphocytic leukemia (CLL). Despite oral therapy being an effective route of administration, studies have shown that nonadherence to treatment occurs. Ibrutinib’s efficacy relies on maintaining the recommended dose. Interruption in ibrutinib treatment of ≥ 8 consecutive days has been shown to be related to disease progression events in CLL patients enrolled in a clinical trial.

OBJECTIVE: Examine real-world treatment patterns including gaps in therapy and characteristics of CLL patients receiving ibrutinib

METHODS: Newly diagnosed CLL patients between November 2013 and December 2014 with at least 1 claim for ibrutinib were identified from MarketScan Commercial Claims and Medicare Supplemental databases. Inclusion criteria were ≥ 18 years of age with continuous enrollment for a minimum of 6 months before and at least 30 days after the index date (i.e., first prescription for ibrutinib). Patients had variable follow-up until either the end of continuous enrollment or the end of the study period. Patient demographics, baseline clinical characteristics, treatment patterns including the total number of days without therapy on hand (gap days) and the total number of consecutive gap days were summarized.

RESULTS: CLL patients identified for inclusion in this study (n = 401) had a mean age of 68 years; 65% were male. Over 58% of patients had Medicare insurance; the remainder were commercially insured. The mean National Cancer Institute comorbidity index score at baseline was 0.8. On average, patients were followed for 234 days. In 95.5% of patients, ibrutinib was received as a single agent; ibrutinib was used in combination with rituximab in 4.2%, with chlorambucil in 0.2% of patients. Median duration of ibrutinib therapy was 194 days (mean 209; range 33-498). Patients with at least 2 prescriptions for ibrutinib (n = 356) were included in the analysis of gap days. The mean number of total cumulative days off therapy was 24. Forty-eight percent of patients had a gap in ibrutinib therapy of ≥ 8 consecutive days, 40.2% had a gap of 1-7 days, and 12% had no gaps in ibrutinib therapy. The mean highest number of consecutive days off therapy was 16.

CONCLUSIONS: Results of this real-world analysis suggest that just under half of CLL patients receiving first-line oral ibrutinib experienced a treatment gap of ≥ 8 consecutive days. Further research is needed to understand the impact that interruptions in ibrutinib therapy have on patient outcomes.

SPONSORSHIP: Teva Branded Pharmaceutical Products R & D.

Real-World Treatment Patterns and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia

Stein E1, Latremouille-Viau D2, Guérin A3, Shi S1, Gagnon-Sanschagrin P1, Briggs O1, Bonifacio G3, Joseph G3. 1275 York Ave, New York, NY 10065; steine@mskcc.org; (212) 639-3314
Memorial Sloan Kettering Cancer Center; 2Analysis Group; 3Novartis Pharmaceuticals

BACKGROUND: There is a paucity of information on current treatment patterns and costs of acute myeloid leukemia (AML) management in U.S. real-world settings.

OBJECTIVE: To describe the setting, duration, and costs associated with induction therapy (tx) and consolidation cycles in the U.S. clinical practice for patients (pts) newly diagnosed with AML who are candidates for standard chemotherapy.

METHODS: Adult pts newly diagnosed with AML who received standard (induction) chemotherapy in an inpatient (IP) setting were identified from a U.S. administrative claims database (2006-2015). Pts were observed from induction tx start (index date) to the first event among an HSCT, death, end of health plan enrollment/data, or 180 days after discharge date of the induction episode (observation period). Induction tx and consolidation cycles were identified using DRG codes for chemotherapy with acute leukemia or procedure codes for AML chemotherapy. AML tx episode setting and duration, and costs (USD2015, payers’ perspective) were analyzed.

RESULTS: 459 pts (mean age = 54 years; 47% female) were observed. During the 6 months before index date, 16% of pts had MDS, 10% had a non-hematologic malignancy (mainly breast, skin, and lung), and mean Charlson Comorbidity Index score was 1.9. During the observation period, 134 (29%) pts had initial induction and subsequent re-induction tx during the same induction episode; 33 (7%) pts had another re-induction episode. The median duration of IP episodes for pts with 1 cycle of induction tx was 28 days, mean costs were $122,412, and mean costs per day were $4,412. The median duration of OP episodes for pts with induction and re-induction tx (2 cycles) was 47 days, mean costs were $200,430, and mean costs per day were $4,296. Following the induction episode, 295 (64%) pts had ≥ 1 consolidation cycle, 183 (40%) ≥ 2, 117 (25%) ≥ 3, and 60 (13%) ≥ 4. 75% of consolidation cycles were in an IP setting, and 25% in an outpatient (OP) setting. In the IP setting for consolidation, the median duration per cycle was 6 days, mean costs were $28,137, and mean costs per day were $3,823. In the OP setting, the median duration per cycle was 4 days of tx over 5 days, mean costs were $11,271, and mean costs per day of tx were $2,419.

CONCLUSIONS: This is the first exploratory study reporting the most recent tx patterns and costs of AML management. While granular information on the type of tx administered is not available in claims data, these findings suggest that, for commercially insured pts newly diagnosed with AML, there is substantial heterogeneity in the consolidation tx setting and costs of AML.

SPONSORSHIP: Novartis.

Daratumumab Compared to Pomalidomide for Refractory Multiple Myeloma: A Cost-Effectiveness Analysis

Gong C, Studdert A. 130 Monterey Rd, #103, South Pasadena, CA 91030; cgong@stanfordhealth care.org; (650) 736-1749
Stanford Health Care

BACKGROUND: Options for relapsed/refractory multiple myeloma have been limited. Recently, the FDA approved several new drugs for this population, including daratumumab, elotuzumab, pomalidomide, carfilzomib, panobinostat, and ixazomib.

OBJECTIVE: To determine the cost-effectiveness of daratumumab compared to pomalidomide for the treatment of multiple myeloma in patients refractory to both lenalidomide and bortezomib.

METHODS: Based on clinical trial data, we developed a Markov model for patients to transition between stable disease, progressed disease, and death. We derived transition probabilities, costs, and utility values from the literature. We calculated the discounted total costs, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs) and net monetary benefits (NMBs) of daratumumab relative to pomalidomide, and we assessed the sensitivity of these estimates through a series of one-way sensitivity analyses and a probabilistic sensitivity analysis.
RESULTS: Relative to pomalidomide, and at the current average U.S. willingness-to-pay estimate of $150,000 per QALY gained, dara- tumumab is approximately cost-effective with a base case ICER of $150,122 per QALY. The ICER remains relatively robust to changes in the parameter values in one-way sensitivity analyses, with results most sensitive to overall survival of daratumumab and costs of post-progression therapy. Probabilistic sensitivity analyses suggest that daratumumab is cost-effective more than 50% of the time at a will- ingness-to-pay threshold of $170,000. Daratumumab also has higher net monetary benefits at willingness-to-pay thresholds of $150,000 or greater compared to pomalidomide.

CONCLUSIONS: Daratumumab monotherapy may be a cost-effective option for patients with refractory multiple myeloma compared to pomalidomide.

SPONSORSHIP: None.

C25 Medication Adherence and Persistence of Dasatinib and Nilotinib in a National Cohort of Veterans

Kreys E1, Frei C2, Villarreal S3, Bollinger M4, Jones X5, Koeller J1.

5420 Dutch Iris Ct, Elk Grove, CA 95757; ekreys@cnsu.edu; (734) 819-0882
1California Northstate University; 2The University of Texas at Austin; 3University of Texas Health Science Center; 4South Texas Veterans Health Care System

BACKGROUND: The introduction of tyrosine kinase inhibitor, ima- tinib, was a breakthrough in the treatment of CML that drastically improved outcomes. Medication adherence is essential to achieve these outcomes. Second-generation TKIs, dasatinib and nilotinib, are commonly used as second-line treatment after imatinib failure, yet studies comparing adherence between the two drugs have revealed conflicting results.

OBJECTIVE: To compare treatment persistence and medication adher- ence between dasatinib and nilotinib as second-line treatment.

METHODS: This observational study utilized internal Veterans Health Administration (VHA) databases for the time period of 10/1/2000-9/20/2012. The study included VHA beneficiaries, aged 18-89 years, with ≥1 encounter at any of the VHA institution with a diagnosis code for CML (ICD-9 205.1x). Patients had to have filled ≥1 prescription of nilotinib or dasatinib as second-line treatment, defined as TKI treatment subsequent of previous treatment of one other TKI. Primary study endpoints included medication adherence, as measured by Proportion of Days (PDC), and treatment persistence in the first year of treatment. Appropriate level of adherence was defined as achieving PDC≥80%. Persistence was evaluated using Kaplan-Meier analysis in conjunction with a log-rank test. Multivariable analyses were performed to control for pertinent confounding variables.

RESULTS: As second line treatment 457 patients received dasatinib while 124 received nilotinib. The average PDC was 51% (±35%) for dasatinib-treated patients as compared to 47% (±34%) of nilotinib-treated patients, resulting in a mean difference of 4% (95% CI: -3.5 -11.0%, P = 0.309). Thirty-three percent of the dasatinib-treated patients were deemed adherent during first-year of treatment relative to 28% of nilotinib-treated patients resulting in an adjusted odds ratio (OR) of 1.24 (95% CI: 0.78-1.95, P = 0.361). A Kaplan-Meier analysis did not demonstrate a statistically significant difference in time to discontinuation between dasatinib and nilotinib (P = 0.740). Forty-five percent of patients receiving dasatinib continued therapy beyond one year relative to 44% of patients receiving nilotinib resulting in an adjusted OR of 1.10 (95% CI 0.71-1.68, P = 0.680).

CONCLUSIONS: In this national cohort of VHA patients receiving dasatinib or nilotinib as second-line treatment, no significant differences in the persistence or adherence were identified.

SPONSORSHIP: Funding provided by Bristol-Myers Squibb.

C26 Budget Impact Analysis of Treating Patients with Chronic Lymphocytic Leukemia and Rituximab-Refractory Indolent B-Cell Non-Hodgkin Lymphoma with Bendamustine Hydrochloride in the United States

Krus E1, Gabriel S2, Prasad S3, Parthan A4, Banevicius L5, Tang B2.

41 Moores Rd, Frazer, PA 19355; susan.gabriel@tevapharm.com; (610) 786-7326
1Optum; 2Teva Pharmaceuticals

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a subtype of B-cell non-Hodgkin lymphoma (NHL), and one of the most com- mon leukemias in U.S. adults, with an estimated 18,960 new cases in 2016. Indolent B-cell NHL (iNHL) makes up 30% of all NHL cases in the U.S., with an estimated 72,580 new cases in 2016. Bendamustine hydrochloride is indicated for CLL first-line and iNHL refractory to rituximab. It has been reformedulated (2016) with a reduced infusion time of 10 minutes (bendamustine rapid infusion) as compared with 30-60 minutes (bendamustine 30/60) for formulations launched in 2008 and 2014.

OBJECTIVE: Estimate the budget impact associated with the introduction of bendamustine rapid infusion for the treatment of patients with first-line CLL and second-line iNHL from a U.S. payer perspective

METHODS: A budget impact model was developed to estimate the changes in drug, administration, and adverse event costs associated with projected increases in the market share of bendamustine rapid infusion (80% from bendamustine 30/60 in year 1, 90% in year 2, and 95% in year 3) for a 1-million-member health plan. Ibrutinib was projected to take 5% market share from bendamustine 30/60 in year 1, 8% in year 2, and 11% in year 3. The model included two populations and different competitors, reflecting the approved indications for bendamustine. Total budget impact was calculated annually in years 1, 2, and 3, as well as for the difference in per-member per-month (PMPM) cost between scenarios (with and without bendamustine rapid infusion); one-way sensitivity analyses were conducted.

RESULTS: For CLL, inclusion of bendamustine rapid infusion was associated with total costs decreasing by $10,566 (PMPM = $0.0009), $10,829 (PMPM = $0.0009), and $10,174 (PMPM = $0.0008) in years 1, 2, and 3, respectively. For iNHL, inclusion of bendamustine rapid infusion was associated with total costs decreasing by $8,336, $8,554, and $8,006 in years 1, 2, and 3, respectively (each PMPM = $0.0007). Across both indications, the cumulative 3-year total cost changed from $20,609,358 to $20,552,894, a budget impact of -$56,464. The model was most sensitive to changes in the annual drug cost for bendamustine 30/60 and bendamustine rapid infusion in both indications.

CONCLUSIONS: The average total budget impact of bendamustine rapid infusion over 3 years was -$18,800 and the average PMPM impact was -$0.0016. This decreasing budget impact over time is due to bendamustine rapid infusion’s slightly lower drug and administration costs compared with bendamustine 30/60.

SPONSORSHIP: Teva Branded Pharmaceuticals R & D.

C27 Cost Impact of Elotuzumab in Second-Line+ Versus Third-Line+ Relapsed-Refractory Multiple Myeloma in a Commercial Health Plan

O’Day K1, Conner C2, Brown D3, Mahenbhiria D4, Xcenda; 411H Woodlands Pkwy, Ste 500, Palm Harbor, FL 34685; ken.oday@xcenda.com; (727) 771-4100 x2034156
1Xcenda; 2Bristol-Myers Squibb

BACKGROUND: Multiple myeloma (MM) is a rare hematologic malignancy with an expected 30,330 new cases and 12,650 deaths in the United States in 2016. Several new triplet regimens have been
approved by the Food and Drug Administration for treatment of relapsed-refractory (RR) MM, including the monoclonal antibodyelo-
tuzumab (EMPLICITI) in combination with lenalidomide (REVLIMID)
dexamethasone (d)–ERd. Based on the current NCCN guidelines, triplet regimens have become the standard of care in RRMM.

**OBJECTIVE:** This analysis examined the estimated cost impact of utilizing ERd in RRMM as a second-line plus (+) therapy compared to limiting ERd to third-line + therapy over a 1-year time horizon from a U.S. commercial health care payer perspective.

**METHODS:** An Excel-based treatment cost model was developed. Treatment regimens included ERd, carfilzomib (KYPROLIS) + Rd, ixazomib (NIÑALORO) + Rd, daratumumab (DARZALEX) + Rd, and daratumumab+bortezomib (VELCADE) and d in RRMM patients. The size of the annually treated patient population was estimated for a hypothetical 1-million member commercial health plan using MM incidence rate data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program. Estimates of the proportion of MM patients by line of therapy were based on a retrospective health care claims analysis. Shifts in market shares of treatment regimens were used to compare a scenario where ERd is utilized second-line+ vs. limited to third-line+. Dosing for the regimens over a 12-month treatment period was based on published clinical trials and package inserts. Drug costs for an average-sized patient (74.5 kg, 1.91 m²) were based on wholesale acquisition costs from Red Book. Administration costs by Current Procedural Terminology code were obtained from the Centers for Medicare & Medicaid Services Physician Fee Schedule. The incremental cost impact of using ERd second-line + vs. third-line+ was estimated in terms of total cost, cost per-treated-patient-per-month (PTPPM), and cost per-member-per-month (PMPM).

**RESULTS:** The model estimated 10 second-line and 5 third-line MM patients initiating treatment annually in a 1-million member commercial health plan. Utilizing ERd second-line+, as compared to limiting use to third-line+, would cost an incremental $10,628 over a 1-year period. This amounts to a cost of $890 PTPPM and $0.001 PMPM.

**CONCLUSIONS:** Allowing RRMM patients second-line access to ERd would likely have a negligible cost impact on a commercial health plan due to the comparable cost per month of the alternative novel RRMM triplet regimens.

**SPONSORSHIP:** Research funded by Bristol-Myers Squibb.

---

**D2** Economic Evaluation of Patient-Centered Medical Homes Among Long-Term Cancer Survivors in the United States

**An J. 309 E 2nd St, Pomona, CA 91766; jan@westernu.edu; (909) 469-8778**

**Western University of Health Sciences**

**BACKGROUND:** Cancer survivors require long-term follow-up care after active cancer treatment and systematic planning for secondary cancer prevention and surveillance. Patient-centered medical homes (PCMHs) may improve outcomes for cancer survivors, however, currently little evidence exists.

**OBJECTIVE:** To evaluate the association between PCMHs and total medical expenditures and health care utilizations among long-term cancer survivors in a nationally representative U.S. sample.

**METHODS:** Using the 2008-2012 longitudinal files from the Medical Expenditure Panel Survey data, adult cancer patients who survived ≥3 years and had a usual care provider were identified. Patients with all PCMH features at baseline year (received comprehensive care, patient-centered care, and accessible care) were categorized as the PCMH group, which was compared with patients without PCMH features. Total medical expenditures as well as office visit, hospitalization, emergency department (ED), and pharmacy related expenditures and utilizations were determined during one year of follow-up. A propensity score methodology was used to balance baseline characteristics between the PCMH and non-PCMH groups. Generalized linear models for the cost analysis, and negative binomial models or logistic regressions were used for the utilization analysis. All analyses considered sampling strata and weights in survey design.

**RESULTS:** A total of 4,288 cancer survivors were identified representing 106 million U.S. population. The mean (SE) age was 65.7 (0.4) years and mean (SE) survival years from the cancer diagnosis was 12.4 (0.3) years. Approximately 43.5% of the patients were categorized as...
The PCMH group at baseline. The crude mean (SE) total expenditures were similar between the PCMH and non-PCMH groups at baseline and follow-up ($11,587 ($903) vs. $11,455 ($434) for PCMH and non-PCMH respectively (P = 0.896) at baseline; $11,728 ($854) vs. $13,883 ($968) for PCMH and non-PCMH respectively (P = 0.092) during follow-up). Applying propensity score weights, the PCMH was associated with a reduction in health care expenditures ($2,238, P = 0.024). The odds of being admitted to the hospital (odds ratio (95% CI) = 0.82 (0.67, 0.99)) and the number of ED visits were lower in the PCMH group compared to the non-PCMH group (P = 0.049). However, the number of office visits, prescription fills, and related expenditures were similar between the two groups.

CONCLUSIONS: The PCMH features were associated with lower health care expenditures among long-term cancer survivors mainly due to reduction of hospitalizations and ED visits.

SPONSORSHIP: No outside funding supported this study.

D3 U.S. Medical and Pharmacy Director Cancer Concerns
Brook R, Smedding J. 18 Hrth Dr, Newfoundland, NJ 07435; rbrook@jestarx.com; (973) 208-8621
The JeSTARx Group and National Payor Roundtable

BACKGROUND: Cancer is costly, managed by a variety of treatments that include traditional and robotic surgery, radiation, chemotherapy, and immunotherapy. Diagnostic tests have guided clinicians towards more effective treatments. Treatments are shifting from chemotherapy with limited effectiveness and multiple side-effects to effective targeted immunotherapies with fewer side-effects, multiple treatment pathways/guidelines with indications alone and in combination, and receiving fast-track approvals.

OBJECTIVE: To determine the types of cancers most concerning to U.S. managed care plans.

METHODS: Survey invitations were sent to 210 medical and pharmacy directors (MDs+PDs) of U.S. health plans, insurers, and pharmacy benefit managers. The online interactive survey topics included: advisor + plan information; Ranking (highest = 12-to-1 = lowest) of cancer types, Copays; benefit-design; and top concerns today and in 5 years from budgetary and medical points of view.

RESULTS: The survey received 61 responses (29%) and 54% of respondents were MDs. Most worked for a health plan (83.6%) and 39.6% of respondents were MDs. Most plans cover multiple member types and 91.3% covered commercial lives, 89.1% Medicaid, 91.3% Medicare MA-PDP and 76.1% Medicare PDP-only lives. Average ranking (out of 12): Breast Cancer = 10.6; Lung Cancer = 10.0; Colon and Rectal Cancer = 9.1; Prostate Cancer = 7.9; Melanoma = 7.5; Leukemia = 7.2; Non-Hodgkins Lymphoma = 6.5; Pancreatic Cancer = 5.2; Kidney Cancer = 4.7; Endometrial Cancer = 3.8; Bladder Cancer = 3.6; Thyroid Cancer = 2.7. In open-ended questions, cancer/ oncology was consistently reported the top concern from medical (38.9% today, 51% in 5 years) and budgetary (52% today, 71.1% in 5 years) points of view. Oncology was the 2nd highest ranked Specialty-Pharmacy (SP) condition with 64.3% of plans always managing under the medical-benefit, 54.4% always under the pharmacy-benefit. SP copays are decreasing in fixed (2015 = 15.8%; 2017 = 13.0%) and percentage-based (2015 = 42.1%; 2017 = 37.0%), the rest varied by group and benefit-design. Respondents were concerned about increasing costs of diagnostics, infused/oral treatments and comorbid conditions as survival increases and cancer shifts to a chronic condition. Plans liked pharmacy benefit management for oral therapies.

CONCLUSIONS: The environment for cancer treatment is changing. The shifts towards targeted immunotherapies and chronic maintenance have cost implications requiring P&T committees to adapt and evaluate agents and pathways along the same rapid timelines as they become available.

SPONSORSHIP: TPG-National Payor Roundtable.

D7 Adherence, Persistence, and Dosing Patterns of Eltrombopag for Treatment of Immune Thrombocytopenia
Stafyey-Mailley D1, Bhur M1, Lokhandwala T1, Elliott B2. 4114 Woodlands Pkwy, Ste 500, Palm Harbor, Florida 34685; stafyey-mailley@xcenda.com; (727) 771-4100 x2034039
1Xcenda; 2Novartis Pharmaceuticals

BACKGROUND: There is limited information on the medication adherence and persistence of eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA) approved for treatment of chronic immune thrombocytopenia (ITP).

OBJECTIVE: Evaluate eltrombopag dosing patterns, medication adherence, and persistence among adults diagnosed with ITP in a real-world study.

METHODS: The study employed a retrospective longitudinal cohort design using integrated health care claims data from July 2008-September 2015 for patients identified by ICD-9 codes, with ≥2 eltrombopag prescription claims from January 2009-July 2014 were included. The index date was the first eltrombopag claim date. Patients not continuously enrolled in medical and pharmacy benefits for 6-months prior or 12-months post the index date and those who received eltrombopag during the pre-index period were excluded. All outcomes were assessed during the 12-month post-index window: initial dose, stable dose, dose escalation and reduction, adherence, persistence (12- and 6-months), and time to discontinuation. Adherence was measured using medication possession ratio (MPR) and assessed between the first and last prescription fill. Patients without a gap ≥ 30 days were considered persistent.

RESULTS: Of the 336 patients included, 46.3% (156) were male and the mean age was 58.8 years. During the 6-month pre-index period prior to eltrombopag initiation, patients received the following ITP treatments: 5.9% (21) had a splenectomy, 22.2% (79) corticosteroids, 19.1% (68) intravenous immunoglobulin, 18.3% (65) romiplostim, and 17.1% (61) rituximab. Median initial and stable dose of eltrombopag were 50 mg. Dose escalation and reductions occurred among 29.2% (104) and 30.3% (108) of patients, respectively. Median escalation and reduction in dose were 25 mg. Median time on stable dose was 180 days. Median MPR was 0.9, 78.7% (280) of patients were adherent (MPR ≥ 0.8), and 37.6% (134) were persistent for 12-months (58.9% [210] of patients were persistent over the first 6 months). Among those patients who discontinued, median time to discontinuation (time to gap ≥ 30 days) was 111 days.

CONCLUSIONS: ITP patients on eltrombopag demonstrated good medication adherence, although 1 year persistence was low. Further research is needed to assess the relationship between eltrombopag adherence and persistence and clinical outcomes (e.g., platelet counts and bleeding symptoms), in the real-world setting.

SPONSORSHIP: Novartis.

D8 Trend Analysis of Medicare Hemophilia Drug Utilization, 2011-2015
Wang Y, Stevens A. 200 5th Ave, New York, NY 10010; yan.wang@wg-group.com; (727) 771-4100 x2034039

BACKGROUND: Hemophilia is a costly, rare disease that requires long-term management and treatment. For Medicare patients, hemophilia is
covered under Medicare Part B. Recently, novel long-acting coagulator factor treatments have been developed that may improve patient care.

**OBJECTIVE:** To understand the trend of hemophilia drug utilization under Medicare from 2011 to 2015.

**METHODS:** We analyzed Medicare Part B drug utilization and costs published by CMS in 2016 (range 2011-2015). All coagulation factors for the treatment of hemophilia A without inhibitors (HA), hemophilia B without inhibitors (HB), hemophilia with inhibitors (inhibitor) and Von Willebrand disease (VWD) were included.

**RESULTS:** From 2011 to 2015, Medicare spending on hemophilia drugs increased from $488,271,249 to $589,153,676, but decreased as part of the overall Medicare Part B spend (2.78% to 2.40%). Among Medicare patients, HA had the highest prevalence (>45%). HA patients had the highest overall spend (~50%), followed by HB, inhibitor and VWD. Over time, the PMPM of treating hemophilia patients increased from $0.83 to $0.88 and the patient’s out of pocket was 16-20% of the CMS spend. The annual spend per inhibitor patient decreased from $539,952 to $405,967 but still remained the highest compared with other hemophilia types. The annual spend per VWD patient was the lowest, but increased from $73,148 to $79,334. For HA patients, PMPM increased from $0.40 to $0.46. Patients using recombinant factors increased from 74% to 85% with the total spending on recombinant factors increasing from 83% to 89%. The annual spend per patient increased from $234,788 to $240,544 using recombinant factor and increased from $131,505 to $171,965 for plasma-derived factor. For HB patients, PMPM increased from $0.11 to $0.16. Alprolix received FDA approval as the first long-acting factor IX in 2014, and J7201 was used from 2015. From 2011 to 2014, the spend on recombinant factors increased from 70% to 75%. In 2015, 10% of HB patients started using Alprolix and cost 29% of the total spend on HB. The annual spend per patient on long-acting factor IX was $482,149 in 2015, higher than that of recombinant factors ($78,608-$204,007) and plasma-derived factors ($61,224-$97,371).

**CONCLUSIONS:** The Medicare spend on hemophilia increased over the period 2011-2015, and there was a decrease compared with overall spend in Medicare Part B. Inhibitor patients cost the highest per patient compared with other hemophilia types. There was an increased spend on recombinant factors and it is expected that long-acting factors will continue to have increased uptake.

**SPONSORSHIP:** WG Group.

**D10 Improving Payer-Provider Collaboration and Data Reporting for Hemophilia Management: Metric Development for Quality Improvement**

Pindolia V1, Rice M2, Koulanos K2. 2850 W. Grand Blvd, 4th Fl, Pharmacy, Detroit, MI 48202; vpindolia@hap.org; (313) 664-8501

1Henry Ford Health System/Health Alliance Plan; 2National Hemophilia Foundation

**PROBLEM DESCRIPTION:** Hemophilia represents a significant driver of health care resource utilization and requires expert hematologic and multidisciplinary services to achieve optimal outcomes. Despite serving as federally-recognized centers of excellence in managing this unique patient population for more than 40 years, hemophilia treatment centers (HTCs) may be underused in the current framework of managed care. This is largely due to a lack of communication and information shared between payers and HTC stakeholders.

**GOAL:** Routine information sharing between HTC and payer stakeholders is paramount to improving outcomes in hemophilia; the Comprehensive Care Sustainability Collaborative (CCSC) initiative provides a unique forum for such dialogue and data exchange. The CCSC set forth to develop a set of quality improvement and cost management metrics. These metrics will be used in a first-of-its-kind series of pilot programs that are anticipated to forge innovative collaboration between payers and HTCs.

**PROGRAM DESCRIPTION:** The National Hemophilia Foundation (NHF), in conjunction with Impact Education, developed CCSC: an initiative among 18 leading clinicians and managed care decision-makers. Over the course of consensus meetings, CCSC is developing a framework for quality improvement pilot programs that can be replicated across the United States between payers and HTCs, to facilitate cost-effective hemophilia management integrating the HTC comprehensive care model.

**OBSERVATIONS:** The services delivered by HTCs exceed payer expectations in care delivery, quality, and value. The intensive level of care and oversight provided by HTCs has the potential to result in cost savings for payers through the avoidance of bleeding-related
complications and rigorous management of factor replacement therapy, which may also come at a lower cost due to the 340B discount drug pricing available through many centers.

**FINDINGS/RECOMMENDATIONS:** The following measures will be reported by HTCs and payers via a series of pilot programs (reporting group indicated in parentheses): patient classification by diagnosis (HTC); total cost of clotting factor (payer); prescribed factor dose/dispensed dose/weight (± range) (payer and HTC); emergency department (ED) visits/hospitalizations (payer and HTC); home infusion of clotting factor (%) (HTC); total cost per patient (payer); and patient contacts (clinic visits, follow-ups, telemedicine, e-mail, etc.) (HTC).

**SPONSORSHIP:** The CCSC initiative is jointly sponsored by the National Hemophilia Foundation and Impact Education and supported via a charitable donation from Shire.

**D13 A Real-World Cost Comparison of IVIG- and SCIG-Treated PIDD Patients**

Noone F1, Runkel C2, Blanchette C1, Zacherle E3, Howden R1

9201 University City Blvd, Charlotte, NC 28223; fnoone1@uncc.edu; (704) 687-1044

1University of North Carolina at Charlotte; 2Grifols

**BACKGROUND:** Primary Immune Deficiency Disorder (PIDD) is a rare, chronic disease limiting a patient’s ability to fight off infection due to immune system deficiencies. Acute or recurrent infections often occur, thereby resulting in higher rates of office, emergency department, and inpatient hospital utilization. Compounding these expenses are the high costs of immunoglobulin (IG) therapy which are either nurse-infused intravenous (IV) or self-administered subcutaneous (SC) products.

**OBJECTIVE:** This study’s purpose was to compare real-world PIDD-related and total annual costs between PIDD patients receiving IVIG and SCIG treatments.

**METHODS:** The 2010-13 Marketscan commercial dataset was used to identify PIDD patients (ICD-9 code 279 XX) with at least two PIDD claims > 90 days apart who were treatment naive. Patients who switched administration routes were excluded, with the exception that SC patients could receive up to two IV loading infusions per treatment guidelines. Claims with a primary diagnosis of PIDD and costs related to therapy were identified as “PIDD-related” costs. To adjust for physician treatment preferences and differences in base population characteristics, the two cohorts were matched on age, gender, and all 31 Elixhauser index criteria using propensity score matching. To better represent the spectrum of IV products, the annual costs for patients receiving the three most common IV products were grouped and compared with median annual costs of the SC product using t-tests for means and Wilcoxon Rank-Sum tests.

**RESULTS:** 1,094 PIDD patients met all necessary criteria with 853 being IV infused and 241 SC treated. SC patients were significantly younger (median age 46 vs. 53 for IV), more female (74.3% vs. 61.3%), and had lower Charlson Comorbidity Index scores (CCI, 1.4 vs. 2.0) (P≤0.05 for all). Pre-matched PIDD-related and total median annual costs were lower for the IV group ($31,098 vs. $33,609 and $62,571 vs. $64,325, respectively). After matching, there were 178 patients in each group with no demographic differences. Post-matched PIDD-related and total median annual costs remained lower for the IV group ($29,493 vs. $33,267 and $52,278 vs. $63,367, respectively), but with limited sample sizes, differences were not statistically significant.

**CONCLUSIONS:** In this analysis we confirmed previous research that IV patients have higher prevalence of comorbid conditions. Additionally, when comparing matched cohorts of PIDD patients, costs for both groups go down and small differences in costs become larger favoring IV patients.

**SPONSORSHIP:** Grifols SSNA.

**E1 The Impact of Various Clinical Strategies on Achieving 5 Stars for the MTM Program Completion Rate for CMR Star Rating Measure**

Makanji S1, Santilli M1, Ferro C1, Adams J1, Braginca E2, Dimani M2, Mah-Adedapo O2, Li R2. 130 Bellevue Ave, Ste 201, Newport, RI 02840; smahkanji@magellanhealth.com; (401) 344-1025

1Magellan Rx Management; 2AlphaCare

**PROBLEM DESCRIPTION:** As the United States health care system transitions away from fee-for-service models, health insurers are
placing an increased emphasis on quality of care. To assist AlphaCare in improving the quality of care delivered to their beneficiaries, Magellan Rx Management has collaborated on the development and implementation of a clinical program designed to specifically address the CMS Star Rating measure D15-MTM Program Completion Rate for CMR, which is defined as the percent of Medication Therapy Management (MTM) program enrollees who received a Comprehensive Medication Review (CMR) during the measurement year.

GOAL: To obtain a 5-Star rating for CMS Star Rating measure D15-MTM Program Completion Rate for CMR by leveraging various methods of member engagement and clinical intervention.

PROGRAM DESCRIPTION: A clinical program was implemented to improve the CMR completion rate through various methods of member engagement and clinical intervention, including distribution of quarterly member letters, telephonic outreach, sending outreach materials to prescribers offices and community pharmacies, collaboration with member care management (MCM) teams, scheduling evening shifts (after 5 pm) to reach members with busier schedules, conducting CMRs with long-term care (LTC) facility caregivers or primary care providers, and working with visiting nurses for members unwilling to complete a telephonic CMR or those who were recently discharged from the hospital.

OBSERVATIONS: Between January and November of 2016, a total of 183 members were identified as being MTM-eligible and 132 CMRs were completed, resulting in a CMR completion rate of 72.1%. After applying the 60-day MTM enrollment criteria per the Star Ratings technical notes, the completion rate increased to 77.9%, which is equivalent to a 5-Star rating based on existing thresholds. Of the 132 completed CMRs, 51.3% are attributable to collaboration with the MCM team, 40.2% to direct telephonic outreach, 4.5% to collaboration with visiting nurses/LTC facilities/PCPs, and 3.8% to evening shifts.

FINDINGS/RECOMMENDATIONS: Member engagement is critical in improving the CMR completion rate for Star ratings. Leveraging multiple sources of member engagement helps improve reach rates in a clinically synergistic manner. It has been estimated that a cumulative 1-star improvement across all measurements (from 3 to 4) is worth $50 per member per month. Such results support the efficacy and viability of a clinical program that incorporates care coordination and customized outreach.

SPONSORSHIP: Conducted by AlphaCare and Magellan Rx Management, affiliates of Magellan Health, without external funding.

METHODS: Pharmacists called study participants at specific time-points during the trials. The pharmacist call was in addition to the normal monitoring provided by the clinical trial site staff. During each call, the number and types of interventions were documented. Descriptive statistics (frequencies) and stratification by cost impact were performed to determine the number and type of interventions by call and by patient across 2 NIGLM Drug A and Drug B studies.

RESULTS: Overall, 25,829 calls were made across all trials. Of these calls, 11,765 calls (45.5%, \( P < 0.001 \)) had at least one intervention involving 3,573 patients (92.3%, \( P < 0.001 \)). The most frequent interventions were regarding adverse events (3,774, 14.6%), and protocol violations for medication usage (3,341, 12.9%), concurrent medications (1,630, 5.9%), and misc concerns (1,269, 4.6%). The greatest numbers of interventions were high cost interventions (4,772, 18.5%, \( P < 0.001 \), e.g., serious adverse events) that would seriously impact trial outcomes data, medication adherence and patient retention.

CONCLUSIONS: Clinical trial research pharmacist calls can be used to identify and correct medication management and patient compliance issues within a clinical trial. These trial issues, if left unchecked, could have negatively impacted the trial results and outcomes. Larger controlled clinical trials are needed to fully evaluate the use and impact of clinical trial research pharmacist support in clinical trials.

SPONSORSHIP: Sponsored by a grant from Center Point Clinical Services to Cedarville University School of Pharmacy.
**OBSERVATIONS:** Patients working with the CVRS pharmacists for 12 months had improved GA scores compared to those receiving usual care. GA scores are highly correlated to established CMS quality measures. CVRS pharmacists had an 88% acceptance rate for 331 recommendations among 35 PCPs. Discussions with PCPs suggest fewer in-clinic visits needed for uncomplicated state cases managed by the CVRS. The CVRS is a novel, efficient, scalable model that can be adapted to specific needs of various payers, clinics, and patient populations.

**FINDINGS/RECOMMENDATIONS:** The CVRS was successful in operationalizing selected sets of quality measures, managing chronic diseases, and improving access to care. Findings suggest a rigorous tele-health intervention with EMR access and PCP engagement is a promising way to improve care and can be incorporated into alternative payment structures.

**SPONSORSHIP:** NIH grant R01HL116311.

---

**E4** Medicare Part D Plan Formulary Coverage, Utilization Management Tools, and Cost Sharing for Insulins and Other Newer Antidiabetic Drugs

Li P1, Hsu H1, Lezcano V1, Fan T1, Raffaele M2, Doshi J3. University of Pennsylvania, Division of General Internal Medicine, 1215 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104; penhi@mail.med.upenn.edu; (215) 573-4708

**BACKGROUND:** Research has shown that persistent use of antidiabetic drugs and effective control of A1c are associated with improved clinical outcomes in diabetes. For the newer antidiabetic drugs, little is known about formulary restrictions and cost sharing under Medicare Part D plans.

**OBJECTIVE:** To compare insulin dose changes in a real-world setting across Medicare Part D plans in formulary coverage, utilization management tools, and cost sharing for insulins and newer antidiabetic drugs.

**METHODS:** Medicare Part D Plan Characteristic and Formulary files were examined during the 2007-2013 period. Descriptive analyses were used to profile the coverage for insulins, GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors that were FDA-approved and available during the study period.

**RESULTS:** Large variations within and between drug classes were identified across Medicare Part D plans pertaining to formulary coverage, utilization management restrictions, and cost-sharing requirements for newer antidiabetic drugs within the same year and across 2007-2013. In 2013, percentage of Medicare Part D plans with off-formulary drugs excluded from the plans ranged from 5-46% for GLP-1 agonists, 3-37% for DPP-4 inhibitors (excluding Nesina, alogliptin, which was 93%), and 7-25% for insulins. In 2013, prior authorization and step therapy policies were seen in 2-7% and 21-34% of plans for GLP-1 agonists, 0% and 0-22% of plans for DPP-4 inhibitors, and 0-2% and 0% of plans for insulins, respectively. For most drugs, approximately 1/3 of the plans required a coinsurance, except for SGLT-2 inhibitor canagliflozin (52% of plans). Among these plans, coinsurance levels ranged from 23 to 43% for GLP-1 agonists, 20 to 30% for DPP-4 inhibitors, 1 to 25% for SGLT-2 inhibitors, and 20 to 25% for insulin in 2013. In the same year, among the remaining plans using copayments, the mean copayments per 30-day prescription were $39-55 for GLP-1 agonists, $40-78 for DPP-4 inhibitors, $38 for the SGLT-2 inhibitor canagliflozin, and $37-38 for insulins. Intra-brand variations existed, with most variation in the GLP-1 agonist class and least in the insulin class.

**CONCLUSIONS:** Large variations in formulary restrictions and cost sharing identified across Medicare Part D plans over time suggest that beneficiaries need to carefully select plans during the annual open enrollment period to ensure their access to needed antidiabetic drugs. Future research should examine the impact of such restrictions on drug use, adherence, and outcomes in Medicare Part D beneficiaries.

**SPONSORSHIP:** Sanofi U.S.

---

**E5** Clinical Outcomes of Patients with Type 2 Diabetes Who Switched to Insulin Glargine 300 U/mL from Insulin Glargine 100 U/mL in Real-World U.S. Treatment Settings

Ye F1, Zhou F2, Xie L3, Kariburyo F1, Meneghini L1. 700 American Ave, Ste 102, King of Prussia, PA 19406; fen.ye@sanofi.com; (908) 981-6061

**BACKGROUND:** In the EDITION 1 and 2 trials, which assessed the efficacy, safety, and dose optimization of insulin glargine 300 U/mL (Gla-300) in patients (pts) with T2D on prior basal insulin, pts randomized to Gla-300 used 10% more basal insulin than pts randomized to insulin glargine 100 U/mL (Gla-100).

**OBJECTIVE:** To compare insulin dose changes in a real-world setting for adult pts with T2D on prior Gl-100 who either switched to Gla-300 or remained on Gla-100.

**METHODS:** Retrospective pt-level data were extracted from the Optum Clinformatics database (October 1, 2014 to March 31, 2016). Pts had ≥2 Gla-100 claims at baseline, and either ≥1 Gla-100 or ≥1 Gla-300 claims from April 1 to December 31, 2015. Data were assessed at baseline (≤6 months [mo] prior to inclusion), and follow-up (≤6 mo after the first Gla-300 claim, or a randomly selected Gla-100 claim in the study period). Pts switching to Gla-300 were matched to those continuing Gla-100 based on baseline characteristics via propensity score matching (PSM) at a ratio of 1: up to 3. The main endpoint was daily average consumption (DACON) of basal insulin, calculated as the total number of study drug units dispensed from initiation to last refill, divided by the number of days during that period. Average percent change of DACON per pt from baseline to follow-up was also calculated. Pts were considered persistent if they remained on index basal insulin during follow-up.

**RESULTS:** The PSM yielded 443 pts on Gla-300, and 1,241 pts on Gla-100 with matched baseline characteristics. Within the matched sample, Gla-300 and Gla-100 cohorts had comparable DACON at baseline (56.0 U/day vs. 55.6 U/day, respectively; P = 0.467). For the subset of pts with ≥6 months of follow-up (58.8 U/day vs. 55.0 U/day, respectively; P = 0.0975), corresponding to comparable percent changes in DACON (13.8% vs. 12.6%, respectively; P = 0.753). In persistent pts, DACON also increased from baseline to follow-up (Gla-300: 56.45 U/day to 59.2 U/day, n = 346; Gla-100: 54.7 U/day to 55.0 U/day, n = 1,090), with no statistical difference in percent change in DACON between cohorts (Gla-300: 9.7%; Gla-100: 7.3%; P = 0.467). For the subset of pts with available A1c measures, both cohorts showed comparable mean A1c at baseline and follow-up.

**CONCLUSIONS:** In a real-world clinical setting, switching to Gla-300 from Gla-100 was not associated with a higher basal insulin dose in pts with T2D compared with continuing on Gla-100, and similar changes in DACON and A1c were observed. Despite the increase in DACON, mean A1c remained elevated, possibly reflecting the need for additional therapy intensification and insulin dose optimization.

**SPONSORSHIP:** Study funding and writing/editorial support was provided by Sanofi U.S.
Preblick R1, Gupta S2, Liebert R2, Lee L2, Wang H1. Sanofi U.S., Bridgewater, NJ 08807; ronald.preblick@sanofi.com; (800) 981-2491
1Sanofi U.S.; 2Kantar Health

BACKGROUND: The usage patterns and effectiveness of a longer-acting formulation of insulin glargine 300 units/mL (Gla-300) have not been studied in a real-world setting after becoming available to eligible patients.

OBJECTIVE: This study evaluated changes in dosing and clinical outcomes pre- and post-initiation of Gla-300.

METHODS: This was a retrospective observational study using medical-claim data obtained by physician survey for 390 insulin-naive patients who initiated insulin glargine 100 units/mL (Gla-100; n = 92) or Gla-300 (n = 298), and 184 patients who switched to Gla-300 from another basal insulin (BI). Differences in dosing patterns and clinical outcomes during the 6-months pre- vs. a mean of 4-months post-initiation or switching were examined by generalized linear mixed-effect models adjusting for demographics and clinical characteristics.

RESULTS: Among patients switching to Gla-300, 65.9% switched from Gla-100 and 25.1% from insulin detemir. On their previous insulin regimen, 43.2% of patients injected twice daily (b.i.d.). After switching to Gla-300, only 9.8% of patients required b.i.d. dosing. Units per injection was similar for patients on the same dosing frequencies: patients with once-daily dosing had least-squares (LS) means of 0.53 units/kg and 0.56 units/kg pre- and post-switch, respectively (adjusted difference [95% CI] 0.03 [-0.12, 0.18]; P = 0.684); patients with b.i.d. dosing had LS means of 0.94 units/kg and 0.76 units/kg pre- and post-switch, respectively (adjusted difference [95% CI] -0.18 [-0.48, 0.12]; P = 0.230). Post-switching, compared with pre-switching, mean Alc (LS means: 7.61% vs. 8.57%; adjusted difference: -0.96 [95% CI -1.14, -0.77]; P < 0.0001) and hypoglycemic events per patient-year (LS means: 0.17 vs. 0.79; relative risk: 0.23 [95% CI 0.16, 0.32]; P < 0.0001) were lower. In insulin-naive patients who initiated BI, no difference in dose (units/kg) was seen in titrated Gla-300 vs. Gla-100 initiators (LS means: 0.42 vs. 0.44; P = 0.77). Both groups had reductions in Alc (LS means: 1.21% vs. 1.12%; P < 0.001) with no between-group difference (P = 0.62). Initiation of Gla-300 was associated with lower hypoglycemic risk vs. Gla-100 (relative risk: 0.31 [95% CI 0.12, 0.81; P = 0.018]) at similar daily doses.

CONCLUSIONS: Switching to Gla-300 resulted in lower frequency of dosing vs. prior Gla-100 or insulin detemir therapy, with fewer hypoglycemic events and without compromising Alc reduction. In insulin-naive patients, initiation of Gla-300 vs. Gla-100 resulted in fewer hypoglycemic events and a similar Alc reduction, with no difference in insulin dose.

SPONSORSHIP: Study funding provided by Sanofi U.S.

E7 Pharmacist-Led Diabetes Wellness Clinical Outreach Program Significantly Decreases Hemoglobin Alc

Taddei-Allen P, Banks J, Page R. PO Box 90369, Lakeland, FL 33804; ptaddei-allen@welldynexrx.com; (888) 479-2000 x6085
WelldynexRx

BACKGROUND: Diabetes affects approximately 29.1 million people in the U.S., with an estimated total medical cost of $245 billion annually. Approximately $1 out of every $10 health care dollars is spent on diabetes medications with an overall trend of 14% increase in drug spend annually. Better disease management through improved medication use and ongoing self-management education and support is needed to reduce health care costs. For optimal outcomes, diabetes care must be individualized for each patient.

OBJECTIVE: To evaluate the effectiveness of a pharmacist-led diabetes wellness clinical outreach program administered by a pharmacy benefits manager (PBM).

METHODS: A random sample of 50 patients who participated in a pharmacist-led diabetes wellness clinical outreach program was compared to a random sample of 50 patients who did not participate in the program. The patients in both sample sets were continuously enrolled in the same PBM-administered plan between October 1, 2015 and September 30, 2016. Recent hemoglobin A1c levels of both sample groups were compared using a student’s t-test. The proportion of members receiving a statin, an ACE inhibitor/ARB, and adherence to diabetes medication was also recorded and differences were analyzed using a chi-square analysis.

RESULTS: Out of 702 clinic records of members within the plan continuously enrolled with at least one A1c during the study period, 298 were enrolled in the program and met at least once with the pharmacist. The average A1c level among the sample pharmacist-led program group was significantly lower at 6.4 ± 1.2% whereas the average A1c level for the sample group that did not meet with a pharmacist was 7.6% ± 1.4% (P < 0.001). There were no statistically significant differences among members in terms of statin use, ACEI/ARBs, or adherence rates.

CONCLUSIONS: Members enrolled in the pharmacist-led diabetes wellness program showed a significant decrease in hemoglobin A1c levels compared to members not enrolled in the program, despite similar diabetic medication adherence rates. Implementing a pharmacist-led multi-factorial diabetes wellness program that addresses appropriate medication, diet, and weight management results in significant decreases in A1c levels.

SPONSORSHIP: WellDyneRx

E8 Real-World Analysis of Patient Characteristics in Patients Who Received an Eye Exam Within the First Year of Type 2 Diabetes Mellitus Diagnosis Compared with Patients Who Did Not Receive an Exam

Polson M1, Lord T1, Evangelatos T1, Hammond E2, Conner B2, Kaznich A2. 130 Bellevue Ave, Ste 201, Newport, NY 02840; mpolson@magellanhealth.com; (401) 344-1000
1Magellan Rx Management; 2Regeneron Health Care Solutions

BACKGROUND: Diabetes is the leading cause of new cases of blindness, but patients with diabetic retinopathy are often asymptomatic until significant damage occurs. Prevention and early detection are crucial, but only about 62% of adults with type 2 diabetes mellitus (T2DM) had dilated eye exams in 2010. At risk patients may benefit from eye exams, which may increase early detection and patient engagement, potentially improving health care resource utilization.

OBJECTIVE: To analyze real world health plan claims data to assess differences in characteristics between those receiving an eye exam in the first year of T2DM diagnosis compared to those who did not and to assess screening rates over time.

METHODS: A retrospective study of real-world medical and pharmacy claims from regional health plans in Magellan’s medical and pharmacy claims database. Qualifying patients were 18-75 years old at start of study period (1/1/2011 and 12/31/2015), had a T2DM diagnosis in the baseline period (either 2 outpatient claims or one inpatient claim with appropriate diagnosis code), and eligible for the entire calendar year of interest for annual screening calculations. Patients were segmented into 2 cohorts based on evidence of an eye exam within the first year of
The 2013 updated guidelines from American College of Cardiology (ACC) and American Heart Association (AHA) recommend primary prevention with statins for nearly all adults with diabetes mellitus (DM) age 40 to 74. However, there remains uncertainty of the real world value statins provide.

**OBJECTIVE:** To determine the proportion of commercially insured members with diabetes (MwDM) age 40 to 64 without history of atherosclerotic cardiovascular disease (ASCVD); percentage of 2015 adverse cardiovascular events (CV events) in MwDM that occurred in this subset; percentages of this subset that had any pharmacy claim (Rx) for a statin and were adherent to statin therapy in 2014, and the association between statin therapy in 2014 and 2015 CV events.

**METHODS:** All 15 million members from 10 clients were queried to identify those continuously enrolled 2014-2015, younger than 65 years without adjustment for rebates or coupons. Expense described is the sum of insurer and member payments for drugs and secondary preventive care. Atherosclerotic cardiovascular disease (ASCVD) and conditions usually due to ASCVD accounting for 10.0%, claims with DM as first Dx 9.2% (DM without complications 5.1%), chronic kidney disease 8.8%, infections 5.1%, other categories 9.6%, and all other Dx codes 22.1%.

**RESULTS:** Out of an average of about 13.8 million member-years per year, there were 5.5 million continuously enrolled members who met stated criteria, of whom 281,221 (5.1%) were categorized as MwDM. Mean total cost per member per year (PMPY) in 2014 for all MnotDM was $4,322 vs. $14,198 for MwDM (3.28 × higher) and in 2015 $4,849 vs. $17,345 (3.58 × higher). However, PMPY for matched MnotDM was $5,938 in 2014 (DM 2.39 × higher) and $6,832 in 2015 (DM 2.54 × higher), showing that about 16% of the difference from MnotDM was due just to the older age distribution of MwDM. Of the remaining difference in PMPY for 2014+2015 combined Rx accounted for 35.2% with DM drugs and supplies accounting for 25.3% and lipid regulators and antihypertensives 4.5%; medical claims accounted for 64.8% (28.2% inpatient + 36.6% outpatient) with atherosclerotic cardiovascular disease (ASCVD) and complications 5.1%, chronic kidney disease 8.8%, infections 5.1%, other categories 9.6%, and all other Dx codes 22.1%

**CONCLUSIONS:** This recent real world data quantifies the substantial value statin therapy imparts to commercially insured individuals with diabetes, allowing for estimated program clinical event rate avoidance calculations. In 2014, the year following the latest ACC/AHA guidelines update, only 55% of these members had a statin claim and only 28% were adherent to statin therapy. Those adherent to statin therapy had about 25% lower incidence of adverse cardiovascular events.

**SPONSORSHIP:** Prime Therapeutics.
E11 Real-World Basal Insulin Intensification Patterns in the United States

Mocarski M1, Yeaw J2, Divino V2, DeKoven M2, Guerrero G2, Langer J3, Thorsted B3, 800 Scudders Mill Rd, Plainsboro, New Jersey 08536, mmkc@novonordisk.com; (609) 786-5251
1Prime Therapeutics; 2Schwan’s Shared Services; 3Novo Nordisk

BACKGROUND: Basal insulin is an important component of the treatment strategy in patients with type 2 diabetes mellitus (T2DM). However, many patients remain sub-optimally controlled after initiating basal insulin.

OBJECTIVE: To examine the prevalence of uncontrolled patients on basal insulin in a real-world setting and treatment intensification patterns and outcomes while uncontrolled.

METHODS: Adults diagnosed with T2DM newly initiating a basal insulin analog (insulin glargine or detemir) from 1/2010-12/2014 were identified in the QuintilesIMS PharMetrics Plus Health Plan Claims Database linked to ambulatory EMR data. Patients were previously naïve to insulin and GLP-1, persistent on therapy for ≥ 6 months, and had ≥12 months of continuous health plan enrollment. Intensification patterns (increase in basal dose of ≥10%), addition of bolus insulin, GLP-1 or a new oral antidiabetic drug) and outcomes were assessed among patients uncontrolled (A1c >7% i.e., in poor glycemic control) at 6-months following initiation over the available (minimum ≥12 months) follow-up. Kaplan-Meier (KM) analysis evaluated time to treatment intensification and time to A1c goal.

RESULTS: Of 427 eligible patients with A1c available at 6 months, 59% were male, mean age was 53.9 years, mean follow-up was 29.4 months and mean dose at initiation was 29.6 (median 24). Six months after initiating basal insulin, 81% of patients (n=346) remained in poor glycemic control and mean basal insulin dose was 31.0 insulin units (U; median 25U). Most (88%; n=306) of these uncontrolled patients subsequently intensified treatment over the available follow-up. Using KM analysis, these patients intensified treatment in a median of 38 days, with the vast majority remaining in poor glycemic control despite treatment intensification. Majority of those intensifying increased their basal insulin dose (76%; n=231); when intensified, mean dose at initiation was 61.7U (median 38U). Six months following basal insulin increase, 94% remained persistent, of those with an A1c value (n=152), 92% were still uncontrolled. Twelve months following basal insulin increase, only a third (34%) of uncontrolled patients added another antidiabetic agent.

CONCLUSIONS: The vast majority of patients remained uncontrolled in the 6 months following basal insulin initiation. Subsequently, most patients failed to achieve glycemic targets despite intensification with basal insulin. This suggests a substantial unmet need for effective treatment intensification among T2DM patients treated with basal insulin who remain uncontrolled.

SPONSORSHIP: No external sponsorship.

E12 Zero Dollar Diabetes Drug Coverage: Impact on Utilization, Costs, and Adherence

Bowen K1, Vaughn M2, Gleason P3, 1305 Corporate Center Dr, Eagan, MN 55121, kbowen@primetherapeutics.com; (612) 777-5436
1Prime Therapeutics; 2Schwan’s Shared Services

BACKGROUND: Providing zero dollar generic diabetes drug coverage has been associated with improved diabetes medication adherence. However, the impact of zero dollar diabetes drug coverage for both generics and branded formulary products has not been assessed.

OBJECTIVE: Compare pre/post annual diabetes drug utilization, costs, and adherence from a matched control group to the intervention group that implemented a zero dollar formulary brand and generic diabetes drug coverage benefit.

METHODS: The intervention group was a large national self-insured employer, with 20,000 insured lives. On 1/1/2015 a zero dollar formulary brand and generic diabetes drug coverage began and non-formulary diabetes drugs cost share remained at $70 per month or a 20% coinsurance. The control group consisting of continuously enrolled members during 2014 and 2015 who met HEDIS diabetes diagnosis criteria. All analyzable continuously enrolled intervention members were each matched to 10 control members on age, gender, and state from Prime Therapeutics national commercially insured database of 15 million members. Analyzable members diabetes drug claims total cost, defined as member plus plan paid, were obtained to calculate a per patient per year (PPPY) diabetes drug cost. Diabetes drug adherence was calculated annually using the CMS Star rating proportion of days covered (PDC) methodology of percentage with ≥80% PDC.

RESULTS: 816 intervention group members were matched to 8,160 control members. The change PPPY in diabetes drug claims was 4.2 (13.5 in 2014 to 19.7 in 2015) for the intervention group and 2.2 (14.9 to 17.1) for the control group. Member cost share (i.e., out of pocket expense) for diabetes drugs decreased $253 PPPY ($327 in 2014 to $74 in 2015) for the intervention group and increased $42 PPPY ($367 to $409) in the control group. Total cost for diabetes drugs increased $1,010 PPPY ($1,694 in 2014 to $2,704 in 2015) for the intervention group and increased $855 PPPY ($2,082 to $2,937) for the control group. Intervention group 2014 to 2015 adherence increased 4.4 percentage points, 71.6% to 76.0%, with the control group increasing 2.5 percentage points, 69.8% to 72.3%.

CONCLUSIONS: A zero dollar cost share for both generic and branded formulary diabetes drugs was associated with increased diabetes drug utilization, improved diabetes drug adherence, a substantial $253 PPPY member cost share savings, and an incremental additional $155 PPPY increase in total diabetes drug cost compared to the matched control group. The self-insured employer continues to provide zero dollar diabetes coverage into 2017.

SPONSORSHIP: No external sponsorship.

E13 Primary Care Physician Perception of the Diabetes Empowerment Education Program Within a Medicare Advantage Plan

Adodo B1, Essé T2, Serna O2, Abughosh S2, Vadhariya A3, 26203 Longmont Park Ln, Katy, TX 77494, blessing.adodo@gulfquest.net; (713) 437-3275
1Cigna-HealthSpring; 2University of Houston; 3University of Houston College of Pharmacy Dept of Pharmaceutical Health Outcomes and Policy

BACKGROUND: Diabetes self-management education (DSME) programs may be beneficial in handling non-compliant diabetic patients. The progression and daily burden of diabetes often take a toll on patients. DSME programs can provide patients comprehensive education for improved outcomes. However, primary care physician (PCP) perceptions of DSME programs in the literature have been mixed.

OBJECTIVE: To investigate Medicare Advantage Plan (MAP)-contracted PCP awareness of a geographically-focused DSME pilot, known as the Diabetes Empowerment Education Program (DEEP), which the MAP began facilitating in January 2016. In addition, perceptions of the program regarding necessity and views of patient outcomes among PCPs who reported referrals to the program were also evaluated.

METHODS: A survey was developed and administered to PCPs in South Texas/El Paso during December 2016 all-PCP meetings. PCP characteristics gender, race, age, and years in practice were included. The survey contained 14 questions using Likert scale answer choices and a free response section, and were validated using past literature and MAP medical director feedback. Group differences in program
Spontaneous adaptive capacity post-DEEP: PCP perceived clinical benefits post-DEEP. Responses were reported overall by PCP characteristics and group differences were evaluated using chi square tests.

RESULTS: A total of 80 surveys were distributed and 80 surveys were received back. 70% of PCPs reported awareness of DEEP (n = 56). There was a significantly lower awareness in PCPs located in South Texas (35.6%), compared to PCPs located in El Paso (100%) (P = 0.03). Among those aware, the majority of the responses were positive, displaying perceptions of moderately/extremely improved patient outcomes. There were no statistically significant differences in responses with PCP and practice characteristics.

CONCLUSIONS: Awareness of DEEP was significantly lower in the South Texas region compared to El Paso, indicating the need to educate PCPs in this area. Overall, DEEP was well received, and results indicated positive perception amongst PCPs that referred patients to the program. Future research should focus on evaluating patient perceptions of DSME programs like DEEP, as this feedback is crucial to program improvement coupled with the enhancement of patient care.

SPONSORSHIP: Center Point Clinical Services sponsored this project.

E15 Formulary Change Impact on Health Care Resource Use and Cost Among Patients with Type 2 Diabetes Treated with Insulin

Sudharshan L1, Saundankar V2, Cao D2, Nair R1, Curtis B1, Hoogwerf B2, Mondy R2, Meah Y3, Pasquale M1, Zhao Z2, 515 W Market St, 7th Fl, Louisville, KY 40202, lsudharshan@humana.com; (502) 301-2363
1Comprehensive Health Insights, Humana; 2Eli Lilly and Company; 3Humana

BACKGROUND: Beginning January 1, 2015, patients on insulin in closed commercial plans were subject to a formulary change, wherein Manufacturer A insulins required prerequisite therapy with Manufacturer B insulins.

OBJECTIVE: The objective of this study was to understand the impact of this formulary change on health care resource use (HCRU) and costs among patients with type 2 diabetes mellitus (T2DM) treated with insulin.

METHODS: This was a retrospective analysis of patients diagnosed with T2DM, enrolled in a commercial health plan with at least two pharmacy claims for insulin in the baseline period (2014). The new policy date of January 1, 2015 was set as the index date. At least 12-months pre- and post-index date enrollment was required. Patients were categorized into formulary change and no formulary change cohorts, and weighted by inverse probability of treatment weighting (IPTW) to help obtain comparable cohorts. HCRU [inpatient, outpatient and emergency department (ED) visits] and costs prior to and after formulary change were compared between cohorts using difference-in-difference (DID) analyses. Generalized linear mixed models with Gamma distribution and log link function were used to estimate treatment impact in pre- and post-change periods.

RESULTS: There were a total of 882 in the formulary change and 2,291 patients in the no formulary change cohorts. After weighting, baseline demographic and clinical characteristics were very similar between the two cohorts. Overall, mean age was 58 years, and > 50% of the patients were male. For the formulary change cohort as compared to the no formulary cohort, there was a net increase (DID) in outpatient visits (1.4), ED visits (0.2) and inpatient visits (0.06) resulting in a net increase in mean/median total health care cost ($5,941/$205), including increases in total medical cost ($6,184/$83), as well as a net change in total pharmacy cost (net decrease mean $244/net increase median $21); however, regression analyses found no statistical significance between the cohorts in costs over time (total health care P = 0.190, medical P = 0.355, pharmacy P = 0.919).

CONCLUSIONS: In this analysis, implementation of formulary change regarding insulin was found to be associated with an insignificant change in total HCRU and cost among patients with T2DM. These results should be interpreted with caution given the limited scope of this study.

SPONSORSHIP: Sponsored by Humana Lilly Research Collaboration.
E16 Assessment of New Onset Diabetes and Statin Medication Utilization

Barr P, Patel B. 401 Whittier Dr, Feasterville-Trevose, PA 19053; peri.barr@indegenecom; (610) 501-2583
Indegene

BACKGROUND: HydroxyMethyl Glutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (also called statins) and the development of new onset diabetes has been recently confirmed in the literature. A 2012 warning letter from the Food and Drug Administration (FDA) providing caution on statin drug use in diabetes patients merits research on management of diabetes as well as concomitant statin utilization in newly diagnosed patients.

OBJECTIVE: This study retrospectively examines medical records of patients newly diagnosed with type 2 diabetes mellitus. We assess potential contributing factors and statin use, while evaluating patients’ current diabetes control compared to national standards.

METHODS: A United States retrospective medical chart review of 1,000 randomly selected adult patients with new onset diabetes, identified from 3 Accountable Care Organizations (ACOs), was conducted. Patients with a current diagnosis of diabetes (ICD-9 codes 250.00-250.93) in the study timeframe of January 1st 2013-December 31st 2014, and had at least one recorded follow-up visit after diagnosis. Patient demographics, comorbidities, blood pressure control, LDL screening and A1c level data were collected from the medical record and analyzed using t-tests or chi-square tests where appropriate. Analyses were stratified by statin use and A1c levels. A two-sided alpha level of 0.05 determined statistical significance.

RESULTS: The sample was 51% male and 49% Caucasian with a mean age of 66±12.7 years. A total of 501 (50.1%) diabetes patients were on a statin by the end of the study period. Patients on a statin were significantly more likely to have blood pressure below 130/80 (P=0.032) and LDL below 100 mg/dl (P=0.018) than patients not on a statin. No significant difference in age, gender or A1c level was present between statin and non-statin use patients. Out of 978 total patients that had a recorded A1c level in their medical record, 794 (81%) patients had a recent A1c level at 8% or less. Statin usage was comparable between ≤8% and >8% A1c groups of patients, with Atorvastatin and Simvastatin being the most common statins used.

CONCLUSIONS: In this real-world observational study, only 50% of diabetes patients were on a statin. Diabetes patients taking a statin were more likely to have their blood pressure and LDL levels within national controls, compared to diabetes patients not on a statin.

SPONSORSHIP: Kowa Pharmaceuticals.

E17 Cost Offsets Predicted with Empagliflozin in Patients with Type 2 Diabetes and Established Cardiovascular Disease

Wilson M*, Sander S*, Kuti E1, Lucas A1. 3040 Cornwallis Rd, Research Triangle Park, NC 27709-2194; mwilson@rti.org; (919) 316-3731
1RTI Health Solutions; 2Boehringer Ingelheim Pharmaceuticals

BACKGROUND: The randomized EMPA-REG OUTCOME trial demonstrated that the addition of empagliflozin (empa) to standard-of-care (SoC) therapy reduced the risk of cardiovascular (CV) outcomes in patients with type 2 diabetes (T2DM) who have established CV disease.

OBJECTIVE: To model the health-plan cost offsets of empa plus SoC versus SoC only in patients with T2DM and established CV disease.

METHODS: We created an economic model to compare the cost offsets associated with treating adult T2DM patients with established CV disease with empa plus SoC versus treating the same patients with SoC only. Patients incurred annual risks for CV outcomes (nonfatal myocardial infarction, noncardiac stroke, or CV death), renal outcomes (continuous renal replacement therapy, acute renal failure, and chronic kidney disease) and adverse events observed in the EMPA-REG OUTCOME trial. Annual costs associated with these outcomes were taken from the published literature. Annual drug costs were estimated based on resource use in the trial and wholesale acquisition costs from Redbook. We modeled a 5-year time horizon to estimate the annual, per-member per-month (PMPM) and per-treatment-member per-month (PTMPM) costs and outcomes for patients receiving empa plus SoC and SoC only. Results were reported as incremental PMPM and PTMPM.

RESULTS: When compared with SoC only, treating a starting population of all 23,220 adult T2DM patients with established CV disease with empa plus SoC was found to have incremental PTMPM total costs of $3790, $205, $401.3, $83.51, and -$130.22 in years 1 through 5, respectively. Incremental PMPM total costs were estimated to be 0.88, 0.54, 0.11, -0.43, and -1.08 in years 1 through 5, respectively. Over the 5-year period, treating all adult T2DM patients with established CV disease with empa plus SoC was associated with the avoidance of 2,089 CV outcomes (including 966 avoided CV deaths) compared with SoC only.

CONCLUSIONS: In adult T2DM patients with established CV disease, use of empa plus SoC was associated with overall health care cost savings over a 5-year time horizon, driven by reductions in fewer CV outcomes including CV death.

SPONSORSHIP: Boehringer-Ingelheim Pharmaceuticals.
and $793 (61%) more per month than non-SH/AH comparison patients ($2,098 vs. $1,305). About one-third of index patients were hospitalized again for SH.

CONCLUSIONS: The burden associated with SH is not trivial. About 4% of T1DM patients are hospitalized at least once due to SH. Not only do those patients incur the costs of their SH hospitalization, but they also incur at least $776 more per month after their hospitalization than comparison patients. Limitations include: not all SH events may have been captured or coded, we do not know of patients used insulin as directed, clinical information may be incorrectly coded or not captured at all, and these results may be biased due to confounding factors we cannot measure using administrative data.

SPONSORSHIP: Funded by Novo Nordisk.

E19 Health Care Resource Costs and Utilization for Type 2 Diabetes Patients on New Antidiabetic Classes Compared to Traditional Classes in Central Texas

Yu S1, Godley P1, Liao F1, Ivy D2, Cryar A3, Bell K3, Hardisty J. 1Lark Tree Way, Hacienda Heights, CA 91745; stephanie.yu@bswhealth.org; (254) 724-9696
1Baylor Scott & White Health; 2Texas A&M School of Pharmacy; 3AstraZeneca

BACKGROUND: According to 2016 AACE/ACE Comprehensive Type 2 Diabetes (T2D) Management Algorithm, new anti-diabetes classes (NAC): SGLT2i, GLP1-RA, or DPP4i, are preferred over more traditional anti-diabetes classes (TAC: SU, TZD, Meglitinide) for dual therapy. Incorrect dosing that delivers excess amounts of insulin can cause severe hypoglycemia (SH), a condition that requires immediate medical attention and that could result in seizures, coma, and death.

OBJECTIVE: To estimate and compare all-cause and diabetes-related health care resource utilization and costs associated with NAC and TAC in patients with T2D.

METHODS: This was a retrospective analysis of medical and pharmacy claims from the Scott and White Health Plan. Patients were required to be > 18 years old, with ICD9 diagnosis of T2D and use of TAC at least one year prior to first claim for a NAC for the index date. Differences in inpatient, emergency department, and outpatient utilization from baseline period (one year prior to index date) were evaluated between the NAC vs. TAC groups.

RESULTS: About 1.1% of T2D patients were hospitalized for SH (712 index vs. 1,909 SH comparison and 63,358 non-SH/AH comparison patients); most (67%) index patients were hospitalized for SH not only occurred the costs of their SH hospitalizations, with and without an accompanying emergency department (ED) admission, for SH; to estimate the prevalence and costs of SH-related hospitalizations; and to estimate the long-term costs of those SH-related hospitalizations.

CONCLUSIONS: The immediate and long-term impacts of SH in patients with T2D are substantial. Patients with T2D who were hospitalized for SH not only incurred the costs of their SH hospitalization, but also at least $1,222 more per month following their hospitalization than comparison patients. Limitations include: not all SH events may have been captured or coded, we do not know of patients used insulin as directed, clinical information may be incorrectly coded or not captured at all, and these results may be biased due to confounding factors we cannot measure using administrative data.

SPONSORSHIP: Funded by Novo Nordisk.

E20 The Burden of Severe Hypoglycemia in Type 2 Diabetes

Liu J1, Wang R1, Ganz M2, Paprocki Y2, Weatherall J2. 500 Totten Pond Rd, 5th Fl, Waltham, MA 02451; jieruo.liu@evidera.com; (781) 960-0237
1Evidera; 2Novo Nordisk

BACKGROUND: More than 27 million people in the United States have type 2 diabetes mellitus (T2DM), a chronic metabolic disease that develops from insulin resistance and may ultimately require insulin therapy. Incorrect dosing that delivers excess amounts of insulin can cause severe hypoglycemia (SH), a condition that requires immediate medical attention and that could result in seizures, coma, and death.

OBJECTIVE: To identify patients with T2DM who have been hospitalized, and without an accompanying emergency department (ED) admission, for SH; to estimate the prevalence and costs of SH-related hospitalizations; and to estimate the long-term costs of those SH-related hospitalizations.

METHODS: Using Truven MarketScan claims we identified adult T2DM patients basal (without bolus) insulin who were hospitalized for SH (index patients) from 2010-2015. We estimated lengths of stay (LOS) and costs for SH-related hospitalizations. We defined two T2DM comparison groups: those with SH-related outpatient encounters only, including ED admissions not resulting in hospitalization (SH comparison) and those without any SH- (or acute hyperglycemia [AH]) related events (non-SH/AH comparison). Propensity scores and inverse probability weighting methods were used to adjust for baseline differences across the groups.

RESULTS: About 1.1% of T2DM patients were hospitalized for SH (712 index vs. 1,909 SH comparison and 63,358 non-SH/AH comparison patients); most (67%) index patients were admitted to the hospital through the ED. Index patients spent on average 2.81 (SD: 3.40) days in the hospital and incurred an average of $6,898 during their stay. Index patients incurred $1,222 (52%) more per month following their SH hospitalization than SH comparison patients ($3,586 vs. $2,364) and $1,316 (82%) more per month than non-SH/AH comparison patients ($2,928 vs. $1,612). About 40% of index patients were hospitalized again for SH.

CONCLUSIONS: The immediate and long-term impacts of SH in patients with T2D are substantial. Patients with T2D who were hospitalized for SH not only incurred the costs of their SH hospitalization, but also at least $1,222 more per month following their hospitalization than comparison patients. Limitations include: not all SH events may have been captured or coded, we do not know of patients used insulin as directed, clinical information may be incorrectly coded or not captured at all, and these results may be biased due to confounding factors we cannot measure using administrative data.

SPONSORSHIP: Funded by Novo Nordisk.

E29 Evaluating Physician-Perceived Benefit of Lumacaftor/ Ivacaftor in Patients with Cystic Fibrosis

Pike T, Reportosi S, Tungol Lin A. Mail Code 512C, 600 E Lafayette Blvd, Detroit, MI 48226; tpike@bcbsm.com; (313) 448-7868
Blue Cross Blue Shield of Michigan

BACKGROUND: Lumacaftor/ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients 12 and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, which affects nearly 8,500 patients in the United States. Medical directors of certified Cystic Fibrosis Foundation centers in Michigan challenge if pulmonary function tests (PFTs) are appropriate before coverage determination of lumacaftor/ivacaftor since it is not solely used in practice, although used to assess efficacy in its...
OBJECTIVE: Evaluate physician reported outcomes in members on lumacaftor/ivacaftor therapy.

METHODS: Commercially insured members with Blue Cross Blue Shield of Michigan pharmacy coverage on lumacaftor/ivacaftor therapy were identified using pharmacy claims data and prior authorization (PA) requests from July 2015 to March 2016. Surveys were faxed to physicians of members with complete renewal requests and 8 (17.8%) discontinued therapy; 12 (26.7%) with incomplete renewal requests were excluded. Renewal group had a 48.0% response rate (n = 25) and clinical benefit was observed among the majority of respondents: reduction in antibiotic use (88.9%, n = 9), pulmonary exacerbations (88.9%, n = 9), hospitalizations (77.8%, n = 9) and improvements in quality of life (75.0%, n = 8), PFTs (60.0%, n = 10) and weight gain (55.6%, n = 9). Discontinued group had a 23.0% response rate (n = 8), citing respiratory events (100.0%, n = 2) as rationale for discontinuation. Lack of benefit, cost and non-adherence were not identified as reasons for discontinuation.

RESULTS: A total of 45 unique members were continuously enrolled with an approved PA and initial paid claim for lumacaftor/ivacaftor from July 2015 to March 2016. Twenty-five (55.6%) members had complete renewal requests and 8 (17.8%) discontinued therapy, 12 (26.7%) with incomplete renewal requests were excluded. Renewal group had a 48.0% response rate (n = 25) and clinical benefit was observed among the majority of respondents: reduction in antibiotic use (88.9%, n = 9), pulmonary exacerbations (88.9%, n = 9), hospitalizations (77.8%, n = 9) and improvements in quality of life (75.0%, n = 8), PFTs (60.0%, n = 10) and weight gain (55.6%, n = 9). Discontinued group had a 23.0% response rate (n = 8), citing respiratory events (100.0%, n = 2) as rationale for discontinuation. Lack of benefit, cost and non-adherence were not identified as reasons for discontinuation.

CONCLUSIONS: Respondents cite top benefits of lumacaftor/ivacaftor as reductions in antibiotic use and pulmonary exacerbations. Physicians discontinued lumacaftor/ivacaftor treatment due to respiratory adverse reactions.

SPONSORSHIP: Blue Cross Blue Shield of Michigan.


Klein R1, Kabadi S2, Cinchio F1, Bly C1, Taylor D1, Szymanski K2. 201 N. Illinois, #1730, Indianapolis, IN 46204; rwk@mdm-inc.com; (317) 704-3801
1Medical Decision Modeling; 2AstraZeneca

BACKGROUND: Gout is an inflammatory condition that arises with the formation and deposition of urate crystals as a consequence of chronic hyperuricemia.

OBJECTIVE: To estimate the budget impact on U.S. payers adopting lesinurad as an add-on to allopurinol treatment for second-line urate-lowering therapy in gout patients for whom allopurinol monotherapy has failed to reduce serum uric acid (sUA) below the American College of Rheumatology recommended target (≤ 6.0 mg/dL).

METHODS: A Markov cohort model was developed for a U.S. payer perspective, using a Markov model to estimate costs, survival, and discontinuation in a 1-million-member health plan. The model population included patients failing first-line gout therapy; patients were followed for 5 years. A scenario based on allopurinol and febuxostat use was compared with a future scenario in which lesinurad is added to a portion of allopurinol patients not meeting sUA goal. The proportion of patients using lesinurad was assumed to increase from 1.2% to 5.2% over 3 years. The model inputs were primarily derived from the CLEAR1 and CLEAR2 phase III trials of lesinurad. Indirect comparison methods were used to estimate febuxostat parameters. Annual and cumulative incremental costs between the 2 scenarios were reported as total cost, per-member per-month (PMPM) cost, and cost per treated patient per year. One-way sensitivity analysis was conducted to evaluate uncertainty using approximate 95% confidence intervals.

RESULTS: A total of 8,205 or 8,228 patients would be treated with a second-line therapy in treatment mixes with and without lesinurad, respectively. The incremental costs of adding lesinurad compared with no lesinurad were $241,907 in the first year and $1,098,220 in the fifth year, for a cumulative 5-year incremental cost of $3,633,440. Cumulative 5-year cost per treated gout patient per year was $112 and cumulative incremental 5-year PMPM was estimated at $0.06. Sensitivity analysis indicated the model was most sensitive to the proportion of patients receiving lesinurad, male gout prevalence, and lesinurad+allopurinol cost, each with a range of total incremental costs exceeding $750,000 or PMPM $0.01. Allopurinol discontinuation rate and cost, female gout prevalence, and annual gout prevalence increase were the only other inputs tested with a 5-year incremental cost range exceeding $100,000.

CONCLUSIONS: Initiating the use of lesinurad would result in a cumulative total incremental PMPM cost of approximately $0.06 over 5 years.

SPONSORSHIP: Sponsored by AstraZeneca.

E31 Cost-Effectiveness of Adding Lesinurad to Allopurinol for Second-Line Urate-Lowering Therapy in Gout Patients: A U.S. Payer Perspective

Klein R, Kabadi S, Khanna P1, Gahn J1, Bly C, Kelton K1, Taylor D1, Morlock R1. 201 N. Illinois, #1730, Indianapolis, IN 46204; rwk@mdm-inc.com; (317) 704-3801
1Medical Decision Modeling; 2AstraZeneca; 3University of Michigan; 4Ironwood Pharmaceuticals; 5YourCareChoice

BACKGROUND: Gout is a painful inflammatory condition that arises as a consequence of chronic hyperuricemia and is characterized by sudden, severe attacks of pain, redness, and tenderness in joints. Long term, tophi may form. Many patients do not achieve target serum uric acid (sUA) (< 6.0 mg/dL) using allopurinol monotherapy.

OBJECTIVE: To determine the cost effectiveness of adding lesinurad to allopurinol, for second-line treatment in gout patients for whom allopurinol monotherapy has failed to reduce sUA levels below the American College of Rheumatology recommended target.

METHODS: A Markov cohort model with a U.S. private-payer perspective and life time horizon was developed. The modeled patient population was based on pooled data from the CLEAR 1 and CLEAR 2 phase III trials of lesinurad and adjusted for the U.S. gout prevalence by gender. Epidemiology, flare prophylaxis and treatment, utility, safety, efficacy, and treatment costs data were combined to estimate the costs and cost-effectiveness of sUA-lowering treatment using allopurinol alone or in combination with lesinurad or febuxostat. Data were obtained from clinical trials, published literature, government resources, and augmented with assumptions where necessary. Febuxostat inputs were based on comparisons to allopurinol. Key outputs include estimates of mean costs and quality-adjusted life years (QALYs) per patient for each treatment, and incremental cost effectiveness ratios (ICER). Clinical components such as number of flares and tophi changes over time based on sUA were also reported.

RESULTS: When compared to allopurinol monotherapy, lesinurad in combination with allopurinol had an estimated ICER of $132,000 per QALY (rounded to $1,000s). Febuxostat was dominated by allopurinol monotherapy. When compared directly to febuxostat, lesinurad in combination with allopurinol had an ICER of approximately $62,000 per QALY. The discontinuation of treatment results in high sUA levels. Over the
average lifetimes of about 25 years, the mean number of flares per patient year were 10.1 for allopurinol in combination with lesinurad, 11.2 for allopurinol monotherapy, and 12.9 for febuxostat. Mean patient years with tophi were 5.6, 7.3, and 7.0 for allopurinol in combination with lesinurad, allopurinol monotherapy, and febuxostat, respectively.

CONCLUSIONS: In a U.S. commercial health care plan, cost-effectiveness analysis demonstrates that compared to febuxostat and allopurinol monotherapy, lesinurad in combination with allopurinol increases QALYs and result in ICERs that may be considered cost effective.

SPONSORSHIP: This study was sponsored by AstraZeneca.

E32 Osteoarthritis and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
240 E 39th St, Apt 14B, New York, NY 10016; svetlana.krasnokutskysamuel@nymc.org; (646) 645-7899
1New York University; 2AstraZeneca; 3Ironwood Pharmaceuticals; 4CareChoice

BACKGROUND: Gout and osteoarthritis (OA) are common in the U.S., but little is known about potential associations of OA and hyperuricemia/gout with clinical outcomes.

OBJECTIVE: This study examined variations in gout severity, management, and health care utilization among gout patients with and without OA.

METHODS: Data were assessed from a survey of U.S. physicians and patient chart audits. Participating physicians managed the care of ≥50 patients with gout annually; chart audits were of their last 5 consecutive adult patients with confirmed gout. Gout severity was measured by physician global assessment, flares, organ/joint damage, and tophi. Treatment characteristics, presence of clinician-confirmed OA, and sociodemographics were identified. Descriptive and multivariate (stepwise logistic regression) statistics analyzed the differences among gout patients with and without clinician-confirmed comorbid OA, and assessed urate-lowering therapy (ULT) use and gout control.

RESULTS: Overall, 1,159 charts of gout patients were abstracted (230 w/OA, 929 w/o; 81% male; 71% white); the proportion of patients age ≥61 with gout was greater for those with OA than without OA (61% vs. 32%; P < 0.001). Patients with gout and OA had longer mean duration of gout (63 vs. 41 months), were more likely to have tophi (44% vs. 19%), joint damage (31% vs. 11%), and clinician-rated severe gout (31% vs. 12%) than those without OA (all P < 0.01). Patients with gout and OA were also more likely to receive ULT (89% vs. 70%; P < 0.01), and among those receiving ULT, OA patients treated with allopurinol received a higher average daily dose (325 mg vs. 295 mg; P = 0.031). Gout patients with OA were more likely to have additional comorbidities (cardiovascular disease, kidney disease, COPD, depression, diabetes, hyperlipidemia, hypertension, obesity, prostate problems [men]) and have chronic pain than those without OA (all P < 0.05). Gout patients with OA reported more office visits (4.0 vs. 3.5), were more likely to have an emergency department visit (17% vs. 9%), and were more likely to require surgery for gout in the past 12 months (3% vs. 0.3%) (all P < 0.01). In both groups, ULT use was associated with better gout control, but the specific factors predictive of ULT use and disease control varied between those with and without OA.

CONCLUSIONS: Gout patients with OA were more likely to have a greater impact on health system spending, with additional comorbidities and more severe gout than those without OA. These data suggest that gout patients with OA constitute a less healthy group in need of careful monitoring and more aggressive gout management.

SPONSORSHIP: AstraZeneca.

E33 Utilization and Cost of Diabetic Medications Among U.S. Medicare Part D Beneficiaries
Zhao J1, Carlson A2. 17600 Haraldson Dr, Eden Prairie, MN 55347; zhaox086@umn.edu; (612) 298-1867
1University of Minnesota College of Pharmacy; 2Data Intelligence Consultants

BACKGROUND: The total cost of diabetes in the United States in 2012 has been estimated at $245 billion with the second largest expenditure being prescription medications to treat the complications of diabetes (18% or about $64 billion). Medications are a key element in diabetes management.

OBJECTIVE: This study evaluates the diabetes medication prescribing patterns of U.S. health care providers.

METHODS: The 2013 Medicare Part D Prescriber Public Use File was used for analysis. Diabetes medications were identified using drug name and the chemical ingredient information available in the data file. Diabetes-related brand/generic medication prescribing patterns were determined for providers by specialty type, diabetes drug class, and geographic region. Multivariate logistic regression models examined the association between geographic regions and generic prescribing patterns.

RESULTS: In 2013 the total cost paid for all prescriptions in Medicare Part D program was $80.9 billion; diabetes-related medications accounted for 11% ($8.6 billion) of the total cost. Insulin products accounted for 63% of the total diabetes drug cost; other brand name hypoglycemic drugs accounted for 27% of the total diabetes drug cost. Generic drugs accounted for 10% of diabetes drug cost. The most prescribed generic medication was metformin, accounting for 4% of the total diabetes drug costs. The brand drug Januvia (sitagliptin) accounted for $1.3 billion or 15% of all diabetes drug claim expenditures. Practitioners identified as primary care providers (e.g. family practice, pediatrics, nurse practitioner) accounted for 89% of the total diabetes drug claim counts; 11% of the total diabetes drug claims were attributable to specialists. A small number of claims were attributed to unknown providers. A significant difference in the proportion of generic prescribing was noted by geographic region-highest in the West (mean 73%±0.05%) and lowest in the Midwest (68%±0.05%). In the multivariate model, the odds of prescribing generic drugs were higher in the West region (adjusted odds ratio (AOR) = 1.18, 95% CI = 1.16-1.19), compared with the South region. Primary care providers have higher odds of prescribing generic drugs (AOR = 1.50, 95% CI = 1.52-1.49) compared to Specialists.

CONCLUSIONS: Diabetes care, as evidenced by prescription medication prescribing, is largely provided by family practice physicians. Generic medications contribute only 10% of all diabetes drug costs. Insulin and brand name product prescribing have a dramatic effect on total costs of diabetes medications.

SPONSORSHIP: None.

E34 Health Care Resource Utilization Among School-Aged Children with Cystic Fibrosis
Rubin J1, Bonafede M2, Limone B2, Adolph N2, Konstan M3. 50 Northern Ave, Boston, MA 02210; jaime_rubin@vrtx.com; (617) 961-7557
1Vertex Pharmaceuticals; 2Truen Health Analytics; 3Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital

BACKGROUND: CF is a rare, progressive genetic disease affecting patients (pts) from birth. The pattern of health care resource utilization (HCRU) by age among school-aged pts with CF using administrative claims data is not well described.
OBJECTIVE: To evaluate the frequency of inpatient (IP) admissions, outpatient (OP) office visits, medication utilization, and pulmonary exacerbations (PEx) by age in a cohort of school-aged pts with CF.

METHODS: This retrospective study used administrative claims from the Truven Health MarketScan Commercial (COMM) and Medicaid Multi-State (CAID) databases. Pts with CF aged 6-17 years were identified as having ≥1 IP or ≥2 OP claims ≥30 days apart with a primary diagnosis of CF (ICD-9-CM: 277.0x) between 2010-2015 and ≥12 months of continuous health plan coverage. Study outcomes included IP admissions, OP office visits, and PEx events requiring IP admission and/or intravenous (IV) antibiotics, evaluated by 1-year age groups using pts' most recent year of data. Multivariate logistic regression analyses were conducted to determine impact of age on outcomes after controlling for other demographics, common comorbidities, and medications.

RESULTS: The COMM cohort included 2,400 pts with CF (mean [SD] age: 11.9 [3.5] years) and the CAID cohort 1,264 (mean [SD] age: 11.4 [3.5] years). Proportions of pts with IP admissions increased with age: 20.7% (COMM) and 29.6% (CAID) at age 6 and 46.7% (COMM) and 49.6% (CAID) at age 17. Based on logistic regression analyses the odds of an IP admission were 1.048 and 1.063 times greater with each 1-year increase in age for COMM and CAID pts, respectively (P<0.01 for both). OP office visits remained stable with age (range in COMM, 8.8-11.2 visits; CAID, 8.4-12.6 visits). Proportions of pts with ≥1 PEx requiring IP admission/IV antibiotics were higher in older age groups: 21.9% (COMM) and 28.7% (CAID) at age 6 and 45.9% (COMM) and 50.4% (CAID) at age 17 (maximum 47.4% [COMM] and 64.8% [CAID] at age 16). PEx event rates were 0.3 and 1.1 (COMM) and 0.4 and 1.3 (CAID) per person per year at ages 6 and 17 (maximum 1.4 [COMM] and 1.6 [CAID] at age 16). Based on logistic regression analyses the odds of PEx events were 1.041 and 1.048 times greater with each 1-year increase in age for COMM and CAID pts, respectively (P<0.05 for both).

CONCLUSIONS: School-aged pts with CF incur significant HCRU at all ages. The risk of hospitalizations and PEx events increases with age, highlighting the need for treatments that slow disease progression throughout school-aged years.

SPONSORSHIP: Sponsored by Vertex Pharmaceuticals.

RESULTS: The analyses included 47 patients with CF who had ABS, 393 patients who had STD, and 351 patients who had LTD eligibility coverage (overall mean age: 35.7-38.2 years). Of those with eligibility, 74% (n=35), 23% (n=89), and 5% (n=16) had a claim for ABS, STD, and LTD, respectively. Of the 35 patients with an ABS claim, 31 (89%) had a PEx event and used 3.5 times more ABS hours than those without a PEx (n=4) (mean [SD]: 193 [303] vs. 52 [33]). Of the 31 patients with a PEx event, 7 (23%) had ≥1 IP event and used almost 2 times more ABS hours than those with only OP events (mean [SD]: 305 [294] vs. 160 [304]). Of the 89 patients with a STD claim, 80 (90%) had ≥1 PEx event. The odds of a patient having a STD claim increased with additional PEx events (OR: 1.23, P=0.005). All 16 patients with an STD claim had a PEx event. The analyses also included 114 caregivers of patients with CF who had ABS eligibility coverage and an ABS claim in the OY. Of these, 104 (91%) had a dependent patient with a PEx event. Among these, caregivers whose dependent CF patient had ≥1 IP PEx event (n=45) used 1.3 times more ABS hours than caregivers (n=59) whose dependent CF patients had only OP PEx events (mean [SD]: 100 [103] vs. 75 [77]).

CONCLUSIONS: A high burden of lost productivity in terms of ABS, STD, and LTD claims was observed among CF patients with PEx events in this commercially insured population. Additionally, caregivers who had an ABS claim showed greater productivity loss for the dependent CF patients with IP PEx events vs. OP PEx events.

SPONSORSHIP: Sponsored by Vertex Pharmaceuticals.

E35 Productivity Loss Associated with Pulmonary Exacerbations Among Patients with Cystic Fibrosis and Caregivers

Johnson B1, Bhanegounder A2, Hassan M2, Bonafede M1, Limone B1, Unni S3, Brixner D3. 150 Cambridge Park Dr, Cambridge, MA 02140; barbara.h.johnson@truvenhealth.com; (617) 492-9300
1Truven Health Analytics; 2Vertex Pharmaceuticals; 3Pharmacotherapy Outcomes Research Center, University of Utah

BACKGROUND: Pulmonary exacerbations (PEx) are seen in cystic fibrosis (CF), a rare progressive genetic disease.

OBJECTIVE: To assess the impact of PEx on productivity among employed patients with CF and adult caregivers of dependent patients with CF.

METHODS: Adult patients with CF with 12 continuous months of eligibility coverage for nonrecreational absenteeism (ABS), short-term disability (STD), and/or long-term disability (LTD) in MarketScan Commercial and Health and Productivity databases from 2008 to 2014 were included. Caregivers of dependent patients with CF with ABS eligibility coverage were also evaluated. The most recent 12 continuous months of data (observation year, [OY]) were used. PEx (defined hierarchically as inpatient [IP] admission or outpatient [OP] IV/oral antibiotic use) were identified in the OY. Lost productivity due to PEx was analyzed based on ABS, STD, and LTD claims. Logistic regression models were fit to predict the effect of PEx on lost productivity.

RESULTS: The analyses included 47 patients with CF who had ABS, 393 patients who had STD, and 351 patients who had LTD eligibility coverage (overall mean age: 35.7-38.2 years). Of those with eligibility, 74% (n=35), 23% (n=89), and 5% (n=16) had a claim for ABS, STD, and LTD, respectively. Of the 35 patients with an ABS claim, 31 (89%) had a PEx event and used 3.5 times more ABS hours than those without a PEx (n=4) (mean [SD]: 193 [303] vs. 52 [33]). Of the 31 patients with a PEx event, 7 (23%) had ≥1 IP event and used almost 2 times more ABS hours than those with only OP events (mean [SD]: 305 [294] vs. 160 [304]). Of the 89 patients with a STD claim, 80 (90%) had ≥1 PEx event. The odds of a patient having a STD claim increased with additional PEx events (OR: 1.23, P=0.005). All 16 patients with an STD claim had a PEx event. The analyses also included 114 caregivers of patients with CF who had ABS eligibility coverage and an ABS claim in the OY. Of these, 104 (91%) had a dependent patient with a PEx event. Among these, caregivers whose dependent CF patient had ≥1 IP PEx event (n=45) used 1.3 times more ABS hours than caregivers (n=59) whose dependent CF patients had only OP PEx events (mean [SD]: 100 [103] vs. 75 [77]).

CONCLUSIONS: A high burden of lost productivity in terms of ABS, STD, and LTD claims was observed among CF patients with PEx events in this commercially insured population. Additionally, caregivers who had an ABS claim showed greater productivity loss for the dependent CF patients with IP PEx events vs. OP PEx events.

SPONSORSHIP: Sponsored by Vertex Pharmaceuticals.

F00-F99 Mental and Behavioral Disorders (e.g., Depression, Antipsychotics, Schizophrenia, Bipolar Disorder)

A Multichannel Prescriber-Directed Program Including Case Management to Reconcile Potential Opioid Overutilization

Leslie R, Benson T, Frazier M, Patel B, Gonzales P. 10181 Scripps Gateway, San Diego, CA 92128; scott.leslie@medimpact.com; (858) 790-6685
MedImpact Health Care Systems

PROBLEM DESCRIPTION: The 2013 CMS Call Letter introduced the Overutilization Monitoring System (OMS) and directed Part D plans to employ retrospective drug utilization review and case management approaches to address potential opioid overutilization. CMS is currently considering high opioid use as quality measure for the 2019 Display Ratings and started reporting concurrent benzodiazepine (BZD) to encourage management for both drug classes.

GOAL: Two national prescription drug plans, Medicare GenerationRx and Transamérica MedicareRx, implemented a case management program, operated by MedImpact, to coordinate care and survey prescribers to limit potential opioid overuse.

PROGRAM DESCRIPTION: Starting April 2013, monthly claims analysis identified members with cumulative daily morphine equivalent dose (MED) exceeding 120 mg for at least 90 consecutive days and with ≥3 prescribers and ≥3 pharmacies. Prescribers were sent a questionnaire to attest that prescribed opioid medication(s) and current cumulative opioid dosages were appropriate, medically necessary, and safe. Prescribers were also given options to manage opiate use by limiting coverage. Available survey responses included: appropriate therapy, not aware my patient was on high doses, will refer to pain clinic, not my patient, did not prescribe these medications and/or limit quantity or type of opiate. Prescribers not responding by fax were contacted within 10 days of identification. A case management pharmacist reviewed all cases. To measure program effectiveness prescriber responses were clinically evaluated to reconcile final case outcomes.
OBSERVATIONS: A total of 617 patients were identified between April 13th and October 16th. The average daily MED was 276 mg. All prescribers responded and the most common outcome based on case management calls was ‘appropriate pain treatment’ (52%) followed by ‘overutilization resolved’ (31%) and appropriate use for cancer treatment (7%). Opioid summary rates per 1,000 members (January-October) for high dose (HD), multiple provider (MP) and HDMP were lower (27.9, 5.7, 0.3) than national Prescription Drug Plan rates (45.3, 14.1, 1.3).

FINDINGS/RECOMMENDATIONS: This program offers a solution to the OMS recommendations, supports efforts to reconcile opioid use and coordinates care with multiple prescribers. Future program components include detecting concurrent BZD-high opiate use (Phase 2), and coordinates care with multiple prescribers. Future program components include detecting concurrent BZD-high opiate use (Phase 2), flexible identification techniques to address current and future opioid-related quality measures.

SPONSORSHIP: Prime Therapeutics.

F3 Employing Bayesian-Calibrated Microsimulation to Assess the Cost-Effectiveness of Long-Acting Injectable Buprenorphine Versus Sublingual Buprenorphine to Treat Opioid Use Disorder

Carter J1, Danziger E2, Frost M1, Tiberg F3. 1315 W 22nd St, Ste #10, Oak Brook, IL 60523; john.carter@epi-q.com; (630) 696-6980

1EPI-Q; 2Braeburn Pharmaceuticals; 3Eagleville Hospital; 4Camurus AB

BACKGROUND: Responding to an opioid epidemic due partly to misuse of orally-administered opioids, the FDA granted fast-track status to long-acting, injectable buprenorphine (LA-BPN) for opioid use disorder (OUD). A recent 24-week Phase 3 clinical trial demonstrated that LA-BPN was non-inferior and superior to sublingual BPN (SL-BPN) in primary and key secondary endpoints, respectively.

OBJECTIVE: Given the high economic burden of opioid misuse in the United States we sought to assess the health-economic implications of an effective alternative to SL-BPN that cannot be diverted or misused.

METHODS: We developed a patient-level microsimulation to assess the incremental cost of LA-BPN per overdose avoided versus SL-BPN. Transitions occurred weekly through the following 4 health states for 24 weeks: on treatment (1) without or (2) with illicit opioid use, (3) off treatment with illicit opioid use, and (4) death. Between-state transition probabilities were derived from the pivotal Phase 3 clinical trial and were calibrated by Bayesian Monte Carlo methods to address the influence of patient characteristics. Within-state event probabilities were literature-based and included diversion/misuse, infection, hospital and rehabilitation services utilization, productivity loss, and accidental pediatric exposure. With a societal perspective, literature-based costs of within-state events, adverse events, and local reference costs for drug acquisition, administration, and monitoring were included (2016 USD). Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).

RESULTS: Consistent with trial outcomes, treatment retention over 24 weeks was similar between the two groups (~98%). SL-BPN patients encountered 3% higher rates of serious adverse events, 11% more relapses, and approximately 400% greater risk of non-fatal overdose. In the majority of model simulations, LA-BPN patients incurred fewer total costs and fewer drug overdoses versus SL-BPN in the base case analysis. Deterministic sensitivity analysis identified LA-BPN drug acquisition cost and relapse-associated hospital / emergency room utilization rates as key drivers of modeled outcomes. PSA confirmed a strong likelihood of cost-savings and fewer overdoses with LA-BPN depending on initial assumptions.

CONCLUSIONS: LA-BPN may be a cost-effective alternative to SL-BPN. These findings should be interpreted carefully as they are not based on direct observation. Nevertheless, LA-BPN offers an opportunity to improve OUD clinical outcomes and reduce the societal economic burden of OUD.

SPONSORSHIP: This study was sponsored by Braeburn and Camurus AB.
BACKGROUND: Recent analyses have reported that buprenorphine subdermal implant (BSI) is pharmacoeconomically superior to sublingual buprenorphine (SL-BPN), extended-release naltrexone (XR-NTX), and methadone (MTD) for opioid use disorder (OUD). These analyses considered patients who were clinically-stable and primarily abused prescription opioids. However, a large proportion of OUD patients are treatment-naïve and primarily abuse heroin, and are traditionally more difficult to treat owing to higher rates of relapse and treatment discontinuation.

OBJECTIVE: Herein, we report an economic model comparing BSI versus SL-BPN, XR-NTX, and MTD for OUD among this more difficult to treat subgroup.

METHODS: Outcomes from OUD clinical trials populated a Bayesian network meta-analysis (NMA) to derive odds abstinence on therapy. This included 8 trials of SL-BPN, MTD, and XR-NTX and 2 BSI trials that enrolled cohorts who were primarily treatment-naïve and primarily abused heroin. NMA outcomes were used in a Markov model simulating cohort progression for 12 months (cycled monthly) through four mutually-exclusive health states: on therapy (1) with or (2) without illicit opioid use, (3) off therapy with illicit opioid use, and (4) death. Each health state, cohorts accumulated direct medical costs associated with drug acquisition, administration, diversion/misuse, and relapse; and indirect costs associated with death, lost productivity, and accidental pediatric exposure. Event risks and costs not derived from the NMA were literature based. The impact of underlying model uncertainty on outcomes was assessed by deterministic, probabilistic, and scenario sensitivity analysis.

RESULTS: BSI was also the economically advantageous therapy at a total annual cost of $23,917 versus SL-BPN ($25,723), MTD ($27,384), and XR-NTX ($35,878). Sensitivity analysis indicated that the primary driver of total annual cost—other than efficacy—was drug acquisition cost, which was the second largest contributor of costs following relapse-related hospitalizations and emergency room visits.

CONCLUSIONS: BSI was more effective and less costly than SL-BPN, MTD, and XR-NTX to treat OUD among higher risk patients. The outcomes should be interpreted somewhat cautiously given that they were based on an economic model and not entirely on direct observation in a real-world treatment setting. Nevertheless, these findings have important implications for budget-constrained providers and policymakers seeking to ameliorate the intensifying opioid abuse epidemic.

SPONSORSHIP: This study was sponsored by Braeburn Pharmaceuticals.

OBJECTIVE: To determine the impact of physician communication on the utilization of opioid medications.

METHODS: This retrospective review of de-identified pharmacy claims data was conducted at a large managed care organization in Western Pennsylvania. The study included members of the Commercial, Exchange, Medicaid, and Medicare lines of business that were continuously enrolled during the pre-intervention, suppression, and post-intervention periods. To measure the effectiveness of the DUR, the study looked at the percent of members who continued to meet the DUR criteria at nine months post-intervention. Additionally, the study compared the average daily MED each member was prescribed pre- and post-intervention and the median average daily MED pre- and post-intervention.

RESULTS: The percentage of members that continued to meet DUR criteria post-intervention was 38.5% between all intervention periods and all lines of business. 45.4% of members had a decrease in average daily MED pre-to post-intervention. The median average daily MED in the study population also decreased pre- to post-intervention.

CONCLUSIONS: The intervention resulted in a decrease of members qualifying for DUR criteria post-intervention. Also, a higher percentage of members had a decrease in the average daily MED versus an increase or no change in average daily MED from pre-to post-intervention period. Further studies should evaluate the long-term cost effectiveness of the appropriate pain management DUR, long-term sustainability of decreased opioid utilization, and the impact of additional provider communication strategies.

SPONSORSHIP: None.

F6 Predictors of Opioid Use in the United States Using the National Ambulatory Medical Care Survey Data

Vu H1, Gaitonde P2, Shaya F2, Rodríguez de Bittner M1. 511 W Pratt St, Baltimore, MD 21201; hvu@rx.umaryland.edu; (410) 374-2283

1University of Maryland School of Pharmacy; 2University of Maryland School of Pharmacy Dept of Pharmaceutical Health Services Research

BACKGROUND: Addiction to prescription opioids is a major public health issue in the U.S. To our knowledge, very few studies have assessed the recent trends and predictors of opioid prescriptions in recent years. Understanding opioids prescribing patterns will contribute in strategizing provision of interventions for opioid over-prescribing and abuse.

OBJECTIVE: To investigate factors associated with the prescription of opioid analgesics among patients who have visited ambulatory care settings (2009-2013).

METHODS: This is a pooled cross sectional study using 2009-2013 National Ambulatory Medical Care Survey (NAMCS) data. Opioid prescriptions were identified through drug codes for narcotic and narcotics combination. Disease states were categorized based on ICD-9 codes. We conducted descriptive analyses using t-test, Wilcoxon Mann Whitney and chi-square tests where appropriate to assess differences in the distribution of various patient characteristics among opioid, disease states, and other prescription records. We used the multivariate logistic regression model to evaluate the association between the following factors and opioid prescriptions: demographics, number of yearly visits, total prescribed medications, reasons for visits, average physicians visit time, insurance types, physician specialties, having mental disorders, nervous system and musculoskeletal system/connective tissue diseases (statistical significance: P<0.05; 95% confidence interval).

RESULTS: A total of 15,882 from 225,234 visits included opioid prescriptions (7.05%). Statistical significant differences were observed
METHODS: use in a commercial population.

OBJECTIVE: or other prescribing restrictions. Concurrent use can help insurers plan for potential quality measures benzodiazepines (BZD). Advanced knowledge around prevalence of FDA) have reported concerns about the concurrent use of opioids and Several organizations/agencies (e.g., CMS, CDC, Prime Therapeutics cstarner@primetherapeutics.com; (612) 777-5073

BACKGROUND: Several organizations/agencies (e.g., CMS, CDC, FDA) have reported concerns about the concurrent use of opioids and benzodiazepines (BZD). Advanced knowledge around prevalence of concurrent use can help insurers plan for potential quality measures or other prescribing restrictions.

OBJECTIVE: To describe the prevalence of concurrent opioid and BZD use in a commercial population.

METHODS: Pharmacy claims data from ~19 million commercial members was queried to identify members 18 or older with 2 or more opioid claims filled on 2 or more separate days with a 15 days supply or more. Buprenorphine/naloxone combination products were excluded and opioid containing cough/cold products were included. Members also were required to have 2 or more BZD claims on 2 or more separate days. Members were assigned an index date based on the earliest opioid or BZD claim. The measurement period for examining concurrent use was defined as 30 or more cumulative days of overlap based on days supply found on the claims. Using medical claims data, concurrent use was also examined after excluding members with one or more medical claim cancer diagnosis code in 2015.

RESULTS: 3,992,900 members out of ~19 million (21.0%) had at least one opioid or BZD claim in 2015. 2,668,934 (66.8%) had only opioid claims, 674,880 (16.9%) had only BZD and 649,086 (16.3%) had both opioids and BZD. As of 2015, 13% would be taking aripiprazole and $1,894 with aripiprazole lauroxil. Use of aripiprazole based on real-world dosage patterns. Aripiprazole and aripiprazole lauroxil are two long-acting injectable antipsychotics (LAIs) approved for the treatment of schizophrenia. Aripiprazole lauroxil is a prodrug of aripiprazole.

CONCLUSIONS: One of every 6 commercial opioid users without cancer and 7 per 1,000 overall commercial members had evidence of concurrent opioid and BZD for 30 or more days in 2015. Combination opioids and BZD use has been shown to increase risk of overdose and death. Health insurers should consider identifying at risk members and developing clinical programs to help reduce the rate of combination use.

SPONSORSHIP: Prime Therapeutics.

F12 Budget Impact Analysis Comparing Aripiprazole and Aripiprazole Lauroxil Based on Real-World Dosage Patterns
Augusto M1, Greene M2, Hartry A3, Orsini L1, Krasa H2, Heidi W2.
160 Euston Rd, London, England NW1 2DX; margarida.augusto@parexel.com; 44 207-1211-811
1PAREXEL International; 2Otsuka Pharmaceutical Development & Commercialization; 3Lundbeck

BACKGROUND: Aripiprazole and aripiprazole lauroxil are two long-acting injectable antipsychotics (LAIs) approved for the treatment of schizophrenia. Aripiprazole lauroxil is a prodrug of aripiprazole.

OBJECTIVE: The objective of this analysis was to evaluate the cost of utilizing aripiprazole and aripiprazole lauroxil in patients with schizophrenia based on real-world dose mix, timing, and market share information.

METHODS: An economic model based on a hypothetical health plan of 1,000,000 members was developed. The proportion of members with schizophrenia and the subset taking an LAI were based on prior research. The model estimated costs of treatment based on IMS Health market share data and wholesale average costs of the two drugs. Market share and dose mix for each LAI was based on IMS Health National Sales Perspectives™ data from October 2015 to September 2016. The dose mix for aripiprazole lauroxil 882 mg 4 weeks and 6 weeks was adjusted to match national utilization patterns based on IMS Health anonymized patient-level data from October 2015 to March 2016.

RESULTS: In a hypothetical cohort of 1,000,000 patients, 1.1% were assumed to have schizophrenia and of those, 13% would be taking an LAI. Based on market share data, 187 patients were assigned to treatment with aripiprazole while 14 were assigned to treatment with aripiprazole lauroxil. Dose mix for aripiprazole indicated that 83.9% of patients were taking the 400 mg dose while 16.1% were taking the 300 mg dose, both every 4 weeks. Both doses were taken every 4 weeks. Dose mix for aripiprazole lauroxil shown that 15.4% of patients were taking the 441 mg dose every 4 weeks, 32.4% were taking the 662 mg dose every 4 weeks, 21.1% were taking the 882 dose every 6 weeks, and 50.1% were taking the 882 mg dose every 4 weeks. The weighted average cost of treatment per patient per month was $1,784 with aripiprazole and $1,894 with aripiprazole lauroxil.

CONCLUSIONS: Use of aripiprazole lauroxil resulted in higher drug costs compared to aripiprazole in this model based on real-world dose utilization patterns.

SPONSORSHIP: This study was funded by Otsuka Pharmaceutical Development & Commercialization, and Lundbeck.
OBJECTIVE: To compare two-year hospitalization and emergency department (ED) use and costs between Medicaid schizophrenia patients after a switch in antipsychotic therapy to PP vs. OA.

METHODS: Adult patients with a diagnosis of schizophrenia (ICD-9 295.xx) and ≥ 2 claims for PP or OA from 1/1/2010 to 12/30/2014 were selected from the Truven Health MarketScan Medicaid database. Index date was assigned as the date of 2nd observed claim of PP or OA. Patients were required to have continuous enrollment in Medicaid for ≥ 12 months prior to and ≥ 24 months after the index date and ≥ 1 pre-index OA claim. PP patients were matched 1:1 to OA patients based on propensity scores calculated from 6 month baseline demographic, clinical, resource utilization and cost variables. Quarterly, annual, and two-year antipsychotic utilization, health care resource use and costs (in 2015 dollars) were compared using t-tests for continuous variables and chi-square tests for categorical variables.

RESULTS: A total of 7,430 patients met study criteria. In the two years post-index, 51.4% were hospitalized and 74.0% had an ED visit. The study population had 6,439 OA patients and 991 PP patients, of which 55.9% were still on PP during the last 3 months of the 2-year follow-up. After matching, two cohorts of 954 each were well-balanced on baseline characteristics. Among the matched cohorts, a significantly lower proportion of PP patients relative to OA were hospitalized over two years (42.5% vs. 49.4%, P = 0.002), in year 1 (31.2% vs. 37.0%, P = 0.008) and in year 2 (26.8% vs. 31.0%, P = 0.043). Significantly lower proportions of PP vs. OA patients had ≥ 1 ED visit in two years (42.5% vs. 49.4%, P = 0.002), in year 1 (31.2% vs. 37.0%, P = 0.008) and in year 2 (26.8% vs. 31.0%, P = 0.043). Compared to two year costs for OA, PP medical costs (i.e., inpatient + outpatient + ED) were significantly lower ($43,023 vs. $48,596, P = 0.044) and PP pharmacy costs (not including rebates) were significantly higher ($32,367 vs. $21,546, P < 0.001), with no significant difference in total cost.

CONCLUSIONS: Medicaid schizophrenia patients on OA therapy who switched to PP had significantly lower two-year hospitalization and ED usage rates with no difference in total health care costs compared to matched patients switching among OA agents.

SPONSORSHIP: Research funded by Janssen Scientific Affairs.

F14 Two-Year Acute Care Utilization and Cost Outcomes for Schizophrenia Patients in Medicaid Treated with Paliperidone Palmitate or Oral Atypical Antipsychotic

Durkin M1, Song X2, Tran O3, Sedgley R2, McRae J1, Williamson D1. 1125 Trenton-Harbourton Rd, Titusville, NJ 08560; mdurkin@its.jnj.com; (609) 730-2267
1Janssen Scientific Affairs; 2Travenol Health Analytics

BACKGROUND: Data are limited on longer-term real-world acute care use and costs for schizophrenia patients switching from an oral atypical antipsychotic therapy to paliperidone palmitate long-acting injectable antipsychotic (PP) or to a different oral atypical antipsychotic (OA).

OBJECTIVE: To examine how well patient adherence to atypical antipsychotic therapies predicts adherence to other medications to treat other SMI's, type 2 diabetes, or hypertension.

METHODS: We measured adherence using claims data for patients with a diagnosis of schizophrenia, bipolar disorder, or major depressive disorder during the previous year. Patients were required to have both a prescription for an oral atypical antipsychotic as well as a prescription for another SMI or an oral anti-diabetic or an antihypertensive in the same year. We measured concurrent adherence to both a patient’s antipsychotic and one of 23 other medications using the proportion of days covered (PDC) over a 1 year time frame. Patients were considered adherent if PDC ≥ 0.80. We calculated the accuracy, positive predictive value (PPV), and negative predictive value (NPV) of antipsychotic adherence in predicting adherence to their other concurrently taken medication.

RESULTS: Among the 129,614 patients in our sample, the average age was 44.8 years (SD = 14.8) and 13.0% were female. Median prediction accuracy based on atypical antipsychotic adherence to the other 23 medications was 67% (range: 55% to 71%; statistically different from 50% accuracy in all cases, P < 0.001). Accuracy was also higher than estimates of physician predictions of adherence (accuracy = 53%) from previous studies. The antipsychotic adherence’s NPV of 75% (range: 62% to 88%) was generally higher than its PPV of 62% (range: 43% to 67%) and respectively (all P < 0.001).

CONCLUSIONS: Information on antipsychotic adherence provides significant predictive power of patient adherence to other medications, indicating that technologies measuring adherence to antipsychotics may be useful for predicting adherence to other medications commonly used by patients with SMI. As NPV is higher than PPV, adherence to an antipsychotic is likely a necessary but not sufficient condition for patients with SMI to be adherent to their other medication.


F15 Relationship between EMR utilization, health care quality, and patient outcomes: analysis from a nationally representative sample of schizophrenia physicians

Ng-Mak D1, Ruetsch C2, Brady B2, Thacz J2, Rajagopalan K3. 84 Waterford Dr, Marlborough, MA 01752; daisy.ng-mak@sunovion.com; (774) 369-7010
1Sunovion; 2Health Analytics

BACKGROUND: Use of electronic medical records (EMR) has been on the rise, but their impact on health care quality and patient outcomes remain unclear. Effective schizophrenia treatment relies on seamless care coordination between patients and physicians that may be improved through EMR use.

OBJECTIVE: To examine how well patient adherence to atypical antipsychotic therapies predicts adherence to other medications to treat other SMI’s, type 2 diabetes, or hypertension.

METHODS: We measured adherence using claims data for patients with a diagnosis of schizophrenia, bipolar disorder, or major depressive disorder during the previous year. Patients were required to have both a prescription for an oral atypical antipsychotic as well as a prescription for another SMI or an oral anti-diabetic or an antihypertensive in the same year. We measured concurrent adherence to both a patient’s antipsychotic and one of 23 other medications using the proportion of days covered (PDC) over a 1 year time frame. Patients were considered adherent if PDC ≥ 0.80. We calculated the accuracy, positive predictive value (PPV), and negative predictive value (NPV) of antipsychotic adherence in predicting adherence to their other concurrently taken medication.

RESULTS: Among the 129,614 patients in our sample, the average age was 44.8 years (SD = 14.8) and 13.0% were female. Median prediction accuracy based on atypical antipsychotic adherence to the other 23 medications was 67% (range: 55% to 71%; statistically different from 50% accuracy in all cases, P < 0.001). Accuracy was also higher than estimates of physician predictions of adherence (accuracy = 53%) from previous studies. The antipsychotic adherence’s NPV of 75% (range: 62% to 88%) was generally higher than its PPV of 62% (range: 43% to 67%) and respectively (all P < 0.001).

CONCLUSIONS: Information on antipsychotic adherence provides significant predictive power of patient adherence to other medications commonly used by patients with SMI. As NPV is higher than PPV, adherence to an antipsychotic is likely a necessary but not sufficient condition for patients with SMI to be adherent to their other medication.


F15 Relationship between EMR utilization, health care quality, and patient outcomes: analysis from a nationally representative sample of schizophrenia physicians

Ng-Mak D1, Ruetsch C2, Brady B2, Thacz J2, Rajagopalan K3. 84 Waterford Dr, Marlborough, MA 01752; daisy.ng-mak@sunovion.com; (774) 369-7010
1Sunovion; 2Health Analytics

BACKGROUND: Use of electronic medical records (EMR) has been on the rise, but their impact on health care quality and patient outcomes remain unclear. Effective schizophrenia treatment relies on seamless care coordination between patients and physicians that may be improved through EMR use.

OBJECTIVE: To examine how well patient adherence to atypical antipsychotic therapies predicts adherence to other medications to treat other SMI’s, type 2 diabetes, or hypertension.

METHODS: We measured adherence using claims data for patients with a diagnosis of schizophrenia, bipolar disorder, or major depressive disorder during the previous year. Patients were required to have both a prescription for an oral atypical antipsychotic as well as a prescription for another SMI or an oral anti-diabetic or an antihypertensive in the same year. We measured concurrent adherence to both a patient’s antipsychotic and one of 23 other medications using the proportion of days covered (PDC) over a 1 year time frame. Patients were considered adherent if PDC ≥ 0.80. We calculated the accuracy, positive predictive value (PPV), and negative predictive value (NPV) of antipsychotic adherence in predicting adherence to their other concurrently taken medication.

RESULTS: Among the 129,614 patients in our sample, the average age was 44.8 years (SD = 14.8) and 13.0% were female. Median prediction accuracy based on atypical antipsychotic adherence to the other 23 medications was 67% (range: 55% to 71%; statistically different from 50% accuracy in all cases, P < 0.001). Accuracy was also higher than estimates of physician predictions of adherence (accuracy = 53%) from previous studies. The antipsychotic adherence’s NPV of 75% (range: 62% to 88%) was generally higher than its PPV of 62% (range: 43% to 67%) and respectively (all P < 0.001).

CONCLUSIONS: Information on antipsychotic adherence provides significant predictive power of patient adherence to other medications commonly used by patients with SMI. As NPV is higher than PPV, adherence to an antipsychotic is likely a necessary but not sufficient condition for patients with SMI to be adherent to their other medication.

defined as ≥ 90% of their eligible patient panel meeting HEDIS measures. Relationships between EMR use, health care quality, and patient outcomes were examined at the physician level.

RESULTS: Within the sample of 32,178 physicians, 24.3% used EMR. Physicians using EMR systems were significantly more likely to provide high quality health care compared to physicians who did not use EMR, as evidenced by HEDIS measure performance (28.7% vs. 20.9%, P < 0.001). Further, physician provision of high quality health care was associated with improved patient outcomes including a lower mean proportion of patients with a schizophrenia hospitalization (21% vs. 28%) and psychiatric ER visit (43% vs. 53%), HbA1c values for diabetics (6.8% vs. 7.2%), and LDL-C values for patients with CVD (88.3 mg/dL vs. 92.3 mg/dL, all P < 0.01). Physicians utilizing EMR who provided high quality health care had the healthiest patient panels of all groups, with the lowest hospitalization (19.8%) and ER visit (38.3%) rates, mean diabetic HbA1c of 6.8%, and mean CVD patient LCL-C of 83.0 mg/dL.

CONCLUSIONS: EMR utilization by schizophrenia physicians is associated with higher quality health care and improved patient outcomes. Payers who encourage utilization of EMR systems may be able to simultaneously improve patient outcomes and HEDIS ratings and improve the quality of care received by their members.

SPONSORSHIP: This study was funded by Janssen Scientific Affairs.

F17 Health Care Costs and Resource Utilization in Patients with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics

Lafeuille M1, Joshi K2, Tandon N2, Tiggelaar S1, Kamastra R1, Lefebvre P1, Yue Y2, Kim E1. 1000 de la Gauchetière West, Ste 1200, Montréal, Québec H3B 4W5 Canada; marie-helene.lafeuille@analysisgroupp.com; (514) 394-4433

BACKGROUND: Patients with schizophrenia have high prevalence of cardiometabolic comorbidities (CMC) diabetes and cardiovascular diseases.

OBJECTIVE: To compare persistence, health care costs and health care resource utilization (HRU) in schizophrenia patients with CMC treated with once-monthly paliperidone palmitate (PPIM) or an oral atypical antipsychotic (OAA).

METHODS: Medicaid data from six states (07/2009-03/2015) were used to identify adults with schizophrenia and CMC initiated on PPIM or an OAA (index date) on 01/2010 or after. Baseline characteristics evaluated in the 6 months pre-index were compared using standardized differences (Stdiff; ≥ 10% considered significant). Persistence to index medication at 12 months (e.g., no gap ≥ 90 days) was compared using chi-squared tests. The 12-month post-index medical and pre-rebate pharmacy costs were compared using multivariate ordinary least squares regression (mean monthly cost differences [MMCD]). HRU was compared using multivariate Poisson regression (incidence rate ratios [IRR]). Cost and HRU P-values were obtained from a non-parametric bootstrap procedure.

RESULTS: At baseline, PPIM patients (N = 371) were younger (mean age: 45.0 vs. 47.5 years, Stdiff = 24%) and had a lower Quan-Charlson Comorbidity Index (mean: 1.0 vs. 1.4, Stdiff = 27%) than OAA patients (N = 8,296). Persistence at 12 months was higher in PPIM patients than in OAA patients (e.g., no gap ≥ 90 days: 43% vs. 33%, P = 0.006). Adjusted all-cause medical costs were significantly lower in PPIM patients versus OAA patients (MMCD = $-369, P = 0.004) while all-cause pharmacy costs were significantly higher (MMCD = $279, P < 0.001), resulting in no significant difference in total costs (MMCD = $-90, P = 0.357). No significant difference was observed in CMC-related pharmacy or medical costs. Compared to OAA patients, PPIM patients had more schizophrenia-related outpatient visits (IRR = 1.44, P < 0.001) and similar all-cause (IRR = 0.89, P = 0.156) and schizophrenia-related (IRR = 1.07, P = 0.658) inpatient visits. However, PPIM patients had fewer CMC-related inpatient admissions (IRR = 0.73, P = 0.001) with shorter length of stays (IRR = 0.72, P = 0.020), and fewer CMC-related long-term care admissions (IRR = 0.56, P = 0.016) versus OAA patients.

CONCLUSIONS: Medicaid beneficiaries with schizophrenia and CMC who were initiated on PPIM on 01/2010 had lower medical costs, which fully offset the higher pharmacy costs compared to OAA, resulting in no significant difference in total health care costs over 12 months. Moreover,
CJMCM-related utilization of inpatient and long-term care services were lower in patients on PPIM.

SPONSORSHIP: Supported by Janssen Scientific Affairs.

F18 Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting

Van Deventer L, Brown L, Lorenz R, Li J, Dechairo B. 120 Waterloobend, Birmingham, AL 35242; lvandeventer@assurexhealth.com; (205) 944-5006
Assurex Health

BACKGROUND: Major depressive disorder affects 6.8% of the U.S. population and has direct costs of $98.9 billion a year. Psychiatric medications alone cost $30.3 billion per year. Half of patients who seek treatment for depression are expected to respond to their first antidepressant, and the rest often experience many medication failures. Because of medication challenges, some clinicians now use pharmacogenomics to guide treatment and help avoid genetically discordant medications. Combinatorial pharmacogenomic testing has been shown clinically to predict medication response better than single gene testing. The only psychiatric combinatorial pharmacogenomic testing platform with multiple prospective clinical trials supporting its clinical validity and utility over treatment as usual is the GeneSight Psychotropic test powered by CPGx technology (Assurex Health, Mason, OH). A study by the pharmacy benefits manager Medco reviewed over 13,000 patients, and prospectively yielded a medication cost savings of $1,036 per member per year when treatment was guided by GeneSight. This study presents subanalysis data on medication cost savings for patients and payors based on treatment by psychiatrists and non-psychiatrists.

OBJECTIVE: To evaluate direct health care costs, indirect workloss-related costs, and employment status change in TRD.

RESULTS: A total of 2,800 employees with TRD (1,908 with workless data) were selected. Employees with TRD had more direct HCU than either control cohort (e.g., 1.8 and 4.7-times the rate of inpatient visits vs. employees with MDD and without MDD, respectively; all P < 0.001). Furthermore, employees with TRD had higher per patient per year (PPPY) direct health care costs: $5,817 more than employees without MDD and $8,931 more than employees with MDD (both P < 0.001). Employees with TRD had 35.8 workloss days PPPY on average (25.8 disability and 10.6 medical-related absenteeism days), which was 1.7 and 6.2-times the rate of workloss days in employees with and without MDD, respectively. Consequently, TRD was associated with higher PPPY workloss-related costs: $1,811 more than employees with MDD and $3,460 more than employees without MDD (all P < 0.001). Lastly, employees with TRD were more likely to change employment status than employees with MDD (hazard ratio [HR]: 1.28; P = 0.019) or without MDD (HR: 1.37; P = 0.004).

CONCLUSIONS: TRD poses a significant direct and indirect cost burden to U.S. employers even when compared to MDD, and may also be associated with higher rates of employment status change.

SPONSORSHIP: Supported by Janssen Scientific Affairs.

F20 Cost-Effectiveness Evaluation of Vortioxetine in Patients with Major Depressive Disorder Switching from First Antidepressant Therapy in the United States

Atsou K1, Ereshefsky L2, Francois C3, Diamand F1, Brignone M1, Mucha L1, Danchenko N1. 37-45 Quai du Président Roosevelt, Issy-les-Moulineaux Cedex, Paris, France 92445; atsk@landbeck.com; +33 1-79-41-29-00
1Lundbeck SAS; 2The University of Texas; 3Lundbeck; 4Takeda Pharmaceuticals U.S.A.

BACKGROUND: Many patients with major depressive disorder (MDD) do not achieve remission with their first antidepressant (AD) therapy, resulting in a high burden due to treatment failure. Vortioxetine is a multimodal AD with proven efficacy and tolerability.

OBJECTIVE: To compare the cost-effectiveness of vortioxetine vs. levomilnacipran and vilazodone (the 2 most recently approved ADs) for patients switching after an inadequate response to a first AD.

METHODS: A 1-year time horizon analysis was performed using a decision tree model supplemented with a 2-month cycle Markov model to follow patients in subsequent treatment lines. The model

F19 Direct and Indirect Cost Burden and Change of Employment Status Among Employees with Treatment-Resistant Depression in the United States

Amos T1, Tandon N2, Lejehrne P1, Pilon D1, Kamstra R1, Pivneva I1, Greenberg P2. 1125 Trenton Harbourton Rd, Titusville, New Jersey 08560; tamos1@its.jnj.com; (609) 730-2439
1Janssen Scientific Affairs; 2Groupe d'analyse, Ltée; 3Analysis Group

BACKGROUND: Treatment-resistant depression (TRD) poses a substantial burden to health care payers including employers, costing an estimated $29-48B yearly in the U.S. However, the impact of TRD on employment status remains unexplored.

OBJECTIVE: To compare cost-effectiveness of vortioxetine vs. levomilnacipran and vilazodone (the 2 most recently approved ADs) for patients switching after an inadequate response to a first AD.

METHODS: A 1-year time horizon analysis was performed using a decision tree model supplemented with a 2-month cycle Markov model to follow patients in subsequent treatment lines. The model
considered depression, remission and recovery, and disease progression through 3 phases: acute (2 months), maintenance (6-8 months), and recovery (2-4 months). Patients were followed for up to 3 treatment lines after switching ADs. Published data were used for comparative efficacy (2-month remission and withdrawal due to adverse events), tolerability, and relapse information. A societal perspective was adopted. Direct costs and indirect costs due to absenteeism were considered in 2015 U.S. dollars. Utilities associated with health states and disutilities related to short- and long-term adverse events were included. The main outcome was the incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted.

RESULTS: The total costs of managing patients with MDD switching from their first AD were highest in patients treated with levomilnacipran ($6,763), followed by vortioxetine ($6,615) and vilazodone ($6,294). Direct costs were >60% of total costs. The percentage of patients in recovery after the initial line of treatment was highest for vortioxetine (34.1%) followed by vilazodone (28.8%) and levomilnacipran (28.3%). Vortioxetine was the most cost-effective AD based on quality-adjusted life year (QALY) analyses (additional QALY: 0.0083 vs. vilazodone and 0.0070 vs. levomilnacipran). Vortioxetine was more cost-effective than levomilnacipran and comparable to vilazodone (ICER: $38,608/QALY). Similar results were found when only direct costs were considered. In these U.S.-setting analyses, vortioxetine was cost-effective at all willingness-to-pay thresholds (lower limit of the recommended U.S.-based threshold).

CONCLUSIONS: In these U.S.-setting analyses, vortioxetine was comparable in efficacy and cost to levomilnacipran and was cost-effective vs. vilazodone for treating patients with MDD after switching from a first AD. Vortioxetine may be beneficial for patients with MDD who switch from their current generic AD treatment.

SPONSORSHIP: Lundbeck/Takeda.

F25 Comparing the Medication-Specific Child Core Set Among Commercial Health Plans, Managed Medicaid, and Marketplace Children in 2015
Kim S1, Niu C2, Shaw-Taylor Y2. 16901 Melford Blvd, Bowie, MD 20715; skim2@inovalon.com; (301) 809-4000 x1057
1Inovalon; 2Avalere Health

BACKGROUND: As a central component of the overall DHHS strategy for implementing Children's Health Insurance Program Reauthorization (CHIPRA), the Agency for Health Care Research and Quality (AHRQ) recently announced a new initiative called the AHRQ-CMS Pediatric Quality Measures Program, which supported State Medicaid/CHIP agencies in collecting and reporting data on a core set of standardized child health quality measures. In order to better monitor the quality of medication management among young population, quality measures should be validated by multiple data sources.

OBJECTIVE: To compare the quality of children's health care, especially on medication management, among Commercial, managed Medicaid and Marketplace populations.

METHODS: Data were extracted from a large nationally representative and statistically de-identified administrative database, Inovalon's MORE2 Registry. We assessed the following quality measures for the 2015 measurement year: (1) APC, the percentage of children ages 1-17 who were on ≥ 2 concurrent antipsychotic medications; (2) MMA, the percentage of children ages 5-20 who were identified as having persistent asthma and remained on an asthma controller medication for ≥ 50% percent or ≥ 75% of their treatment period; (3) ADD, the percentage of children ages 6-12 newly prescribed ADHD medication who had one follow-up visit with practitioner during the 30-day initiation phase and who had at least two follow-up visits within 9 months after the initiation phase ended.

RESULTS: A total of 3,662 children met the selection criteria for APC-50% with commercial insurance; 46% managed Medicaid; and 4% Marketplace members. Respectively, 2%, 3% and 6% had 2 or more concurrent antipsychotic medications. For the MMA measure, we identified 8,150 children with persistent asthma; the percent of children that remained on the medication at least 75 percent of the treatment period were 27%, 25%, 27% respectively. Out of 7,091 children identified for the ADD measure, the percent of children with 1 follow-up visit during the initiation phase was 15% and 28% of children had at least 2 follow-up visits during the continuation phase.

CONCLUSIONS: Our results demonstrate the feasibility of using the MORE2 Registry to investigate plan performance on the Medication-Specific Child Core Set measures released by DHHS. The performance of plans varied by payer (whether Commercial, Medicaid, or Marketplace), suggesting that there are differences in health service delivery, although the source of the variation has to be investigated.

SPONSORSHIP: Inovalon.

F28 Association Between Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders
Medhekar R1, Fujimoto K2, Aparasu R1, Bhatare V3, Johnson M1, Alonzo J1, Schwarzwald H1, Chen H1. 1441 Moursund St, Rm 216, Houston, TX 77030; medhekar.rohan@gmail.com; (713) 742-3246
1University of Houston; 2University of Texas Health Science Center; 3University of South Dakota; 4Texas Children's Health Plan

BACKGROUND: Psychotropic polypharmacy has been a main safety concern in the management of pediatric mental disorders. Although seeing multiple providers has been identified as an important predictor for the receipt of polypharmacy, no study has yet assessed the impact of care-coordination between providers.

OBJECTIVE: To examine the association between the intensity of care-coordination within a patient's care team and the likelihood of the patient receiving psychotropic polypharmacy.

METHODS: A retrospective cross-sectional study was conducted using the 2013-2015 administrative claims data from a Medicaid Managed Care Organization (Texas Children's Health Plan). The study included individuals: (a) ≥ 18 years of age, (b) diagnosed with a mental disorder, and (c) received psychotropic prescriptions from multiple prescribers. Psychotropic polypharmacy (PP) was defined as the receipt of ≥ 2 psychotropic medications from different drug classes concurrently for 60 days or more. Care coordination was measured using Care-coordination density (CD), a surrogate included in the AHRQ Care Coordination Measures Atlas, calculated as the ratio of the sum of patients shared by physician pairs within a patient's care team to the total number of physician pairs. Guided by Andersen behavioral model, multivariate logistic regression analyses were conducted to assess the association between CD and patients' likelihood of receiving PP after controlling for predisposing and need factors.

RESULTS: A total of 24,147 children and adolescents diagnosed with a mental disorder were identified. Nearly half (n = 11,102; 45.98%) of these individuals received medications prescribed by multiple providers. Logistic regression analysis showed a significant association between care density and the use of psychotropic polypharmacy. However, the direction of this relationship varied depending on the composition of the patient's care team. Among patients with only PCPs involved in their care team, patients in the higher CD group were 84% less likely to receive PP (OR = 0.136; 95% CI 0.056-0.432) than those in low CD group. In contrast, among patients who had both PCPs and specialists involved in their care team, those in the higher CD group were 2.44 times more likely to experience PP (OR = 2.441; 95%
**CONCLUSIONS:** To the opposite from what has been perceived, higher care density between primary care providers and specialists resulted into increased use of psychotropic polypharmacy in children and adolescents.

**SPONSORSHIP:** Not a sponsored study.

### G00-G99 Diseases of the Nervous System

(e.g., Multiple Sclerosis, Migraine, Seizures, Restless Leg, Sleep Apnea)

| G3 Determining the Cost of Care for Spinal Muscular Atrophy Using Retrospective Claims Analysis |
| Wells W1, Hall E1, Scaife J1, Hadler N2, Miyasato G2. 133 Boston Post Rd, Weston, MA 02188; wendy.wells@ishsi.com; (781) 464-2774 |
| Biogen; 2Trinity Partners |

**BACKGROUND:** Spinal muscular atrophy (SMA) is a rare genetic disease characterized by degeneration of the motor neurons resulting in severe and progressive muscular weakness and atrophy. Health Care resource utilization (HRU) and costs for SMA patients are thought to be high due to the progressive and debilitating nature of the disease, but current data are limited.

**OBJECTIVE:** To characterize the direct cost of care for patients with SMA as observed in claims data.

**METHODS:** We conducted a retrospective analysis of patients with 1+ SMA claims across treatment settings between January 2010 and June 2015 using the Truven Health Analytics (MarketScan) database. Costs were evaluated overall and by subgroups: likely vs. unlikely SMA (using a previously published statistical algorithm), age at index, treatment setting, and payer type.

**RESULTS:** 7,992 patients had > 1 ICD-9 claims for SMA after exclusion criteria were applied. Overall their average annualized cost was approximately $37,000; younger patients had higher costs than older patients (P < 0.0001). Inpatient care was the most expensive component, and 42% of patients required a hospitalization. There were significant (P < 0.0001) differences between annualized costs for likely vs. unlikely SMA patients ($101,425 vs. $21,833, respectively). Cost differences between these two groups persisted across subgroups.

**CONCLUSIONS:** Limitations include: The statistical algorithm used to differentiate between these two groups persisted across subgroups. Cost differences between these two groups persisted across subgroups.

**SPONSORSHIP:** Biogen sponsored this research.

### G4 Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis

| Grabowsky T1, Shahkot O1, Kasoji M1, Merrill C2, Agnese W2, Atassi N1. 720 Vandenberg Blvd, King of Prussia, PA 19406; tara.grabowsky@vencore.com; (617) 283-7795 |
| 1Vencore; 2MT Pharma America; 3Neurological Clinical Research Institute, Massachusetts General Hospital |

**BACKGROUND:** The average delay in ALS diagnosis is one year after the appearance of the first symptom. This prolonged diagnostic time is detrimental as it delays initiating approved treatments and may preclude patients from enrolling in clinical trials.

**OBJECTIVE:** Big data analytics of a large claims database may identify early predictors of ALS and potentially shorten the diagnosis timeline.

**METHODS:** The Truven MarketScan database, containing patient-level claims for 170+ million patients, was used without any code preselection for this analysis. A mutual information (MI) measure was used to quantify the statistical relevance of every code in MarketScan as a future ALS diagnosis in four U.S. states. Codes considered include patient demographics, labs, diagnosis codes, procedure codes, medications, standard provider types, and standard care facility types. An ensemble suite of classifiers developed employing machine learning techniques were applied to the MarketScan claims database to optimize the selection and ranking of ALS diagnosis predictors. We specifically looked for predictors within the following time brackets: 3, 6, 9, 12, 18, 24, 36, 48, and 60 months before the initial ALS diagnosis.

**RESULTS:** The ALS ICD-9 diagnosis code identified 12,332 ALS patients with an average of 4.4 years of claims history in the national dataset. Average age was 60 years ± 14 years; male gender represented 58% of ALS patients, and 25% had a prescription claim for riluzole. The top differentiating diagnoses that are more common in the ALS group compared to the overall population were: non-traumatic joint disorders (-60 months), connective tissue diseases (-60 months), skin disorders (-48 months), fatigue (-36 months), lower respiratory diseases (-24 months), gastrointestinal disorders (-18 months) and other nervous system disorders (-12 months).

**CONCLUSIONS:** This study suggests that 5 years before ALS is diagnosed, patients may be presenting with symptoms suggestive of connective tissue disorders, skin disorders, and nonspecific neurological complaints. Based on claims data review, features that differentiate potential ALS patients prior to diagnosis may allow clinicians to diagnose ALS. The next steps of this project are to validate these findings in the national dataset, optimize the algorithm differentiating ALS patients prior to diagnosis, and further characterize early predictors of ALS.

**SPONSORSHIP:** MTPA provided support for the analyses and abstract development.

### G5 A Descriptive Analysis of a Real-World Population with Huntington-Associated Chorea Treated with Tetrabenazine: Findings from an Electronic Medical Records Database

| Anderson K1, Iyer R2, Alevras D1, Schilling T1, Ahler V1, Cao F3, Johnson K1, Gandhi S2. 3800 Reservoir Rd NW, Washington, DC 20007; kea45@georgetown.edu; (202) 444-2000 |
| 1Georgetown University Hospital; 2Teva Pharmaceutical Industries; 3IBM Global Business Services-Watson Health |

**BACKGROUND:** Huntington disease (HD) is a hereditary movement disorder, with chorea as the most prominent feature. Currently, tetrabenazine (TBZ) is the only U.S. Food and Drug Administration-approved treatment for chorea associated with HD; however, neuropsychiatric adverse events (AEs) such as depression exist, and there are tolerability concerns with TBZ use.

**OBJECTIVE:** To examine demographic, clinical, and treatment information about HD-associated chorea (HDAC) in patients prescribed TBZ.

**METHODS:** HDAC patients were identified in electronic medical records (EMR) using the Explorys platform and grouped into those treated with TBZ and those treated with other medications. Patients with ≥ 1 TBZ prescription and complete dosing information were identified. CI 1 899-3 137. CD was not significantly associated with the receipt of PP in specialists only group.

**SPONSORSHIP:** Not a sponsored study.
Mithal A1, Lingala B1, Niyazov A2, Guo A2, Marras C3, Singh G4.

RESULTS: During the study period, there were approximately 11.55 million visits to the emergency and outpatient departments of hospitals. These visits were based on visits to office-based physicians, while NHAMCS surveys use nationally representative samples using a multistage probability design and provide objective information on all outpatient care in the U.S., regardless of insurance status. Comorbidity data was gathered using EMR data provides insights into the real-world use of TBZ in HDAC patients. The findings of low use of TBZ treatment, high rates of discontinuation or switching of TBZ, and lower-than-expected mean daily doses highlight an unmet need for alternative chorea treatment options with improved risk–benefit profiles in these HD patients.

SPONSORSHIP: This study was supported by Teva Pharmaceutical Industries.

G8 Parkinson's Disease and Comorbidity: A U.S. National Perspective

Mithal A1, Lingala B1, Niyazov A2, Guo A2, Marras C3, Singh G4.

BACKGROUND: Parkinson’s disease (PD) is a chronic multi-system progressive neurodegenerative disease. Understanding of patient comorbidities is important in the management of PD. We examined common coexisting comorbidities in Parkinson’s patients in outpatient care using a nationally-representative population.

OBJECTIVE: To study comorbidities in PD in the U.S.

METHODS: We examined all outpatient and urgent care visits with diagnosis of PD (ICD-9 code 332.0) using CDC’s National Ambulatory Medical Care Survey (NAMCS, 2006-2012) and National Hospital Ambulatory Care Survey (NHAMCS, 2006-2011). NAMCS is a national survey based on visits to office-based physicians, while NHAMCS surveys visits to the emergency and outpatient departments of hospitals. These surveys use nationally representative samples using a multistage probability design and provide objective information on all outpatient care in the U.S., regardless of insurance status. Comorbidity data was gathered from physician reports of 14 significant concurrent disease conditions: arthritis, asthma, cancer, cerebrovascular disease, COPD, chronic renal failure, congestive heart failure, depression, diabetes, hyperlipidemia, hypertension, ischemic heart disease, obesity and osteoporosis.

RESULTS: During the study period, there were approximately 11.55 million visits in patients with PD in the U.S. A specified comorbidity was reported in 8.1 million visits (70.2%). Comorbidities were more common in older individuals (72.3% in >65 years vs. 62.0% in <65 years) and men (73.0% vs. 70.2% in women). The most commonly recorded comorbidity was hypertension (37.8%), followed by hyperlipidemia (21.2%), diabetes (19.1%), arthritis (16.82%) and cerebrovascular disease (8.61%). Depression was seen in 18.3% of visits, and was significantly more common in men (18.9%) compared to women (17.5%, P < 0.05), and in older individuals (≥65 years) compared to younger (18.6% vs. 16.8% respectively, P < 0.05).

CONCLUSIONS: Patients with PD have a high burden of comorbid conditions. Understanding the impact of these conditions on outcomes and the management of these disorders in people with and without PD would guide recommendations for clinical practice.

SPONSORSHIP: Funding for this sponsored research was provided by Acorda Therapeutics.

G9 Health Care Utilization and Costs for Patients with Tardive Dyskinesia

Caroll B1, Park T1, Irwin D2, Gandhi S1. 41 Moors Rd, Malvern, PA 19355, benjamin.caroll@tevapharm.com; (610) 727-6329.

1Teva Pharmaceutical Industries; 2Truven Health Analytics

BACKGROUND: Tardive dyskinesia (TD), an often-irreversible movement disorder, can affect any part of the body and is often debilitating. TD is caused by prolonged use of the neuroleptic (antipsychotic) drugs that are frequently prescribed for psychiatric disorders. The estimated prevalence of TD is 15-30% among patients on antipsychotics, and the reported incidence of TD in this same patient population ranges from < 1% to 24% depending on the antipsychotics under study. Furthermore, patients with TD are known to have lower quality of life. To date, very few studies on the economic burden of TD have used real-world data.

OBJECTIVE: To assess health care utilization and costs pre- and post-TD diagnosis in a sample of patients from the commercially insured and Medicare Supplemental U.S. populations.

METHODS: A retrospective cohort analysis was conducted using Truven MarketScan Commercial and Medicare administrative claims data. For each patient included in the analysis, the index date was set as the first TD diagnosis between 1/1/2008 and 9/30/2014. Patients included must have had ≥12 months of both pre- and post-index medical and pharmacy continuous enrollment, ≥1 inpatient (IP) or ≥2 outpatient (OP) non-diagnostic claims for TD (ICD-9 CM 333.85), and no evidence of TD claims during the pre-index period. Descriptive statistics on the incidence of resource utilization and costs of health care were reported.

RESULTS: Of 1,020 patients (mean age of 63.7 years) included in the analysis, 501 (49.1%) patients had commercial insurance and 519 (50.9%) had Medicare. Patients generally had significantly greater utilization during the 12 months after TD diagnosis as compared with the 12 months before TD diagnosis. During the post-TD-diagnosis time, IP admissions occurred for more patients (54.9% vs. 37.3%; P < 0.001), and had longer lengths of stay (mean 4.7 days vs. 3.0 days; P < 0.001) than in the pre-TD-diagnosis time. Emergency room visits also occurred for more patients (59.6% vs. 51.8%; P < 0.001) and more frequently for individual patients (mean 1.8 visits vs. 1.0 visits; P = 0.023) during the post-TD-diagnosis time versus the pre-TD-diagnosis time. Total health care costs were significantly greater ($55,980 vs. $40,418; P < 0.001) during the post-TD-diagnosis time than in the pre-TD-diagnosis time.

CONCLUSIONS: Patients identified as being diagnosed with TD demonstrate significantly higher health care utilization and costs in the 12 months after diagnosis compared with the 12 months before diagnosis.

SPONSORSHIP: Supported by Teva Pharmaceutical Industries.
G10 ADS-5102 (Amantadine Hydrochloride) Extended-Release Capsules Improve Clinician’s Global Impression of Change in Activities of Daily Living by Reducing Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID Study)

Dunn J1, Palhuu R2, Tanner C3, Hauser R4, Isaacs S5, Patri R6. 19 E 200 S, Fl 10, Salt Lake City, UT 84111; jddunn@myvrx.com; (801) 417-9722.

BACKGROUND: Dyskinesia in Parkinson’s Disease (PD) is a complication of levodopa therapy marked by involuntary non-rhythmic, purposeless, unpredictable movements during waking hours. It is associated with negative impacts on QoL, burden of care and health care costs. No FDA-approved drug exists to treat it. ADS-5102 is in development for treatment of levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD).

OBJECTIVE: Investigate 340 mg of ADS-5102 taken once daily at bedtime to reduce LID and evaluate its effect on activities of daily living (ADLs) and Clinician’s Global Impression of Change (CGI-C).

METHODS: A 25-week, double-blind, placebo-controlled study of 126 PD subjects with LID randomized 1:1 to placebo or ADS-5102 (NCT02136914). Primary outcome measure was the Unified Dyskinesia Rating Scale (UDysRS). Key secondary outcome measures included ON time without troublesome dyskinesia and OFF time based on 24-hour PD home diaries. Pre-specified secondary measure included CGI-C in overall PD symptoms, including but not limited to LID. A post-hoc analysis to evaluate the effect of ADS-5102 on ADLs (as reported in UDysRS Part 1B) was also performed.

RESULTS: MITT population included 121 subjects—63 treated with ADS-5102, 58 with placebo. The study met its primary endpoint. Least squares (LS) mean treatment difference of change from baseline to Week 12 in UDysRS total score was -7.9 (P = 0.0009). The Week 12 placebo-adjusted outcomes in diary states were: ON time without troublesome dyskinesia increased by 2.8 hours (P = 0.0001); OFF time decreased by 0.9 hours (P = 0.017); ON time with troublesome dyskinesia decreased by 1.6 hours (P = 0.003). ADS-5102 improved ADLs compared to placebo by reducing the UDysRS Part 1B total score at Week 12—LS mean treatment difference: -3.0, P = 0.012. An approximate 25% improvement was shown in ADS-5102-treated patients vs. placebo in the following ADLs: public and social settings, walking and balance, exciting and emotional settings, and chewing and swallowing. CGI-C results showed that 51 patients (81%) in the ADS-5102 group and 21 patients (36%) in the placebo group were assessed as improved in overall PD symptoms including dyskinesia at week 12. The most frequent AEs were hallucinations, peripheral edema, dizzi- ness, dry mouth, constipation, and falls. Treatment discontinuations due to AEs occurred in 21% of ADS-5102 patients vs. 7% with placebo.

CONCLUSIONS: The reduction in LID in patients with PD was demonstrated by patient diaries along with improvement in CGI-C and ADLs. These results warrant further evaluation of the effect of ADS-5102 on QoL, caregiver burden and health care costs in PD patients with LID.

SPONSORSHIP: Supported by Adamas Pharmaceuticals.

G12 Hospitalizations and Emergency Department Visits in Patients with Parkinson’s Disease in the United States: A National Perspective

Mithal A1, Lingala B2, Niyazov A2, Guo A2, Squillacote D2, Singh G3. 175 Eleanor Dr, Woodside, CA 94062; gsingh@stanford.edu; (650) 530-0020

BACKGROUND: Tardive dyskinesia (TD) is a persistent movement disorder associated with antipsychotic therapy for which there is no approved treatment. Tetrabenazine (TBZ), a vesicular monoamine transporter 2 (VMAT2) inhibitor, is prescribed off-label for TD, but a novel, highly selective VMAT2 inhibitor, valbenazine (VBZ), has shown promising efficacy and tolerability.

OBJECTIVE: Systematically review the safety and efficacy of VBZ and TBZ for the treatment of TD.

METHODS: A systematic literature search for clinical trials of VBZ and TBZ in the treatment of TD was performed using Pubmed, Embase, OVID, and Google Scholar (1980 to September 2016). Data were collected for study design, sample size, study sites, comparators, efficacy and safety measures.

RESULTS: Of 479 search results, 10 studies met the criteria for systematic review. In 7 open-label, observational studies with mixed designs and outcome measures (total N = 473), moderate or marked clinical improvement was reported in 42% to 89% of TD patients treated with TBZ (mean dose range, 39-175 mg/day [thrice-daily dosing]). One uncontrolled, single-blind trial with standardized Abnormal Involuntary Movement Scale (AIMS) video scoring reported a 54% decrease in AIMS mean score from 17.9 (SD = 4.4) to 8.2 (SD = 5.3) (P < 0.001) in 19 TD patients receiving TBZ (mean dose, 58 mg/day TID; mean duration, 20 weeks). Two studies of once-daily VBZ (KINET 2 and KINET 3, total N = 325) were multi-site, randomized, placebo (PBO)-controlled trials using the AIMS (assessed by blinded centralized videotape raters) as the primary efficacy measure. After 6 weeks, treatment with VBZ led to a mean AIMS score change of -3.6 vs. -1.1 for PBO (KINET 2), and -3.2 (80 mg) and -1.9 (40 mg) vs. -0.1 for PBO (KINET 3, P < 0.01, both trials). 6-week treatment with VBZ also led to higher AIMS 50% responder rates (≥ 50% score decrease from baseline): 48.9% vs. 18.2% for PBO (KINET 2); 40.0% (80 mg) and 23.8% (40 mg) vs. PBO (8.7%; KINET 3, P < 0.05, both trials). The most common adverse events (AE) reported with TBZ were parkinsonism, akathisia, sedation, insomnia, and worsening of mood (depression, anxiety). The most common AEs reported with VBZ were fatigue, headache, and decreased appetite, with no significant differences in extrapyramidal or psychiatric measures compared to PBO.

CONCLUSIONS: Two randomized PBO-controlled trials support the efficacy of VBZ in reducing TD severity. No direct comparisons can be made between VBZ and TBZ trial results, but VBZ may have fewer side effects in addition to a more favorable once-daily dosing regimen for the treatment of TD.

SPONSORSHIP: Neurocrine Biosciences.
the Nationwide Emergency Department Sample (NEDS) and the National Inpatient Sample (NIS) databases. NEDS is a 20-percent stratified sample of all U.S. hospital-based EDs and is the largest all-payer emergency department database in the United States. NIS is a stratified random sample of all U.S. community hospitals. It is the largest inpatient care database with information on all inpatient care regardless of insurance status. Prevalence of ED visits and hospitalizations was calculated using population statistics of U.S. taken from U.S. Census Bureau (2013 estimates).

RESULTS: In 2013, there were 134.8 million all-cause ED visits in the U.S., with a prevalence of 42,662 visits per 100,000 population. PD patients accounted for 408,830 ED visits (129 visits/100,000 population/year). One-half of these ED visits resulted in hospitalization. Men accounted for 55.2% of the ED visits (prevalence 149/100,000/year vs. 114/100,000/year in women). Although prevalence increased with age, over 14% of ED visits were in patients younger than 65 years of age. Medicare paid for 85.7% of these visits while Medicaid paid for 3.5% of these visits. There were 271,520 hospitalizations in patients with PD. Approximately 10% of these were directly related to a primary diagnosis of PD. Men accounted for 55.8% of hospitalizations (prevalence 97/100,000/year vs. 75/100,000/year in women). Medicare paid for 87.2% of hospitalizations.

CONCLUSIONS: In this study, PD patients had a substantial number of ED visits and hospitalizations in the U.S. Nearly 14% of ED visits and 12% of hospitalizations were among patients younger than 65 years of age, suggesting a potential impact on work-loss and productivity.

SPONSORSHIP: Funding for this sponsored research was provided by Acorda Therapeutics.

G18 Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Chirikov V1, Ma P2, Joshi N1, Patel D1, Smith A2, Giambraone C2, Cornelio N1, Hashemi L2. 13450 East West Highway, Bethesda, MD 20814;
vcchirikov@pharmerit.com; (240) 821-9662
1Pharmerit International; 2Sanofi Genzyme

BACKGROUND: Relapsing multiple sclerosis (RMS) is a neuro-degenerative disease associated with significant clinical, economic, and humanistic burden. Several disease modifying treatment options are available for RMS but evidence is lacking regarding the cost-effectiveness (CE) of new high efficacy therapies such as alemtuzumab.

OBJECTIVE: To evaluate the CE of alemtuzumab compared with fingolimod (FIN), and natalizumab (NAT) among a pooled population of patients with RMS in the U.S.

METHODS: A Markov CE model with annual cycles and 20-year time horizon was run from a U.S. managed care perspective. The modeled RMS population represented the demographics and clinical characteristics of pooled treatment-naïve and –experienced patients from the CARE-MS I and CARE-MS II trials. The comparative efficacy of alemtuzumab, fingolimod (FIN), and natalizumab (NAT) among a pooled population of patients with RMS in the U.S.

RESULTS: Alemtuzumab dominated comparators by accumulating higher total QALYs (8.851) and lower total costs ($421,996) compared to NAT (8.456; $1,048,599) and FIN (7.955; $1,085,814). Patients on alemtuzumab had the lowest number of relapses. The CE dominance of alemtuzumab was mostly driven by savings in treatment acquisition costs as alemtuzumab has long-term durable effect and is administered over only 2 annual courses while other comparators need to be used daily or monthly on a chronic basis. In conservative model scenarios where the long-term durable effect of alemtuzumab is assumed not to hold and the therapy has to be administered annually, probabilistic sensitivity analyses showed that alemtuzumab remained cost-effective versus NAT at a CE threshold of $100,000/QALY in 92%-100% of all model runs.

CONCLUSIONS: Patients on alemtuzumab accrued lower incremental total costs and higher incremental number of QALYs than other comparators over a time-horizon of 20 years. Model results should be used to optimize clinical and managed care decisions for the patients with RMS.

SPONSORSHIP: Sanofi Genzyme.

G19 Prior Disease-Modifying Drug Use and the Relationship with Patient-Reported Outcomes

Kozma C1, Phillips A2. CK Consulting Associates, Saint Helena Island, SC 29920; ckozma@c-k-consulting.com; (843) 838-8064
1CK Consulting Associates; 2EMD Serono

BACKGROUND: Patient-reported outcome (PRO) measurement in multiple sclerosis (MS) can provide valuable information as it captures the patient perspective, complementing and supporting the meaningfulness of clinical or economic outcomes. Understanding the relationship between PROs and prior disease-modifying drug (DMD) use may provide insights into treatment patterns and patient characteristics.

OBJECTIVE: To evaluate PROs by prior use of DMDs in patients with MS.

METHODS: Data were obtained from patients with MS from the U.S. National Health and Wellness Survey or Lightspeed Research panel and its affiliates who completed a 30-minute Internet survey from April to October 2015. Questions about demographics, disease severity, prior and current DMD use, symptoms, comorbidities, quality of life (QoL), and life satisfaction were included. The Patient-Determined Disease Steps (PDDS) scale assessed MS disease status/disability; the Multiple Sclerosis Rating Scale, Revised (MSRS-R) assessed self-reported functional disability; and the MS Quality of Life questionnaire (MSQoL) assessed disease-specific patient QoL. Patients were grouped based on prior DMD use: no prior use, use of 1, 2, or ≥3 prior DMDs.

RESULTS: A total of 902 survey respondents reported currently using DMDs: 311 (34.5%) reported no DMD use prior to the current DMD, 296 (32.8%) reported prior use of 1 DMD, 154 (17.1%) reported prior use of ≥2 DMDs, and 141 (15.6%) reported prior use of ≥3 DMDs. Compared to patients without prior DMD use, those with prior DMD use were younger when their symptoms started, younger at the time of MS diagnosis, and younger when first treated (P < 0.05). A higher number of prior DMDs was associated with self-reported prior relapse, presence of MS symptoms, greater functional disability, and worse QoL (P < 0.05). Life satisfaction did not differ significantly between patients with and without prior DMD use. A greater proportion of patients with no prior DMD use reported treatment with a self-injectable (66.6%, P < 0.01), while a greater proportion with prior DMD treatment were currently receiving treatment with oral DMDs or infusion therapies (55.7%, P < 0.001).

CONCLUSIONS: Many patients with MS report prior DMD use, with almost one-third reporting ≥2 DMDs. Those with prior DMD use had greater disability and worse QoL, yet no difference in life satisfaction vs. patients with no prior DMD use.

SPONSORSHIP: EMD Serono.
**G20 Impact of Multiple Sclerosis Relapse Severity on Health Care Costs**

Nicholas J.¹, Li F.², Vieira M.³, Zhou H.¹, Wang C.¹, Herrera V.²

1OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital; ²Novartis Pharmaceuticals; ³KMK Consulting

**BACKGROUND:** A multiple sclerosis (MS) relapse is a new neurologic symptom which lasts greater than 24 hours in the absence of fever or infection. Relapses are the clinical hallmark of relapsing remitting multiple sclerosis (RRMS) and contribute to neurologic disability as recovery is variable. Relapses often require additional medical visits and treatment based on severity, which implies differential health care costs.

**OBJECTIVE:** To estimate the medical care costs associated with MS relapse severity, under the perspective of private payers in the U.S.

**METHODS:** Newly diagnosed adult MS patients (ICD-9-CM: 340.x) from a large U.S. insurance claims database between 2011 and 2015 were included in the analysis. These patients were stratified into three cohorts: no relapse, low/moderate relapse, and severe relapse, according to the Chastek validated claims-based algorithm. A severe relapse is characterized by a hospitalization with a principal diagnosis of MS. A low/moderate relapse is characterized by an outpatient or emergency room visit with a diagnosis of MS followed by a corticosteroid pharmacy or medical claim within 7 days. The incremental all-cause and MS-related medical costs between the year prior to and the year post relapse for each cohort were estimated, adjusted for age, gender, region, insurance type and year of identification. Costs included inpatient, outpatient, emergency room and pharmacy spending.

**RESULTS:** Among the 9,597 MS patients identified, the mean age was 48.3, 75.6% were women, 84.8% had a fee-for-service insurance. Geographically, 34.5% lived in the South, 30.6% in the North Central, 17% in the Northeast and 17% in the West. In terms of severity of relapses, 7,054 (73.5%) had no relapses, 2,013 (21%) had low/moderate relapses, and 530 (5.3%) had severe relapses. Compared to the no relapse cohort, the mean and standard deviation of incremental all-cause and MS related costs were $8,680 ($900) and $7,587 ($1,185) higher for the low/moderate relapse cohort and $36,938 ($1,758) and $32,731 ($2,103) higher for the severe relapse cohort, respectively.

**CONCLUSIONS:** In a large retrospective analysis of insurance claims across 3.5 years, relapse severity was significantly and positively associated with higher medical costs. Providing MS patients with access to disease-modifying treatments that are effective in decreasing the number and severity of relapses is likely to lower medical costs.

**SPONSORSHIP:** Sponsored by Novartis Pharmaceuticals.

**G22 The Burden of Relapsing-Remitting Multiple Sclerosis on Workers in the United States: A Cross-Sectional Analysis of Survey Data**

Nicholas J.¹, Witt E², Electricwala B³, Johnson K.³

1OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital; ²Kantar Health; ³Novartis Pharmaceuticals

**BACKGROUND:** Real-world studies that assess the impact of Relapsing Remitting Multiple Sclerosis (RRMS) on individuals’ ability to maintain employment and performance at work are limited.

**OBJECTIVE:** To assess the burden of RRMS on the work productivity and health resource utilization of persons with MS (pwMS).

**METHODS:** Data were drawn from the 2015-2016 U.S. National Health and Wellness Surveys (NHWS). Individuals who reported a diagnosis of RRMS were propensity matched to individuals without a diagnosis of MS at a 1:1 comparison to target ratio on: year of survey, age, gender, household income, marital status, education, health insurance, body mass index, experience of anxiety, sleep problems, and depression (past 12 months), alcohol use, smoking status, exercise status, and comorbidity burden as assessed by the Charlson Comorbidity Index. A separate match was conducted with employed RRMS respondents as the target group. Respondents in each match were then compared on to chronic conditions for which there are multiple established therapies. Here, the cost-effectiveness of fingolimod as an oral therapy for relapsing-remitting multiple sclerosis (RRMS) versus intramuscularly-administered interferon beta-1a (Avonex) has been explored, with and without the inclusion of price reductions following a potential loss of exclusivity (LOE).

**OBJECTIVE:** To investigate the impact of including price reductions following LOE into health economic models, using disease-modifying therapies for RRMS as an example.

**METHODS:** The model was adopted from a previously published model and was conducted from a U.S. payer’s perspective over a 10-year time horizon. Outcomes included per-patient total direct costs (medication, administration and monitoring, disease-related costs including relapses) and quality-adjusted life years (QALYs), and the incremental cost per QALY. Price reductions on LOE were based on published, historical estimates for oral medicines (fingolimod) and the relative prices of branded and generic injectables already available for use in RRMS (Avonex). Scenario analyses were conducted to test assumptions regarding LOE, including the proportion of patients switching to generic versions.

**RESULTS:** Assuming no price reductions following LOE, fingolimod was considered cost-effective versus Avonex (QALYs: 4.99 fingolimod vs. 4.77 Avonex; incremental: $139,219 per QALY, fingolimod vs. Avonex), despite having higher total direct costs than Avonex over 10 years (costs: $485,820 fingolimod vs. $454,628 Avonex). Including future price reductions following LOE, total direct costs were reduced with fingolimod and were lower than those accrued with Avonex over the model time horizon ($327,536 fingolimod vs. $451,583 Avonex).

**CONCLUSIONS:** These analyses demonstrate the importance of including future price reductions following LOE into health economic models and show how the costs associated with established therapies may be overestimated if LOE is not considered. In some cases, the inclusion of LOE may determine whether or not an intervention is considered cost-effective and as such may influence reimbursement decisions based on cost-effectiveness analyses.

**SPONSORSHIP:** Novartis Pharmaceuticals.
a number of health outcomes including health care utilization (physician visits, emergency room [ER] visits, and hospitalizations), work productivity and activity impairment (WPAI: 6-item validated scale that assesses work and activity impairment).

**RESULTS:** Individuals with RRMS (n = 543) compared to matched controls (n = 2,172) were more likely to use health care resources (% used past 6 months: ER = 21.4% vs. 15.1%, Hospitalized = 13.1% vs. 8.7%, HCP = 95.9% vs. 87.0%; P < 0.05) and to use them more often than non-RRMS patients (average # of HCP visits in past 6 months = 6.29 vs. 4.83, P < 0.05). They were also more likely to report time lost work time and being more unproductive while at work (% lost in last 7 days: absenteeism = 12.3% vs. 6.0%, presenteeism = 33.4% vs. 19.7%; P < 0.05). Moreover, they also reported more impairment in their day-to-day activities (% lost in last 7 days = 50.2% vs. 28.7%; P < 0.05). Results of the separate match within employed RRMS respondents showed a similar pattern of results-increased health care resource use and activity impairment among the employed RRMS group (n = 196) relative to employed controls (n = 784).

**CONCLUSIONS:** This research suggests that RRMS has a substantial impact on work productivity and increased health care resource utilization.

**SPONSORSHIP:** Novartis provided funding for this analysis.

---

**G24 Multiple Sclerosis Medication Adherence Within Walgreens Local Specialty Pharmacies Is Significantly Higher Compared to Other Class-of-Trade Pharmacies**

*Staskon F1, Fu C2, Kirkham H1. 1415 Lake Cook Rd, MS# L444, Deerfield, IL 60015; francis.staskon@walgreens.com; (847) 964-8954
1Walgreen Co.; 2QuintilesIMS*

**BACKGROUND:** Walgreens local specialty pharmacies (LSPs) are on health system campuses and located in select communities that focus on managing complex chronic health conditions such as cancer, HIV/AIDS, hepatitis C, multiple sclerosis, CID, transplant and cystic fibrosis in addition to others. For multiple sclerosis (MS) patients, LSPs provide personalized, comprehensive pharmacy care, copay assistance and have access to therapies, even those with a limited distribution label.

**OBJECTIVE:** To compare patient adherence for MS medication therapies for patients treated at Walgreens LSPs to patients treated at food stores, mass merchandisers, independent pharmacies, traditional Walgreens pharmacies or other chain stores (i.e., Class of Trade, CoT). A second objective compared the same cohort of MS patients’ adherence to non-specialty drug treatment groups of oral antidiabetics, antihypertensives, and antihyperlipidemics from LSPs to the other pharmacies (i.e., CoT).

**METHODS:** QuintilesIMS conducted a retrospective cohort design using their longitudinal retail prescription database (LRx) that includes pharmacy claims information across CoT. Inclusion criteria required patients to be exclusive to the Walgreens cohorts and compared to exclusive CoT patients from January 2015 through December 2015. Additional requirements included patient having at least two sold MS medications and being at least 18 years of age. MS medications included were glatiramer acetate, interferon beta-1a, interferon beta-1b, peginterferon beta-1a, teriflunomide, alemtuzumab, natalizumab, dimethyl fumarate, dalfampridine, and fingolimod HCl. Proportion of days covered (PDC) was calculated at the drug subclass level and then overall as either a weighted average or average level of adherence.

For the three comorbid conditions, PDCs were calculated at the same subclass level, but reported at the drug group level, using the weighted average approach.

**RESULTS:** For MS medications, mean PDC in Walgreens LSPs (M = 78.5) was significantly higher than the CoT cohorts (P < 0.0001; mean CoT PDC ranged from 75.0 to 72.1). Also the adherence rate (percent of patients with PDC > 80%) was significantly higher in Walgreens LSP compared to CoT cohorts (P < 0.0001). Mean PDC levels indicated no significant differences between cohorts for antihyperlipidemics and antihyperlipidemics.

**CONCLUSIONS:** Patients utilizing Walgreens LSPs for their MS medications were significantly more adherent to these medications than other Class of Trade pharmacies and similar to CoT pharmacies in levels of adherence to antihypertensives or antihyperlipidemics.

**SPONSORSHIP:** Walgreens Co and QuintilesIMS.
Multiple sclerosis (MS) is a chronic and complicated disease that requires a multi-factorial treatment approach to achieve the best clinical outcomes. Improved communication among pharmacy providers, patients, and providers is necessary to achieve the best clinical outcomes.

**GOAL:** To improve the overall care of patients living with MS through a pharmacist-led clinical outreach program.
RESULTS: A total of 5,600, 1,110, and 795 patients, respectively, initiated DMF, FTY, and TER. Differences were observed in mean age at initiation, proportion receiving an alternate DMT in the prior year and average follow-up (years) after initiation. In the overall study cohort, no difference in risk of relapse was observed between FTY vs. DMF following initiation of treatment (HR: 0.995, P=0.94), whereas TER was associated with a 30% (HR: 1.302, P<0.01) increased risk relative to DMF. Similar findings were observed in the subgroups stratified by receipt of DMT in the prior year (newly-treated or switching patients).

CONCLUSIONS: In this retrospective study, no difference in risk of relapse between FTY and DMF was evident, whereas TER was associated with a significantly higher risk of relapse, relative to DMF. Results were consistent among newly-treated and switching patient subgroups.

SPONSORSHIP: Biogen.

G29 Hospital Readmissions in Epilepsy Patients: A U.S. National Perspective
Singh G1, Mithal A2, Lingala B3, Mithal A4, 175 Eleanor Dr, Woodside, CA 94062; gsingh@stanford.edu; (650) 530-0020
1Stanford University; 2ICORE

BACKGROUND: Readmission rates are an indicator of the quality of care that patients receive during a hospital admission and after discharge. There is little data on hospital readmission rates in patients with uncontrolled seizures.

OBJECTIVE: To examine hospital readmissions in patients 18 years and older after an index hospitalization for primary diagnosis of epilepsy.

METHODS: We examined all hospitalizations in the State of California from 2005-2011 in patients 18 years or older, using California State Inpatient Database. Index hospitalizations with primary diagnosis of epilepsy (ICD-9 code 345 and 780.39) were identified. Readmission was calculated as the first subsequent unscheduled hospital admission for any cause within 30, 60 and 90 days following an index stay.

RESULTS: There were 27 million all-cause hospitalizations and 160,249 hospitalizations for primary diagnosis of epilepsy from January 2005-December 2011. Of these, 15,910 (15.6%), 22,626 (22.5%), and 26,830 (27%), resulted in readmissions in 30, 60 and 90 days, respectively. Readmission rates were highest in 45-64 years age group, in Native Americans and African-Americans (P<0.001 for all comparisons). White Caucasian populations had lowest readmission rates. Patients covered by Medicaid had higher readmission rates (18%, 27% and 32% at 30, 60 and 90 days, respectively) as compared to those with Medicare (17%, 25% and 30%) and Private Insurance (11%, 15% and 18%). Patients in the poorest income quartile had higher readmission rates than the richest income quartile (P<0.001).

CONCLUSIONS: Hospital readmission rates are high in patients with epilepsy, indicating a need for better in-patient management and post-discharge care. We identified specific population groups at greater risk for readmissions (ages 45-64, Native Americans and African Americans, persons in lower income quartiles and those on Medicaid). More effective education regarding their disease management and better follow up care after hospitalization is needed to reduce the health care disparity in these populations.

SPONSORSHIP: This study was supported by a research grant from Acora Therapeutics.
**Methods**: Retrospective medical chart review by neurologists recruited from a nationwide panel. Patients with epilepsy (age ≥18 years, AED initiated between January 1, 2014 and January 1, 2016) were followed for 6 months from AED initiation. Titration duration was time from AED initiation to beginning of maintenance as determined by physician. Outcomes were epilepsy-specific HRU (hospitalization, emergency department [ED] and outpatient visits, physician referral, lab testing/diagnostic imaging, phone calls) and related costs by titration vs. maintenance and AED type. HRU rate = (sum of HRU incidence) / (sum of person months) during titration/maintenance period. HRU costs = unit cost; adjusted to 2016 = HRU incidence during titration/maintenance.

**Results**: Of 811 cases, 13.2% initiated carbamazepine (CBZ), 15.8% lamotrigine (LTG), 19.2% levetiracetam (LEV), 14.8% valproate (VPA), 14.1% topiramate (TPM), 15.4% lacosamide (LCM), and 7.5% phenytoin (PHT). Most cases received monotherapy (77.1%; 18.3% and 4.6% had adjunct therapy with 1 or ≥2 other AEDs). Baseline characteristics were similar across AEDs (mean [SD] age, 36.6 [14.4] years; 59.0% male). Across AEDs, median titration duration was 5.1 weeks (range: 2.8 [PHT] to 8.0 weeks [LTG]). Total HRU for epilepsy-related costs decreased from $80.48 to $42.77 per person per month (PPPM), or 46.9% from AED titration period to maintenance period. The overall incidence of HRU PPPM decreased 52.9%-89.2% from titration to maintenance for each HRU measure except outpatient visits (24.4% decrease). Across AEDs, seizure-related hospitalizations, a high cost driver, decreased 50.0% from titration to maintenance. Specific AEDs associated with higher total costs PPPM during titration were CBZ ($119.30) and PHT ($122.54). During titration, highest HRU costs PPPM were: outpatient visits (CBZ, $56.82), testing/imaging (PHT, $32.27), hospitalization (CBZ, $31.78), and ED visits (PHT, $26.99). CBZ, PHT, and VPA were associated with the highest overall costs PPPM during the 6-month study period.

**Conclusion**: Across AEDs, titration periods had higher HRU rates and costs than maintenance periods, suggesting use of AEDs without titration could substantially save health care costs. Disease severity may also factor into overall cost.

**Sponsorship**: Sponsored by UCB Pharma.

**G32 Cost Sharing for Antiepileptic Drugs: Implications for Medication Utilization and Health Plan Costs**

**Objectives**: To examine the association between health plan co-insurance and health plan costs among U.S. commercial health plan beneficiaries with epilepsy.

**Methods**: This retrospective cohort study of patients with epilepsy used the Truven MarketScan Commercial Claims research database for calendar years 2010 to 2015. Patients ≤65 years were included if they had a minimum 12-months of continuous enrollment prior to meeting the case definition for epilepsy. Index was defined as the date when the first criteria was met after a 12-month period of continuous enrollment. All analyses were adjusted for age group (0-18, 19-45, ≥46-65), gender, beneficiary relationship, insurance plan type, and Charlson Comorbidity Score. Primary outcome measures included proportion of days covered (PDC), health care utilization including inpatient, outpatient and emergency department (ED) visits, and health care spending in each 90-day period following index. PDC was calculated using standard methods. Out-of-pocket (OOP) costs were calculated using a market-basket index set of representative AEDs. Multivariate linear models estimated the association between OOP spending for each plan on the mean PDC, health care utilization and plan health care spending in each 90-day period.

**Results**: A total of 187,421 beneficiaries across 5,159 plans met the eligibility criteria; 54% were female; 42% of beneficiaries were 45-65 years of age. The most common plan type was PPO (66%). Across all post-index 90-day periods, the mean (SD) PDC was 0.85 (0.26), mean (SD) epilepsy-specific hospitalizations, outpatient visits, and ED visits were 0.02 (0.13), 0.54 (0.47), and 0.05 (0.22), respectively. Median (IQR) overall spending in a 90-day period was $1,848 ($597-$5,569); median overall epilepsy-specific spending was $140 ($85-$559). In multivariable linear regression models without health plan fixed effects, higher OOP spending was associated with a decrease in PDC (coefficient -0.008 [95% CI -0.009, -0.006]; P < 0.001), and increases in overall plan (coefficient 194.5 [0.8, 388.1], P < 0.05) and epilepsy-specific spending (coefficient 93.9 [54.1, 133.7], P < 0.0001). Health plan fixed effects model estimates were similar though confidence intervals were wider.

**Conclusion**: Increased co-insurance costs shifted to epilepsy patients leads to higher overall spending and lower PDC.

**Sponsorship**: Sponsored by UCB Pharma.

**G33 Utilization Patterns of Topiramate Formulations in Epilepsy and Migraine: Analysis of Administrative Claims Comparing Trokendi XR (Extended-Release Topiramate) and Immediate-Release Topiramate**

**Objectives**: To examine adherence and persistence patterns associated with use of Trokendi XR vs. TPM-IR in epilepsy and migraine populations.

**Methods**: Medical and pharmacy claims data were retrieved from HealthCore Integrated Research Database. Key inclusion criteria were initial prescription (index claim) between 8/1/2013 and 10/31/2014, patients ≥6 yrs old, continuous health plan enrollment ≥12 months pre-index and ≥6 months post-index, and epilepsy or migraine diagnosis. Adherence was measured as medication possession ratio (MPR). Persistence was assessed with Kaplan-Meier survival analysis. Claims for potential drug-related complications served as proxies for adverse events (AEs).

**Results**: Analysis populations: 9,064 migraineurs (Trokendi XR, 1,463 epilepsy patients (Trokendi XR, 99; TPM-IR, 1,364). Migraine: Persistence significantly (P < 0.001) favored Trokendi XR. Mean (SD) time to discontinuation was 7.7 (0.36) months with Trokendi XR vs. 6.4 (0.08) months for TPM-IR. Average MPR was significantly greater (P < 0.001) with Trokendi XR (32%) vs. TPM-IR (43%). Migraine: Persistence significantly (P < 0.005) favored Trokendi XR. Mean (SD) time to discontinuation was 9.7 (0.82) months with...
Trokendi XR vs. 7.5 (0.22) months for TPM-IR. Average MPR was significantly greater (P<0.001) with Trokendi XR (65%) vs. TPM-IR (50%). In both populations, the difference in persistence emerged within first 2 months; claims for potential drug-related complications (AEs) tended to be lower with Trokendi XR vs. TPM-IR.

**CONCLUSIONS:** In this retrospective claims-based study, initiation of Trokendi XR was associated with greater persistence and adherence vs. TPM-IR in migraineurs and epilepsy patients. Better overall tolerability and adherence with Trokendi XR may have influenced the improved persistence observed early on since the peak period of CNS and cognitive AE occurrence with TPM-IR has historically been the first several months of treatment. Analyses of larger datasets and prospective studies are needed to confirm these observations.

**SPONSORSHIP:** Supernus Pharmaceuticals.

### G37 Utilizing Electronic Health Records to Assess the Severity and Impact of Chronic Pain

**Mata J1, Agnihotri P2, Reda L2, Tribuzio B3, Fung F2, Smith R3, Hartman T2, Carda E2. 2020 Genesee Ave, San Diego, CA 92123; josemata@uic.cochranehealthsolution.com; (858) 499-2600**

**1Sharp Rees-Stealy; 2Pfizer**

**BACKGROUND:** The management of chronic noncancer pain can be improved by the systematic, consistent use of multidimensional assessment tools. Measurement of several dimensions of pain may alert busy clinicians to significant comorbid disorders before poor outcomes and treatment failures disappoint and frustrate both patients and providers. The use of technology may facilitate data capture.

**OBJECTIVE:** To describe common pain conditions and their impact on patient general well-being, function, and resource utilization through use of a multidimensional assessment tool administered via electronic health record (EHR).

**METHODS:** A multidimensional chronic pain assessment tool (CPAT) was devised for use in this retrospective, cross-sectional study. The CPAT consisted of separately validated questions to assess pain severity, function interference, pain duration, anxiety/depression, and risk for opioid abuse. The CPAT was built into a multispecialty medical group’s EHR and administered by pain specialists to adult patients with noncancer pain who were currently receiving, or being considered for opioid therapy.

**RESULTS:** The CPAT was administered to a total of 216 patients between January and July, 2016. 198 patients were included in the final analysis. Of those, the average pain intensity score was 6.7 (0-10), average function interference due to pain was 6.1 (0-10), and the average composite CPAT score was 18.8 (0-58). The patient population as a whole reported a low likelihood of depression, anxiety, and risk for opioid abuse as measured by the PHQ-4 (avg. anxiety 2.1, avg. depression 1.9) and ORT (avg. 2.1). Lower back pain (81%), back pain (71%), joint pain (44%), and fibromyalgia (43%) were the most frequently identified chronic pain conditions. Three or more co-morbid chronic pain conditions were noted in 86% of patients. Analysis comparing the average # of encounters/month for 12 months prior to CPAT administration to 6 months post administration demonstrated a significant decrease from 1.9/pt/month to 1.67/pt/month (P=0.013).

**CONCLUSIONS:** The treatment of chronic pain can be improved through multidimensional assessment. The inclusion of the CPAT into an EHR facilitated the capture and tracking of pain attributes such as severity, function, anxiety, depression, and opioid abuse risk potential. This tool provides valuable information at the point of care that can assist with pain management strategies as well as provide broader chronic pain type and prevalence information. Important next steps include discussions to further the relevance, effectiveness and validity of this research.

**SPONSORSHIP:** Pfizer.

### H0-H95 Diseases of the Eye and Adnexa

**H1 Burden of Noninfectious Inflammatory Eye Diseases: A Systematic Literature Review**

**Rice J1, White A1, Scarpati L1, Philbin M2, Wan G2, Nelson W2. 111 Huntington Ave, 14th Fl, Boston, MA 02199; brad.rice@analysisgroup.com; (617) 425-8247**

1Analysis Group; 2Mallinckrodt Pharmaceuticals

**BACKGROUND:** Non-infectious inflammatory eye diseases (IEDs), although rare, can have detrimental effects. Treatment goals are to prevent vision loss, reduce inflammation, and minimize complications.

**OBJECTIVE:** To conduct a systematic literature review on the burden of IED, focusing on clinical and economic outcomes across all treatment options.

**METHODS:** Scientific literature databases accessed via the Ovid search platform (Wolters Kluwer) included MEDLINE, Embase, Cochrane libraries, Health Technology Assessment, and the NHS Economic Evaluation database. The search strategy targeted clinical and economic outcomes research in 2009-2016, and excluded conference abstracts and papers assessing pediatrics. Titles and abstracts resulting from inclusion criteria were screened, and two reviewers independently extracted relevant information from the selected full-text articles.

**RESULTS:** The review included 39 studies (21 clinical trials, 7 database analyses, 6 systematic literature reviews, 3 chart reviews, and 2 patient surveys), assessing steroids, immunosuppressants, implants, and biologics. Mainstay therapy was corticosteroids delivered via topical, oral, intravitreal, or peri-bulbar routes. Prevalence of treatment related adverse events is notable: glaucoma (3%-65%), cataracts (2%-91%), retinal detachment (11%), hyperglycemia (25%), and ocular hypertension (12-28%). In particular, patients treated with corticosteroids had significantly higher rates of glaucoma, cataracts, cystoid macular degeneration, and retinal detachments than other treatment options. The average annual cost of IED patients was between $13,728 to $32,268 in 2009 dollars, or 3.1 to 8.3 times the cost of patients without IED. Inpatient admissions were 83% higher for patients receiving corticosteroid treatment than those receiving biologics: 24 vs. 44 admissions per month per 1,000 patients. Implants, as compared to systemic therapies, are associated with higher up-front costs ($43,100 vs. $8,100 during first 6 months), requirements of close monitoring, potential need for implant removal, and increased rates of adverse ocular events, including cataract surgery (80% vs. 31%) and IOP-lowering surgery (26% vs. 4%).

**CONCLUSIONS:** IEDs are rare conditions that impact quality of life, and threaten a patient’s vision; however, the treatment can be ineffective, with many of the same adverse ocular outcomes that treatments are supposed to prevent. Further research is needed to more fully explore the burden of IED and treatment-related adverse events, and that more proactive treatment intensification may be warranted.

**SPONSORSHIP:** Sponsored by Mallinckrodt Pharmaceuticals.

### I00-I99 Diseases of the Circulatory System

**I1 Statins Are Differentially Sensitive to the Medication Possession Ratio**

**Stauffer M1, Hutson P2, Kaufman A1, Morrison A2. 217 Wood St, Walworth, WI 53184; melstauff@charter.net; (262) 394-5258**

1ScribCo; 2University of Wisconsin School of Pharmacy

**BACKGROUND:** The management of chronic noncancer pain can be improved by the systematic, consistent use of multidimensional assessment tools. Measurement of several dimensions of pain may alert busy clinicians to significant comorbid disorders before poor outcomes and treatment failures disappoint and frustrate both patients and providers. The use of technology may facilitate data capture.

**OBJECTIVE:** To describe common pain conditions and their impact on patient general well-being, function, and resource utilization through use of a multidimensional assessment tool administered via electronic health record (EHR).

**METHODS:** A multidimensional chronic pain assessment tool (CPAT) was devised for use in this retrospective, cross-sectional study. The CPAT consisted of separately validated questions to assess pain severity, function interference, pain duration, anxiety/depression, and risk for opioid abuse. The CPAT was built into a multispecialty medical group’s EHR and administered by pain specialists to adult patients with noncancer pain who were currently receiving, or being considered for opioid therapy.

**RESULTS:** The CPAT was administered to a total of 216 patients between January and July, 2016. 198 patients were included in the final analysis. Of those, the average pain intensity score was 6.7 (0-10), average function interference due to pain was 6.1 (0-10), and the average composite CPAT score was 18.8 (0-58). The patient population as a whole reported a low likelihood of depression, anxiety, and risk for opioid abuse as measured by the PHQ-4 (avg. anxiety 2.1, avg. depression 1.9) and ORT (avg. 2.1). Lower back pain (81%), back pain (71%), joint pain (44%), and fibromyalgia (43%) were the most frequently identified chronic pain conditions. Three or more co-morbid chronic pain conditions were noted in 86% of patients. Analysis comparing the average # of encounters/month for 12 months prior to CPAT administration to 6 months post administration demonstrated a significant decrease from 1.9/pt/month to 1.67/pt/month (P=0.013).

**CONCLUSIONS:** The treatment of chronic pain can be improved through multidimensional assessment. The inclusion of the CPAT into an EHR facilitated the capture and tracking of pain attributes such as severity, function, anxiety, depression, and opioid abuse risk potential. This tool provides valuable information at the point of care that can assist with pain management strategies as well as provide broader chronic pain type and prevalence information. Important next steps include discussions to further the relevance, effectiveness and validity of this research.

**SPONSORSHIP:** Pfizer.
BACKGROUND: Examination of the medication possession ratio (MPR) is a common method of assessing patient adherence to a prescribed drug regimen. When defining adherence in a binary manner, an MPR of 0.8 is often used as the threshold between adherence and non-adherence. However, this threshold for adherence is somewhat arbitrary, and dosing regimens corresponding to MPR 0.8 may not provide a satisfactory clinical effect for all drugs.

OBJECTIVE: The objective of this study was to demonstrate that the MPR corresponding to adherence may differ between drugs within the same class.

METHODS: We used pharmacokinetic/pharmacodynamic (PK/PD) modeling to predict serum levels of low-density lipoprotein cholesterol (LDL-C) in patients taking simvastatin 20 mg or atorvastatin 5 mg once daily for 30 days. Model parameters were derived from published sources. Real-world dosing regimens corresponding to MPR values of 1.0, 0.8, 0.6, 0.4, and 0.2 were obtained from an online database of medication event monitoring system data. The effect of MPR on LDL-C reduction was assessed within a cardiovascular prevention scenario in which a patient with an initial LDL-C level of 100 mg/dL took simvastatin or atorvastatin to achieve an LDL-C goal of <70 mg/dL. The results were expressed as the percentage of time spent at the LDL-C goal. Adherence was defined as any dosing regimen that facilitated attainment of the LDL-C goal for the same amount of time as perfect adherence (i.e., MPR 1.0), subject to a x2 test of proportions.

RESULTS: For simvastatin 20 mg, the dosing regimen corresponding to MPR 0.8 resulted in a significant loss of time at the LDL-C goal compared to MPR 1.0 (54.8% versus 85.1%; P < 0.001), and MPRs < 0.8 resulted in progressively less time at goal (21.1%, 8.3%, and 0.0%, for MPRs 0.6, 0.4, and 0.2, respectively). For atorvastatin 5 mg, MPRs 0.8 and 0.6 allowed attainment of the LDL goal for essentially the same amount of time as MPR 1.0 (87.8% and 87.7%, respectively, versus 88.1%; P > 0.05 for both), with a reduction of time at goal only occurring at MPRs ≤ 0.4 (63.5% for MPR 0.4 and 22.4% for MPR 0.2; P < 0.001 for both).

CONCLUSIONS: In PK/PD simulations, statins exhibited differential sensitivity to the MPR, with simvastatin requiring an MPR > 0.8 to maintain clinical effectiveness, while atorvastatin did so with MPR values ≥ 0.6. These findings suggest that an MPR of 0.8 cannot be applied as a universal threshold for adherence and demonstrate the usefulness of PK/PD modeling for determining the correct MPR threshold.

SPONSORSHIP: No external funding supported this study.

A Systematic Review of Cost-Effectiveness Analyses of Antihypertensive Medications

Park C1, Wang G1, Durthaler J2, Fang J3. 1215 Marsh Trail Cir, Sandy Springs, GA 30328; muz6@cdc.gov; (770) 488-0369

1Centers for Disease Control and Prevention; 2Centers for Disease Control and Prevention via IHRC

BACKGROUND: Many cost-effectiveness analyses (CEA) of antihypertensives have been published, but a systematic review has not been available.

OBJECTIVE: To conduct a systematic review of the CEA of antihypertensives.

METHODS: Based on the PRISMA guidelines, we searched Pubmed, Embase, Cochrane library, and Health Technology Assessment to identify original CEA published in 1990-2016. Results were summarized by drug classes of: angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), thiazide-type diuretics, beta-blockers, and others. The incremental cost-effectiveness ratio (ICER) was adjusted to the 2016 U.S. dollar.

RESULTS: Among 76 studies reviewed, 26 studies compared the cost-effectiveness of medications with no treatment, 29 studies compared between drug classes, 13 studies compared within drug class, and eight studies compared combination therapies. All antihypertensives were cost-effective compared to no treatment (ICERs: dominant to $35,670/quality-adjusted life year [QALY]). Between drug classes, nine studies compared ARBs and CCBs; ARBs were more cost-effective than CCBs (ICERs: dominant to $43,714/QALY) (e.g., eprosartan vs. amiodipine) in seven studies, while CCBs were more cost-effective than ARBs (ICERs: dominant to $1,606/QALY) in six studies. When comparing ARBs with ACEIs or beta-blockers, ARBs were more cost-effective than ACEIs (ICERs: dominant to $43,715/QALY). Results were confirmed in all nine studies.

CONCLUSIONS: Although all antihypertensives were cost-effective compared to no treatment, ARBs appeared to be more cost-effective.
than ACEIs and beta-blockers. However, caution should be taken due to publication bias and the heterogeneity of study setting.

**SPONSORSHIP:** None.

### A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence

Abighosh S1, Wang X2, Serra O3, Esse T1, Vaidyaratnam A1, Mann A2, Eissen E2, Fleming M1. 1441 Moursund St, Houston, TX, 77030; smabigho@central.uh.edu; (832) 842-8395

1University of Houston; 2Cigna-HealthSpring; 3University of Houston College of Pharmacy, Dept of Pharmaceutical Health Outcomes and Policy

**BACKGROUND:** Patients with comorbid Diabetes (DM) and hypertension (HTN) are at high risk for developing micro and macrovascular complications. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are recommended for these patients, having shown to reduce such complications. However, adherence remains suboptimal, compromising the potential benefit. Interventions to improve adherence are greatly needed. Motivational interviewing (MI) is a patient-centered collaborative communication style utilized to strengthen internal motivation for change that may prove effective in enhancing adherence.

**OBJECTIVE:** To demonstrate the benefit of an MI telephonic intervention conducted by pharmacy students to improve adherence to ACEIs/ARBs among Medicare Advantage Plan (MAP) patients with DM and HTN.

**METHODS:** A randomized trial was conducted among patients enrolled in a Texas MAP. Patients with DM and HTN who filled a prescription for an ACEI/ARB during June, 2014 were included. Patients with a 6-month proportion of days covered (PDC) < 0.80 in the previous 6 months were determined to be non-adherent and randomized to an intervention or control group. The intervention was a phone call by pharmacy students on rotation at the MAP followed by 5 monthly follow-up calls. Prior to implementing calls, 11 participating students attended a 3-day MI training. Patients receiving calls were randomly selected from those randomized to intervention until 250 was reached; 500 controls were randomly selected from controls. Refill data during the 6-month post-intervention were evaluated using 2 outcomes: PDC and PDC ≥ 0.80 vs. not. Multivariate linear and logistic regression models were constructed to control for imbalances in baseline characteristics including age, gender, number of medications, regimen complexity, low income subsidy status, prescriber specialty, comorbidities, 6-month prior hospitalization, baseline 6-month PDC, and Centers for Medicare and Medicaid Services risk score.

**RESULTS:** 743 patients were included in multivariate models. Patients completing ≥3 calls were more likely to be adherent in both linear (β = 0.0604, P < 0.001) and logistic model (OR: 1.53, 95% CI: 1.02-2.28, P = 0.009). Other significant factors included baseline PDC, depression and number of medications.

**CONCLUSIONS:** The MI phone intervention by students was effective in improving adherence during the 6 months following initial call. Future research should examine the sustainability of intervention effect for longer periods and its influence on clinical outcomes.

**SPONSORSHIP:** Pharmaceutical Research and Manufacturers of America Foundation.

### Time to Approval in Patients Requesting Access to PCSK9i Therapy by Payer Type

Baum S1, Chen C1, Rane P2, Patel J1, Maya J2, Harrison D2, Mequeness K3, Yurin N2, Wade R1. 7900 Glades Rd Ste 400, Boca Raton, CA 33434; sjbaum@fpim.org; (561) 488-5335

1Excel Medical Clinical Trials; 2Amen, 3QuintilesIMS

**BACKGROUND:** Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) have demonstrated unprecedented reductions in LDL-C for patients uncontrolled by statin and/or ezetimibe. Payers often restrict access to new therapies with utilization management criteria that are more restrictive than the approved indications, and that may lead to longer wait times for patients requesting these therapies.

**OBJECTIVE:** The goal of this study was to compare time to approval for a PCSK9i among Medicare beneficiaries and commercially insured patients.

**METHODS:** This is a retrospective cohort study of patients requesting evolocumab and/or aliroculumab in the IMS Formulary Impact Analyzer (FIA) database (7/29/15-7/15/16). FIA is a nationally representative transactional claims database of paid, rejected, and reversed
prescription claims. Patients were required to have ≥30 days of follow-up to allow time for prescription adjudication. Time from first submission to approval and the percentage of patients who filled their prescription post-approval were evaluated.

RESULTS: There were 44,234 new prescriptions for PCSK9i during the study period. Overall, the approval rate (within 1-year) was 30% for commercially insured and 57% for Medicare patients requesting reimbursement for a PCSK9i. The mean (SD) time to approval was 20.3 days (39.8) for commercially insured, and 16.1 days (29.9) for Medicare patients. Nearly 60% of commercial and 57% of Medicare patients approved were approved within 7-days, however 91% of commercial and 17% of Medicare patients were approved between 31-60 days after their initial request. 10.3% of commercial and 11.9% of Medicare patients waited for more than 60-days for approval. Nearly three quarters (74.4%) of approved, commercially insured patients filled their prescription, compared to only 60.3% of approved, Medicare patients. Fill rates were relatively constant over time for both groups.

CONCLUSIONS: The approval rate for PCSK9is was low for both payer types but was much lower for commercially insured patients. Although the majority of patients who are eventually approved are approved in the first week, substantial numbers of patients wait ≥30-days for an approval. Overall, time to approval appears to be lower, and approval rate appears to be higher in Medicare than in commercially insured patients. However more Medicare patients never fill their approved prescriptions. This may be the result of higher copayments for patients as they reach the “donut hole” in coverage.

SPONSORSHIP: This study was funded by Amgen.

Treatment Patterns Among Early Initiators of Evolocumab and Alirocumab

Hines D1, Rane P2, Patel J1, Harrison D3, Wade R1. 8280 Willow Oaks Corporate Dr, Ste 775, Fairfax, VA 22031; dhines@U.S.imshsah.com; (980) 253-9115
1QuintilesIMS; 2Amgen

BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are indicated for patients with ASCVD or familial hypercholesterolemia who require additional lowering of LDL-C in addition to diet and maximally tolerated statin dose.

OBJECTIVE: The goal of this study was to assess utilization of lipid lowering therapy (LLT) prior to initiation of PCSK9i therapy, and the utilization patterns of PCSK9is evolocumab and alirocumab within the first 6 months of their market availability.

METHODS: The Quintiles-IMS longitudinal prescription claims database (LRx) was used to identify patients with ≥1 prescription fill for evolocumab or alirocumab between 8/1/2015 and 1/31/2016. The date of the first fill was the index date. Baseline LLT (prior to PCSK9i initiation) was evaluated in the 12 months pre-index. Patients were followed for 6 months post-index to estimate PCSK9i titration and switch rates.

RESULTS: There were a total of 4,853 PCSK9i users identified (mean age [SD] 63.8 [10.9], 52.3% male) with 2,834 patients initiating evolocumab (mean age [SD] 64.5 [11.1], 51.1% male) and 2,019 patients initiating alirocumab (mean age [SD] 62.9 [10.6], 54.1% male). Among all PCSK9i users, 60.4% had commercial health insurance, and 31% had Medicare. Pre-index LLT use was seen in 60.2% of evolocumab and 58.4% of alirocumab patients. All evolocumab patients started at 140 mg every 2 weeks (Q2W) and the majority (93.6%) initiated alirocumab at 75 mg Q2W. Among alirocumab patients, 10.2% titrated up from 75 mg to 150mg Q2W, and 5.9% patients switched to evolocumab in the 6-months post initiation, compared to 0.9% of patients switching from evolocumab to alirocumab.

CONCLUSIONS: Patients initiating evolocumab and alirocumab in the first year after approval had similar patient characteristics. Approximately 15% of patients initiating alirocumab modified treatment (uptritated or switched therapy) in the first 6-months compared to less than 1% of evolocumab patients. Additional data is being collected with longer follow-up time, adequate to evaluate adherence and effectiveness of these therapies using real world data.

SPONSORSHIP: This study was funded by Amgen.

Cost-Effectiveness of Influenza Vaccination Against Major Adverse Cardiac Events

Peasah S, Vu M. 3001 Mercer University Dr, Atlanta, GA 30341; peasah_sh@mercer.edu; (678) 547-6260
Mercer University College of Pharmacy

BACKGROUND: Influenza vaccination has been shown to reduce the incidence of major adverse cardiac events (MACE) among those with existing cardiovascular disease (CVD). Although CDC’s Advisory Committee on Immunization Practices, the American Heart Association, and the American College of Cardiology recommend influenza vaccination for high risk patients, only 48%-60% of persons with CVD report influenza vaccination.

OBJECTIVE: To estimate the cost-effectiveness of both existing influenza vaccination rates and of increasing influenza vaccination among hospitalized acute coronary syndrome (ACS) patients, with the goal of reducing incidence of MACE.

METHODS: We built a Monte Carlo (probabilistic) spreadsheet-based decision tree to estimate the average cost-effectiveness of influenza vaccination to prevent MACE hospitalization among approximately 60% (status quo scenario) of the estimated 625,000 U.S. ACS discharges from the health care perspective. We also estimated the incremental cost per additional MACE case averted if all admitted ACS patients were vaccinated. We obtained input values from published literature on the cost of vaccination and cost of MACE-related hospitalizations. We also estimated the impact of increasing vaccination to 100% among only adults ≥65 years or adults 18-64 years old. Outpatient, nursing home, and outpatient prescription costs and time lost from work were not included.

RESULTS: In the status quo scenario, vaccination was cost-saving from the health care perspective and resulted in 683 (95% CI: 444-904) averted MACEs. When increasing the vaccination rate to 100% of all ACS patients admitted to hospital, each additional MACE case averted cost $89,123 (95% CI: 52,030-143,506). Increasing vaccination rate only in adults > 65 years cost $86,682 (47,395-136,426) per additional MACE averted, and $90,767 (54,297-136,426) per additional MACE case averted in focus is only on adults 18-64 years old. Vaccinating 100% of all ACS patients could prevent an additional 1,268 (CI: 828-1,678) MACE cases.

CONCLUSIONS: Vaccinating ACS patients is cost-saving at current vaccination coverage estimates. Expanding coverage to all ACS patients will increase costs, but almost double number of current MACE cases averted.

SPONSORSHIP: None.

Utilization and Adherence Rates to Pulmonary Arterial Hypertension Medications

Leo S, Liu Y, Brown-Gentry K, Hunter B, Mahanji H, Cutts S. 130 Bellevue Ave, Newport, RI 02840; leo@magellanhealth.com; (401) 344-1021
Magellan Rx Management
BACKGROUND: Due to high costs of drug therapy and extensive utilization of ancillary medical services, patients with pulmonary arterial hypertension (PAH) can lead to significant financial burden on the health care system. The treatment of PAH is goal oriented. New medications are added onto existing treatments if the patient fails to reach treatment goals. However, lack of adherence to PAH medications may also contribute to treatment failure. Although adherence data is limited, one study suggested that more than 50% of patients reported suboptimal adherence. Suboptimal adherence may be associated with increased emergency room visits, hospitalizations, and increased overall medical expenses.

OBJECTIVE: To determine cost and utilization trends as well as adherence rates to PAH medications.

METHODS: Medical and pharmacy claims data from four regional and national payers between January 1, 2010 and December 31, 2015 were evaluated. Analysis included commercial members who were continuously enrolled for at least 2 years with a diagnosis of PAH and at least 2 pharmacy claims for a PAH medication. Adherence was measured by proportion of days covered (PDC).

RESULTS: 441 distinct members with PAH were identified. 59%, 28%, 12%, and 1% of patients were on mono, dual, triple, and quadruple therapies, respectively. Overall, annualized per patient cost was $42,649 and $56,555 for pharmacy and medical drugs, respectively. The most frequently utilized pharmacy products in order were sildenafil (38%), tadalafil (40%), bosentan (29%), and ambrisentan (28%). The most commonly seen dual therapy combinations in order were ambrisentan+tadalafil (10%), bosentan+sildenafil (10%), and ambrisentan+sildenafil (8%). Overall, average PDC for all drugs was 66% and only 40% of members had a PDC of ≥80%. Pharmacy products with the highest adherence rates in order were macitentan (97%), treprostinil diolamine (86%), and riociguat (84%), and those with the lowest adherence rates were iloprost (53%), treprostinil oral inhalation (58%), and sildenafil (61%).

CONCLUSIONS: Low adherence rates were observed consistently for majority of PAH medications. Further study is warranted to determine the impact of low adherence on outcome measures including ER visits, hospitalizations, and overall medical expenses. In response to the rising cost in the PAH space and entrance of additional therapies, payers should evaluate clinical program opportunities that focus on increasing adherence and promoting appropriate long-term utilization of PAH medications.

SPONSORSHIP: Magellan Rx Management.

112 Characteristics of Patients Treated for Pulmonary Arterial Hypertension in Real-World Database Representing a Large U.S. Health Plan

Hull M1, Pruett J2, Koep E3, Tsang Y4, Drake W5. 11000 Optum Circle, MN101-E300, Eden Prairie, MN 55344; michael.hull@optum.com; (952) 205-7703

1Optum, 2Actelion Pharmaceuticals U.S.

BACKGROUND: Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by abnormally high pressure in the pulmonary arterioles, with increased pulmonary vascular resistance that can result in right heart failure and premature mortality. In the U.S., the estimated incidence of PAH is 2-8/million with an estimated prevalence of 15-50/million. In the REVEAL registry, PAH has been associated with common comorbidities including systemic hypertension, sleep apnea, diabetes, and renal insufficiency. With several new PAH medications available since 2013, more information is needed to characterize the patients treated with these medications.

OBJECTIVE: The purpose is to describe the characteristics and comorbidities of current patients in a large representative U.S. health plan.

METHODS: Patients with a diagnosis code for pulmonary hypertension and treated with an approved medication for PAH (ERAs, PDE-5is, prostacyclins, sGCs) identified by pharmacy claims between January 2010 and March 2015 were included. Patients were ≥18 years old with continuous enrollment in a large U.S. health plan with medical and pharmacy coverage for 6 months before and ≥1 year after initiating a PAH-related therapy. Patients were excluded for a PAH-related therapy claim in the prior 6 months. Patients were followed until disenrollment from the plan or end of study (March 2016). Diagnosis codes were used to identify baseline comorbidities and procedures.

RESULTS: The study included 1,637 patients. Most patients were female (63.7%) with mean (+SD) age 65.3 ± 13.8 years, and slightly more (54.4%) enrolled in Medicare Advantage than in commercial insurance plans. The mean (+SD) follow-up duration was 2.5 ± 1.2 years, with 53.8% followed ≥2 years and 12.7% followed ≥4 years. The mean Charlson Comorbidity Index score was 3.3, with 67.7% scoring ≥3. The most common comorbidity was lower respiratory disease (91.6%) followed by systemic hypertension (80.9%), lipid metabolism disorders (55.2%), other connective tissue diseases (42.6%), type II diabetes (39.2%), sleep apnea (37.2%), respiratory failure or insufficiency (31.8%), thyroid disease (23.3%), and depression (13.3%). Baseline cardiovascular medication usage included diuretics (72.3%), anticoagulants (48.6%), and digoxin (12.9%).

CONCLUSIONS: In this large U.S. health plan database study, the majority of patients maintained consistent health plan coverage for over 2 years following initiation of PAH therapy. These patients frequently presented with complex comorbidity profiles consistent with previously published data.

SPONSORSHIP: Actelion Pharmaceuticals.

113 Impact of Entresto on Overall Medical Cost in Heart Failure Patients

Cully A, Brink D, Powell K, Williams A, Sheen J. 3020 Straight Rd, Fredonia, NY 14063; amy.cully@xerox.com; (716) 572-5734

Conduct

BACKGROUND: National heart failure (HF) treatment guidelines recommend patients with stage C HF and reduced ejection fraction, who are on an angiotensin-converting enzyme inhibitor (ACE) or angiotensin II receptor antagonist (ARB) be switched to Entresto (sacubitril/valsartan) to reduce cardiovascular death and HF hospitalizations. Data from Medicaid recipients was reviewed to assess the real-world effects of initiating sacubitril/valsartan.

OBJECTIVE: To determine if sacubitril/valsartan reduces overall cost of care in patients with HF to a greater extent than traditional care with an ACE/ARB.

METHODS: Claims data from 9/1/15-3/1/16 was analyzed to identify Medicaid recipients who were continuously eligible and had a hospital admission due to HF and were not on sacubitril/valsartan prior to admission. The target group consisted of individuals who received sacubitril/valsartan post admission while the control group did not. The cost of pharmacy and medical care 6 months pre- and post-admission was calculated for both groups. A secondary comparison involved individuals from the target group and the control group who were not on a maximum dose of an ACE/ARB pre-admission.

RESULTS: The control group consisted of 4,650 individuals that did not start sacubitril/valsartan at any point. Their pharmacy cost decreased by $850 (-6.85%) and medical cost decreased by $4377 (-2.54%) resulting in an overall decrease of $52.27 (-2.83%). The target
group consisted of 14+ individuals who were not on sacubitril/valsartan pre-admission, but were post-admission. Their pharmacy cost increased by $147.99 (84.4%), but medical cost decreased by $886.40 (-48.5%) resulting in an overall decrease of $738.40 (-36.8%). Of the 14+ individuals, 10+ were not at a maximum ACE/ARB dose pre-admission and went on to start sacubitril/valsartan post-admission. Their pharmacy cost increased by $143.79 (98.98%) and medical cost decreased by $1,019.33 (-51.53%) resulting in an overall decrease of $875.53 (-41.23%). Of the 4,650 individuals in the control group, 627 were at a maximum ACE/ARB dose pre-admission, but were post-admission. Their pharmacy cost increased by $244.44 (20.59%) and medical cost decreased by $875.53 (-41.23%) resulting in an overall decrease of $429.02 (-22.17%).

CONCLUSIONS: The data revealed that individuals with HF had an overall decrease in cost of care after starting sacubitril/valsartan compared to those who continued on traditional care with an ACE/ARB.

SPONSORSHIP: Boehringer Ingelheim Pharmaceuticals and Humana.

I15 Estimation of Decrements of Utility Associated with Hospitalizations in a Population with Heart Failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT)

Krotneva S1, Kansal A1, Zheng Y1, Patel H2, Kielhorn A2, Bohm M1, Tavazzi L1, Ford P1, Evidera, 7101 Wisconsin Ave, Ste 1400, Bethesda, MD 20814; mira.krotneva@evidera.com; (301) 654-9729
1Evidera; 2Amen; 3Universitätsklinikum des Saarlandes; 4Maria Cecilia Hospital; 5University of Glasgow

BACKGROUND: Patients with heart failure (HF) are at high risk of recurrent hospitalizations. Reducing the rate of hospitalization is an essential treatment goal in this population, as there are patient quality of life, clinical, and economic benefits.

OBJECTIVE: The aim of this study was to estimate the impact of recurrent cardiovascular (CV) hospitalizations and treatment on patient quality of life (utility), as measured by the EuroQol instrument EQ-5D.

METHODS: Utility data was obtained from PRO-SHIFT (N = 5,038), a sub-study of the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). SHIFT was a randomized, double-blind, placebo-controlled study evaluating the effect of ivabradine on CV mortality and morbidity in patients with moderate-to-severe chronic HF and left ventricular systolic dysfunction with a heart rate ≥70 bpm. A linear mixed model was used to derive an equation for change from baseline in EQ-5D Index Score for patients with a baseline and at least one post-baseline value (N = 4,199). The model included treatment, baseline EQ-5D score, beta-blocker use at randomization, and time-dependent variables for number of HF- and non-HF CV hospitalizations at each follow-up visit (none, one, two, or three or more).

RESULTS: Baseline utility score in the selected population was 0.677. A trend was found for a positive effect of ivabradine on the utility of 0.009 (P = 0.055) when compared with placebo. The utility decrements associated with experiencing one or two consecutive HF-related hospitalizations vs. no hospitalizations were similar: 0.076 and 0.074, respectively. There was a larger utility decrement of 0.133 following the third or more HF-related hospitalization. Non-HF CV hospitalizations had smaller utility decrements of 0.020, 0.053, and 0.072 for the first, second, and third or more hospitalizations, respectively.

CONCLUSIONS: Reducing the incidence of hospitalization, particularly those related to HF, may avoid further decreases in HF patients’ quality of life in addition to the economic benefits associated with fewer hospitalizations.

SPONSORSHIP: This study was funded by Servier, and this analysis was funded by Amgen.
hospital admissions after adjusting for patient characteristics and HF treatment. We hypothesize that, adjusting for confounding and HF treatment, higher K levels are associated with excess ED visits and hospitalizations.

METHODS: We conducted a retrospective cohort study in adult HF patients with ≥2 outpatient serum K values between 2005 and 2013 at Kaiser Permanente Northwest. Patients’ start of follow-up was their highest K value: normal-K (3.5-5.1 mmol/L), mild-K (5.2-5.4), moderate-K (5.5-5.8), or severe-K (≥ 5.9). We estimated the incremental effect of K values during 90 days of follow-up using negative binomial regression, which adjusted for age, sex, race, dyspnea, HF emergency visits and hospitalizations, diabetes, kidney function, blood pressure and a comorbidity index. We stratified by current HF treatment: (ACE/ARB) or ACE/ARB plus aldosterone receptor antagonists (ACE/ARB/ARA).

RESULTS: The ACE/ARB/ARA subgroup included 4,966 patients. The ACE/ARB subgroup included 1,791 patients. Unadjusted rates of ED visits per 100 for the ACE/ARB subgroup were 46.0 (normal-K), 60.3 (mild-K), 73.7 (moderate-K), 118.7 (severe-K); P<0.0001. Rates of ED visits for the ACE/ARB/ARA subgroup were 38.1 (normal-K), 57.7 (mild-K), 58.8 (moderate-K), 110.3 (severe-K); P<0.0001. In the ACE/ARB subgroup, patients with severe-K (n=132, 2.6%) visited the ED nearly twice as often (rate ratio = 1.94; 95% CI, 1.49-2.51). In the ACE/ARB/ARA subgroup, severe-K occurred more frequently (n=107, 6.0%), but the effect was similar (RR = 2.21, 95% CI, 1.62-3.02). Unadjusted rates of hospitalization per 100 for the ACE/ARB subgroup were 31.6 (normal-K), 40.2 (mild-K), 55.7 (moderate-K), 76.7 (severe-K); P<0.0001. Rates of hospitalization for the ACE/ARB/ARA subgroup were 27.0 (normal-K), 46.7 (mild-K), 45.6 (moderate-K), 76.0 (severe-K); P<0.0001. In the ACE/ARB/ARA subgroup, patients with severe-K were hospitalized 58% more often (RR = 1.58; 95% CI, 1.20-2.03). In the ACE/ARB/ARA subgroup, the effect was similar (RR = 1.71, 95% CI, 1.22-2.38).

CONCLUSIONS: Patients with severe hyperkalemia had a higher adjusted rate of emergency department visits and hospital admissions.

Sponsorship: Relypsa sponsored this study through a contract with the Center for Health Research, Kaiser Permanente Northwest.

A Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Veenstra D1, Bounthavong M2, Butler J3, Dolan C4, Dann J5, Fisher K1, Oestricher N6, Pitt B7, Haapimain P8, University of Washington, Dept of Pharmacy, Box 357630, Seattle, WA 98195; veenstra@uw.edu; (206) 221-6936

1University of Washington; 2Dept of Pharmacy, University of Washington; 3Div of Cardiology, SUNY at Stony Brook; 4CMD Consulting; 5VRx Pharmacy Services; 6Relypsa; 7University of Michigan School of Medicine; 8Division of Cardiology, Dept of Medicine, Saint Louis University School of Medicine

BACKGROUND: Managing hyperkalemia in patients with heart failure (HF) can be challenging partly due to renin angiotensin aldosterone system inhibitor (RAASI) use causing the condition. Patiromer is a once daily oral suspension for the treatment of hyperkalemia and thus is a potentially important tool for providers to treat hyperkalemia. However, the economic implications of using patiromer in this patient population are unknown.

OBJECTIVE: To estimate the clinical and economic outcomes of using patiromer with spironolactone in patients with NYHA III-IV HF receiving an ACE inhibitor and otherwise unable to add spironolactone due to hyperkalemia.

METHODS: A Markov disease simulation model was developed to assess outcomes from a U.S. payer perspective over a 10-year time horizon. We assumed patiromer and spironolactone were co-administered for the first 3 years. Clinical inputs were derived from the RALES trial evaluating spironolactone vs. placebo in patients with NYHA class III-IV HF on an ACE inhibitor (angiotensin receptor blockers not studied), which showed a 30% reduction in mortality over 3 years; we assumed the RALES data applied to our model population. Quality of life estimates (utilities) were derived from the literature. The wholesale acquisition cost (WAC) was used for drug cost and hospitalization cost was estimated from a national survey. Outcomes included quality-adjusted life years (QALYs), costs and the incremental cost-effectiveness ratio (ICER). One-way sensitivity analyses were performed.
OBJECTIVE: The study estimates market uptake for the class, share chosen both exclusive and parity contracts providing a case-study to inhibitors (PCSK9is) were approved in 2015 and Medicare plans have may lower overall costs. Proprotein convertase subtilisin/kexin type 9 treatment in exchange for higher rebates for the preferred treatment. Typically health plans do not receive a rebate on non-preferred treatment before reimbursing for the non-preferred treatment. In plans with parity access, a single preferred treatment would have fail the preferred treatment. Market share and product uptake for preferred and non-preferred treatments was compared in plans with exclusive vs. parity contracts.

RESULTS: Market uptake was similar in Medicare plans with exclusive and parity contracts. Substantial use of non-preferred treatment was seen; and in the absence of a large additional rebate health plans would receive a lower net effective rebate if an exclusive vs. a parity contract was implemented. This suggests that parity access may actually save money for Medicare plans, while preserving choice for patients and physicians.

SPONSORSHIP: The study was funded by Amgen.

124 Sustained Attainment of Low-Density Lipoprotein Cholesterol Thresholds with Alirocumab Beyond 24 Weeks: Pooled Analysis of ODYSSEY Phase 3 Trials

Roth E1, Valdcheva V2, Wang H1, Guillonneau S4, 2230 Auburn Ave, Cincinnati, OH 45219; eoth@sterlingresearch.org; (513) 381-4100
1The Sterling Research Group & University of Cincinnati; 2Sanofi, Paris, France; 4Sanofi, Bridgewater, NJ; 3Sanofi, Chilly-Mazarin, France

BACKGROUND: Lowering elevated levels of low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular (CV) events; however, reductions must be sustained over time for optimal effectiveness. OBJECTIVE: This pooled analysis examined attainment of LDL-C thresholds with alirocumab (ALI) for up to 104 weeks.

METHODS: Six ODYSSEY Phase 3 trials involving 4,219 patients at very high (established coronary heart disease [CHD] or CHD risk equivalents) or high (heterozygous familial hypercholesterolemia without CHD or risk equivalents) CV risk were pooled by ALI dose and comparator. Pool 1 (COMBO I, FHI, FHII), ALI 75 mg every two weeks (Q2W) with increase to 150 mg Q2W at Week (W)12 if pre-specified LDL-C target not met at W8, vs. placebo (PBO); Pool 2 (COMBO II), ALI 75/150 mg Q2W vs. ezetimibe; Pool 3 (LONG TERM, HIGH FH), ALI 150 mg Q2W vs. PBO. Patients received statin±other lipid-lowering therapies. Achievement of risk-based LDL-C thresholds (≥70 mg/dL for very high risk or ≥100 mg/dL for high risk) and LDL-C reductions were assessed at W24, 52, 78 and/or 104.

RESULTS: In Pool 1, the proportion of ALI-treated patients in the intent-to-treat population at LDL-C threshold at W24 was 76.6% (487/636), remaining stable at 74.3% (447/602) at W52 (corresponding values for PBO-treated patients were 5.9% [19/324] and 5.0% [15/303], respectively). Similarly, proportions were stable over time in Pool 2 (77.8% [333/428] at W24, 77.5% [321/414] at W52 and 71.1% [276/388] at W104) and Pool 3 (79.9% [1,155/1,446] at W24, 77.1% [1,080/1,400] at W52 and 73.0% [966/1,323] at W78). Corresponding values were 47.5% (105/221), 43.6% (92/211) and 40.4% (57/143) for ezetimibe (Pool 2) and 8.3% (63/741), 4.6% (32/703) and 8.4% (57/679) for PBO (Pool 3). On-treatment results in each pool were similar. Corresponding with the threshold achievement data, significant reductions from baseline in LDL-C with ALI vs. control were observed across all pools and time-points (LS mean percent change -49.6 vs. +4.2 at W24 and -46.6 vs. +6.4 at W52 in Pool 1; -30.6 vs. -20.7 at W24, -49.5 vs. -18.3 at W52, and -44.2 vs. -15.2 at W104 in Pool 2; -60.4 vs. +0.5 at W24, -56.2 vs. +41 at W52 and -51.7 vs. +3.5 at W78 in Pool 3). Incidence of treatment-emergent adverse events (TEAEs) was similar across groups, TEAEs more frequent with ALI vs. control were nasopharyngitis (Pool 1) and upper respiratory tract infection (Pools 2 and 3).

CONCLUSIONS: ALI provided sustained lowering of LDL-C and was well-tolerated for up to 104 weeks in clinical trials.

SPONSORSHIP: Sanofi and Regeneron Pharmaceuticals.
Impact of CYP3A4/P-gp Interacting Medications on Clinical Outcomes in Rivaroxaban Patients at a Health Plan Located in Central Texas

Goble J1, Godley P1, Zollfaghari K2, Copeland L1, Michel J1. 2401 S 31st St, Temple, TX 76508. joseph.goble@bswhealth.org, (903) 278-4497
1Baylor Scott & White Health; 2University of Houston; Texas A&M Health Science Center

BACKGROUND: Rivaroxaban has been identified as a substrate of the CYP3A4 enzyme and the P-glycoprotein (P-gp) system. Concomitant interacting medications (CIM) that affect these mechanisms of drug metabolism may significantly affect rivaroxaban pharmacodynamics. Evidence is lacking to assess the real-world risk of bleed or thromboembolism (TE) arising from use of rivaroxaban with CIM.

OBJECTIVE: To assess the individual and additive risk of bleeding or TE associated with CIM in patients starting rivaroxaban therapy over one year of follow-up.

METHODS: This is a retrospective review of claims merged with EMR data from 2011-2016. Patients were included if they had ≥ 1 prescription claim for rivaroxaban (index event) and continuous enrollment for ≥ 9 months pre- and post-index date to assess CIM use, bleed or TE occurring ≥ 3 days after the prescription date of a CIM and/or rivaroxaban, and pre-index comorbidity. Covariates included age, gender, and prior-year diagnosis of hypertension, atrial fibrillation, hypercholesterolemia and other conditions in the Charlson Comorbidity Index. The primary endpoints were bleed and TE. Multivariable logistic regression assessed risk effects as odds ratios (OR) with their 95% confidence intervals (CI).

RESULTS: We identified 747 patients from January 2011 through December 2015 meeting enrollment criteria. Half of the patients were male (50%), with a mean age of 70.5 and an average Charlson Comorbidity Index score of 1.4. Use of CIM (51% overall) included P-gp inhibitors (29%), CYP3A4/P-gp inhibitors (17%), CYP3A4 inducers (4%), PAs (8%) and NSAIDs (10%). Major comorbidities included hypertension (55%), atrial fibrillation (24%), and hypercholesterolemia (27%). 12% of patients had cancer. The rate of any bleed was 7% and of TE, 10%. In adjusted models, those with CYP3A4/P-gp inhibitors and PAs were more likely to experience a bleed compared to non-users (OR = 4.4, CI 2.2-8.9, P < 0.001, OR = 4.4, CI 1.8-10.6, P < 0.001). No single CIM group was associated with lower rate of TE, but CIM users generally had lower rates of TE than non-users (7% vs. 13%, P = 0.003). Hypertension (OR = 2.1, CI 1.1-4.2, P = 0.03) was a significant predictor of any bleed. Hypercholesterolemia (OR = 1.98, CI 1.11-3.55, P = 0.02) and atrial fibrillation (OR = 0.14, CI 0.07-0.29, P < 0.001) were identified as significant predictors of TE with opposite effects.

CONCLUSIONS: CYP3A4/P-gp inhibitor use was common in patients on rivaroxaban in a central Texas health plan population and was associated with higher likelihood of bleeding but lower likelihood of TE.

SPONSORSHIP: This research did not receive any internal or external funding.

J00-J99 Diseases of the Respiratory System (e.g., Asthma, COPD, Rhinitis, RSV)

J1 Relationship Between Antibiotic Treatment Failure and 30-Day Mortality in Adult Outpatients with Community-Acquired Pneumonia

Mildvan D1, Lodise T2, Lepore A1, Classi P2, Tillotson G3. Mount Sinai Beth Israel Medical Center, New York, NY 10003, mildvand@tx.netcom.com, (212) 420-4005
1Mount Sinai Beth Israel Medical Center; 2Albany College of Pharmacy & Health Sciences; 3Cempra

BACKGROUND: Community-Acquired Pneumonia (CAP) is a significant cause of morbidity and mortality across the U.S. Despite the high reported rates of Antibiotic treatment failure (ATF), the association between treatment failure and mortality has not been well described.

OBJECTIVE: This study sought to compare 30-day mortality rates between adult outpatients who experienced ATF to those who did not.

METHODS: U.S. retrospective claims analysis of MarketScan Commercial & Medicare Supplemental Databases was employed. Patients were included if: (1) ≥ 18 years old, (2) ICD-9-CM codes for CAP in the outpatient setting from 2011 to 2013, and (3) received one
of the following antibiotic classes as monotherapy: fluoroquinolone, macrolides, beta-lactam, or tetracycline. Patients were excluded if an antibiotic prescription claim was identified in the 30 days prior to the CAP episode. Treatment failure was defined as any of the following events within 30 days of initial antibiotic claim: (1) antibiotic refill, (2) antibiotic switch, (3) ER visit or (4) hospitalization. Patient demographics, insurance data, comorbid conditions, pharmacy claims, and vital status were collected. The Charlson Comorbidity Index (CCI) was calculated for each patient.

RESULTS: 251,947 unique patients met inclusion criteria. Mean age 52.2 years old, 47.7% were male, 21.5% had Medicare coverage and 20.3% had a CCI score of ≥2. The majority of patients received fluoroquinolones (44.4%) or macrolides (43.6%), with beta-lactams (6.5%) and tetracyclines (5.5%) being prescribed less frequently. Of the included patients, 22.1% were classified as ATF. The most common ATF event was antibiotic switch (70.7%) followed by antibiotic refill (20.6%), hospitalization (3.4%), and ER visit (3.3%). ATF rates for tetracyclines (22.5%) and macrolides (22.9%) were similar, while failure rates were lower for fluoroquinolones (20.8%) and higher for beta-lactams (25.7%) [P<0.0001]. Among patients classified as ATF, mortality rate was 18.1% compared to 4.8% in the non-ATF cohort (OR = 4.60 [4.46-4.74], P < 0.0001). In the working age (i.e. 18-64 years old) cohort, 16.1% of ATF patients died compared to 3.9% of non-ATF patients (OR = 4.09 [3.94-4.24], P < 0.0001). In the elderly (i.e. ≥65 years old) cohort, 24.3% of ATF patients died compared to 7.3% of non-ATF patients (OR = 3.39 [3.17-3.53], P < 0.0001).

CONCLUSIONS: The high incidence of ATF-associated 30-day mortality rates observed in this study highlights the vulnerable nature of this population and the critical importance of reducing antibiotic treatment failure.

SPONSORSHIP: Cempra.

J5 Per-Member-Per-Month Cost of Subcutaneous Immunotherapy in a Large Insured Population in the United States

Mao J1, Heithoff K2, Koep E1, Murphy T1. 30 Squanto Rd, Woburn, MA 01801; jianbin.mao@optum.com; (781) 419-8363

1Optum; 2Merck; 3National Allergy and Asthma

BACKGROUND: Direct costs of subcutaneous immunotherapy (SCIT) to payers and patients are important for health policy and coverage decisions.

OBJECTIVE: To determine per-member-per-month (PMPM) cost of SCIT in a large U.S. administrative claims database and to understand characteristics of patients receiving SCIT relative to the general population.

METHODS: The SCIT cohort consisted of patients from Optum Research Database with ≥1 medical claim for SCIT and ≥1 claim for allergic rhinitis January 1, 2013-December 31, 2015, and the control cohort were members without SCIT. Index date was either 1st date of SCIT or a randomly-assigned date. All subjects must have ≥90-day continuous enrollment with both medical and pharmacy coverage pre-index for comorbidity measures. Cases must have no claims for insect-venom or insect-bite SCIT. PMPM cost was calculated for 2013, 2014 and 2015 separately, and for all three years combined. Health-plan-paid PMPM cost is a ratio of total health-plan-paid costs for SCITs and related procedures (i.e., skin tests and allergen tests) over total member-months in that period. Total member-months were the number of enrolled months contributed for all members with ≥1 day of coverage. Patient-paid PMPM cost was calculated similarly using total patient-paid costs.

RESULTS: A total of 131,493 SCIT patients were followed-up for a mean 543 (SD 365) days, with a mean SCIT duration of 463 (SD 514) days. Compared to the 406,101 controls, SCIT patients were, on average, significantly younger (39.3 vs. 41.4 years), more likely to be female (56.4% vs. 50.7%), and to have respiratory-related comorbidities: asthma (23.6% vs. 1.9%), acute upper respiratory tract infection (21.6% vs. 8.0%), other upper respiratory conditions (15.6% vs. 1.3%), chronic rhinosinusitis (13.1% vs. 1.0%) and cough (13.1% vs. 3.1%), all P<0.001. The health-plan-paid PMPM cost for SCIT was $0.57, $0.47, $0.40 and $0.48; the patient-paid PMPM cost for SCIT was $0.13, $0.11, $0.10, and $0.11 for 2013, 2014, 2015 and 2013-2015 respectively.

CONCLUSIONS: Our PMPM values are comparable to $0.54 PMPM cost on covering contraceptive and pregnancy-related care. Findings provide insights on cost burden of SCIT to patients and payers, and SCIT patient profile relative to the general population. Given that the SCIT cost may reflect a negotiated price between a payer and its providers, future research with other payers is needed.

SPONSORSHIP: Merck & Co.
J7 Changes in Symptom Control, Work Productivity and Activity Impairment, and Anxiety Symptoms in Chronic Idiopathic Urticaria Patients After 24-Week Treatment with Omalizumab

Bernstein J1, Antonova E2, Trzaskoma B2, Holden M2, Kaplan A3.

BACKGROUND: Patients with chronic idiopathic urticaria (CIU), characterized by itchy hives, may experience significant impact on their health-related quality of life.

OBJECTIVE: To examine changes in percentages of patients achieving complete response (absence of itch and hives, 7-day Urticaria Activity Score, UAS7 = 0), work productivity and activity impairment, and generalized anxiety disorder scores during the 24-week open-label single-arm period of XTEND-CIU: a multicenter, randomized, double-blind, placebo-controlled, Phase IV study of omalizumab in CIU patients (≥12 years of age).

METHODS: XTEND-CIU is an ongoing study that enrolled CIU patients, symptomatic despite guideline-based care. Qualifying patients (those with moderate or worse CIU disease activity [UAS7 ≥ 16 patients, symptomatic despite guideline-based care. Qualifying patients completed Urticaria Patient Daily Diary. At baseline and weeks 12 and 24, patients completed: Work Productivity and Activity Impairment (WPAI, scored 0-100; high scores indicate high impairment), and General Anxiety Disorder 7-item (GAD-7, scored 0-21; thresholds of 5, 10, and 15 indicate mild, moderate, and severe levels of anxiety, respectively).

RESULTS: Among 206 enrolled patients, 75% were female, with a median age of 45 years. The percentages of patients reporting a complete absence of itch and hives (UAS7 = 0) increased as treatment progressed: 0% (baseline), 17.6% (week 4), 28.4% (week 8), 36.8% (week 12), 43.1% (week 16), 47.5% (week 20), and 52.0% (week 24). Mean (SD) GAD-7 scores decreased from 7.6 (6.3) at baseline to 3.8 (4.9) at week 12 and 3.0 (3.9) at week 24. Mean (SD) WPAI percent Activity Impairment scores decreased (improved) from 51.7 (26.8) at baseline to 14.0 (22.6) at week 12 and 6.8 (16.6) at week 24. Mean (SD) WPAI percent Overall Work Impairment scores decreased (improved) from 44.7 (29.3) at baseline to 10.1 (18.2) at week 12 and 8.2 (18.9) at week 24.

CONCLUSIONS: During the open label, non-placebo controlled part of XTEND-CIU, over half (52%) of CIU patients initiating omalizumab achieved a complete response (absence of itch and hives) within 24 weeks of treatment. Treated patients reported considerable reduction in anxiety scores and work productivity and activity impairment. The most dramatic results occurred within the 4 weeks following omalizumab initiation, however, additional improvements continued up until week 24.

SPONSORSHIP: Genentech.

J8 Reduction in Asthma Exacerbations, Hospitalizations, and Work Productivity and Activity Impairment After Omalizumab Initiation: Results from a 48-Week Single-Arm, Open-Label Treatment Registry

Zeiger R1, Antonova E2, Trzaskoma B2, Griffin N2, Lushin A3. 7060 Clairemont Mesa Blvd, San Diego, CA 92111; robert.s.zeiger@kp.org; (858) 573-0299

BACKGROUND: Patients with uncontrolled allergic asthma experience substantial disease burden including exacerbations, impairment in work or school productivity, and health care utilization.

OBJECTIVE: To describe changes in exacerbations, hospitalizations, and work productivity and activity impairment after initiation of omalizumab treatment.

METHODS: The Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) was a U.S.-based, multicenter, 48-week, single-arm, open-label treatment registry in adolescents and adults with allergic asthma, initiating omalizumab treatment based on physician assessment of need. Patients reported exacerbations and hospitalizations at baseline and each monthly study visit and completed the Work Productivity and Activity Impairment-Asthma (WPAI-A) questionnaire at baseline and at 6- and 12-months follow-up. Asthma exacerbations and asthma-related hospitalizations were summed in 6-month groupings 1-6, months 7-12, and for the entire follow-up period.

RESULTS: PROSPERO enrolled 806 patients (median age 49 years, range 12-100 years). In the year prior to initiating omalizumab, 60.8% of patients (489/804) had ≥2 asthma exacerbations and 29.8% of patients (178/598) had ≥1 asthma hospitalization. Exacerbation rates decreased from a mean (SD) of 3.0 (1.3) at baseline to 0.48 (0.96) during months 1-6 (n = 795), 0.35 (0.74) in months 7-12 (n = 698), and 0.78 (1.4) during months 1-12. At 12 months, 80.7% of patients had ≤1 exacerbation. Asthma hospitalization rates decreased from a mean (SD) of 0.1 (0.45) 90 days before baseline to 0.03 (0.23) during months 1-6, 0.03 (0.21) during months 7-12, and 0.06 (0.35) during months 1-12. 96% of patients had no asthma related hospitalization during the study. Mean (SD) WPAI-A percent activity impairment scores decreased (improved) from 47.7 (28.9) at baseline (n = 784) to 28.9 (27.0) at month 6 (n = 638) and 25.7 (28.3) at month 12 (n = 650). Mean (SD) percent WPAI-A work time missed decreased from 7.7 (19.9) at baseline (n = 404), to 3.9 (14.6) at month 6, (n = 327) and 3.6 (13.0) at month 12 (n = 332). Mean (SD) WPAI-A percent work impairment scores decreased (improved) from 31.2 (27.1) at baseline (n = 401) to 15.2 (21.0) at month 6 (n = 338) and 15.3 (22.1) at month 12 (n = 336).

CONCLUSIONS: Adolescents and adults with uncontrolled allergic asthma reported reductions in asthma exacerbations, hospitalizations, work absenteeism, and activity and work impairment at 6 and 12 months after initiation of omalizumab treatment.

SPONSORSHIP: Novartis Pharma AG and Genentech.

J9 Health Care Costs in Asthma and/or Chronic Obstructive Pulmonary Disease Patients Using Albuterol Inhalation Aerosol with and Without an Integrated Dose Counter

Chipps B1, Ferro T1, Wang L1, Shrestha S1, Baser O2, Parikh R2. 5609 J St, Ste C, Sacramento, CA 95819; bchipps@capitalallergy.com; (916) 453-1454

BACKGROUND: Patients with asthma and/or chronic obstructive pulmonary disease (COPD) may experience significant health care costs. The Prospective Observational Study to Evaluate Predictors in Asthma and COPD (PROSPERO) was a U.S.-based, multicenter, 48-week, single-arm, open-label treatment registry in asthma and COPD. Patients reported exacerbations and hospitalizations at baseline and each monthly study visit and completed the Work Productivity and Activity Impairment-Asthma (WPAI-A) questionnaire at baseline and at 6- and 12-months follow-up. Asthma exacerbations and asthma-related hospitalizations were summed in 6-month groupings 1-6, months 7-12, and for the entire follow-up period.

RESULTS: PROSPERO enrolled 806 patients (median age 49 years, range 12-100 years). In the year prior to initiating omalizumab, 60.8% of patients (489/804) had ≥2 asthma exacerbations and 29.8% of patients (178/598) had ≥1 asthma hospitalization. Exacerbation rates decreased from a mean (SD) of 3.0 (1.3) at baseline to 0.48 (0.96) during months 1-6 (n = 795), 0.35 (0.74) in months 7-12 (n = 698), and 0.78 (1.4) during months 1-12. At 12 months, 80.7% of patients had ≤1 exacerbation. Asthma hospitalization rates decreased from a mean (SD) of 0.1 (0.45) 90 days before baseline to 0.03 (0.23) during months 1-6, 0.03 (0.21) during months 7-12, and 0.06 (0.35) during months 1-12. 96% of patients had no asthma related hospitalization during the study. Mean (SD) WPAI-A percent activity impairment scores decreased (improved) from 47.7 (28.9) at baseline (n = 784) to 28.9 (27.0) at month 6 (n = 638) and 25.7 (28.3) at month 12 (n = 650). Mean (SD) percent WPAI-A work time missed decreased from 7.7 (19.9) at baseline (n = 404), to 3.9 (14.6) at month 6, (n = 327) and 3.6 (13.0) at month 12 (n = 332). Mean (SD) WPAI-A percent work impairment scores decreased (improved) from 31.2 (27.1) at baseline (n = 401) to 15.2 (21.0) at month 6 (n = 338) and 15.3 (22.1) at month 12 (n = 336).

CONCLUSIONS: Adolescents and adults with uncontrolled allergic asthma reported reductions in asthma exacerbations, hospitalizations, work absenteeism, and activity and work impairment at 6 and 12 months after initiation of omalizumab treatment.
BACKGROUND: Accurate tracking of rescue medication remaining in an inhaler is necessary for optimal symptom control, which may affect health care costs.

OBJECTIVE: To assess health care costs among patients with asthma and/or chronic obstructive pulmonary disease (COPD) using albuterol sulfate inhalation aerosol with or without a dose counter.

METHODS: This retrospective claims study used a 5% sample of the Medicare claims database. Patients were included if they had ≥ 1 prescription for albuterol sulfate inhalation aerosol (ProAir HFA only, with or without dose counter) during the identification period (January 1, 2011, through December 31, 2013); had ≥ 1 diagnostic medical claim for asthma and/or COPD; were aged ≥ 65 years on the index date; had continuous enrollment for 12 months pre-index (baseline period); and had continuous enrollment for 12 months post-index (follow-up period) or died during that time. Patients who received other short-acting beta agonists during the follow-up period were excluded. Economic outcomes (utilization and costs for inpatient, outpatient, emergency department [ED], outpatient office, pharmacy, skilled nursing facility [SNF], home health agency [HHA], and hospice services) were assessed during the follow-up period. Total medical costs (inpatient + outpatient + ED) and total costs (medical + outpatient office + pharmacy + SNF + HHA + hospice) were calculated. Propensity score matching was used to create cohorts with similar baseline demographic and clinical characteristics.

RESULTS: After propensity score matching, the albuterol inhalation aerosol with dose counter and without dose counter groups each had 13,339 patients. Compared with albuterol inhalation aerosol without a dose counter, a dose counter was associated with significantly lowered all-cause health care costs including inpatient ($7,803 vs. $10,413, P < 0.0001), outpatient office ($3,584 vs. $3,805, P = 0.0078), HHA ($1,195 vs. $1,384, P < 0.0001), SNF ($1,776 vs. $2,404, P < 0.0001), hospice ($441 vs. $649, P < 0.0001), total medical ($10,563 vs. $13,274, P < 0.0001), and overall total costs ($22,011 vs. $25,653, P < 0.0001) but significantly increased all-cause ED costs ($211 vs. $186, P < 0.0001) and pharmacy costs ($4,452 vs. $4,137, P < 0.0002).

CONCLUSIONS: Use of albuterol inhalation aerosol (ProAir HFA) with a dose counter is associated with lower all-cause inpatient and total health care costs. Outpatient ED and pharmacy costs with dose counter use may be higher due to increased utilization of corticosteroids and a greater number of prescription refills.

SPONSORSHIP: This study was supported by Teva Pharmaceuticals.

J10 Development and Validation of a Predictive Model to Identify Patients at Risk of Severe Chronic Obstructive Pulmonary Disease Exacerbations Using Administrative Claims Data

Annavarapu S1, Goldfarb S1, Gelb M2, Moretz C1, Renda A3, Kaila S2. 1027 Flakne Ct, South Plainfield, NJ 07080; annavarapu@humana.com; (848) 702-8233

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often experience severe exacerbations involving hospitalizations which accelerate lung function decline and reduce quality of life. Identification of patients at risk of future exacerbations can facilitate appropriate disease management programs.

OBJECTIVE: Develop and validate a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data.

METHODS: A predictive model was developed using a retrospective cohort of COPD patients, 55-89 years, from Medicare Advantage Prescription Drug and commercial plans, identified between July 1, 2010 and June 30, 2013 using Humana’s claims data. Patients had a minimum of 2 years post- and 6 months pre-diagnosis continuous enrollment. The baseline period was diagnosis date to 12 months post-diagnosis and prediction period was 12 to 24 months post-diagnosis. Patients with and without severe exacerbations (resulting in a hospitalization) in the prediction period were compared to identify characteristics associated with a severe COPD exacerbation. Stepwise logistic regression was used to develop the models, and the models were validated in a randomly partitioned subset of the data. The final model was chosen based on the Area Under the Curve (AUC) index and the optimal cut-off point of the Receiver Operating Characteristics (ROC) curve was based on optimization of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

RESULTS: Out of 45,722 patients, 5,317 had severe exacerbations in the prediction period. Patients with severe exacerbations had significantly higher comorbidity burden, use of respiratory medications and tobacco cessation counseling compared to those without severe exacerbations in baseline period. The predictive model included 29 variables that were significantly associated with severe exacerbations; the strongest predictors were prior severe exacerbations and higher Deyo Charlson Comorbidity Index score (odds ratios 1.50 and 1.47, respectively). The predictive model selected had an AUC of 0.77, ROC cutoff of 0.4, sensitivity of 17%, specificity of 98%, PPV of 48%, and NPV of 90%. Out of every 2 patients identified by the model to be at risk for severe exacerbation, one patient may have severe exacerbation.

CONCLUSIONS: This predictive model may provide an economically efficient method to identify COPD patients at risk of future severe exacerbations. Once at risk patients are identified, appropriate maintenance medications, implementation of disease management programs, and education may prevent future exacerbations.

SPONSORSHIP: Boehringer Ingelheim and Humana.
RESULTS: In the ARF and TIO cohorts, 7,374 and 148,168 pts were included, respectively. After adjusting for baseline characteristics, non-LIS pts in the ARF cohort had similar mean monthly fills of ARF (0.70 vs. 0.69; \( P = 0.149 \)), but fewer mean monthly fills of any LABD (1.03 vs. 1.14; \( P < 0.001 \)) compared to LIS pts in P2. Regarding percentage change, the reduction in monthly fills in the ARF cohort was 15% vs. 17% on ARF and 19% vs. 11% on any LABD for non-LIS and LIS pts, respectively. For the TIO cohort, non-LIS pts had significantly fewer monthly fills of TIO (0.47 vs. 0.61; \( P < 0.001 \)) and any LABD (0.84 vs. 1.08; \( P < 0.001 \)) compared to LIS pts in P2. The corresponding mean percent reductions in monthly fills of TIO were 33% vs. 13% and of any LABD were 28% vs. 8% in the non-LIS and LIS groups of TIO cohort, respectively.

CONCLUSIONS: Compared to LIS pts, monthly fills for COPD drugs were significantly lower among non-LIS pts during the donut hole period. The adverse impact on prescription fills was much stronger for maintenance drugs reimbursed under Part D (TIO).

SPONSORSHIP: Sunovion Pharmaceuticals, STATinMED Research, and Center for Innovation & Outcomes Research, Columbia University.

**J12 The Burden of Childhood Asthma in the United States: Impact on Productivity Loss in a Nationally Representative Study**

Sullivan P1, Ghushchyan V2, Navaraturam P3, Friedman H3, Kavati A4, Xiang P5, Ortiz B5, Lanier B6. 3333 Regis Blvd, H-28, Denver, CO 80221; psullivan@regis.edu; (303) 625-1298

Regis University School of Pharmacy, 1American University of Armenia, 2DataMed Solutions, 3Novartis Pharmaceuticals, 4Baylor Scott & White Health, 5University of North Texas HSC

BACKGROUND: Previous research has documented a significant national burden of lost productivity due to asthma and poor asthma control in adults. However, asthma-related productivity estimates specific to children are lacking.

OBJECTIVE: To estimate lost productivity due to asthma and poor control in children and their caregivers.

METHODS: This was a retrospective cross-sectional analysis of children (aged 6-17) and their caregivers in the nationally representative 2007-2013 Medical Expenditure Panel Survey. Indicators of poor control included: self-reported exacerbation; use of > 3 canisters of short-acting beta agonist (SABA) in 3 months (self-reported); and asthma-specific (AS) Emergency Department (ED) visit or hospitalization (utilization-based). Missed work days for caregivers of children with asthma and an indicator of poor control were compared to caregivers of children without asthma. Missed school days for children with asthma and an indicator of poor control were compared to children without asthma. Negative binomial regression was used controlling for sociodemographics, current family smoking, caregiver health status and comorbidities. National Vital Statistics Data was used separately to estimate the number of childhood deaths due to asthma and the resultant lost lifetime productivity due to premature mortality. Lost productivity included the present value of future earnings including fringe benefits and household production.

RESULTS: Children with asthma missed more school days (Incident Rate Ratio [IRR] = 1.5; \( P < 0.001 \)) and their caregivers missed more work days (IRR = 1.16; \( P < 0.05 \)) than children without asthma. Children with asthma and an exacerbation, use of > 3 canisters SABA or an AS ED/hospital visit missed more school days than those without asthma (IRR = 1.76; 2.73; 3.82; \( P < 0.001 \)). Caregivers of children with asthma and an exacerbation or an AS ED/hospital visit missed more work days to care for others than caregivers of children without asthma (IRR = 1.2, 1.76; \( P < 0.05 \)). There were 130 deaths in 5-14 year olds due to asthma in 2013. The corresponding lifetime cost of lost productivity due to asthma-related premature mortality was $210.6 million in 2015.

CONCLUSIONS: Despite renewed efforts and availability of guidelines, poor asthma control continues to be a significant burden to children, their caregivers and society. This results in significant school and work absence along with lost productivity due to premature mortality. Improved drug treatment and asthma management programs for children are needed to address this national burden.

SPONSORSHIP: Novartis Pharmaceuticals.

**J18 Budget Impact Analysis of Keytruda for Non-Small Cell Lung Cancer: A U.S. Payer Perspective**

Wu E1, Liu F1, Lou Y2, 351 N Sumneytown Pike UG-1C60, North Wales, PA 19454; chi-tao.wu@merck.com; (267) 305-8674

1Merck; 2Mayo Clinic

BACKGROUND: KEYTRUDA recently received FDA approval for the first-line (1L) treatment of metastatic non-small cell lung cancer (NSCLC) patients who have tumor proportion score (TPS) ≥ 50% with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy. KEYTRUDA is also approved as a second-line plus (2L+) treatment option in patients with TPS ≥ 1% and with disease progression on or after platinum-containing chemotherapy and patients with EGFR or ALK genomic tumor aberration who have disease progression on approved therapy.

OBJECTIVE: We aimed to assess the annual and 3-year budget impact (BI) of including KEYTRUDA into the formulary for the treatment of metastatic NSCLC from a U.S. payer's perspective.

METHODS: The BI was calculated as the cost difference between the reference scenario (RS) and the new drug scenario (NDS) among a hypothetical 1M member health plan in the U.S. In RS KEYTRUDA (200 mg flat dose) is only available as a 2L+ therapy with TPS ≥ 1% and in NDS KEYTRUDA (200 mg flat dose) is available for both a 1L and 2L+ therapy as indicated above. Costs considered in the analysis includes the cost of drug acquisition and administration, hospitalization cost associated with grade 3+ adverse events (AEs), and the drug wastage cost. Wholesale average costs were used to calculate the drug acquisition cost, with 20% patient co-insurance. If any chemotherapy is used in both 1L and 2L+, we assumed same number of doses were used and the incidence of adverse events.

RESULTS: 313 to 320 patients were estimated to have metastatic NSCLC between the base year and year 3. Based on market research, 41% of these patients would receive PD-L1 testing in the base year and the proportion would rise to 80% in year 3. Assuming that 80% of the tested patients received 1L treatment, 28 and 55 patients were eligible to receive KEYTRUDA for the 1L therapy in the base year and year 3, respectively. In the 2L+ setting, 32 patients were eligible to receive KEYTRUDA in the base year and the number increased to 41 in year 3 with expanded 2L+ label. The 3-year annual average cost was estimated to be $4.1M in RS and $5.7M in NDS. The net budget impact was $1.6M per year, $1,559 per treated patient per month and $0.134 per member per month. The results increased to $1.9M, $1,559 and $0.16, respectively, when 20% more patients received PD-L1 testing.

CONCLUSIONS: Including KEYTRUDA for the treatment of metastatic NSCLC resulted in a modest increase in budget. The net increase was primarily driven by the additional drug acquisition cost and results were sensitive to the uptake of PD-L1 testing and market share.

SPONSORSHIP: Merck.
J19 Cost-Effectiveness of Palivizumab Prophylaxis by Gestational and Chronologic Age Among Infants at Increased Risk of Hospitalization for Respiratory Syncytial Virus

Hansen R1, McLaurin K2, Sullivan S3. Box 357630, Seattle, WA 98195-7630; rhansen@uw.edu; (206) 543-2402
1School of Pharmacy, University of Washington; 2AstraZeneca; 3University of Washington

BACKGROUND: Palivizumab is indicated for the prevention of severe respiratory syncytial virus (RSV) disease in preterm and other high-risk infants. New research in U.S. preterm infants has found the risk and cost of RSV hospitalization as well as the cost of palivizumab vary considerably by gestational age (GA) and chronologic age (CA).

OBJECTIVE: To estimate the cost-effectiveness of palivizumab prophylaxis by GA and CA among preterm infants compared with no prophylaxis.

METHODS: A 4-state Markov cohort model consisting of community-dwelling untreated infants, medically treated RSV, post-RSV, and death was developed and populated. The model applied seasonal risk of RSV with and without palivizumab and accrued costs (palivizumab prophylaxis and RSV hospitalizations) and outcomes (health-related quality of life, disability and mortality) over a 1-year time horizon from the health care payer perspective. Subgroups of infants were defined using combined categories of GA (27-30, 31-32, and 33-34 weeks) and CA (<3, 3-6, and >6 months). Risk of RSV hospitalization and hospitalization costs were estimated from 2014-2015 Marketscan health insurance claims data. Palivizumab treatment costs were estimated using Fenton preterm infant growth charts. The incremental costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) associated with palivizumab prophylaxis in the 9 subgroups were estimated. Both one-way and probabilistic sensitivity analyses were conducted to evaluate the robustness of the model and findings.

RESULTS: Palivizumab was associated with positive incremental QALYs in all subgroups. Among infants <3 months regardless of GA, ICERs were below typical cost-effectiveness thresholds. Among the 29-30 and 31-32 weeks GA cohorts at <3 months, palivizumab had lower total costs and slightly higher incremental QALYs compared with no prophylaxis. However, among infants >3 months, increased patient weight resulted in higher incremental costs with palivizumab and >6 months generated ICERs beyond typical cost-effectiveness thresholds. The increased incremental QALYs finding was consistent regardless of the inclusion of wheezing disability and RSV-related mortality and was confirmed by probabilistic sensitivity analysis. The model results were most sensitive to RSV hospitalization cost, RSV hospitalization risk, and palivizumab cost.

CONCLUSIONS: In infants <3 months regardless of GA, palivizumab prophylaxis improved QALYs and reduced costs. Prophylaxis appears to be less cost-effective with increasing CA.

SPONSORSHIP: This study was supported by AstraZeneca.

K2 Naldemedine Treatment of Opioid-Induced Constipation Improved Patient-Reported Outcomes in Subjects with Chronic Noncancer Pain

Camilleri M1, Tack J2, Cai B3, Yamada T4, Arjona Ferreira J3. 200 First St SW, Charlton B-110, Rochester, MN 55905; camilleri.michael@mayo.edu; (507) 266-2305
1Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic; 2Translational Research Center for Gastrointestinal Disorders, University of Leuven, Belgium; 3Stonogi & Co

BACKGROUND: Opioid use for the treatment of chronic pain is associated with constipation. Opioid-induced constipation (OIC) is associated with multiple symptoms that significantly affect quality of life. Naldemedine (NAL) is a peripherally-acting µ-opioid receptor antagonist in development for the treatment of OIC.

OBJECTIVE: To assess the impact of NAL on the Patient Assessment of Constipation Symptoms (PAC-SYM) and Quality of Life (PAC-QOL).

METHODS: Data from two identical randomized double-blind placebo (PBO)-controlled studies of NAL were analyzed. Eligible subjects were 18 to 80 years of age, and had ≤4 spontaneous bowel movements (SBM) over 2 weeks, with ≤3 SBMs in a given week and symptoms of constipation in ≥25% of SBMs. Subjects were either not on laxatives or discontinued their use at screening. Subjects with gastrointestinal (GI) abnormalities or taking drugs that could affect GI motility were excluded. Eligible subjects were randomized 1:1 to NAL 0.2 mg once daily or PBO for 12 weeks. Primary endpoints were change from baseline in the frequency of bowel movements (BM/week) over the 12 weeks’ treatment, and PAC-SYM and PAC-QOL scores at weeks 2, 4, and 12. Data were analyzed using mixed model repeated measures.

RESULTS: Across both studies, 1,100 subjects were randomized (n = 551 to NAL, n = 549 to PBO; 60% female, 81% white). NAL treatment led to a significant (P ≤0.0144) increase in the frequency of BM/week from baseline to week 12 compared with PBO (Study 1: NAL 2.75 vs. PBO 1.71 BMs/week, Study 2: NAL 2.92 vs. PBO 1.60 BM/week). NAL treatment led to significant (P ≤0.0002) improvement from baseline in the mean overall PAC-SYM score for all assessed time points (weeks 2, 4, and 12) compared with PBO (Study 1: NAL -0.88, -0.88, and -0.93; PBO -0.59, -0.55, and -0.62, respectively; Study 2: NAL -0.98, -0.99, and -1.01; PBO -0.69, -0.66, and -0.69, respectively). Similarly, NAL treatment led to significant (P ≤0.0014) improvement from baseline in the mean overall PAC-QOL score in both studies for all these time points compared with PBO (Study 1: NAL -0.85, -0.92, and -0.93; PBO -0.54, -0.92, and -0.93, respectively; Study 2: NAL -1.02, -1.10, and -1.08; PBO -0.73, -0.77, and -0.80, respectively). Treatment with NAL for 12 weeks was generally well tolerated and the most frequently reported adverse events were abdominal pain, diarrhea and nausea.

CONCLUSIONS: Treatment with NAL 0.2 mg once daily for up to 12 weeks significantly improved the frequency of BM, as well as symptoms of constipation and quality of life compared with PBO. Treatment with NAL was generally well tolerated.

SPONSORSHIP: Shionogi & Co.
68-question, IRB-approved online survey. HCPs who treat CIC patients participated in a 30-minute, 32-question online survey.

**RESULTS:** Over 1,100 CIC patients (mean age, 49 yrs; female, 70%; severe, 67%) completed the survey. Only 23% of patients felt “in control” of their symptoms, with many (39%) expressing “acceptance” that CIC was now part of their daily life. Of HCPs (n = 331), the majority (72%) stated their patients had high levels of frustration regarding their CIC, and were “stressed” (49%) or “fed up” (43%) regarding current treatments. A total of 60% of CIC patients and 81% of severe CIC patients reported their symptoms were bothersome and impacted QoL. Participation in personal and daily activities were impacted for 4 days/mo and 9 days/mo, respectively. Most patients had used (62%) or were using (33%) OTC treatments for their CIC, with 16% currently using a prescription treatment. Of patients taking a prescription therapy, 35% felt it was “effective,” but only 14% reported “good experience/satisfaction.” HCPs viewed the greatest challenges in treating CIC patients as response rates (55%), adherence (55%), management of CIC treatment-related diarrhea (34%), and lack of treatment options (34%). Mean monthly out-of-pocket costs to manage CIC was $114 (all) and $182 (severe)—ranging from $75/mo for lifestyle/dietary modifications, $123/mo for OTCs, and $413/mo for prescriptions. Workplace productivity was impacted for 8 days/mo (all) and 10 days/mo (severe) with an average of 3 work days/mo missed due to CIC. In this cohort of CIC patients, 15% had an emergency room (ER) visit in the past year due to CIC symptoms, with an average of 2.9 ER (all) and 3.5 ER (severe) visits in the past year.

**CONCLUSIONS:** Patients with CIC or CIC had significantly greater comorbidities and CCI scores vs. matched controls. In addition, IBS-C and CIC patients sought more health care overall and utilized more prescription medications than matched controls.

**SPONSORSHIP:** Synergy Pharmaceuticals.

**K5**

**Patient-Reported Outcomes with Naldemedine**

**Long-Term Treatment of Opioid-Induced Constipation in Subjects with Chronic Noncancer Pain**

Tach J¹, Camilleri M², Cai B³, Yamada T³, Arjona Ferreira J¹, Herestraat 49, 3000 Leuven, Leuven, Belgium 3000; jan.tach@kuleuven.be; +32-16-344225

¹Translational Research Center for Gastrointestinal Disorders, University of Leuven; ²Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic; ³Shionogi & Co.

**BACKGROUND:** Opioid use for the treatment of chronic pain is associated with constipation. Symptoms of OIC significantly affect quality of life. The efficacy and safety profile of naldemedine (NAL), a peripherally-acting µ-opioid receptor antagonist, as a treatment for OIC has been demonstrated in multiple phase 3 studies up to 52-week duration.

**OBJECTIVE:** To assess the long-term effect of NAL on Patient Assessment of Constipation Symptoms (PAC-SYM) and Quality of Life (PAC-QOL).

**METHODS:** In a randomized double-blind placebo (PBO)-controlled 52-week study, subjects 18 to 80 years of age, having ≤ 4 spontaneous bowel movements (SBMs) over 2 weeks and ≤ 3 SBMs in a given week, were randomized 1:1 to received NAL 0.2 mg once daily or PBO for 52 weeks. Subjects were either not on laxatives or on a stable laxative regimen for the study duration. Subjects with gastrointestinal (GI) abnormalities or taking drugs that could affect GI motility were excluded. Primary endpoints were change from baseline in the frequency of BM/week over the 52 weeks’ treatment, and PAC-SYM and PAC-QOL scores at weeks 12, 24, 36, and 52. They were analyzed using mixed model repeated measures.

**RESULTS:** A total of 1,246 subjects were randomized (n = 623 in each group). Subjects were 63.3% female and 79.7% white. Treatment with NAL led to a significantly (P < 0.001) greater increase in the frequency of bowel movements (BM/week from baseline to each assessed time point (NAL: 3.70, 3.77, 3.88, and 3.92 vs. PBO: 2.42, 2.77, 2.88, and 2.92 BM/week, at weeks 12, 24, 36, and 52, respectively). Treatment with NAL significantly improved (P < 0.001) the mean overall PAC-SYM score from baseline for all assessed time points (weeks 2, 12, 24, 36, and 32) compared with PBO (NAL: −1.13, −1.11, −1.16, −1.21, and −1.22, PBO: −0.81, −0.86, −0.87, −0.85, and −0.98, respectively). Similarly, NAL treatment significantly improved (P < 0.001) the mean overall PAC-QOL score from baseline for all assessed these time points.
BACKGROUND: Czelotizumab pegol (CZP) is a subcutaneously administered TNFα antagonist approved for the treatment of moderate to severe Crohn’s disease (CD). Patients are not always equipped to self-administer injections. A home health nurse program sponsored by UCB Pharma provides skilled nurses who offer home-based assistance with the administration of CZP injections in CD patients.

OBJECTIVE: The aim of this analysis was to measure the impact of the home health nurse program on home care costs for CD patients who were treated with CZP.

METHODS: A retrospective analysis of U.S. patient claims data from PharMetrics Plus was conducted using data from January 1, 2007 through September 30, 2015. Eligible patients starting the nurse assistance program between January 1, 2008 and September 30, 2014 had to have a CD diagnosis on index date (defined as the first dose of CZP) or in the pre-index period; had to be continuously enrolled in a health plan for 12 months prior to the index date and for ≥ 60 days after the index date; and had to be newly treated with CZP within 60 days before or after program initiation. Patients were excluded if they had rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Patients could receive nurse-administered CZP injections or receive instructions on self-administration (or both). Exact matching was performed on gender and categorical age, with a 1:1 ratio of patients with/without assistance. All other baseline variables were balanced. A multivariate regression analysis was performed using a generalized linear model adjusting for additional covariates to compare the effect of CZP with and without nurse assistance on costs related to hospitalization and total costs.

RESULTS: A total of 552 patients (n = 276 in each cohort) were evaluated for the cost of hospitalization and total health care costs. The median cost of hospitalization per patient was lower with nurse assistance than without ($21,448 vs. $25,001). The median total health care cost per patient with nurse assistance was also lower ($40,929 vs. $44,445). Results from the multiple regression analysis revealed a significant reduction in hospitalization costs (35.8%; P = 0.0026) and total health care costs (14.3%; P = 0.0045) with nurse assistance.

CONCLUSIONS: CZP administration with home health nurse assistance led to a significant reduction in hospitalization and total health care costs compared with CZP administration without nurse assistance.

SPONSORSHIP: This study was sponsored by UCB Pharma.

K7 The Impact of Plecanatide on Quality of Life for Patients with Chronic Idiopathic Constipation: Results from Two Phase 3 Clinical Studies

Hixson M1, Rao S2. Synergy Pharmaceuticals, 480 E Swedesford Rd, Wayne, PA 19087; mhixson@synergypharma.com; (610) 225-0010
1Synergy Pharmaceuticals; 2Medical College of Georgia-Augusta University

BACKGROUND: Chronic idiopathic constipation (CIC) significantly affects quality of life.

OBJECTIVE: This analysis investigates whether plecanatide, a uroguanylin analog that increases fluid secretion in gut, improved health-related quality of life (HRQoL) in 2 clinical trials of patients with CIC.

METHODS: Patients who met modified Rome III CIC criteria were randomized to placebo (PBO), plecanatide 3 mg or 6 mg daily for 12 weeks. The primary endpoint was the proportion of durable overall CSBM responders (≥ 3 CSBMs plus increase of ≥ 1 CSBM over baseline in the same week) for ≥ 9 of 12 treatment weeks, including ≥ 3 of the last 4 weeks. Weekly SMB frequency was also assessed. HRQoL assessment included Patient Assessment of Constipation–Symptoms (PAC-SYM), Patient Assessment of Constipation–Quality of Life (PAC-QOL) and Treatment Satisfaction.

RESULTS: A total of 2683 patients were included (ITT) with similar baseline characteristics. Pooled efficacy showed significantly greater overall durable CSMB responders with plecanatide 3 mg (n = 184, 20.5%) and 6 mg (n = 176, 19.8%) vs. PBO (n = 103, 11.5%; P < 0.001 both doses). Significant increases in CSBMs were seen during Week 1 and were maintained through Week 12. Improvements in weekly SMBs for plecanatide 3 mg (+1.5) and 6 mg (+1.7) vs. PBO were observed (P < 0.001, both doses). The PAC-SYM was significantly improved for plecanatide 3 mg and 6 mg vs. PBO at Weeks 4, 8 and 12 in both studies, with a mean change difference from PBO at Week 12 of -0.22 (P < 0.001) and -0.23 (P < 0.001) [Study 1] and -0.18 (P = 0.002) and -0.15 (P = 0.009) [Study 2]. A similar improvement in PAC-QOL was noted for plecanatide 3 mg and 6 mg vs. PBO at Weeks 4, 8 and 12 in both studies; the mean change difference from PBO at Week 12 for plecanatide 3 mg and 6 mg were -0.25 (P < 0.001) and -0.28 (P < 0.001) [Study 1] and -0.20 (P < 0.001) and -0.19 (P < 0.001) [Study 2]. The most common AE was diarrhea (3 mg, 4.6%; 6 mg, 5.1%; PBO, 1.3%). Discontinuation rates were 4.1% (3 mg), 4.5% (6 mg) and 2.2% (PBO) for AEs, and discontinuation rates due to diarrhea were 1.9% (3 mg), 1.8% (6 mg) and 0.4% (PBO). Plecanatide yielded higher mean treatment satisfaction scores at each assessment point and increased over time; treatment differences for plecanatide were significant (P ≤ 0.001) vs. PBO at all assessment points.

CONCLUSIONS: Plecanatide 3 mg and 6 mg significantly improved bowel symptoms and HRQoL at all time points and increased the proportion of durable overall CSBM responders vs. PBO, with a low incidence of diarrhea and other AEs. These data suggest plecanatide will be a useful treatment option in the management of CIC patients.

SPONSORSHIP: Synergy Pharmaceuticals.

K8 Vedolizumab and Infliximab Resource Utilization Among Treatment-Persistent Biologic-Naïve Inflammatory Bowel Disease Patients

Null K, Lissooon T, Luo M. 1Takeda Phwy, Deerfield, IL 60015; kyle.null@takeda.com; (603) 703-9756
Takeda Pharmaceuticals USA

BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) treated with biologic therapies including vedolizumab (VDZ) and infliximab (IFI). VDZ was approved in May 2014 for the treatment of moderately to severely
active CD and UC. Few studies have compared IBD health care resource utilization among biologic-naive VDZ and IFX patients.

**OBJECTIVE:** The objective was to compare IBD-related resource utilization for office visits, emergency department (ED) visits, endoscopies, and scans (eg, magnetic resonance imaging and computed tomography) between biologic-naive IBD patients persistent on either VDZ or IFX therapy.

**METHODS:** Adult IBD patients (≥18 years old) initiating VDZ or IFX therapy (first claim as index date) from 5/20/2014 to 3/31/2015 were identified from the Symphony Health Integrated Dataverse, a longitudinal pharmacy and medical claims database. Biologic-naive patients were required to have ≥12 months pre-/post-index enrollment with no history of prior biologic use and to be persistent on therapy (no therapy gap >90 days) during 12-month follow-up. Poisson models were used to estimate the adjusted mean counts, 95% confidence intervals (CI), and incidence rate ratios (IRR). Covariates included diagnosis (CD/UC), geographic region, 12-month pre-index IBD-related resource utilization counts, and Charlson Comorbidity Index.

**RESULTS:** 1,105 biologic-naive patients (n=164 VDZ, n=941 IFX) persistent on index therapy were identified. After adjusting for covariates, the mean number of office visits for the IFX group was 1,911 per 1,000 (1k) patients (95% CI: 1,824-2,002) versus 1,537 per 1k patients (95% CI: 1,390-1,745) for the VDZ group, reflecting a 23% greater risk of biologic-naive IFX patients having an office visit than biologic-naive VDZ patients (IRR: 1.23, 95% CI: 1.09-1.38, P<0.001). The adjusted mean number of ED visits was higher for the IFX group (123 per 1k) than the VDZ group (70 per 1k), reflecting a 78% greater risk for biologic-naive IFX patients than biologic-naive VDZ patients (IRR: 1.75, 95% CI: 1.00-3.07, P=0.049). The IFX group had a non-statistically significant higher rate of endoscopies than the VDZ group (286 vs. 223 per 1k, P=0.155) and scans (107 vs. 97 per 1k, P=0.683).

**CONCLUSIONS:** Using real-world data, biologic-naive patients persistent on VDZ therapy had a statistically significantly lower adjusted rate of IBD-related office visits and ED visits, and a non-significant lower rate of endoscopies and scans than patients persistent on IFX over a 12-month follow-up period.

**SPONSORSHIP:** Funded by Takeda Pharmaceuticals USA.
CCO compared with 17.61 for MH. Patients treated with CCO experienced 22.73 QALWs at a cost of $6,253 over one year, while MH patients experienced 21.89 QALWs at a cost of $7,230. Therefore, CCO was the economically dominant strategy (i.e., simultaneously conferring greater benefit at less cost). Probabilistic sensitivity analyses determined CCO to be cost-effective in 77% of the 10,000 iterations, assuming a benchmark willingness-to-pay threshold of $50,000/quality-adjusted life year ($962/QALW).

CONCLUSIONS: Results from these cost-effectiveness modeling analyses suggest CCO is a cost-effective alternative to MH in the treatment of adult patients with stage III and IV PUs in the HOPD setting.

SPONSORSHIP: Smith & Nephew.

L6 Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States

Feldman S1, Zhao Y2, Gilioteau P1, Graham C1, Miles L1, McBride D1. Herrera V1. Dept of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Rd, Winston Salem, NC 27104; sfeldman@wakehealth.edu; (336) 716-7740

1Wake Forest University School of Medicine; 2Novartis Pharmaceuticals, East Hanover, NJ. 1Novartis Pharma AG, Basel, Switzerland; 2RTI Health Solutions, Research Triangle Park, NC; 3RTI Health Solutions, Manchester, UK

BACKGROUND: New clearing psoriasis treatments offer the potential for clearing psoriasis more completely than was possible with previous treatments. Whether higher degrees of clearing are clinically meaningful has not been fully determined.

OBJECTIVE: The purpose of this study is to assess whether more complete clearing of psoriasis is associated with a reduction in indirect costs of the disease.

METHODS: The impact of psoriasis on work was determined using patient-reported Psoriasis Work Productivity and Activity Impairment Questionnaire (PWAI) data from a phase 3b study comparing the efficacy and safety of secukinumab vs ustekinumab (CLEAR). Four levels of disease improvement were assessed at 16 and 52 weeks: Psoriasis Area and Severity Index (PASI) improvement of less than 50% (PASI < 50), 50%-74% (PASI 50-74), 75%-89% (PASI 75-89), and at least 90% (PASI ≥ 90). Percentage of work time missed (absenteeism) and impairment while working (presenteeism) for both treatment arms were used to estimate the percentage of work impairment due to psoriasis over the previous 7 days. Data from the U.S. Department of Labor were used to calculate the annual indirect costs due to loss of work productivity.

RESULTS: A total of 675 subjects were assigned to treatment and included in the analysis (secukinumab = 336, ustekinumab = 339). Work impairment due to psoriasis decreased with greater skin clearance at Weeks 16 and 52: 22.8% & 26.3% for PASI < 50, 13.3% & 16.4% for PASI 50-74, 6.4% & 10.4% for PASI 75-89, and 4.9% & 6.9% for PASI ≥ 90, with the majority of impairment being related to presenteeism rather than absenteeism. Absenteeism also decreased with greater skin clearance (W16 & W52 - 8.2 & 9.5 hours/week) for patients with PASI < 50, 4.8 & 5.9 hours/week (250 & 307 hours/year) for PASI 50-74, 2.3 & 3.7 hours/week (120 & 195 hours/year) for PASI 75-89, and 1.8 & 2 hours/week (93 & 130 hours/year) for PASI ≥ 90. Annual indirect costs due to work productivity loss per worker decreased with greater skin clearance at both time points (W16 & W52 - $10,147 & $11,708 for PASI < 50, $5,941 & $7,282 for PASI 50-74, $2,852 & $4,619 for PASI 75-89, and $2,196 & $3,074 for PASI ≥ 90).

CONCLUSIONS: Among working patients with moderate-to-severe psoriasis, those achieving and sustaining PASI improvement ≥90 were associated with a prominent increase in workplace productivity and reduction in annual indirect costs. These results indicate that effective skin clearance may contribute to reduced productivity loss.

SPONSORSHIP: Novartis Pharmaceuticals.

L8 Evaluating the Impact of Treatment Persistence on the Economic Burden of Moderate-to-Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population

Lee S1, Xie L2, Wang Y2, Baser O1. 800 Ridgeview Dr, Horsham, PA 19044; slec8@its.jnj.com; (215) 704-0520

Janssen Pharmaceutical Companies of Johnson & Johnson; 2STATinMED Research; 3STATinMED Research; Center for Innovation & Outcomes Research, Dept of Surgery, Columbia University

BACKGROUND: Psoriasis (PsO) is a chronic, inflammatory, dermatological condition that may be associated with arthritis [psoriatic arthritis (PsA)]. There remains a shortage of real-world evidence for impact of treatment pattern on the economic burden of PsO patients (pts).

OBJECTIVE: Examine the health care costs and utilization between pts who were persistent and non-persistent to biologics among moderate-severe PsO and/or PsA populations.

METHODS: Adult pts with at least two diagnoses of PsO and/or PsA between 11/2010-10/2015 were identified in the U.S. Department of Defense data; the first diagnosis date during 11/2011-10/2014 defined as the index date. Pts were required to have continuous enrollment during the 1-year pre- and post-index period and were considered moderate-severe on index date if they had ≥1 non-topical systemic therapy or phototherapy during the 12 months pre- or 1 month post-index date. Persistence to index therapy, defined as the first biologic used (etanercept, adalimumab, ustekinumab, infliximab) within 30 days post-index date, was determined based on the biologic dosing schedule and a 90-day gap. Generalized linear models were used to compare health care utilization and costs between persistent and non-persistent pts during the 1-year post-index period.

RESULTS: A total of 2,945 moderate-severe PsO and/or PsA pts were identified. Of those, 1,899 (64.5%) were persistent and 1,046 (35.5%) were non-persistent. Compared to non-persistent pts, persistent pts were older (49.2 vs. 45.5 years, P < 0.001), more likely to be male (52% vs. 45%, P < 0.001) and have a diagnosis of dyslipidemia (40% vs. 35%, P = 0.002) and statin use (23% vs. 18%, P = 0.002), but lower anxiety use (30% vs. 37%, P < 0.001). After adjusting for pts demographic and clinical characteristics, non-persistent pts had a significantly higher number of ambulatory visits (23.9 vs. 21.4, P = 0.009), which resulted in higher total medical costs ($12,448 vs. $8,968, P < 0.001) compared to persistent pts. About 40% of the total medical costs were attributed to PsO and PsA. Although persistent pts incurred higher pharmacy costs ($10,774 vs. $7,856, P < 0.001) mainly due to more usage of biologics, their PsO/PsA-related medical costs were significantly lower than non-persistent pts ($3,414 vs. $5,022, P < 0.001). Total costs combining medical and pharmacy costs were similar between the two cohorts.

CONCLUSIONS: Moderate-severe PsO and/or PsA pts who were displaying persistence to biologics incurred significantly lower medical expenditures, albeit with increased pharmacy costs than non-persistent pts.

SPONSORSHIP: Janssen Scientific Affairs.
L9 Connecting Patient and Physician Treatment Satisfaction by Severity in Psoriasis to Patient-Reported Outcomes in the United States

Teeple A1, Villacorta R1, Lee S2, Fakharaudeh S3, Lucas J4, McElligott S1, 800 Ridgeview Dr, Horsham, PA 19044; ateeple@its.jnj.com; (215) 325-4237
1Janssen Scientific Affairs; 2Janssen Pharmaceutical Companies of Johnson & Johnson; 3Adelphi Real World

BACKGROUND: Patient satisfaction is a measure of health system performance and a crucial element of patient-centered care.

OBJECTIVE: To explore psoriasis severity and Dermatologic Life Quality Index (DLQI) score as determinants of treatment satisfaction in a sub-analysis comparing patients across treatment groups in the United States (U.S.) population.

METHODS: This is a retrospective study of eligible adult patients with psoriasis (PsO) and their physicians from the 2015 Adelphi PsO Disease Specific Program (DSP). The PsO DSP captures responses from patients and physicians in the U.S. Patients self-reported responses for the DLQI, a validated questionnaire of 10 questions with a composite score of 0-30 used to measure quality-of-life (QoL) in dermatology.

RESULTS: 70 physicians and 394 eligible patients completed paired responses related to their perceptions of treatment satisfaction. From the patient sample, 45.9% were female, and mean age and DLQI score were 44.5 years and 5.0, respectively. From the physician sample, 37.1% were female and median time in practice was 18 years. Median baseline PsO severity for patient respondents was 12% of BSA. Among U.S. patients, 33.2% were satisfied with biologic treatments compared to 27.4% for all other treatments. Patients satisfied with biologics showed lower DLQI scores (Mean: 3.10; 95% CI: 2.47-3.73) compared to patients not satisfied with biologics (Mean: 7.86; 95% CI: 6.76-8.97). The DLQI question on itching, soreness, pain, and stinging of the skin contributed most to the overall DLQI score. Comparing across treatment groups, patients not satisfied with current therapy had mean DLQI scores ranging from 7.86-14.0. A greater number of unsatisfied patients across treatment groups had severe psoriasis, based on BSA, ranging from 62.3-100%

CONCLUSIONS: Patients unsatisfied with current treatment reported higher DLQI scores and higher BSA severity across treatment groups. New treatment options for psoriasis are needed because a high percentage of patients in both the non-biologic and biologic cohorts were unsatisfied with their current treatment.

SPONSORSHIP: Janssen Scientific Affairs.

M00-M99 Diseases of the Musculoskeletal System and Connective Tissue (e.g., RA, OA, Osteoporosis, Gout, Dupuytren’s Contracture)

M1 Predictors of DMARD Initiation and First-Line Biologic Use in Newly Diagnosed Rheumatoid Arthritis Patients: Results from the Truven Markitcan Commercial and Medicare-Supplemental Claims Database (2009-2013)

Schroeder K, Gelwicks S, Zhang X, Araujo A, Muram D, Larmore C, Boytsov N, Chang L Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285; schroeder_krista_marie@lilly.com; (317) 276-3039

Eli Lilly and Company

BACKGROUND: Clinical guidelines recommend disease-modifying antirheumatic drugs (DMARDs) for all newly diagnosed rheumatoid arthritis (RA) patients. Data on alignment with this guideline and subsequent characterization of patients who initiate on first-line biologic DMARD (bDMARD) are lacking.

OBJECTIVE: To determine characteristics predictive of DMARD initiation and first-line bDMARD selection in newly diagnosed RA patients.

METHODS: We performed a retrospective observational study using the Truven Markitcan claims database. Patients newly diagnosed with RA (ICD-9: 714.0x-714.2x) from 2009-2013, age 18+ at diagnosis (index), with 3+ RA diagnoses, ≥1 year (y) continuous enrollment pre/post-index, and no RA diagnosis or DMARDs in the 1y pre-index were included. Patients with 1+ DMARD claim in the 1y post-index were categorized as DMARD initiators. Within the DMARD initiator group, patients were categorized as bDMARD initiators, as opposed to conventional DMARD initiators. If a bDMARD appeared as the first DMARD claim or in the 14 days after the first cDMARD claim, DMARD initiators, initiators, patients initiating bDMARDs were younger (50 vs. 55y), more frequently female (30 vs. 26%), had 1.6-10 times higher rates of other autoimmune comorbidities (e.g. Psoriasis: 4.8 vs. 1.0%; Ankylosing Spondylitis: 3.4 vs. 0.3%), less likely to have received RA workup (serologic tests: 43 vs. 62%; joint imaging: 56 vs. 72%), opioids (42 vs. 50%), or glucocorticoids (50 vs. 60%), and more likely to have seen a rheumatologist (50 vs. 46%) in the 1y pre-index (all P<0.05).

CONCLUSIONS: 43% of patients failed to initiate a DMARD during follow-up, demonstrating that improvement towards guidelines is needed. Multiple demographic and clinical variables predicted DMARD initiation and first-line use of bDMARD vs. cDMARD. Further research into the role of patients, providers and payers in DMARD decision-making is needed.

SPONSORSHIP: Eli Lilly and Company.

M2 ABP 501 (Amjevita) Biosimilar to Adalimumab: Demonstration of Value with Lower Perception of Injection Site Pain

Kaur P1, Cohen S2, Papp K3, Zhang N1. One Amgen Center Dr, Thousand Oaks, CA 91320; pkaur@amgen.com; (805) 447-2456
1Amgen; 2Metroplex Clinical Research Center; 3Clinical Research and Probity Medical Research

BACKGROUND: ABP 501 was recently approved by the U.S. FDA as the first biosimilar to adalimumab (Humira), a fully human recombinant monoclonal antibody. Totality of evidence based on analytical and pharmacokinetic comparisons and two clinical efficacy, safety, and immunogenicity studies indicates that ABP 501 is highly similar to adalimumab. Formulation excipients of a biosimilar can differ provided there is no clinically meaningful difference with the reference. ABP 501 is formulated with different excipients than are used for the adalimumab reference product and the two phase 3 studies included evaluation of injection site pain perception.

SPONSORSHIP: Eli Lilly and Company.
OBJECTIVE: To present results of patient perception of injection site pain.

METHODS: Both studies were randomized, double-blind, active-controlled trials: one in patients with moderate to severe rheumatoid arthritis (RA; N = 526) and the other in patients with moderate to severe plaque psoriasis (PsO; N = 350). The details of the two study designs and their efficacy, safety, and immunogenicity results have been previously reported. In both studies, injection site pain perception was assessed at baseline and at weeks 4, 8, and 12 using an adjusted 100 mm horizontal visual analog scale measured within 5 minutes after injection.

RESULTS: In the RA study, mean injection site pain perception scores were lower in the ABP 501 group (range: 10.0-10.7 mm vs. the adalimumab group (range: 16.1-21.4 mm) at each evaluated visit. In the PsO study, mean injection site pain perception scores were also lower in the ABP 501 group (range: 3.3-4.5 mm) compared with the adalimumab group (range: 12.4-19.3 mm) at each of the four time-points. There were no withdrawals in either study due to injection site pain.

CONCLUSIONS: These results confirm that in addition to being clinically highly similar, perception of injection site pain was lower with ABP 501 compared with adalimumab reference product. Results are attributed to the different excipients in the ABP 501 formulation from that of the adalimumab reference product.

SPONSORSHIP: Amgen

M3 Adverse Event Data as Proxy to Determine Total Medical Costs for TNF-Alpha Inhibitors

Lukaszewski A1, Hoffman K2, Batholow T1, Dimbil M2, Verden A3, Carter J4. 43 Nob Hill Rd, Madison, WI 53707; ibartholow@weatrust.com; (800) 279-4000

BACKGROUND: Efficacy for new drugs is generally studied carefully, but long-term follow up in populations possessing comorbidities not contemplated in FDA safety evaluations is generally less well studied. We suggest that better ADE awareness and severity stratification may be achieved by combining signal from the aggregated practitioner reported observations along with other insurance claim data. Combined voluntary reported data and claims data may corroborate a suspected ADEs by examining downstream medical costs that are associated with ADEs.

OBJECTIVE: This study examined downstream medical costs associated with infections from the use of TNF-alpha inhibitors. The goal was to establish whether ADE cost analytics can be compared with claims databases to model safer and more cost-effective drug decisions.

METHODS: We analyzed ADE and claims data for six TNF-Alpha inhibitors from August 2013 through July 2015. We examined: (1) ADE and outcome-specific medical costs obtained from AHQR; (2) ADE and outcome data from PAERS; (3) drug usage information from Evaluate Pharma; and (4) claims data from WEA Trust. ICD-9 diagnoses were mapped to each ADE. Focus was limited to EudraVigilance Important Medical Events and “primary suspect” ADE reports. CPT Service Codes were used to establish three cost measurements: ER visits, hospitalizations, and ambulance transportation.

RESULTS: Certolizumab and golimumab were associated with a higher incidence of ADEs compared to other TNF-alphas in both ADE and claims data. Downstream medical cost per dispense were: $322, $256, and $190 for certolizumab, adalimumab and etanercept, respectively, for ER visits. Hospitalization costs were $156, $79, and $57 and ambulance transportation were $30, $19, and $19 for certolizumab, adalimumab, and etanercept, respectively.

CONCLUSIONS: Given that both ADE and claims data suggested that two TNF-alpha inhibitors were more likely to cause infections and higher medical costs, WEA Trust will be working with providers to modulate TNF-alpha inhibitor prescriptions to lower cost and improve safety. Future work will examine other drug classes regarding the use of ADE analytics as a proxy for drug benefit design.

SPONSORSHIP: Collaborative between WEA Trust and Advera Health Analytics, with no sponsorship or funding of the project.

M4 Using Self-Reported Patient Experiences to Evaluate Barriers to Treatment Access: Learnings from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi P1, Doogan S2, Heid J3, Benosman A4, Martin L5, Palmer J6. 301 University Blvd, Galveston, TX 77555; psunkureddi@gmail.com; (281) 957-9127

1University of Texas Medical Branch; 2Real Life Sciences; 3Kinapse; 4Perelman School of Medicine, University of Pennsylvania; 5CreakyJoints, Global Healthy Living Foundation; 6Novartis Pharmaceuticals

BACKGROUND: Psoriatic arthritis (PsA) is a debilitating disease which can be effectively managed with proper access to treatment options such as biologics and small-molecule inhibitors.

OBJECTIVE: To characterize the challenges and barriers to treatment access faced by patients with PsA using self-reported online narratives.

METHODS: Unguided patient narratives were collected between January 2010 and May 2016 from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums and mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment for patients with PsA. Using a natural language processing platform (RLytics) and manual expert curation, these narratives were categorized into 5 high-level concepts of functional impairment (social, physical, emotional and role activity), and 6 categories to assess barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence and doctor guidance).

RESULTS: Of 15,390 narratives collected from 3,139 patients with PsA, physical aspects of disease were the most commonly reported high-level concept (81.6%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%) and social (5.6%) concepts. Overall, 27.5% of 1,485 patients with PsA reported barriers to treatment access. Coverage ineligibility (51.7%) and out-of-pocket costs (31.7%) were the most commonly reported barriers to treatment access, followed by clinical ineligibility (11.7%), issues with assistance programs (8.3%), formulary sequence requirements (8.3%) and doctor guidance (0.8%). Among those who reported coverage ineligibility, patients cited delayed access (19.8%), reduced coverage (11.3%) and discontinued coverage (6.5%); the majority of ineligibility reasons (75.8%) were unspecified. Among patients citing out-of-pocket costs as their main barrier to treatment access, out-of-pocket affordability (79.6%) and copay/insurance affordability (29.6%) were the most common reasons given.

CONCLUSIONS: Physical aspects of PsA were the most discussed concept online. Nearly one-third of patients with PsA reported barriers to treatment access, the most common of which were coverage ineligibility and out-of-pocket costs. Further research is needed to mitigate access barriers in order to optimize treatment and improve clinical outcomes and quality of life in patients with PsA.

SPONSORSHIP: Sponsored by Novartis Pharmaceuticals.
**M5** Real-World Use of Secukinumab Among Patients with Psoriatic Arthritis in the United States: Patient Profile and Dosing

Oelke K1, Chun G2, Fi P3, Liu X3, Palmer J4, 7080 N Port Washington Rd, Glendale, WI 53217; rheumdoc@hotmail.com; (414) 351-4009

1Rheumatic Disease Center; 2Novartis Pharmaceuticals; 3KMK Consulting

**BACKGROUND:** As of January 15, 2016, secukinumab became the first fully human anti-interleukin-17 monoclonal antibody approved for the treatment of patients with psoriatic arthritis (PsA) in the United States. The use of secukinumab in a real-world setting of patients with PsA has not been evaluated since its approval.

**OBJECTIVE:** To describe the demographic and clinical characteristics of patients with PsA treated with secukinumab and examine its dosing in routine clinical practice in the United States.

**METHODS:** Retrospective data from the Symphony Health Solutions Lx commercial claims database were used to identify patients who were ≥18 years of age, had ≥1 ICD-9 code of 696.0 or ICD-10 code of L40.5 for PsA, had ≥1 pharmacy or medical claim in the 12 months prior (baseline period) to their index date (first secukinumab claim between 01/15/2016 and 06/30/2016) and had ≥1 secukinumab claim during the study period. Patient demographics and secukinumab dosage were examined at the index date. Clinical characteristics, comorbidities and treatment history were identified during the baseline period.

**RESULTS:** A total of 1,797 patients treated with secukinumab were included; at the index date, 1,475 patients (82.1%) received secukinumab at the 300-mg dose and 322 patients (17.9%) received the 150-mg dose. The mean (SD) age was 50.7 (11.4) years, 56.9% of patients were female and 41.1% of patients were from the south. The most prevalent comorbidities were psoriasis (PsO; 65.7%), hypertension (32.7%) and hyperlipidemia (24.9%). The majority of patients (76.2%) received a biologic during the baseline period, with the most common being prior secukinumab (36.4%) and ustekinumab (20.3%). Other prior treatments included csDMARDs (33.4%), oral corticosteroids (25.8%) and csDMARDs (21.5%). The most common specialties prescribing secukinumab to patients with PsA were rheumatologists and dermatologists (40% each), with both more likely to prescribe the 300-mg dose (99% dermatologists, 64% rheumatologists).

**CONCLUSIONS:** This claims-based study found the majority of patients with PsA received secukinumab at the 300 mg dose. Most patients had received a prior biologic, including previous treatment with secukinumab, which is an indicator of patients with comorbid PsA and PsO who began treatment in the previous year for the drug’s PsO indication. Overall, secukinumab was equally prescribed for PsA by both rheumatologists and dermatologists. These results provide insight into real-world use of secukinumab in patients with PsA in the United States.

**SPONSORSHIP:** Sponsored by Novartis Pharmaceuticals.

**M6** Patterns of Treatment Adherence, Persistence, and Discontinuation of Biologic Therapy Among Patients with Psoriatic Arthritis in the United States—Descriptive Analyses from an Administrative Claims Database

Walsh J1, Adeyoro O2, Chastek B2, Chun G3, Palmer J4, 30 N 1900 E, Salt Lake City, UT 84132; jessica.walsh@hsc.utah.edu; (801) 581-5599

1University of Utah School of Medicine; 2Optum; 3Novartis Pharmaceuticals

**BACKGROUND:** In patients with psoriatic arthritis (PsA) receiving biologic therapy, treatment persistence is critical to achieving optimal outcomes; however, recent real-world data on biologic treatment patterns in patients with PsA are limited.

**OBJECTIVE:** To describe patterns of adherence, persistence and discontinuation of biologic therapies in patients with PsA.

**METHODS:** This study used administrative claims data from the Optum Research Database. Adults with PsA who newly initiated (no evidence of use in the 12 months prior) a biologic between January 1, 2013 and January 31, 2015, and were continuously enrolled in a commercial or Medicare Advantage health plan 12 months before (baseline period) and 15 months following the index date, defined as the date of first pharmacy fill or medical infusion, were included. Outcomes included persistence and discontinuation (>90-day gap) of the index biologic, post-persistence treatment patterns (switching to a different biologic, discontinuing and restarting the index biologic or discontinuing the index biologic without switching or restarting), and treatment adherence (proportion of days covered [PDC] by index medication).

**RESULTS:** Of the 1,235 patients with PsA included, 52.5% were female and the mean (SD) age was 50.3 (12.1) years. The mean (SD) baseline Charlson Comorbidity Index score was 0.7 (1.2); the most common Agency for Health Care Research and Quality comorbidities were other inflammatory conditions of the skin (97.4%) and non-traumatic joint disorders (73.4%). Patients initiated etanercept (48.1%), adalimumab (24.0%), infiximab (10.4%), golimumab (8.3%), ustekinumab (7.2%) or certolizumab (2.0%) as their index biologic. The mean (SD) duration of persistence with the index biologic was 246 (128) days; 44.5% of patients persisted on the index biologic for ≥12 months. Infliximab had the highest 12-month persistence rate (61.2%), and certolizumab had the lowest (32.0%). During the 12-month follow-up period, 22.9% of patients switched to a different biologic, 5.8% discontinued and restarted the index biologic and 26.8% discontinued without switching or restarting. The overall mean (SD) PDC was 0.59 (0.30).

**CONCLUSIONS:** In this descriptive, administrative claims-based study, the majority of patients with PsA discontinued their index biologic prior to 1 year, among those who discontinued, only 10.5% restarted the same biologic within that year. These findings provide a better understanding of real-world treatment patterns of biologics in PsA and unmet treatment needs of patients.

**SPONSORSHIP:** Sponsored by Novartis Pharmaceuticals.

**M11** Using Self-Reported Patient Experiences to Evaluate Barriers to Treatment Access in Ankylosing Spondylitis: Learnings from Digital Patient Communities

Sunkureddi P1, Gibson D2, Doogan S3, Heid J4, Benosman S4, Park Y5, 301 University Blvd, Galveston, TX 77555; psunkureddi@gmail.com; (281) 957-9127

1University of Texas Medical Branch; 2Global Healthy Living Foundation; 3Real Life Sciences; 4Knappe; 5Novartis Pharmaceuticals

**BACKGROUND:** Accessibility of treatment options is critical in achieving optimal monitoring and treatment in patients with ankylosing spondylitis (AS).

**OBJECTIVE:** To examine the disease burden and barriers to treatment access faced by patients with AS by analyzing patient narratives reported in online communities.

**METHODS:** Patient narratives were collected between January 2010 and May 2016 from 52 online sources (i.e., disease-specific/general health social networking sites and forums, treatment review forums, patient-doctor Q&A discussions and mainstream social media sites). Using a natural language processing platform (RLytics) and manual expert curation, patient narratives were categorized into 5 high-level functional concepts (social, physical, emotional, cognitive and role activity) and 6 categories for access barriers (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence and doctor guidance).

www.jmcp.org  Vol. 23, No. 3-a  March 2017  JMCP  Journal of Managed Care & Specialty Pharmacy  S87
RESULTS: Of 34,780 narratives collected from 3,449 patients with AS, physical aspects of AS (e.g., pain and mobility) were by far the most commonly reported concept (87%), followed by emotional (33%), cognitive (24%), role activity (9%) and social (5%) concepts. About one-third of patients with AS (n=1,303) reported barriers to treatment access; coverage ineligibility (44%) and out-of-pocket costs (27%) were the most frequently reported barriers to treatment access, followed by doctors’ guidance (7%), limited access to assistance programs (6%), clinical ineligibility (3%) and formulary placement/sequence (2%). Among patients who reported coverage ineligibility as their main barrier to treatment access, 19% cited coverage discontinuation, 12% reported delayed access to coverage and 7% had reduced coverage (71% reported coverage ineligibility for unspecified reasons). As for the patients who reported out-of-pocket costs as their main barrier to treatment access, 93% reported inability to afford expensive medication, while 19% reported difficulties with copay/insurance affordability.

CONCLUSIONS: Analysis of patient narratives from online sources highlighted some functional impairment concepts that may be critical in understanding the burden of AS. In addition, recognizing barriers to treatment access and identifying means of improvement would be critical in providing optimal therapy for patients with AS.

SPONSORSHIP: Sponsored by Novartis Pharmaceuticals.

M12 Patterns of Treatment Adherence, Persistence, and Discontinuation of Biologic Therapy Among Patients with Ankylosing Spondylitis in the United States: Descriptive Analyses from an Administrative Claims Database

Walsh J1, Adejoro O2, Chastek B3, Chun G4, Park Y4. 30 N 1900 E, Salt Lake City, UT 84132; jessica.walsh@hsc.utah.edu; (801) 581-5599
1University of Utah School of Medicine; 2Optum; 3Novartis Pharmaceuticals

BACKGROUND: Adherence and persistence to biologic therapy in patients with ankylosing spondylitis (AS) is critical to achieve optimal outcomes by alleviating pain and delaying radiographic progression; however, the number of real-world studies examining biologic therapy use in patients with AS is limited.

OBJECTIVE: To examine adherence, persistence and discontinuation of biologic therapies in patients with AS.

METHODS: This study used administrative pharmacy and medical claims data from the Optum Research Database. Adult patients with AS who newly initiated (no evidence of use in the 12 months prior) a biologic between January 1, 2013 and January 31, 2015, and were continuously enrolled in a commercial or Medicare Advantage health plan 12 months before (baseline period) and 15 months following the index date, defined as the date of first pharmacy fill or medical infusion, were included. Outcomes included persistence and discontinuation (> 90-day gap) of the index biologic; post-persistence treatment patterns (switching to a different biologic, discontinuing and restarting the index biologic without switching or restarting); and treatment adherence (proportion of days covered [PDC] by index medication).

RESULTS: Of the 426 patients included (45.8% female; mean [SD] age: 45.1 [13.1] years), approximately half of the patients (45.1%) initiated etanercept, followed by adalimumab (28.6%), golimumab (11.7%), infliximab (11.7%) and certolizumab (2.8%). The most common Agency for Health Care Research and Quality comorbidities were non-traumatic joint disorders (97.4%) and spondylosis/intervertebral disc disorders/other back problems (79.6%). The mean (SD) PDC (treatment adherence) and duration of persistence with the index biologic were 0.56 (0.29) and 236 (131) days, respectively; only 40.6% of patients persisted on the index biologic for ≥12 months. During the 12-month follow-up period, 21.4% of patients switched to a different biologic, 7.0% discontinued and restarted the index biologic and 31.0% discontinued without switching or restarting.

CONCLUSIONS: In this descriptive, administrative claims-based study, a high proportion (> 59%) of patients with AS either switched or discontinued their biologic therapy in the 12 months of follow-up. Further research is needed to better understand the reasons for discontinuation and switching between biologic therapies in patients with AS.

SPONSORSHIP: Sponsored by Novartis Pharmaceuticals.

M13 Real-World Use of Secukinumab Among Patients with Ankylosing Spondylitis in the United States: Patient Profile and Dosing

Oelke K1, Chun G2, Li F3, Liu X3, Park Y2. 7080 N Port Washington Rd, Glendale, WI 53217; rheumdoc@hotmail.com; (414) 351-4009
1Rheumatic Disease Center; 2Novartis Pharmaceuticals; 3KMK Consulting

BACKGROUND: Secukinumab is a fully human anti-interleukin-17 monoclonal antibody approved for the treatment of patients with moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis (AS). The use of secukinumab in a real-world setting of patients with AS has not been evaluated since its approval in the United States on January 15, 2016.

OBJECTIVE: To describe the demographic and clinical characteristics of patients with AS who were treated with secukinumab and to examine secukinumab dosage use in routine clinical practice in the United States.

METHODS: Retrospective data from the Symphony Health Solutions Lx commercial claims database between January 13, 2016 and June 30, 2016 were included in the study. Patients eligible for inclusion were ≥18 years of age who had the diagnosis of AS and ≥1 pharmacy or medical claim in the 12 months prior (baseline period) to their index date (first secukinumab claim) and ≥1 secukinumab claim during the study period. Patient demographics and secukinumab dosage were examined at the index date. Clinical characteristics, comorbidities and treatment history were identified during the baseline period.

RESULTS: A total of 250 patients treated with secukinumab were included in the study. At the index date, 101 patients (40%) received secukinumab at the 300 mg dose and 149 patients (60%) received the 150 mg dose. The mean (SD) age was 45.5 (11.5) years and 54% of patients were female. The most prevalent comorbidities included hypertension (20%), hyperlipidemia (17%) and psoriatic arthritis (13%). The majority of patients (66%) received a biologic during the baseline period, the most common being adalimumab (22%) and etanercept (17%). Other prior treatments included conventional synthetic disease-modifying antirheumatic drugs (30%; including 19% methotrexate), oral corticosteroids (32%), targeted synthetic disease-modifying antirheumatic drugs (7%) and nonsteroidal anti-inflammatory drugs (25%).

CONCLUSIONS: In this retrospective, administrative claims-based study, the majority of patients received secukinumab at the 150 mg dose and had received a biologic prior to secukinumab. The most prevalent comorbidities among patients with AS who received secukinumab were hypertension, hyperlipidemia and psoriatic arthritis. The results of this study provide early insights into real-world use of secukinumab in patients with AS in the United States.

SPONSORSHIP: Sponsored by Novartis Pharmaceuticals.
Ng D1, Gooch K1, Caplan E2, Abbass I2, Abbott P3, Kirby C3, Suehs B2.

OBJECTIVE: The primary objective of the study was to examine the impact of co-occurring OAB on health care resource utilization (HRU) in older patients with OP. Secondary outcomes included clinical outcomes and costs.

METHODS: This historical cohort study compared patients with OP and co-occurring OAB to a comparison group of patients with OP but no OAB. Patients with a diagnosis of OP, enrolled in a Medicare plan, and aged ≥65 and <90 years were eligible. Patients with OAB were required to have a diagnosis of OAB after OP diagnosis and the non-OAB comparison group could not have evidence of OAB during the study period. The date of diagnosis of OAB was considered the index date for the OAB group, the non-OAB comparison group was assigned an index date. Propensity score matching was used to balance the cohorts on baseline demographic and clinical characteristics. A 12-month post-index period was used to evaluate HRU, falls and/or fractures and costs. Analyses included bivariate comparisons and regression models. Ordinary least squares regression was used to examine the relationship between OAB and log transformed total health care costs.

RESULTS: A total of 142,318 patients (OP and OAB = 5,527; OP and no OAB=136,791) were eligible for inclusion. After matching, 11,052 (5,526 per cohort) were included in the analyses. Patients with OP and OAB had greater all-cause inpatient utilization (19.7% vs. 15.3%, P < 0.001), emergency room use (32.8% vs. 27.4%, P < 0.001), and physician office visits [10.8 (7.1) vs. 8.8 (7.0), P < 0.001]. Mean OP-related outpatient visits were greater among patients with OAB (0.96 vs. 0.93, P = 0.009); however, no other OP-related HRU measures differed between groups. A greater proportion of patients with co-occurring OAB had a fall and/or fracture in the post-index as compared to the non-OAB controls (17.7% vs. 14.9%, P < 0.001). Patients with co-occurring OAB had total health care costs that were approximately 35% greater than non-OAB OP patients (P < 0.001).

CONCLUSIONS: Co-occurring OAB was associated with greater HRU and health care costs in patients with OP. Comorbid OAB was also associated with increased prevalence of falls and/or fractures in patients with OP.

SPONSORSHIP: Study was funded by Astellas and conducted as part of the Astellas-Humana Research Collaboration.

N1 Economic Burden of Anemia in Patients with Nondialysis-Dependent Chronic Kidney Disease

Brunelli S1, Kabadi S2, Bullano M2, Pendergraft T2, Anzalone D2, Catini J2, Sibbel S1. DuVita Clinical Research, 825 S 8th St, Minneapolis, MN 55404; steven.brunelli@davita.com; (888) 345-2567

BACKGROUND: Although the economic burden of anemia among dialysis-dependent chronic kidney disease (DD-CKD) patients is well-characterized, contemporary data characterizing the economic burden of anemia in non-DD-CKD (NDD-CKD) patients are very limited.

OBJECTIVE: To evaluate the association between hemoglobin (Hb) level and economic burden in NDD-CKD patients.

METHODS: This retrospective analysis used electronic health records from patients enrolled in the Health Care Partners managed care provider group between July 1, 2013 and June 30, 2015. Patients were ≥18 y/o, with ≥1 Hb measurement while eGFR <60 mL/min/1.73m² and not receiving ESA: they were categorized by Hb level <9.0, 9.0-9.9, 10.0-12.0, 12.1-12.9, and ≥13 g/dL, and also eGFR 45-59, 30-44, 15-29 and <15 mL/min/1.73 m² (CKD stages 3a, 3b, 4 and 5, respectively). Total health care costs (inpatient, outpatient, and pharmacy)
and hospitalization rates were compared across Hb/eGFR subgroups. Multivariable regression was used to adjust for differences in pre-index characteristics between CKD stages.

**RESULTS:** Overall, 26,833 patients (CKD stage 3a, n = 17,559; 3b, n = 6,848; 4, n = 1,976; 5, n = 450) were included. Total health care costs (mean [SD], US$ per member/month) were significantly higher for patients with Hb < 10.0 g/dL compared with Hb 10.0-12.0 g/dL. This was also evident by CKD stage; the adjusted mean difference (AMD) in health care costs being significantly higher for patients with Hb 9.0-9.9 g/dL or < 9.0 g/dL versus Hb 10.0-12.0 g/dL: stage 3a, $343 (P < 0.001) and +$998 (P < 0.001); stage 3b, +$275 (P < 0.001) and +$718 (P < 0.01); stage 4, +$263 (P < 0.05) and +$948 (P < 0.01), respectively. AMDs for stage 5 showed a similar but non-significant trend (+$931 and +$1,411), albeit patient numbers were relatively small. Small malization rates (incidence rate ratios [IRRs]) were similarly higher for Hb < 10.0 g/dL versus Hb 10.0-12.0 g/dL. This was similarly evident by CKD stage with IRRs for hospitalization being significantly higher for Hb 9.0-9.9 g/dL and < 9.0 g/dL versus Hb 10.0-12.0 g/dL: stage 3a, 2.87 (P < 0.001) and 5.06 (P < 0.001); stage 3b, 1.87 (P < 0.001) and 3.43 (P < 0.001); and stage 4, 2.14 (P < 0.001) and 3.49 (P < 0.001), respectively. Trends for stage 5 were similar but non-significant.

**CONCLUSIONS:** In patients with CKD stages 3/4 not treated for anemia, Hb levels < 10 g/dL were associated with higher health care costs and greater hospitalization rates compared with a higher Hb level of 10-12 g/dL. This suggests a need for better management of patients with anemia and NDD-CKD.

**SPONSORSHIP:** Study sponsored by AstraZeneca.

---

**N3**

The Economic Burden of Overactive Bladder Among Medicare Beneficiaries with Employer-Sponsored Supplemental Coverage

Durden E1, Walker D2, Gray S1, Fowler R1, Juneau P1, Gooch K2, 7700 Old Georgetown Rd, Ste 650, Bethesda, MD 20814; emily.durden@truvenhealth.com; (650) 800-7074

1Truven Health Analytics; 2Astellas Pharma U.S.

**BACKGROUND:** Within the Medicare population, overactive bladder (OAB) is a prevalent chronic condition that significantly affects quality of life. However, recent published estimates of the economic burden of OAB in Medicare beneficiaries are limited.

**OBJECTIVE:** To quantify the direct cost burden of OAB within a population of Medicare beneficiaries with employer-sponsored supplemental coverage.

**METHODS:** Adults with an OAB diagnosis or OAB prescription therapy between 1/1/2008-12/31/2013 were identified from the MarketScan Medicare database (index date = qualifying claim date). Patients were required to have ≥ 12 months of pre- and ≥ 1 month of post-index continuous enrollment. Patients without OAB were propensity score-matched to the OAB case cohort. Log-transformed, total per patient per month (PPPM) direct health care costs were estimated using ordinary least squares regression, adjusting for patient demographic and clinical characteristics, as well as baseline health care costs. Values were transformed back to the original dollar scale by the use of smearing estimators. The level of statistical significance for all tests was set at 0.05.

**RESULTS:** 36,191 OAB patients were identified and propensity score-matched to the same number of non-OAB patients. Within the combined OAB and non-OAB study population, 81.1% were female and 56.9% were ≥ 75 years of age. The mean and median, multivariable-adjusted PPPM health care costs were $3,448 and $1,987 for OAB patients and $1,858 and $920 for non-OAB patients (P < 0.0001 for both differences in means and medians). Other factors associated with significantly higher costs were: age ≥ 75 years, males, greater comorbid burden as indicated by the Charlson Comorbidity Index score, and having comorbid diabetes, hypertension, multiple sclerosis, and osteoporosis (P < 0.001 for all).

**CONCLUSIONS:** Within this Medicare population, the mean, multivariable-adjusted health care costs of OAB patients were 85.6% higher than those of similar patients without OAB.

**SPONSORSHIP:** Astellas Pharma Global Development.

---

**N4**

Refill Gaps and Dose Reductions in Patients with Prostate Cancer and Visceral Metastases Treated with Abiraterone Acetate Plus Prednisone or Enzalutamide

Pilon D1, Behl A2, Emond B3, Lafayelle M4, Lefebvre P5, 1000 De La Gauchetière West, Ste 1200, Montreal, Quebec H3B 4W5 Canada; dominic.pilon@analyisgroup.com; (514) 394-4434

1Groupe d’analyse, Ltee; 2Janssen Scientific Affairs

**BACKGROUND:** The prognosis for men with metastatic castrate resistant prostate cancer (mCRPC) and visceral metastases is generally poorer when compared to those without visceral metastases. The two oral mCRPC therapies abiraterone acetate plus prednisone (AA+P) and enzalutamide (ENZ) have been shown to improve overall survival in this more severe population. However, dose reductions and refill gaps may be associated with lower drug effectiveness.

**OBJECTIVE:** This study assessed refill gaps and dose reduction events in mCRPC patients with visceral metastases treated with AA+P or ENZ.

**METHODS:** The MarketScan databases (03/2012-10/2015) were used to conduct a retrospective analysis. Patients initiated on AA+P or ENZ (index date) after 09/2012 with ≥ 6 months of continuous eligibility prior to index date (baseline period), ≥ 1 diagnosis for prostate cancer, and ≥ 1 diagnosis for visceral metastases during the baseline period were included. Inverse probability of treatment weighting (IPTW) was used to adjust for observed baseline confounders between groups. Weighted Kaplan-Meier (KM) rates and Cox proportional hazard models were used to compare the occurrence of refill gaps (≥ 14, ≥ 30, or ≥ 60 days) or dose reductions (i.e., relative dose intensity [RDI] ≤ 80%, and ≤ 85%) between groups. RDI was calculated as the ratio of the delivered dose intensity (total delivered dose divided by the period over which the total dose was measured) to the standard dose intensity as recommended in the package insert for AA+P or ENZ.

**RESULTS:** A total of 2,540 AA+P and 1,265 ENZ patients were identified, of which 236 (9.3%) and 111 (8.8%) had baseline visceral metastases, respectively. IPTW resulted in balanced baseline demographic, comorbidities, and disease characteristics. At 12 months post-index, patients initiated on AA+P were 59-65% less likely to have an RDI ≤ 80% or ≤ 85% (all P < 0.05) and 50-73% less likely to have a refill gap ≥ 14, ≥ 30, or ≥ 60 days (all P < 0.05) when compared to patients initiated on ENZ.

**CONCLUSIONS:** This study showed that mCRPC patients with visceral metastases treated with AA+P were less likely to experience a refill gap and to reduce their treatment dose than patients treated with ENZ.

**SPONSORSHIP:** Supported by Janssen Scientific Affairs.

---

**N5**

Potential Drug-Drug Interaction Events in Patients Treated with Abiraterone Acetate Plus Prednisone or Enzalutamide

Pilon D1, Behl A2, Emond B3, Xiao Y4, Lefebvre P1, Kane C1, 1000 De La Gauchetière West, Ste 1200, Montreal, Quebec H3B 4W5 Canada; dominic.pilon@analyisgroup.com; (514) 394-4434

1Groupe d’analyse, Ltee; 2Janssen Scientific Affairs; 3University of California, San Diego
BACKGROUND: The treatment of patients with advanced cancer generally requires multiple medications and consideration of potential drug-drug interactions (DDIs) is important to avoid unintended consequences.

OBJECTIVE: This study assessed potential DDIs in patients treated with oral metastatic castrate resistant prostate cancer (mCRPC) therapies (abiraterone acetate plus prednisone [AA + P] and enzalutamide [ENZ]).

METHODS: The MarketScan databases from 03/2012 to 10/2015 were used to conduct a retrospective analysis, in which patients initiated on AA + P or ENZ after 09/2012 (index date) with ≥6 months of continuous eligibility prior to index date and ≥1 PC diagnosis were included. Inverse probability of treatment weighting (IPTW) was used to adjust for observed baseline confounders between groups. Weighted Kaplan-Meier (KM) rates and Cox proportional hazard models were used to compare the occurrence of potential DDIs. Potential DDI was defined as having a claim for a drug that can interact with the index drug (AA + P or ENZ) during the exposure to index treatment (i.e., the time between the first and last claim [plus days of supply] of the index treatment). Interaction drugs were selected based on the prescribing information for each drug and included strong CYP3A4 inducers and CYP2D6 substrates for AA + P and strong CYP3A4 inducers, CYP2C8 inhibitors, CYP2C9 substrates, CYP3A4 substrates, and CYP2C19 substrates for ENZ.

RESULTS: A total of 2,540 AA + P and 1,265 ENZ patients were identified. IPTW resulted in balanced baseline demographic, comorbidities, and disease characteristics. At 3, 6, 9, and 12 months post-index, patients initiated on ENZ were more likely to have a potential DDI during their exposure to ENZ treatment when compared to patients initiated on AA + P (ENZ vs. AA + P; KM rates at 12 months: 30.3% vs. 15.5%, hazard ratio [95% confidence interval]: 28.9 [14.5, 57.4], P = 0.0001).

CONCLUSIONS: This study showed that mCRPC patients treated with ENZ were more likely to be exposed to a potential DDI during their treatment than those treated with AA + P.

SPONSORSHIP: Supported by Janssen Scientific Affairs.

R00-R99 Symptoms, Signs, and Abnormal Clinical and Laboratory Findings Not Elsewhere Classified (e.g., Pain, Opioids, Vasomotor, Urticaria, Nausea & Vomiting)

R1 Prophylactic Antiemetic Use Reduces Opioid-Induced Nausea and Vomiting and Improves Patient Recovery in the Outpatient Setting

Oak Y1, Gregorion R2, Kwong W2, Kane A1, Zou P1, Marretti E2
One Canal Park, Cambridge, MA 02141; youbeau.oak@simon-kucher.com; (617) 231-4551
1Simon Kucher & Partners; 2Daiichi Sankyo

BACKGROUND: Nausea and vomiting (NV) are common opioid-related side effects often associated with the early treatment of acute pain. Co-prescribing of antiemetic (AntiE) medications with opioids may reduce patient risk and improve recovery, however, little is known about the effectiveness of such an approach in the outpatient setting.

OBJECTIVE: Assess the frequency and effectiveness of AntiE and opioid co-prescribing in the outpatient setting.

METHODS: A cross-sectional survey of adults who received an oral opioid-containing product (≤14 days’ supply) for treatment of acute pain resulting from injury or surgery in the prior 90-days, and with no recent prior opioid use, or cancer/chemotherapy was conducted. Opioid induced nausea and vomiting (OINV), overall effectiveness in daily activities (0-100%) and difficulties in activities of daily living (ADLs) (attend school/work, care of self/others, consume meals/liquids/medicines, perform usual household tasks) for the first week of opioid treatment were assessed. Chi-square tests for categorical and t-tests for continuous variables were used to test for significant differences.

RESULTS: Of 512 respondents, mean (SD) age was 42.9 (15.2) years and 73.4% were female. Twenty-four percent (n = 125) took the AntiE prophylactically (either before or with their opioid), and 50.4% (n = 63) did not [breakdown: 14.4% (n = 18) did not fill Rx, 17.6% (n = 22) filled but did not take Rx, and 18.4% (n = 23) took after experiencing NV symptoms]. The incidence of OINV was lower in patients who took their AntiE prophylactically compared to patients who did not (29.0% vs. 47.6%, P = 0.03). Mean (SD) percent effectiveness in performing daily activities was significantly greater in patients with prophylactic AntiE use compared to no prophylactic use [54.9 (29.4) vs. 41.9 (28.3), P = 0.01]. Overall, proportions of patients indicating difficulties with ADLs trended higher with no prophylactic AntiE use compared to prophylactic AntiE use, with the greatest differences in “care of self” (90.8% vs. 33.9%, P = 0.03) and “care of others” (52.4% vs. 32.3%; P = 0.023), respectively.

CONCLUSIONS: Use of prophylactic AntiE with opioid therapy was associated with significantly lowered risk of OINV and functional impairment. However, concurrent opioid and AntiE Rx were not common and only half of patients who received AntiE Rx concurrently with an opioid took the AntiE preventatively. A more proactive approach to prevent OINV may improve patient recovery.

SPONSORSHIP: Daiichi Sankyo.

R2 How Pricing Changes and Dose Optimization Affected Compound Pharmaceutical Use in the Missouri Medicaid Population

Wilbers K1, Boehmer L1, Williams A1, Moore J, Calloway S2. 3425 W Truman Blvd, Jefferson City, MO 65109, keathleen.wilbers@xerox.com; (888) 581-9797
1Conduent; 2MO HealthNet

BACKGROUND: Compounded pharmaceuticals are prescribed at high rates despite limited efficacy data and high cost when compared to commercial formulations. As a result, Medicaid programs have had to evaluate and implement cost containment methods.

OBJECTIVE: Describe trends in compound pharmaceutical utilization among recipients after implementation of Maximum Allowable Cost (MAC) pricing and clinical dose optimization.

METHODS: MO HealthNet pharmacies and recipients continuously eligible from 1/1/15 to 12/31/15 were identified via claims data. Recipients with a history of at least one compound medication were the target group. After implementing MAC pricing and clinical dose optimization, we compared trends in total spend pre-rebate and total scripts per month from CY15 to those from January-June 2016 as well as per member per month (PMPM). We also evaluated trends in non-compound pharmaceuticals for comparison. As many compounds are for pain, we did sub-analysis of opioids, pregabalin, duloxetine, and gabapentin to determine if recipients shifted from using compounds to commercial formulations.

RESULTS: A total of 13,079 recipients were eligible for the study. Prior to cost containment methods, recipients filled an average of 4.401 compound scripts per month at an average cost of $658,590. The PMPM averages were 0.34 and $30.35 respectively. After MAC pricing and dose optimization the target group filled an average of 3.530 com-
CONCLUSIONS: Results indicate a vast decline in utilization and cost of compound pharmaceuticals after MAC pricing and clinical dose optimization without a significant increase in commercial formulation utilization. Medicaid programs should evaluate and implement cost containment methods to decrease the utilization and cost of compound medications considering the limited efficacy data and substantial cost.

SPONSORSHIP: This research was funded internally by Conduent and used data from MO HealthNet.

T1 Characteristics Associated with Opioid Overdose in a Medicaid Population

Powell K, Sheen J, Williams A. 2810 Parham Rd, Ste 210, Richmond, VA 23294; karen.powell@xerox.com; (404) 902-6842

Conduent

BACKGROUND: Medicaid beneficiaries are prescribed opioids at twice the rate of the rest of the population and are three to six times more likely to overdose. Based on pain guidelines and data analysis, state programs can implement utilization management programs that promote safe use of opioids.

OBJECTIVE: Describe the characteristics and opioid use patterns of recipients who experienced an opioid overdose.

METHODS: Using a claims database, 746 consecutive recipients who had a diagnosis of opioid overdose between January 2015 and June 2016 were identified. Opioid use patterns, coordination of care concerns, history of substance abuse and pain-related diagnoses (acute pain, chronic pain and cancer) of the target group six months prior to overdose were compared to a control group of 140,129 consecutive recipients with opioid utilization during the same period who did not experience an opioid overdose.

RESULTS: The average morphine milligram equivalent (MME) in the target group was 67.7, compared to 58.4 in the control group. The respective PMPM averages were 0.27 and $19.98. Comparison showed a 19.3% decrease in monthly script counts and a 60.3% decrease in monthly cost. The target group filled an average of 73,646 non-compound scripts per month at an average cost of $10M before intervention. Post intervention, the monthly script count increased 2.9% to 75,600 and the monthly average cost increased 3.3% to $10.4M. When assessing alternative commercial therapies, opioid utilization decreased 6.7% and pregabalin, duloxetine and gabapentin use increased 8.3%, 0.3%, and 2.1% of respectively.

CONCLUSIONS: The data indicates opioid overdose is more likely with MME ≥ 90, long-acting opioids, higher prescription counts and a history of abuse, prior overdose, chronic pain and multiple pain-related diagnoses. Medicaid programs should consider utilization management strategies addressing these issues to help reduce the incidence of opioid overdose in prescription opioid users. Patient education addressing the purpose, use and dosing of long acting opioids and alternative pain management strategies should also be considered.

SPONSORSHIP: This research was funded internally by Conduent.

T4 Abuse-Deterrent Opioids and Prescription Drug-Monitoring Programs: A Systematic Review of Their Impact on Misuse, Abuse, and Opioid-Related Harms

Mendoza M, Roland C, Shulman E, Keenan M. 235 E 42nd St, New York, NY 10017; mario.m.mendoza@pfizer.com; (917) 743-9812

Pfizer

BACKGROUND: Opioid misuse, abuse, and opioid-related harms are a significant public health concern.

OBJECTIVE: Evaluate evidence on the impact of abuse-deterrent opioids (ADOs) and prescription drug monitoring programs (PDMPs) on opioid-related harms as reported in the published literature.

METHODS: Systematic review of human literature published in English (2008January 2016). A modified PICO format was used. Sources included Ovid MEDLINE, BIOSIS Previews, and Embase. All relevant terms describing ADOs and PDMPs were combined with terms related to addiction, misuse, abuse, overdose, opioid-related treatment admissions, overdose deaths, and diversion/driver-shopping rates.

RESULTS: Of 580 citations (364 ADO, 216 PDMP), 48 ADO and 62 PDMP papers were critically appraised, and 33 ADO papers and 6 PDMP papers were included for data abstraction. For ADOs there were 3 studies related to misuse, 18 studies on abuse rates, 2 studies on overdose/poisoning rates, 3 studies on addiction rates, 2 studies on overdose deaths, 5 studies on diversion and doctor shopping. For the PDMPs there was 1 study related to misuse/abuse, 3 studies on overdose events including death, 1 study on opioid-related treatment admissions, and 1 study on doctor-shopping. ADO studies demonstrated a decrease in addiction, misuse, abuse, overdose, overdose deaths, and diversion/driver-shopping rates. Abuse rates declined 18-55%, addiction rates declined 17-27%, overdose deaths declined 66-87%, diversion events declined 75%, and doctor-shopping rates declined 38-50%. For PDMPs, 1 study on misuse/abuse showed that PDMP utilization was associated with smaller increases in a surrogate measure for misuse/abuse compared to PDMPs non-utilization (0.2% vs. 1.9%, respectively; P = 0.036). 2 studies found no evidence that implementation of PDMPs had an impact on decreased overdose events including death, and 1 study reported a 25% decrease in oxycodone-caused mortality after implementation of the PDMP in Florida. 1 study showed a smaller increase in opioid-related treatment admissions in states with PDMPs relative to states without PDMPs (P = 0.063). In 1 paper, mandated PDMP use was associated with a decrease (36-75%) in doctor-shopping rates.

CONCLUSIONS: There is literature evidence demonstrating that ADOs decrease addiction, misuse, abuse, overdose, overdose deaths, and diversion/doctor-shopping rates; most evidence is limited to one ADO (extended-release oxycodone). There is limited literature assessing the impact of PDMPs on addiction, misuse, abuse, opioid-related treatment admissions, diversion/doctor-shopping, overdose, and overdose deaths; more research is needed.

SPONSORSHIP: The study was funded by Pfizer.
A Global Context for Drug Value

Jaksa A1, Liden D1, Lising A2. 49 W 38 St, 10th Fl, New York, NY 10018; ashley.jaksa@contextmatters.com; (773) 516-4043
1Context Matters; 2Dymaxium

PROBLEM DESCRIPTION: Government mandated health technology assessment (HTA) agencies such as the UK’s NICE, Germany’s G-BA, and Canada’s CADTH have been conducting efficacy and cost-effectiveness assessments of drugs for years. The U.S. lacks a formal HTA policy but frameworks used by payers for assessing the value and fair prices of drugs and how they align with decision-making goals are a hot topic of discussion.

GOAL: Compare the purpose, intended and current use of various value frameworks for U.S. payer decision-making and identify factors in global HTA frameworks that may add value to a U.S. approach.

PROGRAM DESCRIPTION: A comparative analysis of methodologies from the U.S.-based ICER, ASCO, and NCCN along with frameworks from NICE, G-BA, and CADTH, identified the purpose, audience, scope and implications for decision-making of each framework. An online survey of U.S. payers assessed awareness and use of U.S.-based frameworks.

OBSERVATIONS: The US frameworks are diverse in audience, scope, and purpose. For example, Perspective: NCCN and ASCO: patient and physician; ICER: payer and policy maker; Goals: ASCO: help patients and physicians achieve affordable care through better understanding of relative efficacy, toxicity, and cost specific to oncology drugs; NCCN: provide patients and physicians with a score and visual representation of cancer drug performance to aid in decision-making; ICER: evaluate the efficacy, value, and affordability of drugs to help payers and policy makers’ decision-making with focus on payers and policy at a larger level; Global Comparison: CER’s framework most closely aligns with NICE, G-BA and CADTH; no mandate to follow ICERs decisions; Current Payer Use of U.S. frameworks: of 99 respondents—44% members of P&T committees making listing recommendations, 9% involved with manufacturer pricing negotiations; Use of U.S. frameworks: 46% ICER, 36% ASCO, 36% NCCN.

FINDINGS/RECOMMENDATIONS: Each U.S. framework has a different purpose and intended audience, potentially influencing conclusions regarding efficacy and affordability of drugs. Though not mandated, payers are considering these frameworks, even when not designed toward their decision-making. The U.S. frameworks lack the health care system integration that HTA agencies hold. The U.S. frameworks lack the health care system integration that HTA agencies hold.

SPONSORSHIP: Context Matters and Dymaxium
OBJECTIVE: The aim of this study was to assess whether health care payer decision-making is influenced by information presented in terms of relative versus absolute risks.

METHODS: An online survey was conducted with Xcenda’s Managed Care Network (MCN), a research panel of U.S. managed care professionals. Participants included in the survey were pharmacy and medical directors who worked at a managed care organization and served as active members of an organization’s pharmacy and therapeutics committee. Participants were presented with two near-identical scenarios, summarizing the number of adverse events observed in clinical trials with two fictitious drugs for breast cancer. Adverse events were presented in terms of relative risks in one scenario and absolute risks in the other. In each scenario, one of the drugs had objectively lower adverse events based on calculations, despite being masked by framing. Participants were prompted to choose a preferred drug, based on the adverse event profile presented. Survey results were collected and analyzed using a chi-square test of independence to assess if the likelihood of choosing the optimal drug depended on question framing.

RESULTS: The survey was sent to 76 medical and pharmacy directors within the MCN panel and yielded 54 (71%) responses in total. In the relative risk scenario, 43 (80%) of the 54 participants chose the less optimal drug with a riskier adverse events profile. In contrast, in the absolute risk scenario, only 21 (39%) of the 54 participants chose the less optimal drug. Decision-makers were more likely to choose the drug with more adverse events when the rates were presented in terms of relative risks than when the rates were presented in terms of absolute risks ($\chi^2(1) = 18.56, P < 0.0001$).

CONCLUSIONS: Health Care payers, like other decision-makers, are susceptible to the cognitive bias of the framing effect when information is presented in terms of relative risks. Presenting information in absolute risks may result in better communication of clinical information and help to improve health care decision-making.

SPONSORSHIP: Xcenda.

U6 How Do Payers Utilize the AMCP eDossier System for Preapproval Information and Could It Qualify as a Safe Harbor?

Gladman J1, Sampsel E1, Drummond M2, Fuzio L1. 145 Front St E, Toronto, Ontario M5A 1E3 Canada; gladman@dymaxium.com; (905) 466-5678
1Dymaxium; 2University of York

PROBLEM DESCRIPTION: Currently there is no accepted FDA sanctioned safe harbor mechanism for the exchange of truthful and non-misleading information for payers. Payers are reviewing products up to 18-24 months in advance of approval to meet budget/formulary approval timelines. The AMCP eDossier System (System) is a secure, web-based system within the FormularyDecisions.com platform supporting the exchange of manufacturer-provided approved information since 2009. Supported in partnership with AMCP and participating life sciences organizations, it is designed to support reimbursement decisions for qualified U.S. health care decision makers via a FDA-compliant unsolicited request process. The need for pre-approval information is apparent, as indicated during recent FDA hearings.

GOAL: To investigate how U.S. payers are utilizing the AMCP eDossier System for pre-approval information and whether this System could be a potential safe harbor mechanism for pre-approval information and support the decision-making process.

PROGRAM DESCRIPTION: In November 2016, 172 registered users of the AMCP eDossier System, a secure, web-based system to support P&T recommendations and formulary decision making, participated in an online survey detailing their use of the System for pre-approval information.

OBSERVATIONS: Payer respondents actively involved or part of the exchange of pre-approval product information indicated (62%) the System’s unsolicited request process supports the information exchange between manufacturers and payers. 80% indicated the System’s ease of use, and 67% responded that manufacturers participating in the System respond better or the same than those not participating in the System. Also, the System can better support the information exchange with more manufacturer participation and by making it easier to understand what manufacturer information is available. Respondents to the System pays sufficient tools/information for pre-approval product review, and 85% felt the System met

S94 Journal of Managed Care & Specialty Pharmacy  JMCP  March 2017  Vol. 23, No. 3-a  www.jmcp.org
or exceeded the needs. All payers asked indicated that having ready access to manufacturer curated information within the System would be helpful.

FINDINGS/RECOMMENDATIONS: The research indicates the System could be a safe harbor mechanism for the exchange of pre-approval information between payers and manufacturers. Overall, payers indicated System usage for this purpose and believe the System supports the process. There may be opportunities to increase manufacturer participation, provided identified barriers could be overcome.

SPONSORSHIP: None.

U7 Targeted Prescriber Office Outreach to Grow Adoption of Electronic Prior Authorizations

Radavsky L1, Nowalk L2, Lawrence D3, Leacock R2. 8914 Hilltop Manor Dr, St. Louis, MO 63132; lrudavski@butler.edu; (314) 629-9983
1Butler University; 2Express Scripts

PROBLEM DESCRIPTION: Electronic prior authorizations (ePAs) enable rapid, streamlined processing of prior authorizations (PAs) resulting in decreased prescription turnaround time for prescribers, pharmacies, and patients. Few factors challenge ePA system implementation such as delegation of support staff duties and potential workflow transition and interruption. These surmountable issues take time, focus and resources away from providing patient care due to the use of traditional, lengthy methods of PA submissions. Targeted outreach could help overcome these challenges.

GOAL: Explore the capacity of targeted outreach to prescriber offices in driving growth of ePA submissions.

PROGRAM DESCRIPTION: We conducted a retrospective study using a pre-post case-control analysis. A pharmacy technician experienced in communicating with physician offices gathered feedback on the ePA process from prescribers (case group) associated with three clients of a national pharmacy benefits manager between March and May 2016. Brief one-on-one discussions addressing any concerns that might prevent use of the ePA process were held with those responsible for submitting ePAs in each setting. Prescribers associated with the same three clients that received no outreach from the pharmacy technician constituted the control group. For each prescriber, total ePA submission counts were compared before and after the technician outreach. Monthly rates of ePA utilization were calculated and compared between the two groups to obtain the difference in ePA adoption with and without targeted outreach.

OBSERVATIONS: Based on quarter 1 of 2016 data (prior to outreach), baseline rates of ePA use for case and control groups were 26.8% (n=1,687) and 27.3% (n=1,947), respectively. The case group resulted in a 6.5% increase of ePA submissions over two months (to 33.3%) while the control group experienced an increase of 3.6% (to 30.9%). Overall, this pattern indicates a +2.9 percentage point increase in ePA adoption over two months.

FINDINGS/RECOMMENDATIONS: Based on the unique needs of individual prescriber offices, targeted outreach may serve as a useful form of driving ePA usage. With ePA being relatively new to the health care industry and consequently underutilized, further research is warranted to better discern clinical and financial implications of ePA submission growth. We anticipate greater patient-centric care and subsequent lower health care costs resulting from decreased lost time in the care continuum while simultaneously closing gaps in patient therapies due to increased ePA usage.

SPONSORSHIP: Express Scripts.

U8 Assessment of Health Care Providers’ Training, Awareness, and Management Practices for Chronic Opioid Therapy

Snyder F1, Rowe D3, Lynch K2. 444 Liberty Ave, Ste 2100, Pittsburgh, PA 15222; fsnyder@gatewayhealthplan.com; (412) 255-4243
1Gateway Health Plan; 2Pfizer

PROBLEM DESCRIPTION: The rise in opioid abuse and dependence is a problem for all stakeholders involved in health care. Published research shows that providers report concerns surrounding the misuse of opioid pain medications, patient addiction and insufficient training in prescribing opioids. The rise in the number of opioid related overdoses and deaths, combined with the apprehension associated with prescribing opioids, underscores the need to identify gaps in provider education.

GOAL: The objective was to evaluate providers’ training and awareness of chronic opioid therapy, abuse, and universal precautions as well as their practices for managing patients on these therapies.

PROGRAM DESCRIPTION: A retrospective claims data analysis identified providers with the highest opioid prescribing patterns compared to peers. Providers were invited to complete a brief anonymous survey, via fax or SurveyMonkey, regarding their demographics, training, awareness, and management practices.

OBSERVATIONS: Of 49 responses, the majority were family practice and internal medicine providers. Results show nearly 87% of providers recognize opioid abuse as a priority for their practice and used an average of 6.3 tools or interventions to mitigate risk. Nearly half (n=23) of providers responded with a low level of comfort treating patients on opioids for an extended period of time. Furthermore, 60.8% of providers did not receive training on universal precautions for the assessment and management of chronic pain. This is demonstrated with greater than half (n=30) of the providers requesting more education on universal precautions, approaches to the treatment of chronic pain and use of long-term opioid therapy. The survey revealed a disparity between provider practices and the level of opioid training. This emphasizes the need for additional education to increase the provider’s comfort level regarding patients on chronic opioid therapy.

FINDINGS/RECOMMENDATIONS: Increased understanding of provider’s practices and their needs allows U.S. to offer targeted educational resources to improve management of patient care and their practices. Areas of opportunity include providing educational materials, assessment and prescribing tools and logistical support. Future initiatives will include provider education related to universal precautions, treatment of chronic pain and use of long-term opioid therapy. An assessment of the impact education has on a provider’s level of comfort and practice management will follow.

SPONSORSHIP: None.

U9 Creating a Quality Audit Process to Identify Fraud, Waste, and Abuse

Wahawisan J. 1400 E Michigan Ave, Lansing, MI 48912; joy.wahawisan@phpmn.org; (517) 364-8386

Physicians Health Plan

PROBLEM DESCRIPTION: Physicians Health Plan (PHP), serving 60,000 commercial and self-funded members in the mid-Michigan region, maintains a custom drug formulary. Evidence of fraud, waste, and abuse was discovered at point-of-service pharmacy claims as well as overpayment errors on medical side drug billings. Areas of focus include payment of non-FDA approved prescription drug products, days’ supply fraud, medications filled for excessive quantities, stockpiling of as-needed medications, inappropriate prescribing activities, and pharmacy benefit manager (PBM) errors in formulary
implementation and processing. Errors were also found with incorrect billing for the number of units on medications with HCPCS codes. At the time, there were limited in-house quality checks and auditing of non-specialty medication utilization.

**GOAL:** Identify fraud, waste, and abuse in pharmacy claims processing as well as develop and implement prevention methods and correction through post-payment recovery audits.

**PROGRAM DESCRIPTION:** Formulary assessment and development of scheduled audits started in the first quarter of 2016. Audits were conducted based on past known incidences of similar errors and issues. PHP’s Analytics department developed algorithms for identification of outlier claims billed, based upon units, volume, quantity, and cost. Clinical assessment was done by a pharmacist on all audit findings which were then reported to various departments to either recover funds or implement coding changes.

**OBSERVATIONS:** An in-house quality control process overseeing additions and changes to the custom formulary likely would have lead to discovery of PBM implementation errors at an earlier stage, possibly preventing member impact. Potential fraudulent activity was uncovered based on detecting outliers using standard deviation auditing, where it appeared that prescriptions were billed as 30 day supply for clinically excessive quantities and only filled every 3 months. This was especially prevalent with topical formulations of medications. Improper payments were discovered in the form of excessive over-payments on medications billed by HCPCS coding, generally from out-of-network providers. High-cost pharmacy claims were found on a frequent basis for non-FDA approved drug products mostly in the form of topical products and drug kits, and were subsequently blocked from the formulary.

**FINDINGS/RECOMMENDATIONS:** After finding over $600,000 in recovered and potential savings over the course of 10 months with minimal adverse impact to members and the formulary, PHP plans to expand the operational and quality components of the pharmacy department.

**SPONSORSHIP:** Physicians Health Plan.

**U10** Impact of Motivational Interviewing on Medication Adherence

Jaghasspanian T, Misquitta C. 10540 White Rock Rd. #280, Rancho Cordova, CA 95670; cathrine.misquitta@healthnet.com; (916) 463-9720

Enclave Pharmacy Solutions

**PROBLEM DESCRIPTION:** The Centers of Medicare and Medicaid Services implemented a quality bonus payment system in accordance with the Affordable Care Act. Plans achieving 4- or 5-stars overall are eligible for the bonus. Many metrics are weighted and averaged to determine the overall star rating. Three metrics on medication adherence are included in this program. Patients receiving diabetic medications, renin-angiotensin system antagonists (RASA), and statins are evaluated for their proportion of days covered (PDC). Plans’ star ratings are based on the percentage of patients in each of these categories achieving a PDC of 80% or greater.

**GOAL:** The goal of this project was to determine the impact of motivational interviewing on medication adherence (defined as any improvement in PDC rate) and the percentage of patients who became adherent (defined as the percent of patients with a PDC of 80% or greater).

**PROGRAM DESCRIPTION:** Patients (n = 48,483) were identified for an intervention if they had a year-to-date PDC rate of 50-84%. The intervention was comprised of a telephonic outreach via interactive voice response to verify the patient and then transfer directly to a pharmacist. The pharmacist would introduce the purpose of the call and then use motivational interviewing techniques designed to show empathy, invite collaboration, provide autonomy and support, and evoke a patient directed change in their medication adherence behaviors. To determine if this intervention made an impact, year-end adherence rates were compared between patients who spoke with a pharmacist (n = 16,063) and those who could not be reached (n = 32,420). There were 590 patients excluded from the analysis because a year-end PDC rate was not available. A chi-squared analysis was conducted to determine statistical significance.

**OBSERVATIONS:** Evaluating all patients combined, 68% of patients who talked to a pharmacist had improved PDC rates compared to 60% of patients who could not be reached (P < 0.05). Evaluating each drug class separately, the results were as follows: diabetes 64% vs. 58%, RASA 68% vs. 61%, and statins 69% vs. 59% (P < 0.05). To determine the impact on the star rating, the percentage of patients who achieved a PDC of 80% or greater at year-end was evaluated. Sixty four percent of patients who talked to a pharmacist reached 80% or greater PDC compared to 54% of patients who could not be reached.

**FINDINGS/RECOMMENDATIONS:** As cut-points to achieve 4- and 5-stars become more challenging each year, health plans should consider implementing motivational interviewing to continually improve their results.

**SPONSORSHIP:** None.
FINDINGS/RECOMMENDATIONS: Scientific Advice shows great value for manufacturers and patients. Manufacturers to adjust their CDPs to better demonstrate clinical and economic value to obtain marketing authorization and reimbursement. Integrated Scientific Advice should become a routine part of CDPs as a stepping stone to minimize risk and maximize patient access to promising new treatments.

SPONSORSHIP: None.

U12 Validation of a Budget Impact Model for a Clinical Management Program for Zarxio
Hung A, Vu Q. 9104 Orchard Brook Dr, Potomac, MD 20854; anna.hung@umaryland.edu; (301) 412-7396
University of Maryland School of Pharmacy

BACKGROUND: In March 2015, Zarxio became the first biosimilar to be approved in the U.S. Zarxio is currently the third filgrastim product available in the U.S. market, besides Granix and its reference product Neupogen. In 2015, a large commercial insurer used a clinical management program (CMP) to encourage providers to switch from Neupogen to Zarxio. A budget impact model (BIM) was developed to predict one year cost savings from the CMP. One year post the CMP’s implementation, we want to compare predicted savings to realized costs.

OBJECTIVE: To validate a previously built budget impact model predicting one-year cost savings from implementing a clinical management program from the payer perspective.

METHODS: There were three phases to validating this BIM. Phase 1: Updating key assumptions for the BIM. Two key assumptions in the original BIM were: Zarxio’s price would be 30% off of Neupogen’s price, and 30% of the utilization would switch from Neupogen to Zarxio with the CMP. What we actually saw was: Zarxio’s price was 15% off of Neupogen’s price, 9% of utilization shifted from Neupogen to Zarxio and 26% shifted from Neupogen to Granix. Phase 2: Building an additional component into the BIM. The CMP encouraged not only a utilization shift from Neupogen to Zarxio, but also from Neupogen to Granix. Since the original BIM predicted savings based only on the shift from Neupogen to Zarxio, we added into the BIM cost savings from switching from Neupogen to Granix. Phase 3: Replacing with actual utilization and costs. We updated drug utilization and costs with pharmacy claims data from 9/18/15 to 9/17/16. We also updated realized program review costs and waived copays associated with switches.

RESULTS: The predicted cost savings from the original BIM was $56.94 per utilizing member per month (PUMPM). Phase 1: The predicted cost savings after updating key assumptions was $3.28 PUMPM. Phase 2: The predicted cost savings after adding cost savings from the Neupogen to Granix utilization shift was $20.74 PUMPM. Phase 3: The predicted cost savings after updating drug utilization and costs from pharmacy claims, as well as actual program review costs and waived copays, was $29.45 PUMPM.

CONCLUSIONS: The original predicted cost savings was higher than what was realized primarily due to a smaller reduction in price for Zarxio versus Neupogen. Future BIMs should be validated by updating key assumptions, building in additional components as needed, and comparing against claims data.

SPONSORSHIP: No external sponsorship provided.

U13 Improving Patient Care One Consult at a Time Through Our Clinical Quality Oversight of Medication Therapy Management
Gutierrez S, Ortiz J, Villafuerte M, Barrington C. 1600 McConner Pkwy, 07-020, Schaumburg, IL 60173; salvador.gutierrez@optum.com; (224) 231-1484
OptumRx

PROBLEM DESCRIPTION: The Medicare Modernization Act of 2003 requires that medication therapy management (MTM) services be offered to all eligible Medicare Part D program participants. MTM’s intent is to help patients understand their medications, avoid adverse outcomes, improve adherence, and to help health care providers improve patient care. Beginning in 2017, an enhanced MTM offering will roll out, allowing for more flexibility while providing incentive payments to prescription drug plans (PDP) that are enrolled. The enhanced MTM program (MTMP) will allow plans to overcome the shortcomings of the current MTMP.

GOAL: The goal of our quality program is to support our organization’s approach to provide high quality, clinically appropriate recommendations to members and providers through comprehensive medication reviews. Our MTM is designed to follow the guidance set forth by CMS, NCQA, and URAC.

PROGRAM DESCRIPTION: Cases are randomly selected and audited for clinical quality. Our program is designed to meet 10 key performance indicators (KPIs) that assess clinical quality while following the guidance set by regulatory and accreditation entities. A quality improvement plan is implemented to remediate any KPI that falls below the 95% benchmark for two consecutive quarters. Our collaborative efforts with the MTM team foster discussions that lead to continuous improvements.

OBSERVATIONS: Our quarterly assessments show that 70% of our KPIs are at or above the 95% benchmark. Through our clinical oversight program we have identified three key areas of focus. These include better documentation with a KPI of 83%, addressing gaps in care with a KPI of 90%, and enhancing the identification of drug interactions with a KPI of 90%. Our dynamic clinical oversight program will continue to monitor the KPIs and allow for continuous quality improvements.

FINDINGS/RECOMMENDATIONS: Our program will continue to evaluate the MTM staff’s ability to deliver appropriate consults, ensure consistent clinical performance by all staff, and promote future enhancements that address over and underutilization, adherence, and better disease state management. The improvements brought about by our clinical quality program allow U.S. to enhance our MTM program while delivering overall cost savings and improving patient care.

SPONSORSHIP: None.

U14 Wearable Health Technologies to Treat Chronic Pain: Establishing Baseline Treatment Effects in a Multidisciplinary Pain Program
Graham J1, Alfieri T2, Baylor K1, Robishaw S1, Bond C1, Mayne T2, Han J1, Geisinger Health System, Danville, PA 17822; jghraham1@geisinger.edu; (570) 214-9578
1Geisinger Health System; 2Purdue Pharma

PROBLEM DESCRIPTION: About 100 million chronic pain patients in the U.S. account for > $560 billion in annual costs. Wearable health technologies (WHT) may allow health care providers to monitor patients in real time, improving outcomes at reduced cost.

GOAL: To evaluate the Geisinger Multidisciplinary Pain Program (MPP).
### PROGRAM DESCRIPTION:
The Geisinger Multidisciplinary Pain Program (MPP) takes a bio-psycho-social approach to improve function and quality of life for chronic pain patients. Patients take an educational class (3d) and develop measurable goals with pain specialists, who follow up over 12 months in coordination with primary care providers. This study of electronic health records compares outcomes from the first 91 MPP patients to those of chronic pain patients treated in a primary care (PC) setting. The goal was to establish current treatment effects of the MPP so the incremental value of WHT could be measured in the future. Paired t-tests were used to compare changes over 6 months for pain scale and the PHQ8 depression index. Lower scores indicated improvements.

### OBSERVATIONS:
- At enrollment MPP patients (36% male, 99% Caucasian, mean age 51) had mean (SD) scores of 6.1 (2.0) for pain (n=91) and 9.1 (7.6) for PHQ8 (n=86). 49% of patients met or exceeded the depression cutpoint of ≥ 10 (n=86). Of patients with outcomes measured at 6 months, mean (SD) changes were -0.48 (2.3) for pain (n=62) and -2.1 (7.7) for PHQ8 (n=58), with 36% ≥ 10 (n=61). In the same timeframe, PC patients (38% male, 98% Caucasian, mean age 53) had baseline mean (SD) scores of 6.1 (2.4) for pain (n=1,741) and 5.9 (7.1) for PHQ8 (n=1,609), with 31% ≥ 10 (n=1,609). PC patients with outcomes measured at 6 months had mean (SD) changes of -0.28 (2.4) for pain (n=487) and -0.3 (5.6) for PHQ8 (n=387), with 26% ≥ 10 (n=407). No differences reached statistical significance.

### FINDINGS/RECOMMENDATIONS:
MPP patients showed moderately greater improvement in pain and depression than controls. With mean scores and level of improvement suggesting no clear ceiling effect, there is a potential for further improvement with WHT use. A prospective study integrating WHT into MPP is planned to provide real-time feedback, support physical activity and medication adherence, and integrate treatment data into new patient/provider dashboards.

### SPONSORSHIP:
This research was funded by Purdue Pharma.

### RESULTS:
A total of 20,252 patients met the study criteria. Rheumatoid arthritis (RA; 37.6%) was most prevalent, followed by plaque psoriasis (PP; 21.1%), Crohn’s disease (CD; 15.8%), psoriatic arthritis (PA; 4.8%), and ankylosing spondylitis (AS; 4.3%). Approximately 58.0% of patients discontinued adalumab treatment (range: 62.8% RA to 43.3% CD). Mean (SD) time to discontinuation was longest for patients with PA [132.5 (88.4) days] and shortest for patients with PP [95.7 (95.7) days]. Among patients who discontinued adalumab, 30.2% switched to another biologic, 27.6% restarted adalumab, and 39.0% neither switched nor restarted their treatment. Among patients with a restart, mean (SD) days between medication discontinuation and restart was 82.7 (51.3) days.

### CONCLUSIONS:
The 1-year treatment discontinuation rate for adalumab treatment is high. A significant proportion of patients discontinuing adalumab treatment either restart adalumab treatment or switch to another biologic. Further research is needed to understand why patients on adalumab interrupt, switch, or discontinue treatment altogether.

### SPONSORSHIP:
This study was sponsored by Boehringer Ingelheim Pharmaceuticals.
**U17 Utilization of Geriatric Care Among Medicare Beneficiaries**

Zhang Q, Miyusato G, Wang Z, Aghsaee S, Scalfi J. 230 Third Ave, Waltham, MA 02451; qghang@trinitypartners.com; (781) 577-6306

**Trinity Partners**

**BACKGROUND:** Geriatric care is often critical for many in the Medicare population, given that two-thirds of all people 65+ experience multiple chronic conditions. However, many beneficiaries who could benefit from geriatric care do not receive it. This could lead to downstream effects such as higher costs and decreased patient quality of life due to preventable health care use and uncontrolled chronic disease.

**OBJECTIVE:** To assess the use of geriatric care among Medicare beneficiaries and identify the patient factors most strongly associated with receiving geriatric care

**METHODS:** A case-control claims analysis was performed, comparing patients with and without geriatrician visits. The study cohorts were from a random 5% sample of Medicare FFS beneficiaries that were aged 65+ in 2010. Cases were beneficiaries with an initial geriatric claim in 2011 and 2+ geriatric claims from 2011-2014. Controls were beneficiaries that did not have a geriatric claim from 2011-2014. Overall and regional geriatric care use rates were determined. A subset of patients were then used in a classification tree (CRT) analysis to determine which demographic factors and medical conditions prior to the initial geriatrician visit were most associated with receiving geriatric care.

**RESULTS:** Overall, 3% of Medicare patients utilized geriatrician care (24,664 geriatrician case patients and 845,584 non-geriatrician control patients). On average, cases were three years older than controls (P<0.05) and cases had a higher number of claims in 2010 (43 vs. 31 in controls, P<0.05). The CRT analysis suggested that state of residence was the most important factor associated with receiving geriatric care; the states/districts having the highest rates of geriatric care were DC, MI, NH, CT and HI, while the lowest use rates were found in AK, SD, ND, ID and WY.

**CONCLUSIONS:** The proportion of Medicare beneficiaries receiving geriatric care is very low even though the majority are elderly and suffer from multiple chronic conditions. This proportion varies by state, which likely reflects an access-to-care issue as well as a shortage of geriatricians. Patients who received geriatric care tended to be older and required more resources prior to their first visit. This suggests that when access to geriatrician care is limited, only the sickest patients are provided access, possibly excluding many patients that would benefit. Additional studies are needed to understand whether access to geriatric care reduces overall health care resource utilization and costs among this population.

**SPONSORSHIP:** Trinity Partners conducted this research without external funding.

---

**U18 Epidemiology of Opioid Use in a State Medicaid Program**

Pham T1, Shreepukt G2, Bond C2, Alfieri T2, Cohran T2, Keast S1.

1University of Oklahoma College of Pharmacy, Oklahoma City, OK 73126; timothy-pham@ouhsc.edu; (405) 271-6848

2Purdue Pharma

**BACKGROUND:** Medicaid populations are especially vulnerable to opioid-related disorders, however their characteristics and underlying treatment patterns have not been thoroughly analyzed.

**OBJECTIVE:** Describe the demographics, medical utilization, opioid utilization patterns, and clinical characteristics of Medicaid members who used opioids or had opioid-related disorders during study period.

**METHODS:** A descriptive historical cohort analysis using a state Medicaid pharmacy and medical claims data from 2011-2016 was done. Members were required to have at least 12 months of continuous eligibility prior to their index date: the date of last opioid claim or last medical claim with opioid-related diagnosis. All measures were examined in the year prior to index date: all-cause hospitalizations and ER visits, opioid use, daily morphine equivalent doses (MEQ), overlapping opioids of different classes, and overlapping opioids and benzodiazepines (BZDs). Three overlapping cohorts were analyzed: (1) members with at least one claim for an opioid prescription (OP); (2) members who had at least one ICD (965.0x, T40.x) code for opioid overdose (OD); and (3) members who had at least one ICD (304.0x, 305.5x, F11.x) code of opioid abuse or dependence (AD).

**RESULTS:** There were 227,831 OP members, 1,347 members with reported OD; and 10,753 had reported AD. The OD group had the highest hospitalization (29.5% with ≥2 claims) and ER visits (68.4% with ≥2 claims). By comparison, the AD group had 11.3% with ≥2 hospital and 49.4% with ≥2 ER claims; the OP group had 4.6% with ≥2 hospital and 34.9% with ≥2 ER claims. Both OD and AD groups showed substantial overlap of opioids in different classes (OD: 35.6%, mean overlap of 68.1 days, AD: 35.0%, mean 62.6 days) and overlapping opioids and BZDs (OD: 31.3%, mean 124.2 days; AD: 25.6%, mean 105.6 days). The OP group had 8.6% with overlapping opioids (mean 12.0 days) and 5.7% with overlapping opioid and BZDs (mean 23.3 days). In the AD group, 73.3% had ≥3 claims for opioids with a mean cumulative supply of 256.4 days and mean daily MEQ dose of 91.8 mg. The OD group had a lower proportion with ≥3 claims (59.6%), but a comparable mean supply (256.2 days) with mean MEQ of 73.8 mg. The OP group overall had 30.8% with ≥3 claims, a mean supply of 56.6 days, and mean MEQ of 64.4mg.

**CONCLUSIONS:** Those with OD or AD showed high medical and pharmacy utilization and frequent overlap of opioids of different classes and BZDs. Further research is planned to determine whether these patterns are predictive of opioid-related complications and if early interventions can be developed.

**SPONSORSHIP:** Purdue Pharma.

---

**U19 Impact of Oxycodone HCl Extended-Release Formulary Restrictions on Extended-Release Opioid Market Share, Health Care Resource Utilization, and Costs in Commercial and Medicare Plans**

Howard J1, Chen C2, De A3, Wade R2. 201 Tresser Blvd, Stamford, CT 06901; jaren.howard@pharma.com; (203) 588-7551

1Purdue Pharma; 2QuintilesIMS, HEOR Real World Evidence

**BACKGROUND:** Utilization management through formulary restrictions is designed to reduce pharmacy costs and to promote quality, safety and appropriate prescription utilization. Such access barriers may also have unintended consequences on patient care and
non-pharmacy expenditures. Little is known about the impact to treatment and costs associated with access restrictions on extended-release opioids (ER opioid) in the management of chronic pain across different types of health plans.

**OBJECTIVE:** This study evaluated the ER opioid dispensing patterns, health care resource utilization and costs following prior authorizations (PA), non-formulary (NF) and step therapy (ST) restrictions for branded oxycodone hydrochloride extended release (OER) in national and regional commercial/Medicare plans.

**METHODS:** This retrospective, longitudinal case-control study analyzed pharmacy and medical claims data (2012 to 2015) for adult patients with chronic ER opioid use from U.S. plans that instituted formulary restrictions for OER. Cases (PA, NF or ST plans) and controls (no restriction plans) were matched on key clinical and demographic characteristics and were followed for 6 months. Study groups were segmented by health plan type (commercial/Medicare), and geography (national/regional). ER opioid market share, health care utilization, and costs were evaluated for the 6-month periods before and after the restrictions. A difference-in-difference (DiD) approach was utilized to evaluate the total per patient per month (PPPM) health care utilization and costs.

**RESULTS:** The final sample comprised 1,622 (national commercial PA), 2,020 (regional commercial PA), 34,703 (national commercial ST), and 4,372 (national Medicare NF) chronic ER opioid users, and equivalent number of controls from no restriction plans. Market share for OER decreased after the formulary restrictions, with the national Medicare NF plan showing the greatest decrease (from 23.5% to 14.3%). DiD analyses indicated non-significant decreases in PPPM office visits of 0.12 and 0.16 (P > 0.05) in the PA and NF plans, respectively, and a significant increase (PPPM = 0.07, P < 0.001) in the ST plan. No significant total monthly cost changes were observed: PPPM decreased by $48.74 and $59.87 in the ST and NF plans, and increased by $37.90 in regional commercial the PA plan (P > 0.05).

**CONCLUSIONS:** The results of this study found that formulary restrictions reduced the market share of OER, but did not result in net cost changes. This effect appears to be consistent across national and regional commercial/Medicare plans.

**SPONSORSHIP:** This research was supported by funding from Purdue Pharma.

**U20 Assisting the Impact of Community-Based Overdose Prevention in Rural North Carolina**

Alfieri T, Brason F, Mayne T. Project Lazarus, Moravian Falls, NC 28654; fbrason@projectlazarus.org; (336) 667-8100

**PROBLEM DESCRIPTION:** To address the opioid overdose epidemic from prescription pain medications the North Carolina (NC) Division of Public Health task force recommended community-based overdose prevention programs in 2002.

**GOAL:** Develop and assess the impact of community based prevention programs on the opioid-related overdose, abuse and diversion epidemic.

**PROGRAM DESCRIPTION:** Project Lazarus is a community based overdose prevention program started in 2008 in Wilkes County, NC in response to high unintentional poisoning mortality rates due to prescription opioids. By 2010, all health care providers who prescribed opioids had been trained using the Project Lazarus Medical Care Provider Toolkit, prepared in collaboration with the NW Community Care Network Chronic Pain Pilot. The Project Lazarus intervention model consists of best practices for addressing overdose, abuse and diversion of opioids, including (1) community education, (2) provider education, (3) hospital ED policies to address drug seeking behavior, (4) reducing the presence of unused medications, (5) pain patient support, (6) prevention of overdose by naloxone use and (7) addiction treatment. In addition to provider training, Project Lazarus has supported goals of Safe Kids NC and Operation Medicine Drop by organizing a series of medicine take-back events (starting in 2008) and arranging 5 permanent disposal receptacles installed in police stations and pharmacies across the county.

**OBSERVATIONS:** The Project Lazarus initiative may have had a positive impact on both hospitalization and death rates. The prescription opioid poisoning hospitalization rate per 100,000 persons in Wilkes County decreased from 36.1 in 2009 to 18.7 in 2010. The prescription opioid poisoning death rate per 100,000 persons in Wilkes County was 42.1 in 2009, which was 4 times that of the state. The death rate declined to 20.2 in 2010 and 13.0 in 2011. Furthermore, in 2008, 82% of the people in Wilkes County who experienced a fatal overdose received a prescription for an opioid from a Wilkes county prescriber, which decreased to 10% in 2010. The most recent data, from 2015, shows the opioid poisoning death rate in Wilkes County climbed to 33.6 per 100,000.

**FINDINGS/RECOMMENDATIONS:** Early impacts of Project Lazarus on public health outcomes in Wilkes County are encouraging but may not be permanent. Further research on borderline reclassification rates and drug take back programs are recommended to help communities design statewide initiatives.

**SPONSORSHIP:** This research abstract was supported by funding from Purdue Pharma.

**U21 Adverse Drug Event Reporting Rates: Comparing FAERS to Clinical Trials**

Dimbili M, Chen D, Erdeman C, Overstreet B, Kyle B. 3663 N Laughlin Rd, Ste 102, Santa Rosa, CA 95403; mdimbili@adverahealth.com; (707) 387-9230

**Advera Health Analytics**

**BACKGROUND:** Adverse drug events lead to 700,000 annual emergency room visits and are the fourth leading cause of death in the U.S. However, a large number of serious adverse drug events are not reported to FDA’s Adverse Event Reporting System (FAERS), making the incidence rates of adverse drug events impossible to calculate from FAERS.

**OBJECTIVE:** This study provides a methodology to calculate adverse drug event reporting rates and examine whether reporting rates differ by indications.

**METHODS:** Reported adverse drug event rates in clinical trials were compared to FAERS data for 54 drugs in four indications—Multiple Sclerosis (n = 6), Chronic Hepatitis C (n = 5), Diabetes Mellitus, Type 2 (n = 30), Breast Cancer (n = 13). We examined: (1) the rate of serious adverse drug events in treatment arms of phase II and III trials; (2) the reported post-approval adverse drug events in FAERS; and (3) patient usage data from EudraVigilance. Focus was limited to EudraVigilance Important Medical Event Serious adverse drug events and “primary suspect” adverse drug event reports in FAERS. Chemotherapy drugs, drugs approved for multiple indications, and drugs approved prior to 1997 were excluded. To calculate reporting rate, the FAERS serious adverse drug event rate was divided by the pooled clinical trial serious adverse drug event rate.

**RESULTS:** The final analysis provided a methodology for calculating a “real world” reporting rate of post-approval adverse drug events and demonstrated differential reporting between indications. The analysis showed that Multiple Sclerosis drugs had a 49.8% adverse drug event reporting rate in FAERS, Chronic Hepatitis C had a 27.1% adverse drug event reporting rate, Breast Cancer had a 4.7% adverse
Medicare Part D is a prescription drug benefit program implemented in 2003 and administered by Centers for Medicare and Medicaid Services to subsidize the costs of prescription drugs and prescription drug insurance premiums for Medicare beneficiaries.

BACKGROUND: Medicare Part D (MPD) open enrollment occurs every year from mid-October through early December providing a limited window for many beneficiaries to update or alter their drug coverage. Finding a MPD prescription drug plan can be overwhelming for many beneficiaries due to the number of plans and complexity of the Medicare.gov Plan Finder. Since 2013 the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences AMCP student chapter (CU AMCP) has helped Colorado residents navigate the Medicare.gov Plan Finder site to find the most appropriate prescription drug plan to suit each beneficiary’s needs.

METHODS: For 2017 open enrollment, partnership between CU AMCP and Colorado Gerontological Society (CGS), a grant funded State Health Insurance Assistance Program was implemented. Beneficiaries’ information such as demographics, a current medication list, plan preferences, and additional benefit eligible information was gathered by CGS and volunteer student pharmacists. Then using the Medicare.gov Plan Finder online, students identified a range of possible Part D plans suitable for a beneficiaries’ coverage needs. The CGS then completed the final enrollment process.

RESULTS: A total of six events with 25 student pharmacist volunteers (8 P1, 8 P2, 9 P3) were held at CGS during the 2017 MPD outreach season. Students also received experiential credit through the CU for administration time were provided by 25 CU students and 1 faculty preceptor. Outreach services were provided to Colorado residents with 73% living within Denver Metro area, 24% rural, and 3% undisclosed. The age span of members was 62-90 years, with 2.5% needing extra financial help. Of the 41 plan finders, 78% members were Caucasian, 15% Hispanic, and 7% unspecified race, 65% female. And, 61% of members were previously enrolled in an original MPD prescription plan.

CONCLUSIONS: Medicare Part D outreach is essential to the community due to the complexity for seniors trying to enroll and the limited window in which to complete enrollment. Outreach efforts served to introduce student volunteers to challenges and necessary skills to assist beneficiaries in finding appropriate drug coverage.

SPONSORSHIP: None.

Helping Seniors in the Denver Community: Medicare Part D Outreach and Plan Optimization

Metz K, Olatue J, Dehimi S. 12850 E Montview Blvd, Aurora, CO 80045; kelli.metz@ucdenver.edu; (303) 817-9801
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

CONCLUSIONS: The impact post-approval adverse drug events have on patient safety and medical cost has been difficult to determine without a reliable method to calculate the reporting rate of adverse drug events in FAERS. By comparing post-approval and controlled clinical trial adverse drug events, we provided a reporting rate calculation and showed differential reporting between indications. Based on this analysis, an expanded study covering more drugs and indications will be conducted. In addition, further study will be necessary to learn the causation of the differences in reporting between indications.

SPONSORSHIP: Advera Health Analytics.

Analyzing the Success Rates of Pharmacist Interventions in Resolving Medication Therapy Problems at University of Florida’s Medication Management Center

Connelly A1, Patel A1, Hardin H1, Hall A2, Salo J1, Golub-Neff K3, Segal R2
2046 NE Waldo Rd, Rm 3100, Gainesville, FL 32609; amber.connelly@cop.ufl.edu; (352) 273-9045
1University of Florida College of Pharmacy, Gainesville; 2University of Florida College of Pharmacy, Orlando; 3WellCare Health Plans

BACKGROUND: Medication therapy management (MTM) services are provided to eligible Medicare prescription drug plan members to ensure optimal therapeutic outcomes through improved medication use. During MTM services pharmacists make interventions to address and remedy medication therapy problems (MTP) with prescribers and patients. CMS requires MTM programs to report on the number of MTP recommendations and corresponding resolutions resulting from MTM services. The Pharmacy Quality Alliance (PQA) is currently working to develop a measure that would assess MTP resolution rate as a measure of quality for MTM programs if adopted by CMS. WellCare Health Plans contracted with the University of Florida Medication Management Center for the provision of telephonic MTM services to Medicare prescription drug plan members in 2015. This study examines the frequency of MTP recommendations and corresponding resolutions resulting from these MTM services.

OBJECTIVE: To analyze MTP intervention frequency and resolution rates resulting from pharmacist-provided MTM services in a Medicare prescription drug plan population.

METHODS: A retrospective analysis of MTP interventions was conducted to evaluate the intervention frequencies resulting from MTM services. MTPs were categorized using the newly developed PQA framework for suggested MTP categorization. Analysis included whether interventions were performed with MTM program prescribers, members, or both. Resolution rates were calculated for each MTP category and method of intervention.

RESULTS: MTM services were provided to 6,508 patients. Interventions were performed on 10,156 MTPs with an overall resolution rate of 39%. The most frequent MTPs addressed in interventions were non-adherence, preventive therapy opportunities, and medication interactions. The highest resolution rate was in the MTP category of adherence. A total of 8,376 MTPs were communicated to prescribers, 1,460 were addressed with members, and 320 were addressed with both the prescriber and member. Resolution rates were calculated for each MTP category and method of intervention.

CONCLUSIONS: There is large variation in the frequency and corresponding resolutions rates for MTP interventions performed by pharmacists providing MTM services for a national Medicare prescription drug plan. Highest resolution rates for MTP interventions are seen when the method of intervention is prescriber communication or prescriber communication in tandem with member communication.

SPONSORSHIP: No outside funding was used in conducting this study.

A Cost-Effective Medication Therapy Management Program for the Medicaid Population

Safra J. 1030 Byrnwyck Rd NE, Brookhaven, GA 30319; jared.safra@gmail.com; (248) 752-1122
Centene/Peach State Health Plan

PROBLEM DESCRIPTION: How to improve medication adherence for Medicaid members that have either Asthma, Diabetes, Inflammatory Bowel Disease or Multiple Sclerosis?

GOAL: To improve medication adherence rates for members with Asthma, Diabetes, Inflammatory Bowel Disease or Multiple Sclerosis.
PROGRAM DESCRIPTION: The Pharmacy’s Medication Therapy Management (MTM) clinical outreach team is made up of pharmacy technicians and a pharmacist who are responsible for reaching out to providers, pharmacists, and members. The objective was to improve Medicaid member’s medication adherence in four disease states including Asthma, Diabetes, Inflammatory Bowel Disease and Multiple Sclerosis. Outbound telephone calls were conducted on a daily basis to members. Successful live member calls were transferred to the pharmacist for further clinical consultation. Targeted members were chosen based on lack of 35 or more consecutive calendar days of adherence to medication(s). Medication adherence for each member was confirmed prior to each call based on review real-time claims adjudication. During the phone call contact with the members the disease state along with medication adherence and barriers to adherence are addressed. The goal of each call is to have the member take ownership of their disease state.

OBSERVATIONS: Observations of this process showed that members were overall satisfied. Observations of the process for the treating provider clinical care team revealed appreciation for the additional information the health plan provided.

FINDINGS/RECOMMENDATIONS: Over the last six months, medication and member fills were tracked by the health plan on a monthly basis from June 2016 through the end of November 2016. The year to date (YTD) savings amounted to more than $750,000. The baseline metric was defined as a rolling 12 month period prior to initial outreach. The total per member per month (PMPM) savings was analyzed for each of the four above stated disease states. The YTD savings was defined as a rolling 12 month period after the member telephonic outreach. The total savings was calculated for both medical and pharmacy PMPM.

SPONSORSHIP: This study was not sponsored.

RESULTS: The final sample included 63,648 beneficiaries. The median age was 44 and 58% were female. Of these beneficiaries, 14,115 (22.18%) filled at least one opioid prescription and 4,315 (6.78%) filled at least one BZD prescription during the study period. A total of 2,198 (3.45%) individuals filled at least one opioid and one BZD during the year. Of those who filled both an opioid and BZD prescription, a significantly higher proportion were female compared to those who did not fill both (73% vs. 58%; P<0.0001). The proportion of males vs. females in each of the four subgroups was significantly different (P<0.0001). The age distribution was significantly different in the four subgroups (P<0.0001).

CONCLUSIONS: These findings suggest that many patients fill prescriptions for at least one opioid and BZD in the same year, despite warnings against concomitant use, and that a higher proportion of female patients may be at risk. Further research may serve as the basis for employer and managed care programs to ensure appropriate utilization of these potentially dangerous medications.

SPONSORSHIP: None.

U26 Prescription Opioid Deaths in a State Medicaid Population, 2012-2014
Pham T1, Strepnek G2, Bond C3, Alfieri T2, Cohran T1, Keast S1. University of Oklahoma College of Pharmacy, Oklahoma City, OK 73126; timothy-pham@ouhsc.edu; (405) 271-6484
1University of Oklahoma College of Pharmacy; 2Purdue Pharma

BACKGROUND: According to the CDC, rates of opioid overdose deaths are increasing in the United States from both prescription and non-prescription sources. Medicaid populations are especially vulnerable.

OBJECTIVE: To describe cause of death, medical utilization, opioid use, and demographic and clinical characteristics of a state Medicaid opioid prescription drug overdose deaths from 2012-2014.

METHODS: This cross-sectional study combined medical examiner data for prescription drug overdose deaths from a state Medicaid pharmacy and medical claims. Decedents who were Medicaid eligible at any time in the 12 months prior to death and had an opioid medication recorded in cause of death were included for analysis. Decedents did not have to be Medicaid eligible in the months immediately preceding death to be included in the study. Demographic measures, prevalence of drugs, attributed to death, pharmacy and medical utilization, and comorbidities related to addiction were gathered for the year prior to the date of death. Cases per 100,000 person-years (PY) were estimated by dividing deaths by total eligible person-years for the general state Medicaid population and multiplying by 100,000.

RESULTS: Opioids were involved in a total of 491 deaths over these 3 years in the Medicaid population (15.5 deaths/100,000 PY). Death rates were highest among ages 35-44 (41.4/100,000), 45-54 (72.8/100,000), and 55-64 (48.0/100,000). Decedents were more commonly female (59.7%). Around 55% did not have any opioid prescription claims in the year prior to death. Among those with claims, the mean cumulative supply was 284.2 (±235.2) days and with a daily morphine equivalent dose of 81.8 (±92.8) mg. Nearly 23% had overlapping opioid and benzodiazepines prescriptions with a mean cumulative overlap of 94.4 (±201.4) days. Although only 16.3% had an opioid abuse disorder diagnosis, 51.1% were identified as having a substance abuse disorder diagnosis of some kind. Mental health diagnoses (63.1%) and trauma (40.3%) were also particularly common. A total of 1,006 substances were implicated in cause of death, 57.4% of those substances were opioids. The top five substances involved were oxycodone (17.3%), hydrocodone (14.8%), alprazolam (9.8%), morphine (8.2%), and methadone (7.3%).
CONCLUSIONS: Among current or recent Medicaid enrollees, opioid death rates are high, especially among the middle-aged. An opportunity exists to identify members at risk of overdose death and apply early intervention strategies based on member characteristics and utilization patterns.

SPONSORSHIP: Purdue Pharma.

U27 Medicaid Brand and Generic Drug Utilization Trends: A Quantitative Analysis of Uptake Dynamics Within the First Year of Introducing Generic Competition

Han Y, McDonough J, Harris J. 790 Township Line Rd, Ste 200, Yardley, PA 19067, yhan@cellohealth.com; (215) 504-5821
Cello Health

BACKGROUND: For commercial payers, launch of generics leads to a fast loss of total prescription share; however, the impact on Medicaid expenditures may be different, given different formulary approaches. With biosimilars poised to become widely available in the United States, we sought to understand the market dynamics between generic and branded drugs in the Medicaid program as a baseline for future evaluation of biosimilar market dynamics.

OBJECTIVE: To establish a quantitative understanding of market dynamics under Medicaid coverage resulting from introduction of generics.

METHODS: Quarterly Medicaid State Drug Utilization data were obtained for Q1 2013 through Q2 2016. Monthly data for the National Average Drug Acquisition Cost (NADAC) between October 2013 and October 2016 were retrieved as benchmark pricing. For each generic launched in this window, the average price and volume were calculated for the corresponding branded drug in the quarter prior to launch, and price and volume changes were evaluated during the 4 quarters after launch. Branded drug utilization over the entire time window was analyzed using the Cochran-Armitage trend test, and the relationship between pricing and uptake patterns among generic products and their corresponding branded drugs was explored using descriptive statistics and pairwise t-tests.

RESULTS: From Q1 2013 to Q2 2016, a statistically significant trend was observed for increasing generic product use with each quarter after launch in the Medicaid population (P<0.001). Total prescription share for branded products decreased from 15.08% to 12.42% in this timeframe (P<0.001), but the percentage of drug spending on branded drugs significantly increased (61.98% to 64.89%, P<0.001). Between Q1 2014 and Q2 2015, first generics were launched for 167 National Drug Codes. Over the 4-quarter period post-launch of generics, branded product pricing significantly increased (4% to 12% vs. pre-generic), generic drug prices significantly decreased (76% to 63% of pre-generic brand price), and brand utilization adjusted for population growth decreased (59% to 35% of pre-generic levels).

CONCLUSIONS: Results from this analysis demonstrate that branded drug utilization in the Medicaid program decreases significantly after launch of generics, but this decrease is relatively gradual and brand utilization is 35% at 1 year post-generics. Once sufficient data become available, future analyses will evaluate market dynamics associated with biosimilar introduction in this population.

SPONSORSHIP: None.

U28 Payer Viewpoints on, and Use of, Real-World Evidence

Roberts T1, White K2, Thompson D1, Kelly K1. 36 Knollwood Rd, Morrisstown, NJ 07960, timothy.roberts@inventivhealth.com; (609) 902-3976
1inVentiv Health Consulting; 2inVentiv Health Research & Insights; 3inVentiv Health Clinical

BACKGROUND: As health care management evolves, managed care organizations are seeking more evidence to support product differentiation. Real world evidence (RWE) has become trending tool for establishing product differentiation. Manufacturers need to understand what evidence is relevant to payers as they consider designing their phase III and late stage clinical development programs.

OBJECTIVE: To understand role of RWE in payer organizations across relevant therapeutic areas, when stakeholders are using RWE in product management decisions, and which RWE data payers view as the most, and the least, valuable when making product management decisions.

METHODS: An online survey was conducted with a mix of 20 managed care pharmacy and medical decision makers from national and regional managed care organizations. The survey was designed to obtain quantitative and qualitative data regarding payer views of RWE for diabetes, rheumatoid arthritis (RA), oncology and treatment with PCSK-9 inhibitors.

RESULTS: Analysis of the survey data with 20 managed care decision makers representing 172 million covered lives reveal that when making management decisions payers are currently primarily influenced by RWE from claims data (55% of respondents) and database studies (35%). Respondents indicate that RWE is more influential for management decisions regarding diabetes (ave. rating 5.2 on a scale of 1-7) compared to RA (4.4), PCSK-9 inhibitors (4.35) or oncology (4.0) and indicate that RWE is best suited to influence access decisions in diabetes (5.85) compared to RA (5.15), PCSK-9 inhibitors (5.0), or oncology (4.4). Respondents views on RWE is dependent on therapeutic category with the top RWE mentioned for each category being meeting treatment goals (diabetes), overall treatment costs (RA), cost effectiveness (PCSK-9 inhibitors), and overall survival (oncology).

CONCLUSIONS: Payers are focused on managing high cost and chronic disease categories and welcome RWE that can provide perspective on how to best control cost while maintaining positive clinical outcomes. For chronic care products, MCOs are looking for RWE that can help understand how to best to manage the drug to maximize its clinical value while controlling costs. For oncology, payers are focused on RWE that helps the plan understand overall survival impact. When considering phase III and late stage evidence development, manufacturers must understand which type of RWE best resonates with future payer needs to justify product value.

SPONSORSHIP: This research was funded by inVentiv Health.

U29 ICER Reports: The Role of Cost/QALY Evaluations in the Evolving U.S. Reimbursement Landscape

Macaulay R, Cost P, Anastasakis E. PAREXEL International, Evergreen Bldg North, 160 Euston Rd, London, UK NW1 2DX; richard.macaulay@parexel.com; +44 (0)207-121-1740
PAREXEL Access

PROBLEM DESCRIPTION: The Institute for Clinical and Economic Review (ICER) conducts comparative value assessments of medical technologies in the U.S. ICER reports include economic evaluations in terms of cost-effectiveness and budget impact and have gained increasing attention for concluding many innovative therapies are priced too high. The reports are purely advisory and not formally used for
reimbursement or price setting. Nevertheless, recent Medicare part B rule change propositions included use of ICER reports by CMS to better align drug payments to outcomes.

**GOAL:** This research analyzes all ICER drug reports and discusses their potential future role in drug pricing.

**PROGRAM DESCRIPTION:** All publicly available ICER drug reports of pharmaceuticals to 30/11/2016 were screened and key data extracted.

**OBSERVATIONS:** 11 ICER reports of pharmaceuticals were identified, encompassing 37 drugs in 47 conditions/sub-groups. 45 panel votes of their clinical benefits deemed 69% clinically effective by majority vote. 44% were clearly clinically effective (≥80% positive votes), with 11% clearly not clinically effective. Five votes on whether therapies within a given class could be clinically differentiated were all overwhelmingly negative. Clinical ratings were provided for 22 drugs: 31% achieved ≥B rating; 42% C or D and 27% I or PR. A cost-utility assessment was undertaken and compared to WTP thresholds for 21 drugs. Even at the highest WTP threshold of 150,000/QALY, only 23% of therapies were deemed cost-effective, with a 14% mean discount deemed necessary. Of 22 votes on the “care value” of a product, based on their clinical and cost-effectiveness, 41% were rated as low value, 5% low/intermediate, 45% intermediate, 5% intermediate/high, and 5% high. Of 11 votes on the “health system value” of products, based upon their anticipated budget impact and affordability, 100% were deemed low value.

**FINDINGS/RECOMMENDATIONS:** ICER reports have generally concluded that assessed therapies offer important clinical benefits but generally do not justify their economic impact. These reports currently do not influence coverage decisions. However, there is anecdotal evidence of insurers using these in negotiations, and they are cited in recent CMS reform propositions, indicating ICER reports may play a key role in future reforms to U.S. drug reimbursement as payers struggle to manage increasing costs. Nevertheless, significant legislative changes would be required and the recent Trump presidential election victory casts uncertainty on future direction of policy.

**SPONSORSHIP:** None.

**U30 The Future of U.S. Pharmaceutical Pricing and Reimbursement: What Can We Learn from Europe?**

Macaulay R1, Enev T2, Schoenwaelder T1, Swann R2; PAREXEL International, Evergreen Bldg North, 160 Easton Rd, London, UK NWI 2DX; richard.macaulay@parexel.com; ++44(0)207-121-1740

1PAREXEL Access; 2PAREXEL International

**PROBLEM DESCRIPTION:** The U.S. is largely a free pricing market for pharmaceuticals but escalating costs have spurred discussions on reform. Recent developments include clinical value scorecards against which costs can be bench-marked, alongside the ICER organization reform. Recent developments include clinical value scorecards against which costs can be bench-marked, alongside the ICER organization reform. Nevertheless, there is anecdotal evidence of insurers using these in negotiations, and they are cited in recent CMS reform propositions, indicating ICER reports may play a key role in future reforms to U.S. drug reimbursement as payers struggle to manage increasing costs. Nevertheless, significant legislative changes would be required and the recent Trump presidential election victory casts uncertainty on future direction of policy.

**GOAL:** This research explores the impact of EU HTA bodies on market access and discusses their potential impact if used as hypothetical analogues for U.S. reform.

**PROGRAM DESCRIPTION:** Publicly available reports for three major EU HTA bodies: the G-BA/GKV, NICE and SMC were analyzed (01/01/2011-31/12/2015).

**OBSERVATIONS:** Of 112 G-BA benefit assessments, 45% offered no additional benefit with automatic reference pricing; 53% offered additional benefit, qualifying for price negotiations. 77% had a price negotiated; 14% had price fixed by court; 8% withdrew from market. Of 156 NICE STAs: 51% recommended, 17% restricted, 20% not recommended, and 12% non-submissions. Positive appraisals were an average of 10.5 months post-launch and 48% were associated with a PAS, 86% being simple discount schemes. Of 425 SMC appraisals: 35% accepted, 28% restricted, 17% not recommended and 19% non-submissions. Positive appraisals were an average of 12.7 months post-launch, 24% were associated with a PAS, 88% being simple discount schemes.

**FINDINGS/RECOMMENDATIONS:** HTA bodies issue guidance on whether health technologies should be adopted by their respective public health systems. NICE and SMC exert downwards price pressure but many therapies are denied reimbursement with recommendations following a substantial delay. In Germany, medicines can launch with free pricing post-EC approval, price controls only come into effect after the benefit assessment. Despite a strict definition of additional benefit that just 59% of medicines attained, only 8% were withdrawn from market. In the absence of price control mechanisms in the U.S. such approaches cannot influence price but ICER guidance and the scorecards do stimulate discussion on the value of medicines. Even if the legislative framework existed for price control in the U.S. (and the recent presidential election outcome casts uncertainty over future changes), it could threaten its position as the first launch country and largest revenue market, impacting the ROI and underlying capital supporting future innovations.

**SPONSORSHIP:** None.
controls, \(P<0.05\). Mean daily hospital charges were significantly higher for patients who did not experience any VTE (\$14,682 controls vs. \$11,014 cases, \(P<0.05\)). Mean length of stay was significantly higher for VTE cases than controls (7.2 days cases vs. 4.0 days controls, \(P<0.05\)).

**CONCLUSIONS:** Patients undergoing planned surgery with overnight hospital stay who experience a VTE during their surgery are associated with a longer length of stay and higher total hospital charge compared to those who do not experience a VTE, with lower incidence rates versus those found in literature for the general population. Further study should be encouraged to investigate potential genetic associations to VTE.

**SPONSORSHIP:** Millennium Health.

---

**U32 Risk of Emergency Department Use and Hospitalization in Patients Without Access to Medications in the United States**

Nguyen K, Watanabe J. 12601 Kathy Ln, Garden Grove, CA 92840; khn008@ucsd.edu; (702) 234-1713

University of California, San Diego

**BACKGROUND:** Medication nonadherence has been shown to increase medical health costs by \$290 billion a year. Up to half of the U.S. adult population report not taking medication as prescribed.

**OBJECTIVE:** Our goal was to quantify the failure to access necessary medications and the risk of emergency department (ED) visits and hospitalization in the U.S. population.

**METHODS:** We performed a cohort study using the latest 2013 and 2014 Medical Expenditure Panel Survey (MEPS)-Panel 18 longitudinal data. MEPS is an annual, nationally representative survey containing information on health care utilization in the U.S. Our primary analysis was a survey-weighted Poisson regression to quantify the association between inability to receive necessary medication in 2013 to outcomes of ED visits (1) and hospitalization (2) in 2013 and 2014. Secondary analyses included subpopulation analyses by insurance type (uninsured, private insurance, public insurance). Adjustment was performed for age category, race, income, insurance, marital status, health, education, and census division of the appropriate year. Additional adjustment for 2013 ED visits and 2013 hospitalization was included in our sensitivity analysis for 2014 outcomes. Analyses were conducted using Stata/SE 14 (College Station, TX) with alpha = 0.05.

**RESULTS:** Inability to get necessary prescribed medications was reported by 2% (6 million weighted lives) of respondents. Of those unable to get medication, 56.7%, reported that they could not afford the medication, 21% reported that the insurance did not approve/cover/ pay for their medication. Compared to those able to get medication, inability to get medication in 2013 was associated with increased risk of 2013 ED visit (IRR = 1.32; CI: 1.07-1.63) and 2014 ED visit (IRR = 1.36; CI: 1.15-1.62). There was no statistically significant association between medication access and 2013 or 2014 hospitalizations (IRR = 0.97; CI: 0.66-1.42, IRR = 1.20; CI: 0.88-1.64, respectively). Sensitivity analyses revealed that the risk of ED in 2014 was still prominent (IRR = 1.28, CI: 1.10-1.49). For the secondary outcomes, failure to access necessary medications was associated with increased risk of 2013 ED visits (IRR = 1.46; CI: 1.09-1.94), 2014 ED visits (IRR = 1.63; CI: 1.25-2.13), and 2014 hospitalization (IRR = 1.51; 1.02-2.24) in the public insurance subpopulation.

**CONCLUSIONS:** Inability to get necessary medication increased risk of ER visits in the same and following years. Our findings suggest that improving medication access to necessary medication may reduce catastrophic health utilization.

**SPONSORSHIP:** There was no sponsorship for this study.

---

**U33 The U.S. Payor Landscape: Results from a Survey of Medical and Pharmacy Directors on Formulary Management**

Brook R, Smeeding J. 18 Hirth Dr Newfoundland, NJ 07435; rbrook@jestarx.com; (973) 208-8621

The JeSTARx Group and National Payor Roundtable

**BACKGROUND:** Payors use a variety of formulary management tools to control health care costs and ensure appropriate product use.

**OBJECTIVE:** To understand the P&T decision-making process to determine the types of approaches used for formulary reviews/coverage and changes and opportunities.

**METHODS:** Online survey of U.S. Medical and Pharmacy Directors (MDs+PDs) from public/private health plans, insurers, and pharmacy-benefit managers. Topics included: advisor+plan information; member types; formulary decisions, coverage, restrictions and desired changes, Affordable-Care-Act (ACA) coverage; and their top concerns.

**RESULTS:** Invitations were sent to 210 subjects and received 61 responses (29%) with 59% of respondents MDs from National = 41.1%; local = 38.6%; and regional = 30.4% plans. Clinician-administered products (CAPS) always covered under the medical-benefit (MB = 64.3%), always under the pharmacy-benefit (PB = 5.4%), the remaining 32.7% based on thresholds or plan-design. Changes were: not anticipated (70.9%); being implemented (5.4%), expected by 12/16 (14.5%) or by 12/18 (3.6%). Mental health (MH) products were carved-out by 25.9%, conditions with multiple MH-therapies required: generics-first (50%), step-therapy (31.5%) or specialist care (18.5%). Respondents involved in decisions for: prescription-drugs (All = 66.5%, Some = 22.4%, None = 12.1%) and Medical-devices (All = 53.7%, Threshold-based = 5.6%, None = 40.7%). MH parity policies were in place for: All = 31.2%, None = 20.8%, Mandated-states = 20.8%, Commercial-plans = 14.6%, Select-plans = 10.4%, Medicaid-plans = 4.2%. ACA plans are being eliminated by 21.3% (6.4% - Currently, 8.3% By 12/17) and current ACA family-deductibles were: < $1,000 (7.9%); $1,000-$2,499 (26.3%); $2,500-$4,999 (28.9%); $5,000-$9,999 (15.8%); > $10,000 (5.3%). Most were happy with their PB design, the most requested changes were: Formulary changes (17.1%); Tiering (17.1%); Benefit-alignment (11.4%) and tied at 8.6% Biosimilars, Clinician-involvement, and Evidence-based Medicine (EBM). Cost-Effectiveness Research (CER) results will be used for: Care Value = 34.6%; Care appropriateness = 17.3%; Guideline optimization/improvement = 11.5%; Rx&D = 1.9%; MB/PB management = 23.1%; Other = 0%; Unsure/None of the above = 11.5%. The most desired P&T process change was no-change and better EBM data (both 31.6%). The most requested MB change was moving all drugs to the PB. Top concerns included Oncology; Diabetes and Cardiovascular diseases (present and future).

**CONCLUSIONS:** Formulary management will continue as the cornerstone of pharmacy benefit management. P&T committees, PBMs and health plans are increasingly raising co-pays and co-insurance to control the use of newers agents and specialty pharmaceuticals.

**SPONSORSHIP:** TPG-National Payor Roundtable.

---

**U34 Covered California’s Specialty Drug Cap Regulation: Impact on Cost and Utilization**

Ejuwa J, Yang W, Samani N. 50 Beale St, San Francisco, CA 94105; jacqueline.ejuwa@blueshieldca.com; (415) 229-5846

1Member, AMCP; 2Blue Shield of California

**SPONSORSHIP:** There was no sponsorship for this study.
BACKGROUND: On January 1, 2016, Covered California became the first health insurance marketplace in the nation to adopt regulations mandating a maximum-per-prescription consumer cost-share for specialty outpatient prescription drugs, henceforth referred to as the Specialty Drug Cap. Specialty drugs are novel or biologic drugs, whose utilization is growing by >15% annually despite only about 1% of the U.S. population’s use of specialty drugs. In 2015, these drugs accounted for $151b of the total $425b U.S. prescription drug spend. Specialty drugs offer tremendous promise, as many provide highly sophisticated treatment for conditions such as Hepatitis C, Rheumatoid Arthritis and Multiple Sclerosis, which have few other viable treatment options. However, significantly higher consumer cost-sharing threatens consumer access and availability of affordable care. At the time of the Specialty Drug Cap regulation finalization in May 2015, Covered California projected premium impact of would be less than 1% in 2016 and less than 3% through 2018. With barely 12 months since implementation of this regulation, little to no data is available on its impact.

OBJECTIVE: This study’s objective is to identify the short term impact of the Specialty Drug Cap on utilization and overall health care costs; and provide a perspective on how the impact can be leveraged to influence future Covered California and state wide legislative or regulatory changes related to outpatient prescription drugs.

METHODS: This retrospective observational study analyzed a Covered California Individual Family Plan sample population of 3,117 enrollees. Study participants were adults 18 to 64 years old with at least one paid claim for a newly started specialty drug; and active continuous enrollment in an eligible Covered California Individual family plan (IFP) for at least 6 months in 2014, through 2016. Data was collected from a health insurer’s pharmacy claims database for 12 months in 2015 and 9 months in 2016. An analysis of changes in specialty drug utilization and consumer cost sharing changes from 2015 to 2016 was performed.

RESULTS: Consumer cost-sharing decreased from 17.2% to 6.6%. Specialty drug utilization increased 23%, 8% higher than Express Scripts Drug Trend Report’s 17% forecast; and higher than United Health Group’s forecast of 14-20%.

CONCLUSIONS: The Specialty Drug Cap achieved its consumer out-of-pocket cost-sharing reduction goal. However with an increase in utilization that far exceeds industry predicted benchmarks, its impact to consumer premiums in 2018 and beyond requires further analysis.

SPONSORSHIP: Internally sponsored by Blue Shield of California.

GOAL: The objective of the analysis was to evaluate outcomes of a site of service optimization program for IVIG and infliximab implemented in Blue Shield of California commercial membership on 1/1/2016.

PROGRAM DESCRIPTION: Members receiving IVIG or infliximab at an outpatient facility and targeted for site of care medical necessity review during January-August 2016 were included in the analysis. Members were followed for 3 months to determine intervention outcome. Successful redirection was measured by agreement from providers to convert and subsequent member claims observed at preferred site of care for the medication. Savings was calculated by total number of successful cases multiplied by the average monthly cost difference between preferred and non-preferred sites of care and the average months of therapy per year.

OBSERVATIONS: 435 total cases were contacted for redirection during the study period. On average, 22 (24%) of the 92 IVIG and 113 (33%) of the 343 infliximab users were approved by the prescribers for redirection. 21% (19/92) and 25% (87/343) of cases were converted with subsequent claims confirmation for IVIG and infliximab respectively. Savings was estimated to be 4% of total IVIG and infliximab spend, 28% for IVIG and 72% for infliximab.

FINDINGS/RECOMMENDATIONS: Site of service redirection that integrates with medical necessity review process is an effective, cost saving measure for select specialty drugs that can be safely given at the physician’s office or at home. Additional member directed strategies such as benefit design incentives should be explored to enhance overall program effectiveness.

SPONSORSHIP: Internally sponsored by Blue Shield of California.
CONCLUSIONS: These results reinforce the need to educate patients about the importance of disposing unused opioid medications, and for providing easy access to disposal through kiosks and drug take back programs. Health care providers may help by taking the time to discuss disposal with all patients prescribed opioids, including the significant risks associated with inappropriate self-medication and sharing medications with others, as well as the diversion risks of retaining unused medicine.

SPONSORSHIP: This research was supported by funding from Purdue Pharma.

U37 A Four-State Assessment of Patient-Centered Medical Home Elements at Physician Practices

Khan S, Spotts H, Spooner J. WNE College of Pharmacy, 1215 Wilbraham Rd, Springfield, MA 01119; shammina.khan@wne.edu; (413) 796-2440
Western New England University

BACKGROUND: Patient-Centered Medical Home (PCMH) has been hailed by some as the solution to the many challenges faced by the U.S. health care system.

OBJECTIVE: To assess the presence of key PCMH features within physician practices, and to understand physician beliefs regarding physician-patient orientation.

METHODS: A mixed method (paper, internet, and telephone) survey design was utilized to survey practicing physicians in 4 states (NY, MS, TX, CO). The 48 question survey instrument was developed following a thorough literature review and pilot testing. A survey was sent to practicing physicians via mail, non-responders received 3 additional surveys and 2 post card reminders. Following this, 2 attempts were made to contact non-responding physicians via phone.

RESULTS: A total of 248 surveys were completed, providing an adjusted response rate of 24%. Respondents represented all geographic locations (32% rural, 31% suburban, 36% urban) and indicated they devote 83% of their work time to patient care and 13% to administrative responsibilities. Many elements of PCMH were present in this sample; 62% of practices employed ancillary care providers (most frequently nurses, nurse practitioners, and physician assistants); 56% offered programs or services to increase patient self-management skills beyond traditional physician counseling (most frequently for diabetes and obesity management); and 92% provide a variety of patient care scheduling options. Electronic medical records and nationally recognized evidence-based practice guidelines are utilized by 76% and 79% of practices, respectively. Physician performance is measured at 57% of practices via a variety of methods (outcomes data, results of quality improvement projects, or adherence to evidence based guidelines), though performance feedback was reported to physicians at a lower rate (35%). Patient satisfaction surveys are utilized by 46% of practices. Measurements of physician-patient orientation found that 86% of physicians viewed patients as an equal partner regarding health and obesity management; and 92% provide a variety of patient care scheduling options. Electronic medical records and nationally recognized evidence-based practice guidelines are utilized by 76% and 79% of practices, respectively. Physician performance is measured at 57% of practices via a variety of methods (outcomes data, results of quality improvement projects, or adherence to evidence based guidelines), though performance feedback was reported to physicians at a lower rate (35%). Patient satisfaction surveys are utilized by 46% of practices. Measurements of physician-patient orientation found that 86% of physicians viewed patients as an equal partner regarding health and obesity management; and 92% provide a variety of patient care scheduling options.

CONCLUSIONS: Elements of PCMH are present in the majority of surveyed physician practices. These findings, in addition to the results demonstrating alignment between physician and patient interests, indicate an environment fertile for continued expansion of PCMH services in the United States.

SPONSORSHIP: None.

U38 FDAMA 114 for the Exchange of Health Care Economic Information: Payer Experiences, Attitudes, and Perceptions of Current Legislation and Future Directions

Popelar B1, Sarnes M2, Duhig A3, Kaufman S1, Sahu S2, Carden M2. 1450 Brochton Ave, #9, Los Angeles, CA 90025; breanna.popelar@xcenda.com; (949) 275-3818
1Xcenda; 2Academy of Managed Care Pharmacy

BACKGROUND: Section 114 of the Food and Drug Administration (FDA) Modernization Act of 1997 (FDAMA 114) was intended to allow the sharing of health care economic information (HCEI) with formulary decision makers. However, its use in practice has been limited and the evolving health care environment has spawned renewed interest for legislative and regulatory updates.

OBJECTIVE: To understand payer experiences, attitudes, and perceptions of FDMA 114 and help shape future regulatory guidance for the proactive dissemination of HCEI.

METHODS: Payer stakeholders completed a survey assessing the importance of HCEI during formulary decision-making, delivery and utility of HCEI from manufacturers as well as limitations of, and proposed changes to current legislation.

RESULTS: Respondents (N=58) were largely from managed care organizations (76%) and most (66%) served as voting Pharmacy and Therapeutics Committee members. The majority ranked HCEI as somewhat to extremely (78%) important for formulary or medical policy decisions and 78% thought that the importance of HCEI would increase in 3-5 years. Respondents indicated that HCEI has impacted decisions regarding product formulary inclusion (47%), utilization management criteria (45%), and differential tiering (36%). However, 76% of respondents included HCEI for ≤50% of products discussed over the past 6 months. Over 60% noted a gap between needed and available HCEI and shared that decision-making would be very much or extremely improved (54%) if the gap were addressed. Resource use data from head-to-head trials (69%) and retrospective studies comparing effectiveness and costs (64%) were rated as very or extremely useful for decision-making. HCEI from manufacturers met payer needs only somewhat (52%) or not very much (38%). Many felt that proactive exchanges of HCEI via a structured AMCP dossier-like format would be very or extremely helpful (40%) with medical outcomes data from head-to-head trials (69%) and retrospective studies. Only 27% expressed having a reliable source (66%) to deliver HCEI. With regard to the changes proposed in a recent AMCP Partnership Forum to add clarity to FDAMA 114, the majority (52 to 66%) very much or completely agreed that the suggested changes would be helpful with medical outcomes liaisons considered very or extremely reliable (66%) to deliver HCEI. With regard to the changes proposed in a recent AMCP Partnership Forum to add clarity to FDAMA 114, the majority (52 to 66%) very much or completely agreed that the suggested changes would be helpful with medical outcomes liaisons considered very or extremely reliable (66%) to deliver HCEI.

CONCLUSIONS: Per payer stakeholders, despite the importance of HCEI in decision-making, availability and communication of HCEI is varied and limited. Recent updates to the 21st Century Cures Act and potential future FDA guidance may improve the effective exchange of and payers’ ability to consider HCEI in formulary decisions.

SPONSORSHIP: None.

U39 Real-World Evidence on Everolimus Compliance and Persistence Among Tuberous Sclerosis Complex Patients with Renal Angiomyolipoma or Subependymal Giant Cell Astrocytoma

Song X1, Saad Q2, Tran O1, Bissler J1, Prestifilippo J2, Krueger D1. 130 Cambridge Park Dr, Cambridge, NJ 02140; xe.song@truevenhealth.com; (508) 842-5312
1Trueven Health Analytics; 2Novartis Pharmaceuticals; 3LeBonheur Children’s Hospital; 4St. Jude Children’s Research; 5Cincinnati Children’s Hospital Medical Center

BACKGROUND: Per payer stakeholders, despite the importance of HCEI in decision-making, availability and communication of HCEI is varied and limited. Recent updates to the 21st Century Cures Act and potential future FDA guidance may improve the effective exchange of and payers’ ability to consider HCEI in formulary decisions.

CONCLUSIONS: Per payer stakeholders, despite the importance of HCEI in decision-making, availability and communication of HCEI is varied and limited. Recent updates to the 21st Century Cures Act and potential future FDA guidance may improve the effective exchange of and payers’ ability to consider HCEI in formulary decisions.

SPONSORSHIP: None.
BACKGROUND: Tuberculous sclerosis complex (TSC) is a rare multi-organ disease, often with neurologic and renal complications. Everolimus is the only FDA approved drug for treatment of adults with renal angiomyolipoma and TSC, not requiring immediate surgery, and pediatric and adult patients with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. There are potential differences on everolimus use between patients with commercial and Medicaid insurance. However, information on real-world use of everolimus is limited.

OBJECTIVE: To compare compliance and persistence of everolimus among TSC patients with renal angiomyolipoma or SEGA between those with commercial insurance and Medicaid using most recent claims data from U.S.

METHODS: This retrospective study used MarketScan databases to select patients with ≥ 1 claim of TSC diagnosis with renal angiomyolipoma or SEGA in commercial (1/1/09-8/31/16) and Medicaid (1/1/09-6/30/15) databases. Patients were followed from index date (earliest date of TSC, renal angiomyolipoma, or SEGA diagnosis) to inpatient death or end of data. Non-persistence was defined as a ≥ 60-day gap without everolimus during the entire follow up period. Medication possession ratio (MPR) was calculated for the subset of patients with at least one year of follow up from the first everolimus use.

RESULTS: A total of 1,497 TSC patients met the study criteria (896 renal angiomyolipoma only, 411 SEGA only, and 190 both). Compared to Medicaid patients (N = 513), commercial patients (N = 984) had the same ages (22 years), a lower proportion of males (42.9% vs. 50.0%, P = 0.006), and a shorter length of follow up period (38 vs. 48 months, P < 0.001). Medicaid and commercial patients had similar rates of being treated with everolimus (14.4% vs. 13.6%, P = 0.668), but it took Medicaid patients a longer time to start everolimus (871 vs. 704 days, P < 0.001). Although the non-persistence rate was not significantly different between commercial and Medicaid patients (42.5% vs. 35.1%, P = 0.561), the number of days from everolimus initiation to non-persistence was significantly lower for commercial patients (945 vs. 1132, P < 0.001). During the first year post everolimus initiation, commercial patients had a significantly higher MPR (0.81 vs. 0.74, P < 0.001) and higher percentage of patients with MPR ≥ 0.80 (67.8% vs. 58.1%, P < 0.001).

CONCLUSIONS: This claims analysis demonstrated that among TSC patients with renal angiomyolipoma or SEGA, everolimus MPR was between 0.74-0.81. Medicaid patients had lower MPR than commercial patients but better persistence rate.

SPONSORSHIP: Novartis Pharmaceuticals.

PROGRAM DESCRIPTION: The health system partnered with pharmacy services to ensure successful implementation of new requirements across the system’s roughly 75 primary care and specialty clinics, 6 hospitals, 30 retail pharmacies and specialty pharmacy. As part of this process, a central team was created, consisting of 10 employees with varying pharmacy, clinic and referral management background responsible for processing all PAs for the health system. Centralization and transition to the ePA process began with 6 clinics in December 2015, then system-wide in three phases starting January 2016. The ePA process largely shifted all PA work from the pharmacy and providers to the central PA team. To evaluate the impact of the program, performance metrics, such as enabled prescribers, active prescribers, and PA processing time, were summarized almost a year after ePA implementation.

OBSERVATIONS: The health system processes about 2,700 prior authorization requests per month. Prior to ePA initiation, processing times took an average of 72 hours. As of November 2016, 63% of providers had ePA enabled systems, however, only 25% are active users. As a result, only about 30% of PA requests are completed via the ePA process but the processing time for the ePA prescriptions was an average of 2 hours, a 97% reduction.

FINDINGS/RECOMMENDATIONS: Implementation of an ePA system can decrease PA processing time from days to hours. This process provided several benefits to our health system including (1) removing the responsibility of individual clinics to complete prior authorization requests, (2) removing the prior authorization work from the pharmacy workflow, and (3) increasing the proportion of patients that are able to obtain PA-required medications the same day the prescription was written. Regular provider education, increased pharmacy benefit manager connectivity, and EMR system upgrades will help expand use of ePA across the health system.

SPONSORSHIP: None.

U41 Retrospective Analysis of Pregabalin and Gabapentin Concomitant Utilization in a Medicaid Population

Chang H1, McClenton K2, Armstrong C2. 5100 Commerce Crossings Dr, Louisville, KY 40229; kevin.chang2@passporthealthplan.com; (502) 212-6781
1Sullivan University/Passport Health Plan; 2Evolent Health

BACKGROUND: Pregabalin (Lyrica) is indicated for the management of neuropathic pain, fibromyalgia, and partial onset seizure. Gabapentin, a generic drug that has a similar mechanism of action and biological effects, is commonly used as an alternative to Lyrica. However, Lyrica and gabapentin should not be taken concurrently due to therapeutic duplication and aggravating adverse effects. On September 1, 2016, Passport Health Plan, a Kentucky Managed Medicaid Plan, removed the grandfathering policy for Lyrica which allowed members to receive it without prior authorization (PA) if the member has a historical paid claim within the past 180 days. Impacted members required a PA to continue Lyrica. The issue of concurrent Lyrica and gabapentin use was identified after the policy changes.

OBJECTIVE: The objectives of this study are to (1) analyze the concomitant utilization data of Lyrica and gabapentin, and (2) identify the clinical and financial impact of grandfathering policy changes.

METHODS: The claims data between June 1, 2016 and November 30, 2016 were retrieved from Passport Health Plan claims database. Members who received at least one fill of either gabapentin or Lyrica were included in the analysis. Members with at least two overlapping fills (refill within 30 days) between Lyrica and gabapentin were identified as “concomitant users”. Utilization data for concomitant users, including average daily dose, time to prescriber information, and drug...

U40 Implementation of Electronic Prior Authorization Process in an Integrated Health System

Budlong H, Dorr A, Peterson J. 711 Kasota Ave SE, Minneapolis, MN 55444; hbudlon1@fairview.org; (612) 617-3501 Fairview Pharmacy Services

PROBLEM DESCRIPTION: The prior authorization (PA) process is intended to optimize patient outcomes by ensuring patients are receiving the most appropriate medications while reducing waste, error and unnecessary prescription drug use and costs. However, the time required to complete the prior authorization process is an area of concern for patients, prescribers, and pharmacists. As of January 1, 2016, Minnesota requires all drug prior authorization requests be submitted electronically.

GOAL: This project describes the changes in PA processing as a result of legislative requirements for electronic PA (ePA) submissions.
expenses, were calculated and compared 3 months before and after the policy changes. The impact from the policy change was analyzed in the overall population as well as concomitant users.

RESULTS: There were 194 concomitant users identified before policy changes, which decreased by 41% to 114 after the policy changes. Prescription fills of concomitant users for Lyrica and gabapentin also dropped from 479 to 253 and 555 to 333, respectively. However, the average daily dose of Lyrica significantly increased from 296 mg to 329 mg ($P = 0.0145$) while gabapentin dose remained the same, from 2,126 mg to 2,156 mg ($P = 0.6827$). Within the concomitant users, 42% received both Lyrica and gabapentin prescriptions from the same prescriber and 49% from different prescribers. There is an average cost savings of $1,777 for every concomitant user that discontinued Lyrica and gabapentin. A 49% decrease in pharmacy costs for Lyrica among concomitant users, and 38% decrease overall, was observed.

CONCLUSIONS: Removal of grandfathering policy significantly decreased the concurrent use rate of Lyrica and gabapentin. The changes also reduced pharmacy cost and promoted medication safety.

SPONSORSHIP: None.

U42 Recent Trends in Payer Perception and Use of Value Frameworks in the United States

Campbell C, Migliaccio-Walle K, O’Day K, Byars C, Jackson J. 4114 Woodlands Pkwy, Ste 500, Palm Harbor, FL 34685; chelsey.campbell@xcenda.com; (727) 771-8147

Xcenda

BACKGROUND: The increasingly high cost of specialty and oncology drugs has resulted in greater focus on value. In the U.S., this has given rise to private sector organizations developing value assessment frameworks (VAF) to guide decision-making. How payers view and utilize VAFs remains unclear.

OBJECTIVE: To assess payer familiarity with and perceptions of VAFs.

METHODS: A blinded electronic survey was conducted with current U.S. pharmacy and medical directors across national and regional health plans in July 2016. Respondents were asked about knowledge, use, and perceptions of the American Society of Clinical Oncology (ASCO) Net Health Benefit, Institute for Clinical and Economic Review (ICER), Memorial Sloan Kettering Cancer Center (MSKCC) Drug Abacus, and National Comprehensive Cancer Network (NCCN) Evidence Blocks VAFs.

RESULTS: Over half (63%) of the 56 respondents were pharmacy directors, 34% medical directors, and 4% (n = 2) noted another role. Respondents had the highest level of familiarity with NCCN Evidence Blocks (43% very familiar) and lowest with MSKCC Drug Abacus (25% very familiar). Respondents had the highest level of familiarity with NCCN Evidence Blocks (43% very familiar) and lowest with MSKCC Drug Abacus (25% very familiar). Very familiar) and lowest with MSKCC Drug Abacus (25% very familiar). Familiarity with evidence blocks increased from 55% in 2015 (36% NCCN, 13% ASCO, 20% ICER, 12% MSKCC) to 63% in 2017 (45% NCCN, 23% ASCO, 20% ICER, 12% MSKCC). The average familiarity was 52% for evidence blocks (50% NCCN, 19% ASCO, 21% ICER, 10% MSKCC). Overall, 25% of respondents had an average familiarity of 50% for evidence blocks (50% NCCN, 19% ASCO, 21% ICER, 10% MSKCC). Among those who have not used VAFs, the most common reasons included insufficient validation, too difficult to use, or awaiting for a revised/better version. With regard to how useful VAFs are perceived to be, most (45%) rated them as “somewhat useful” (4 on 7-point Likert scale). Viewing each VAF separately, 38% of payers reported that they are more likely to use ASCO in the next 6-12 months, and 62% anticipated no change (ICER, 40%; ASCO, 20%; NCCN, 50%; MSKCC, 48%). A vast majority (77%) indicated a desire for more emphasis on the payer perspective in future VAFs.

CONCLUSIONS: Compared with similar research conducted in 2015, payers are increasingly familiar with VAFs and are beginning to utilize them in decision-making, yet still in a limited capacity. VAFs are primarily being used (most commonly NCCN, ASCO, and ICER) as supporting information in a clinical and/or economic capacity or contextually to support proprietary assessment processes. As VAFs evolve, continued research is needed to gauge changing attitudes and payer application of VAFs in decision-making.

SPONSORSHIP: Research conducted by Xcenda without external funding.
U44 Patient Perceptions of a Posthospitalization Transitions-of-Care Program

Aguilar A1, Campbell P1, Bingham J2, Johnson K2, Leal S3, 1237 W. Sandtrap Way, Tucson, AZ 85737, aguilara@pharmacy.arizona.edu, (520) 971-6635
1University of Arizona College of Pharmacy; 2University of Arizona College of Pharmacy Medication Management Center; 3SinfoniaRx

BACKGROUND: Most hospital-related medication errors occur at these transition-of-care points: admission, transfer, discharge and in outpatient settings. Medication reconciliation is a Joint Commission National Patient Safety Goal and a vital component of optimal care transitions; it is also a key element of medication therapy management (MTM), a comprehensive service available to eligible Medicare Part D beneficiaries. For this project, a university-based MTM provider developed the Discharge Companion Program (DCP) to help patients transition from hospital to home, with the overall goal of reducing medication errors and readmissions. A local hospital contracted with the MTM provider to implement and evaluate the DCP, including assessing patients’ perceptions about the program.

OBJECTIVE: To evaluate patient experiences with the DCP; and analyze the optimal timeframe to administer a feedback survey to maximize patient response rate, following program completion.

METHODS: A 17-item survey developed for the DCP, using items from two published questionnaires, measured: medication knowledge, self-management, patient concerns, and overall patient experience. A 4-point scale measured item response options (‘strongly agree’ to ‘strongly disagree’). Telephonic surveys were administered to patients completing the DCP. The timeframe for survey completion after last follow-up phone call was categorized as: < 50 days; 50-99 days; ≥ 100 days; a chi-square test was used to determine the optimal timeframe for survey administration after program completion. Survey data were collected from January to March 2016; data were input into Qualtrics for survey administration.

RESULTS: Of the 295 eligible patients, 153 were reached and 72 consented to participate (24% response rate). Most patients (n = 68; 94%) ‘agreed’ or ‘strongly agreed’ that they were satisfied with the pharmacists’ overall care and valued the information provided. Nearly all (n = 66; 92%) agreed that the service would improve their overall health. No significant differences were observed in the number of patients reached in the follow-up timeframe for survey administration (P = 0.14) or those consenting to participate (P = 0.44).

CONCLUSIONS: Overall, patients were satisfied with the DCP. No difference in patient response rate relative to time since last follow up with pharmacist was observed. These results are promising, yet more investigation is needed to define the optimal timeframe for patient feedback survey administration.

SPONSORSHIP: University of Arizona College of Pharmacy and SinfoniaRx.

U45 Impact of Cash Prescriptions and Use of Affiliate Provider Identifiers on Measures of Opioid Use from Multiple Providers

Ramachandran S1, Inguva S1, Banahan B2, Kirby T3, Noble S1, University of Mississippi, Oxford, MI 38677, sramachan@go.olemiss.edu; (662) 380-3006
1Pharmacy Administration Dept, University of Mississippi; 2Center for Pharmaceutical Marketing and Management, University of Mississippi; 3Mississippi Division of Medicaid

BACKGROUND: The Pharmacy Quality Alliance (PQA) measure for use of opioids from multiple providers can be used as a quality measure for comparing data from different programs. Also it can be a quality improvement tool to identify substance use disorder (SUD) high risk beneficiaries for potential intervention efforts. For both purposes, underestimate can occur when only administrative claims are available and beneficiaries pay cash for opioid prescriptions. Overestimates can also occur due to counting providers in the same practice site as multiple providers when individual provider IDs are used.

OBJECTIVE: The objectives of this study were to estimate the impact of including cash paid prescriptions and using affiliate provider identifiers (IDs) to identify beneficiaries using multiple providers for opioids.

METHODS: A retrospective analysis was conducted using Mississippi Medicaid pharmacy administrative claims, linked with Mississippi Prescription Monitoring Program (MPMP) data for the period July 1, 2015-June 30, 2016. MPMP data were obtained through a memorandum of agreement between Mississippi Medicaid and the Board of Pharmacy. Affiliate provider IDs were created linking prescribers in the same physical practice setting to a single ID and pharmacies in networked chains in the same zip code to a single ID. The PQA measure for use of opioids from multiple providers was calculated according to the measure specifications. Beneficiaries were identified as “provider shopping” (using + prescribers and pharmacies), both with and without the inclusion of cash prescriptions and affiliate provider IDs.

RESULTS: A total of 26,796 beneficiaries were identified as having 2 or more opioid prescriptions for greater than 15 days supply. Using only administrative claims, 1,390 (5.2%) beneficiaries were classified as provider shopping. Including cash payments added 148 (0.6%, P < 0.001) more beneficiaries. When using only administrative claims, affiliate provider IDs reduced the number of beneficiaries identified as provider shopping by 269 (1.0%, P < 0.001).

CONCLUSIONS: Inclusion of cash paid prescriptions and use of affiliate provider IDs makes a statistically significant, although very small difference when identifying opioid provider shopping. Although the impact when used as a quality measure will be minimal, the additional beneficiaries identified using cash payments should enhance quality improvement efforts since these beneficiaries are probably at higher risk than others. The use of affiliate provider IDs also will reduce the number of false positives identified for possible intervention.

SPONSORSHIP: Mississippi Division of Medicaid.

U46 Preparing Pharmacy Students to Meet Challenges in Managed Care Pharmacy: Evidence of Student Learning About Managed Care Pharmacy from a U.S. Pharmacy School

Desai R, Shanbhag P, Nayak R. 182-30, Tudor Rd, Jamaica, New York, NY 11432; rajdesai223@gmail.com; (646) 436-3243
St. John’s University

BACKGROUND: Integration of managed care courses in pharmacy school curricula is mostly inadequate, despite a pivotal role the pharmacist plays in the delivery of managed care product and services to the general public. There is dearth of information regarding student perceptions of managed care pharmacy, evidence of successful learning, and student desire to pursue a career in this area.

OBJECTIVE: (1) To assess pharmacy students’ knowledge of managed care pharmacy (MCP) concepts and understanding of the role of the managed care pharmacist. (2) To measure student attitudes toward and perceptions regarding a career in MCP.

METHODS: A pre-post survey research design utilizing a self-administered paper-pencil questionnaire technique was adopted in a pharmacy classroom setting at a private New York university. Students in multiple sections entering the first professional year of pharmacy program (between 2006-2015), and enrolled in a semester-long, two-credit introductory elective MCP course, completed a 20-item questionnaire pre- and post-course instruction (Pretest, P1, n = 280; Post-test, P2, n = 234). A knowledge component score (KCS) was developed specifically to assess student improvement in knowledge. Survey items also assessed students’ understanding and knowledge of MC concepts, both pre- and post-instruction, and perceptions towards the course content and prospects for a career in MCP post-graduation.
RESULTS: About 30% (P1) of the students surveyed stated they had heard of or had some knowledge of MCP before course enrollment. The proportion of students who reported an improved understanding of MCP rose from 22% to 68% post-test. Overall, 208 students (88.9%, P2 vs. 72.1%, P1) had favorable impressions of the course, and a clear majority (91.4% vs. 49%) reported having developed a better understanding of the pharmacist's role in MCP. Nearly half of the students expressed favorable opinions regarding MCP, more than three-fourths of the sample (76%) also identified correctly five or more (out of 8) role functions of the pharmacist in managed care. A t-test performed to test the difference in KCS revealed a statistically significant difference in learning about MCP between pre- & post groups (t=16.6, P=0.001). Percentage of students wanting to consider a career in MCP rose from 6.6% to 67.9%.

CONCLUSIONS: Early and repeated exposure to MC training would lead to a better understanding of MCP and improved learning outcomes. Pharmacy school curricula across the country must adopt courses geared towards managed care to increase awareness and opportunities for students early in the program.

SPONSORSHIP: None.

Z00-299 Factors Influencing Health Status and Contact with Health Services (e.g., Adherence, Oral Contraceptives)

Z2 Effect of AbbVie’s Patient Support Program on Patient Adherence and Work Productivity in Patients Initiating Adalimumab Therapy

Mittal M1, Sherman B2, Liu H1, Brouillette M3, Juneau P4, Ganguli A5, Fendrich M2, 1 N Waukegan Rd, Dept. GMH1, AP31-1 NE, North Chicago, IL 60064; 2AbbVie; 3Employers Health Coalition, Case Western Reserve University School of Medicine; 1RAND; 3Truven Health Analytics; 5University of Michigan

BACKGROUND: AbbVie’s Patient Support Program (PSP) assists adalimumab (ADA)-treated patients with medication costs, nurse support, injection training, and medication reminders. Improved adherence to ADA and reduced health care costs have been demonstrated for patients enrolled in PSP compared with those who were not. The effect of PSP on absenteeism has not been studied.

OBJECTIVE: To compare various outcomes in ADA-treated patients based on PSP-enrollment.

METHODS: A longitudinal study was conducted using patient-level data from AbbVie’s PSP combined with health care claims and workplace absence data from the 2008-2014 MarketScan databases. Patients (≥18 years) with ≥1 claim for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were included. Medical and pharmacy coverage ≥6 months before and ≥12 months after index date (date of first ADA claim) was required. Multivariate regression analysis was used to compare outcomes over 12 months for patients enrolled in PSP within 90 days of initiating ADA and non-PSP (patients not enrolled in PSP but who initiated ADA) groups. Adherence was defined as the proportion of days covered during follow-up. Persistence was assessed using Kaplan-Meier analysis of discontinuation rates. Absenteeism was based on work days lost for employed patients with available absence data.

RESULTS: For PSP (n = 19,171) vs. non-PSP groups (n = 41,151), respectively, significant differences (all P < 0.0001) were seen at baseline for mean age (47 vs. 46 years), women (64% vs. 58%) and patients with prior anti-tumor necrosis factor therapy (71% vs. 66%). After adjusting for baseline characteristics, adherence was 64.9% vs. 39.6% (Δ = 25.3%, 95% CI: 22.3% to 28.3%) and risk of discontinuing ADA was 29% lower (hazard ratio = 0.71, 95% CI: 0.69 to 0.73) in the PSP vs. non-PSP groups, respectively. For patients with absence data (PSP, n = 236; non-PSP, n = 418), a significantly smaller proportion of patients in the PSP group incurred any absence days than patients in the non-PSP group (74% vs. 85%; odds ratio = 0.56, 95% CI: 0.36 to 0.85). On average, the PSP group gained ~5 work days per patient per year (25.4 vs. 29.9 work days lost, Δ = 4.5 days, 95% CI: 3.0 to 5.8 days).

CONCLUSIONS: Enrollment in AbbVie’s PSP was associated with significantly higher adherence and persistence to ADA therapy and reduction in absenteeism.

SPONSORSHIP: Support for this study was provided by AbbVie.

Z6 Undertreatment of Chronic Interstitial Cystitis in the United States: A Population-Based Study

Lai L1, Kleier J1, Shah A1, Ting A2. 3200 S. University Dr, Davie, FL 33328; leanne@nova.edu; (954) 262-1320
1Nova Southeastern University; 2University of Florida

BACKGROUND: Interstitial cystitis (IC) affects 3 to 8 million women in U.S., but the management of IC is both frustrating and difficult. The American Urological Association (AUA) recently provided an updated guidelines to assist clinicians who evaluate and treat IC. However, real-world clinical practice remains unknown.

OBJECTIVE: The objective of the study was to investigate the prevalence and socio-demographic characteristics associated with under-treatment of chronic IC in the U.S. outpatient settings.

METHODS: A cross-sectional study was conducted by analyzing a national database from 2012 National Ambulatory Medical Care Survey. All patient visits with a diagnosis of chronic IC were included. A series of weighted descriptive analyses were used to estimate the prevalence of IC and its pharmacological treatment recommended from AUA guidelines. A multivariate logistic regression was further conducted to predict the maximum likelihood of IC pharmacotherapy associated with patient’s socio-demographic characteristics. All data management and analyses were performed using Statistical Analysis System (SAS) version 9.4. The survey sampling and analysis procedure was accounted for in all analyses to ensure proper representation of the study population and to render nationally representative estimates. Two-tailed statistic with P-value less than 0.05 was considered statistically significant.

RESULTS: An estimated total of 281,291 outpatient visits related to interstitial cystitis occurred in the U.S. in 2012. Among them, only 76% of visits received at least one prescription for IC treatment. Anxiety agents were the most commonly prescribed class of medication (23.68%) following by narcotic analgesics and anesthetics (22.3%), urinary antispasmodic and genitourinary tract agents (15.79%), vitamins and minerals (11.84%), and antidepressants (9.21%), etc. The results from multivariate logistic regression identified that patient’s age (OR = 1.81, 95% CI: 1.65-1.81), insurance type (OR > 1, 95% CI: >90->99), and physician specialty (OR = 26.5, 95% CI: 1.1-628) contributed significant impacts on the IC treatment.

CONCLUSIONS: The study revealed that under-treatment of IC is a significant problem in the U.S. Future studies are recommended to explore intervention and educational strategies to ensure physicians are well-informed of evidence-based practice guidelines and provide timely and appropriate treatment for people with IC.

SPONSORSHIP: None.
Examining Pharmacy Quality Among Medicare Patients with Hypertension: Implications of Pharmacy Impact on Star Ratings

Maharinkin A1, Iyengar R1, Decembrele S1, Hadavanhallit Mariyappa D1, Jhawar S2, Chang C2, Rui S2. 4600 N Hanley Rd, St. Louis, MO 63134; amaharkin@express-scripts.com; (314) 522-5869

BACKGROUND: Nearly three out of five Medicare beneficiaries have hypertension. Pharmacies employing pharmacists that frequently interact with patients present enormous opportunities to positively impact patients' medication adherence. However, financial arrangements have not been adequately leveraged to incentivize pharmacies to provide high quality care and improve patient safety and adherence.

OBJECTIVE: To define, quantify and evaluate pharmacy quality improvement vis-à-vis adherence to antihypertensives among Medicare patients, when pharmacies participate in financial risk and reward agreements.

METHODS: A retrospective study of community-based retail pharmacies participating in a pay-for-performance program from January 1, 2015 to December 31, 2015, and dispensing antihypertensives to Medicare patients aged 65 and above. Data included pharmacy (using National Association of Board of Pharmacy identifier) and patient level information from a large, nationally representative pharmacy benefit manager. Eligible patients and the days' supply of their prescriptions were used as proxy to assess pharmacy quality. The control group consisted of pharmacies matched on patient demographics and not contracted for the program. Medication adherence was measured for each pharmacy as a percent of members with proportion of days covered (PDC). Average percentage of adherent (PDC ≥ 80.0%) patients for case and control pharmacies was used to assess differences in pharmacy quality. Descriptive analyses (one tailed t-test with \( P \leq 0.01 \)) was used to examine improvement in quality of case over control group.

RESULTS: The final study sample consisted of 366 pharmacies in each group with a similar demographic mix of patients. Case pharmacies had a significantly higher proportion of Medicare patients adherent on antihypertensives compared to control pharmacies (72.5% vs. 66.4%, \( P < 0.01 \)). Case pharmacies on average had more than six percentage point higher proportion of adherent patients that translated to a higher star rating, per the Centers of Medicare and Medicaid Services (CMS) cut-offs.

CONCLUSIONS: Findings indicate an improvement as a result of financial risk and reward contract with pharmacies. As higher star ratings are tied to higher financial remuneration from CMS, improved patient adherence translates to better clinical outcomes for patients and financial outcomes for plans. Continued collaboration between CMS, payers, benefit managers and pharmacies can result in value-based networks that lead to better patient outcomes.

SPONSORSHIP: Financial support is provided by Florida Blue and Prime Therapeutics.

Preemptive Pharmacogenetic Testing: Exploring the Knowledge and Perspectives of U.S. Payers

Keeling N1, Rosenthal M1, West-Strum D2, Patel A2, Haidar C3, Hoffman J1. 2703 Southwind Cove, Oxford, MS 38655; njkeeling@gmail.com; (601) 239-6120

1University of Mississippi; 2Medical Marketing Economics; 3St. Jude Children’s Research Hospital

BACKGROUND: Preemptive pharmacogenetic testing aims to improve the safety and efficacy of medications by using genetic information to inform drug prescribing. Further investigation is needed to describe the position of the payer stakeholder on preemptive pharmacogenetics, as their coverage and reimbursement decisions will impact the adoption of this technology.

OBJECTIVE: The purpose of this study was to investigate payer’s knowledge, awareness, and perspectives on preemptive pharmacogenetic testing.

METHODS: We conducted a qualitative study using semi-structured, in-depth interviews. Participants were screened for eligibility using an online survey. A blended inductive and directed approach was used to analyze the transcripts. Two authors conducted an iterative reading process, the constant comparative methodology; to code and categorize meaning units, which were aggregated to develop major themes and subthemes.
RESULTS: A total of 14 payers were interviewed, and they represented plans that covered 122 million lives in the United States. Three major themes were identified. First, payers understood the potential benefits for patients and the health system from preemptive pharmacogenetic testing, but further demonstrations of clinical utility were needed. The Clinical Pharmacogenetics Implementation Consortium (CPIC) prescribing guidelines were unfamiliar, yet welcomed, support tool. Second, the idea of widespread testing without the ability to definitively project downstream economic benefits was a barrier to adoption. Finally, population health implications for the possibility of using pharmacogenetics as a preventive service and role of other stakeholders, such as the FDA and CMS, were mentioned frequently.

CONCLUSIONS: Payers’ limited exposure to preemptive pharmacogenetics and its potential benefits gave pause to rapid adoption of this approach to optimize drug therapy. Furthermore, a payer’s ability to judge the value of preemptive pharmacogenetics may be limited by their cost-benefit tradeoff determination, often made on a one-year budget cycle. The ability to enable and influence clinician prescribing based on genetic data in CPIC guidelines was viewed as a valuable resource. Evidence from real-world implementation projects, prospective outcomes studies, population health metrics, and robust budget impact models to predict downstream economic benefits are important considerations for future research in this area.

SPONSORSHIP: None.

<table>
<thead>
<tr>
<th>Z10</th>
<th>The Impact of Medication Therapy Management and Text Message Reminders on Medication Adherence and Health Care Utilization in a Disabled Medicaid Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strohecker J, Hendricks J, Baxter J, Fratello E, Liebhardt N.</td>
<td>Out of 12,303 eligible patients, 503 were enrolled and 1,559 declined participation. A belief in lack of benefit (38%), access to a phone (18%) and failure to know how to text (14%) were top reasons for declining participation. Among enrollees, the average age was 54.4 years; 70% were female; disease and medication burden was heavy (average 7.6 conditions/13.6 medications monthly). Patient engagement with text message reminders was high, with over 70% of patients responding to more than half of delivered texts. In addition, patient/pharmacist interaction via text was ongoing and enhanced collaboration. Results for the first 205 patients enrolled was assessed after 60 days and compared with a 4.5 month average baseline value. The PDC for statin, antihypertensive, and oral diabetes medications improved by 5.1%, 7.1%, and 7.3%, respectively, from baseline. Total cost of care was reduced by $183.83 PMPM; with a subsequent reduction by $102.18 PMPM for inpatient costs; and $81.65 PMPM for ED utilization.</td>
</tr>
</tbody>
</table>

CONCLUSIONS: Preliminary results indicate a MTM intervention combined with interactive mobile phone text messaging improves medication adherence and reduces health care utilization for a Medicaid population with high disease burden.

SPONSORSHIP: None.

<table>
<thead>
<tr>
<th>Z13</th>
<th>Comparing Adherence to Treatment Guidelines After an Opioid Dependence Hospitalization in Medicaid and Commercially Insured Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teigland C, Jones B, Niu C, Parente A, Shaw-Taylor Y.</td>
<td>After an Opioid Dependence Hospitalization in Medicaid and Commercially Insured Populations. Molina Health Care, Salt Lake City, UT 84106; <a href="mailto:jennifer.strohecker@molinamedicaid.com">jennifer.strohecker@molinamedicaid.com</a>; (801) 858-0402.</td>
</tr>
</tbody>
</table>

BACKGROUND: There is an unprecedented opioid epidemic in the U.S. leading to health care and social costs estimated at $55 billion annually. Each day on average more than 650,000 opioid prescriptions are dispensed and 78 people die from overdose. The DHHS has made prevention, treatment and research a top priority, and expanding use of medication-assisted treatment is a key initiative. However, recent studies found privately insured patients receive limited or no services after an opioid related hospitalization.

OBJECTIVE: To evaluate adherence to treatment guidelines and differences in receipt of FDA-approved opioid dependence medications shown to reduce addictive behaviors in Medicaid and commercial patients within 30-days of discharge from an opioid hospitalization.

METHODS: We used claims data from Inovalon’s MORE2 Registry. Methods followed a recent study by Naeger, et al (2016) of a commercially insured population in order to provide comparable analyses of Medicaid beneficiaries. Our cohort included members aged 18-64 between January 1, 2010 and September 30, 2014 who were hospitalized for opioid abuse, dependence or overdose and continuously enrolled at least 90-days prior to hospitalization and at least 30-days post-discharge. Use of FDA-approved medication was defined as receipt of buprenorphine, naltrexone or methadone. We also evaluated use of benzodiazepines (contraindicated), antipsychotics and antidepressants (prevalent use).

RESULTS: We identified 76,611 patients with an opioid misuse hospitalization; 16,859 (22%) with commercial insurance and 59,752 (78%) with Medicaid. Medicaid members were more likely to be female (57% vs. 44%) and older on average. A similar proportion filled an opioid prescription following hospitalization (20%). The percent receiving recommended treatment post-discharge is low for both cohorts, but significantly smaller for Medicaid members (8.6% vs. 18.5%). Overall, a higher proportion of Medicaid patients did not fill a prescription for any of the medications evaluated (41% vs. 28%).

CONCLUSIONS: This study found more than 90% of Medicaid beneficiaries do not receive recommended opioid dependence medications and found disparities in treatment between Medicaid and commercial patients. Further research is needed to adjust for socioeconomic and clinical risk factors to identify the most at-risk patients to better target interventions and treatment, but these findings point to the need for greater awareness and effort to increase use of evidence-based guidelines and reduce treatment disparities to reduce opioid overdoses and deaths in the U.S.

SPONSORSHIP: This study was funded by Inovalon.
Join thousands of your fellow managed care professionals this fall in the heart of Texas for a look at how value-based health care is changing all the rules. Go inside the current health care market and the factors shaping a radically different future, one that will emphasize value and improved patient outcomes as the metrics for success. Enjoy the content and contacts that build a career, while exploring the role you and your colleagues will play in this brave new world.

Registration opens Tuesday, June 20 at 1:00 pm ET.

www.amcpmeetings.org
Notes

Registration opens Tuesday, June 20, at 1:00 pm ET.

Join thousands of your fellow managed care professionals this fall in the heart of Texas for a look at how value-based health care is changing all the rules. Go inside the current health care market and the factors shaping a radically different future, one that will emphasize value and improved patient outcomes as the metrics for success. Enjoy the content and contacts that build a career, while exploring the role you and your colleagues will play in this brave new world.

Registration opens Tuesday, June 20 at 1:00 pm ET.

www.amcpmeetings.org

AMCP 2017

NEXUS

Changing the Way We Pay for Health Care

It's more than dollars and cents. More than co-pays and risk-shares, payers and patients. It's about value. And it's coming at you faster than you think.

OCTOBER 16 – 19 | GAYLORD TEXAN HOTEL & CONVENTION CENTER | DALLAS
7,548 hours per year that AMCP staff spends on advocacy and policy

446 state bills tracked per year

200 meetings per year on Capitol Hill

**REASONS to JOIN**

**NETWORK**

SOCIAL MEDIA

MEETINGS

MEMBERSHIP DIRECTORY

**LEARN**

- NEW AMCP Learn – an online learning platform
- AMCP Webinars
- Digital Science & Innovation Theaters

**ADVOCATE**

**STAY CURRENT**

- AMCP Daily Dose™
- Journal of Managed Care & Specialty Pharmacy
- Members Only Online Sections
- Specialty Pharmacy Central
- Toolkits and White Papers

**JOIN AMCP today!**

AMCP Academy of Managed Care Pharmacy®
AbbVie starts with research and innovation to develop and deliver new treatments to manage some of the world’s most difficult diseases. Our global biopharmaceutical company builds our pipeline to provide solutions in therapeutic areas served by our proven expertise.

To make new solutions available to patients, we team with our scientific peers, physicians, governments and advocacy groups. When we work together, the result is a remarkable impact on patients’ lives and the healthcare systems which serve them.

abbvie.com

170+ Countries
28,000+ Employees
21 R&D and Manufacturing Sites
ONE Priority: Our Patients